1	The	DT	O	the	det	4	SENT_1	[p1l958t81r1004b102],
2	NEW	NNP	O	NEW	nn	4	SENT_1	[p1l1022t83r1107b102],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_1	[p1l1126t83r1314b102],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_1	[p1l1333t83r1513b109],
5	of	IN	O	of	_	0	SENT_1	[p1l1532t81r1561b108],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_1	[p1l1573t83r1772b102],

1	I	PRP	O	I	nsubj	2	SENT_2	[p1l665t186r667b303],
2	ORIGINAL	VBP	O	original	_	0	SENT_2	[p1l1154t234r1377b260],
3	ARTICLE	NN	O	article	nsubj	4	SENT_2	[p1l1390t234r1576b260],
4	I	PRP	O	I	xcomp	2	SENT_2	[p1l2063t186r2065b303],

1	Combined	VBN	O	combine	_	0	SENT_3	[p1l785t378r1100b433],
2	BRAF	NN	O	braf	nn	5	SENT_3	[p1l1127t383r1297b436],
3	and	CC	O	and	_	0	SENT_3	[p1l1326t378r1436b433],
4	MEK	NN	O	mek	nn	5	SENT_3	[p1l1463t383r1614b434],
5	Inhibition	NN	O	inhibition	dep	1	SENT_3	[p1l1639t378r1944b433],
6	in	IN	O	in	_	0	SENT_3	[p1l724t461r782b515],
7	Melanoma	NN	O	melanoma	prep_in	5	SENT_3	[p1l809t461r1131b516],
8	with	IN	O	with	_	0	SENT_3	[p1l1156t461r1290b517],
9	BRAF	NN	O	braf	nn	11	SENT_3	[p1l1318t465r1487b519],
10	V600	NN	O	v600	nn	11	SENT_3	[p1l1514t465r1668b516],
11	Mutations	NNS	O	mutation	prep_with	7	SENT_3	[p1l1696t461r2002b516],

1	Keith	NNP	PERSON	Keith	nn	3	SENT_4	[p1l816t568r897b599],
2	T.	NNP	PERSON	T.	nn	3	SENT_4	[p1l910t570r940b599],
3	Flaherty	NNP	PERSON	Flaherty	_	0	SENT_4	[p1l957t567r1097b609],
4	,	,	O	,	_	0	SENT_4	[p1l957t567r1097b609],
5	M.D.	NNP	O	M.D.	dep	3	SENT_4	[p1l1115t567r1323b609],
6	,	,	O	,	_	0	SENT_4	[p1l1115t567r1323b609],
7	Jeffery	NNP	PERSON	Jeffery	nn	9	SENT_4	[p1l1115t567r1323b609],
8	R.	NNP	PERSON	R.	nn	9	SENT_4	[p1l1338t570r1365b599],
9	Infante	NNP	PERSON	Infante	appos	5	SENT_4	[p1l1382t567r1507b605],
10	,	,	O	,	_	0	SENT_4	[p1l1382t567r1507b605],
11	M.D.	NNP	O	M.D.	appos	5	SENT_4	[p1l1524t570r1614b605],
12	,	,	O	,	_	0	SENT_4	[p1l1524t570r1614b605],
13	Adil	NNP	PERSON	Adil	nn	14	SENT_4	[p1l1627t568r1691b599],
14	Daud	NNP	PERSON	Daud	appos	5	SENT_4	[p1l1709t567r1806b605],
15	,	,	O	,	_	0	SENT_4	[p1l1709t567r1806b605],
16	M.D.	NNP	O	M.D.	appos	5	SENT_4	[p1l1823t570r1913b605],
17	,	,	O	,	_	0	SENT_4	[p1l1823t570r1913b605],

1	Rene	NNP	PERSON	Rene	nn	2	SENT_5	[p1l712t620r792b649],
2	Gonzalez	NNP	PERSON	Gonzalez	_	0	SENT_5	[p1l806t618r973b655],
3	,	,	O	,	_	0	SENT_5	[p1l806t618r973b655],
4	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l990t620r1080b655],
5	,	,	O	,	_	0	SENT_5	[p1l990t620r1080b655],
6	Richard	NNP	PERSON	Richard	nn	8	SENT_5	[p1l1098t618r1222b649],
7	F.	NNP	PERSON	F.	nn	8	SENT_5	[p1l1239t620r1264b649],
8	Kefford	NNP	PERSON	Kefford	appos	2	SENT_5	[p1l1281t617r1409b655],
9	,	,	O	,	_	0	SENT_5	[p1l1281t617r1409b655],
10	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1427t620r1517b655],
11	,	,	O	,	_	0	SENT_5	[p1l1427t620r1517b655],
12	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_5	[p1l1534t617r1751b659],
13	,	,	O	,	_	0	SENT_5	[p1l1534t617r1751b659],
14	jeffrey	NNP	PERSON	jeffrey	nn	15	SENT_5	[p1l1534t617r1751b659],
15	Sosman	NNP	PERSON	Sosman	appos	2	SENT_5	[p1l1764t620r1910b655],
16	,	,	O	,	_	0	SENT_5	[p1l1764t620r1910b655],
17	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1927t620r2017b655],
18	,	,	O	,	_	0	SENT_5	[p1l1927t620r2017b655],
19	Omid	NNP	PERSON	Omid	nn	20	SENT_5	[p1l736t667r830b698],
20	Hamid	NNP	PERSON	Hamid	appos	2	SENT_5	[p1l848t667r971b704],
21	,	,	O	,	_	0	SENT_5	[p1l848t667r971b704],
22	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l988t670r1078b704],
23	,	,	O	,	_	0	SENT_5	[p1l988t670r1078b704],
24	Lynn	NNP	PERSON	Lynn	nn	25	SENT_5	[p1l1095t670r1170b708],
25	Schuchter	NNP	PERSON	Schuchter	appos	2	SENT_5	[p1l1186t667r1364b704],
26	,	,	O	,	_	0	SENT_5	[p1l1186t667r1364b704],
27	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1381t667r1635b707],
28	,	,	O	,	_	0	SENT_5	[p1l1381t667r1635b707],
29	Jonathan	NNP	PERSON	Jonathan	nn	30	SENT_5	[p1l1381t667r1635b707],
30	Cebon	NNP	PERSON	Cebon	appos	2	SENT_5	[p1l1651t667r1767b704],
31	,	,	O	,	_	0	SENT_5	[p1l1651t667r1767b704],
32	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1785t670r1875b704],
33	,	,	O	,	_	0	SENT_5	[p1l1785t670r1875b704],
34	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_5	[p1l1892t667r1991b704],
35	,	,	O	,	_	0	SENT_5	[p1l1892t667r1991b704],
36	Nageatte	NNP	PERSON	Nageatte	nn	37	SENT_5	[p1l697t719r848b757],
37	Ibrahim	NNP	PERSON	Ibrahim	appos	2	SENT_5	[p1l864t716r1003b753],
38	,	,	O	,	_	0	SENT_5	[p1l864t716r1003b753],
39	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1020t719r1110b753],
40	,	,	O	,	_	0	SENT_5	[p1l1020t719r1110b753],
41	Ragini	NNP	PERSON	Ragini	nn	42	SENT_5	[p1l1127t719r1229b757],
42	Kudchadkar	NNP	PERSON	Kudchadkar	appos	2	SENT_5	[p1l1246t716r1453b753],
43	,	,	O	,	_	0	SENT_5	[p1l1246t716r1453b753],
44	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1470t719r1561b753],
45	,	,	O	,	_	0	SENT_5	[p1l1470t719r1561b753],
46	Howard	NNP	PERSON	Howard	nn	51	SENT_5	[p1l1578t716r1709b747],
47	A.	NNP	PERSON	A.	nn	51	SENT_5	[p1l1722t718r1754b747],
48	Burris	NNP	PERSON	Burris	nn	51	SENT_5	[p1l1771t719r1868b747],
49	Ill	NNP	PERSON	Ill	nn	51	SENT_5	[p1l1885t719r1925b753],
50	,	,	O	,	_	0	SENT_5	[p1l1885t719r1925b753],
51	M.D.	NNP	O	M.D.	appos	2	SENT_5	[p1l1942t719r2032b753],
52	,	,	O	,	_	0	SENT_5	[p1l1942t719r2032b753],

1	Gerald	NNP	PERSON	Gerald	nn	2	SENT_6	[p1l851t765r961b796],
2	Falchook	NNP	PERSON	Falchook	_	0	SENT_6	[p1l978t765r1137b802],
3	,	,	O	,	_	0	SENT_6	[p1l978t765r1137b802],
4	M.D.	NNP	O	M.D.	appos	2	SENT_6	[p1l1154t768r1244b802],
5	,	,	O	,	_	0	SENT_6	[p1l1154t768r1244b802],
6	Alain	NNP	PERSON	Alain	nn	7	SENT_6	[p1l1258t765r1341b796],
7	Algazi	NNP	PERSON	Algazi	appos	2	SENT_6	[p1l1355t765r1467b806],
8	,	,	O	,	_	0	SENT_6	[p1l1355t765r1467b806],
9	M.D.	NNP	O	M.D.	appos	2	SENT_6	[p1l1484t768r1574b802],
10	,	,	O	,	_	0	SENT_6	[p1l1484t768r1574b802],
11	Karl	NNP	PERSON	Karl	nn	12	SENT_6	[p1l1591t765r1651b796],
12	Lewis	NNP	PERSON	Lewis	appos	2	SENT_6	[p1l1669t768r1769b802],
13	,	,	O	,	_	0	SENT_6	[p1l1669t768r1769b802],
14	M.D.	NNP	O	M.D.	appos	2	SENT_6	[p1l1786t768r1876b802],
15	,	,	O	,	_	0	SENT_6	[p1l1786t768r1876b802],
16	Georgina	NNP	PERSON	Georgina	nn	18	SENT_6	[p1l842t817r997b855],
17	V.	NNP	PERSON	V.	nn	18	SENT_6	[p1l1009t817r1041b845],
18	Long	NNP	PERSON	Long	appos	2	SENT_6	[p1l1058t817r1147b855],
19	,	,	O	,	_	0	SENT_6	[p1l1058t817r1147b855],
20	M.D.	NNP	O	M.D.	appos	2	SENT_6	[p1l1165t817r1255b851],
21	,	,	O	,	_	0	SENT_6	[p1l1165t817r1255b851],
22	Ph.D.	NNP	O	Ph.D.	appos	2	SENT_6	[p1l1272t814r1371b851],
23	,	,	O	,	_	0	SENT_6	[p1l1272t814r1371b851],
24	Igor	NNP	PERSON	Igor	nn	25	SENT_6	[p1l1388t817r1454b855],
25	Puzanov	NNP	PERSON	Puzanov	appos	2	SENT_6	[p1l1468t817r1619b851],
26	,	,	O	,	_	0	SENT_6	[p1l1468t817r1619b851],
27	M.D.	NNP	O	M.D.	nn	29	SENT_6	[p1l1636t817r1726b851],
28	,	,	O	,	_	0	SENT_6	[p1l1636t817r1726b851],
29	M.S.C.l.	NNP	O	M.S.C.l.	appos	2	SENT_6	[p1l1743t816r1885b851],
30	,	,	O	,	_	0	SENT_6	[p1l1743t816r1885b851],

1	Peter	NNP	PERSON	Peter	nn	14	SENT_7	[p1l775t866r860b894],
2	Lebowitz	NNP	PERSON	Lebowitz	nn	14	SENT_7	[p1l874t863r1032b900],
3	,	,	O	,	_	0	SENT_7	[p1l874t863r1032b900],
4	M.D.	NNP	O	M.D.	appos	14	SENT_7	[p1l1049t866r1139b900],
5	,	,	O	,	_	0	SENT_7	[p1l1049t866r1139b900],
6	Ph.D.	NNP	O	Ph.D.	appos	14	SENT_7	[p1l1156t863r1255b900],
7	,	,	O	,	_	0	SENT_7	[p1l1156t863r1255b900],
8	Ajay	NNP	PERSON	Ajay	appos	14	SENT_7	[p1l1268t865r1339b904],
9	Singh	NNP	PERSON	Singh	nn	14	SENT_7	[p1l1352t863r1455b904],
10	,	,	O	,	_	0	SENT_7	[p1l1352t863r1455b904],
11	M.D.	NNP	O	M.D.	appos	14	SENT_7	[p1l1473t866r1563b900],
12	,	,	O	,	_	0	SENT_7	[p1l1473t866r1563b900],
13	Shonda	NNP	PERSON	Shonda	appos	14	SENT_7	[p1l1578t863r1705b894],
14	Little	NNP	PERSON	Little	_	0	SENT_7	[p1l1721t863r1810b900],
15	,	,	O	,	_	0	SENT_7	[p1l1721t863r1810b900],
16	M.P.H.	NNP	O	M.P.H.	dep	14	SENT_7	[p1l1828t866r1954b900],
17	,	,	O	,	_	0	SENT_7	[p1l1828t866r1954b900],

1	Peng	NNP	PERSON	Peng	nn	2	SENT_8	[p1l678t925r759b963],
2	Sun	NNP	PERSON	Sun	_	0	SENT_8	[p1l772t924r845b959],
3	,	,	O	,	_	0	SENT_8	[p1l772t924r845b959],
4	Ph.D.	NNP	O	Ph.D.	dep	2	SENT_8	[p1l862t922r961b959],
5	,	,	O	,	_	0	SENT_8	[p1l862t922r961b959],
6	Alicia	NNP	PERSON	Alicia	nn	7	SENT_8	[p1l974t922r1065b953],
7	Allred	NNP	PERSON	Allred	appos	4	SENT_8	[p1l1078t922r1185b959],
8	,	,	O	,	_	0	SENT_8	[p1l1078t922r1185b959],
9	Ph.D.	NNP	O	Ph.D.	appos	4	SENT_8	[p1l1202t922r1301b959],
10	,	,	O	,	_	0	SENT_8	[p1l1202t922r1301b959],
11	Daniele	NNP	PERSON	Daniele	nn	12	SENT_8	[p1l1318t922r1444b953],
12	Ouellet	NNP	PERSON	Ouellet	appos	4	SENT_8	[p1l1457t922r1589b959],
13	,	,	O	,	_	0	SENT_8	[p1l1457t922r1589b959],
14	Ph.D.	NNP	O	Ph.D.	appos	4	SENT_8	[p1l1606t922r1705b959],
15	,	,	O	,	_	0	SENT_8	[p1l1606t922r1705b959],
16	Kevin	NNP	PERSON	Kevin	nn	18	SENT_8	[p1l1722t925r1809b953],
17	B.	NNP	PERSON	B.	nn	18	SENT_8	[p1l1827t925r1855b953],
18	Kim	NNP	PERSON	Kim	appos	4	SENT_8	[p1l1872t925r1944b959],
19	,	,	O	,	_	0	SENT_8	[p1l1872t925r1944b959],
20	M.D.	NNP	O	M.D.	appos	4	SENT_8	[p1l1961t925r2051b959],
21	,	,	O	,	_	0	SENT_8	[p1l1961t925r2051b959],

1	Kiran	NNP	PERSON	Kiran	nn	2	SENT_9	[p1l881t974r964b1003],
2	Patel	NNP	PERSON	Patel	_	0	SENT_9	[p1l981t972r1069b1009],
3	,	,	O	,	_	0	SENT_9	[p1l981t972r1069b1009],
4	M.D.	NNP	O	M.D.	appos	2	SENT_9	[p1l1087t974r1177b1009],
5	,	,	O	,	_	0	SENT_9	[p1l1087t974r1177b1009],
6	M.B.A.	NNP	O	M.B.A.	appos	2	SENT_9	[p1l1194t974r1314b1009],
7	,	,	O	,	_	0	SENT_9	[p1l1194t974r1314b1009],
8	andjeffrey	NN	O	andjeffrey	appos	2	SENT_9	[p1l1329t971r1507b1013],
9	Weber	NNP	PERSON	Weber	nn	13	SENT_9	[p1l1518t972r1636b1009],
10	,	,	O	,	_	0	SENT_9	[p1l1518t972r1636b1009],
11	M.D.	NNP	O	M.D.	appos	13	SENT_9	[p1l1653t974r1743b1009],
12	,	,	O	,	_	0	SENT_9	[p1l1653t974r1743b1009],
13	Ph.D.	NNP	O	Ph.D.	dep	8	SENT_9	[p1l1760t972r1849b1003],
14	.	.	O	.	_	0	SENT_9	[p1l1760t972r1849b1003],

1	ABSTRACT	NN	O	abstract	_	0	SENT_10	[p1l1253t1105r1475b1128],

1	BACKGROUND	NN	O	background	_	0	SENT_11	[p1l667t1218r882b1237],

1	The	DT	O	the	det	2	SENT_12	[p1l90t1264r139b1288],
2	authors	NNS	O	author	nsubj	3	SENT_12	[p1l151t1264r257b1288],
3	’	VBP	O	’	_	0	SENT_12	[p1l151t1264r257b1288],
4	affiliations	NNS	O	affiliation	nsubjpass	6	SENT_12	[p1l270t1264r408b1288],
5	are	VBP	O	be	auxpass	6	SENT_12	[p1l420t1272r459b1288],
6	listed	VBN	O	list	ccomp	3	SENT_12	[p1l471t1264r539b1288],
7	in	IN	O	in	_	0	SENT_12	[p1l553t1266r574b1287],
8	the	DT	O	the	det	9	SENT_12	[p1l586t1264r627b1288],
9	Resistance	NN	O	resistance	prep_in	6	SENT_12	[p1l665t1261r838b1293],
10	to	TO	O	to	_	0	SENT_12	[p1l852t1267r884b1291],
11	therapy	NN	O	therapy	prep_to	6	SENT_12	[p1l898t1260r1020b1299],
12	with	IN	O	with	mark	17	SENT_12	[p1l1030t1260r1105b1291],
13	BRAF	NN	ORGANIZATION	braf	nn	15	SENT_12	[p1l1118t1263r1212b1293],
14	kinase	NN	O	kinase	nn	15	SENT_12	[p1l1225t1260r1332b1291],
15	inhibitors	NNS	O	inhibitor	nsubjpass	17	SENT_12	[p1l1345t1260r1505b1291],
16	is	VBZ	O	be	auxpass	17	SENT_12	[p1l1519t1261r1544b1291],
17	associated	VBN	O	associate	advcl	6	SENT_12	[p1l1559t1260r1728b1291],
18	with	IN	O	with	_	0	SENT_12	[p1l1739t1260r1814b1291],
19	reactivation	NN	O	reactivation	prep_with	17	SENT_12	[p1l1827t1261r2018b1291],
20	of	IN	O	of	_	0	SENT_12	[p1l2032t1260r2070b1291],
21	Appendix	NNP	O	Appendix	prep_of	19	SENT_12	[p1l90t1301r219b1332],
22	.	.	O	.	_	0	SENT_12	[p1l90t1301r219b1332],

1	Address	NN	O	address	nsubj	2	SENT_13	[p1l228t1301r332b1325],
2	reprint	VB	O	reprint	_	0	SENT_13	[p1l343t1303r428b1332],
3	requests	NNS	O	request	dobj	2	SENT_13	[p1l438t1305r546b1332],
4	to	TO	O	to	_	0	SENT_13	[p1l555t1305r580b1325],
5	Dr.	NNP	O	Dr.	prep_to	2	SENT_13	[p1l591t1303r626b1325],
6	-	:	O	-	_	0	SENT_13	[p1l765t1310r770b1315],
7	_	SYM	O	_	dep	18	SENT_13	[p1l868t1326r879b1331],
8	-	:	O	-	_	0	SENT_13	[p1l933t1310r938b1315],
9	-	:	O	-	_	0	SENT_13	[p1l1129t1310r1134b1315],
10	-	:	O	-	_	0	SENT_13	[p1l1195t1310r1200b1315],
11	Weber	NNP	PERSON	Weber	dep	15	SENT_13	[p1l1822t1310r1827b1315, p1l90t1339r175b1363],
12	at	IN	O	at	_	0	SENT_13	[p1l186t1343r209b1362],
13	the	DT	O	the	prep_at	11	SENT_13	[p1l219t1339r260b1362],
14	Comprehensive	NNP	MISC	Comprehensive	nn	15	SENT_13	[p1l271t1339r475b1370],
15	Melanoma	NNP	MISC	Melanoma	dep	18	SENT_13	[p1l489t1339r626b1362],
16	the	DT	O	the	dep	15	SENT_13	[p1l666t1310r716b1340],
17	mitogen	NN	O	mitogen	dep	15	SENT_13	[p1l728t1316r866b1349],
18	activated	VBN	O	activate	parataxis	2	SENT_13	[p1l880t1310r1027b1341],
19	protein	NN	O	protein	prep	18	SENT_13	[p1l1038t1316r1159b1349],
20	kinase	NN	O	kinase	nn	24	SENT_13	[p1l1171t1310r1279b1341],
21	(	CD	NUMBER	(	num	24	SENT_13	[p1l1292t1312r1421b1345],
22	MAPK	NN	O	mapk	nn	24	SENT_13	[p1l1292t1312r1421b1345],
23	)	NN	O	)	nn	24	SENT_13	[p1l1292t1312r1421b1345],
24	pathway	NN	O	pathway	dep	19	SENT_13	[p1l1434t1310r1579b1349],
25	.	.	O	.	_	0	SENT_13	[p1l1434t1310r1579b1349],

1	To	TO	O	to	aux	2	SENT_14	[p1l1591t1312r1632b1340],
2	address	VB	O	address	purpcl	18	SENT_14	[p1l1644t1310r1770b1340],
3	this	DT	O	this	det	4	SENT_14	[p1l1783t1310r1845b1340],
4	problem	NN	O	problem	dobj	2	SENT_14	[p1l1857t1310r2005b1349],
5	,	,	O	,	_	0	SENT_14	[p1l1857t1310r2005b1349],
6	We	PRP	O	we	dep	2	SENT_14	[p1l2017t1320r2063b1341],
7	Research	NNP	O	Research	nn	8	SENT_14	[p1l93t1376r208b1400],
8	Came	NNP	O	Came	dep	6	SENT_14	[p1l222t1378r313b1404],
9	,	,	O	,	_	0	SENT_14	[p1l222t1378r313b1404],
10	’	CD	NUMBER	’	num	11	SENT_14	[p1l222t1378r313b1404],
11	Mom	NN	O	mom	appos	8	SENT_14	[p1l329t1376r420b1400],
12	,	,	O	,	_	0	SENT_14	[p1l329t1376r420b1400],
13	Came	NNP	O	Came	appos	8	SENT_14	[p1l432t1378r522b1400],
14	,	,	O	,	_	0	SENT_14	[p1l432t1378r522b1400],
15	Came	NNP	O	Came	appos	8	SENT_14	[p1l535t1378r625b1404],
16	,	,	O	,	_	0	SENT_14	[p1l535t1378r625b1404],
17	’	NN	O	’	nsubj	18	SENT_14	[p1l535t1378r625b1404],
18	conducted	VBD	O	conduct	_	0	SENT_14	[p1l666t1360r837b1391],
19	a	DT	O	a	det	20	SENT_14	[p1l849t1370r867b1390],
20	phase	NN	O	phase	dobj	18	SENT_14	[p1l878t1360r975b1399],
21	1	CD	NUMBER	1	dep	20	SENT_14	[p1l989t1362r1006b1390],
22	and	CC	O	and	_	0	SENT_14	[p1l1019t1360r1080b1391],
23	2	CD	NUMBER	2	num	24	SENT_14	[p1l1093t1362r1112b1390],
24	trial	NN	O	trial	conj_and	20	SENT_14	[p1l1125t1360r1194b1391],
25	of	IN	O	of	_	0	SENT_14	[p1l1207t1360r1246b1391],
26	combined	JJ	O	combined	amod	27	SENT_14	[p1l1252t1360r1416b1391],
27	treatment	NN	O	treatment	prep_of	24	SENT_14	[p1l1429t1366r1594b1391],
28	with	IN	O	with	_	0	SENT_14	[p1l1603t1360r1679b1391],
29	dabrafenib	NN	O	dabrafenib	prep_with	18	SENT_14	[p1l1692t1360r1880b1397],
30	,	,	O	,	_	0	SENT_14	[p1l1692t1360r1880b1397],
31	a	DT	O	a	det	33	SENT_14	[p1l1895t1370r1912b1391],
32	selective	JJ	O	selective	amod	33	SENT_14	[p1l1925t1360r2063b1391],
33	Tampa	NNP	LOCATION	Tampa	appos	29	SENT_14	[p1l90t1416r185b1445],
34	.	.	O	.	_	0	SENT_14	[p1l90t1416r185b1445],

1	FL	NN	O	fl	_	0	SENT_15	[p1l205t1416r234b1437],
2	33612	CD	NUMBER	33612	dep	1	SENT_15	[p1l249t1416r331b1442],
3	.	.	O	.	_	0	SENT_15	[p1l249t1416r331b1442],

1	or	CC	O	or	_	0	SENT_16	[p1l349t1422r375b1438],
2	at	IN	O	at	dep	1	SENT_16	[p1l391t1418r414b1438],
3	Jeffrey-weber	JJ	O	jeffrey-weber	pobj	2	SENT_16	[p1l429t1414r625b1445],
4	@	SYM	O	@	dep	6	SENT_16	[p1l429t1414r625b1445],
5	BRAF	NN	O	braf	nn	6	SENT_16	[p1l665t1413r759b1443],
6	inhibitor	NN	O	inhibitor	rcmod	3	SENT_16	[p1l773t1410r928b1447],
7	,	,	O	,	_	0	SENT_16	[p1l773t1410r928b1447],
8	and	CC	O	and	_	0	SENT_16	[p1l943t1410r1005b1441],
9	trametinib	NN	O	trametinib	conj_and	3	SENT_16	[p1l1018t1410r1205b1447],
10	,	,	O	,	_	0	SENT_16	[p1l1018t1410r1205b1447],
11	a	DT	O	a	det	18	SENT_16	[p1l1220t1420r1237b1441],
12	selective	JJ	O	selective	amod	18	SENT_16	[p1l1250t1410r1389b1441],
13	MAPK	NN	O	mapk	nn	18	SENT_16	[p1l1401t1413r1509b1442],
14	kinase	NN	O	kinase	nn	18	SENT_16	[p1l1520t1410r1629b1441],
15	(	CD	NUMBER	(	num	18	SENT_16	[p1l1644t1413r1747b1446],
16	MEK	NN	O	mek	nn	18	SENT_16	[p1l1644t1413r1747b1446],
17	)	NN	O	)	nn	18	SENT_16	[p1l1644t1413r1747b1446],
18	inhibitor	NN	O	inhibitor	appos	9	SENT_16	[p1l1762t1410r1918b1441],
19	.	.	O	.	_	0	SENT_16	[p1l1762t1410r1918b1441],

1	moffittorg	NN	O	moffittorg	_	0	SENT_17	[p1l92t1451r242b1482],
2	.	.	O	.	_	0	SENT_17	[p1l92t1451r242b1482],

1	M	NN	O	m	nn	4	SENT_18	[p1l668t1488r688b1507],
2	ETH	NN	O	eth	nn	4	SENT_18	[p1l696t1488r751b1507],
3	o	NN	O	o	nn	4	SENT_18	[p1l757t1488r778b1507],
4	DS	NN	O	d	_	0	SENT_18	[p1l784t1488r820b1507],

1	D'	NN	O	d'	dep	124	SENT_19	[p1l93t1526r144b1548],
2	5	CD	NUMBER	5	dep	124	SENT_19	[p1l93t1526r144b1548],
3	-	:	O	-	_	0	SENT_19	[p1l93t1526r144b1548],
4	F	NN	O	f	dep	124	SENT_19	[p1l160t1524r264b1555],
5	'	''	O	'	_	0	SENT_19	[p1l160t1524r264b1555],
6	a	DT	O	a	dep	124	SENT_19	[p1l160t1524r264b1555],
7	"	``	O	"	dep	124	SENT_19	[p1l160t1524r264b1555],
8	°	NN	O	°	dep	124	SENT_19	[p1l160t1524r264b1555],
9	'	''	O	'	_	0	SENT_19	[p1l160t1524r264b1555],
10	t	NN	O	t	dep	124	SENT_19	[p1l160t1524r264b1555],
11	>	JJR	O	>	dep	124	SENT_19	[p1l160t1524r264b1555],
12	’	CD	NUMBER	’	dep	124	SENT_19	[p1l160t1524r264b1555],
13	*	NN	O	*	dep	124	SENT_19	[p1l277t1524r322b1548],
14	'	''	O	'	_	0	SENT_19	[p1l277t1524r322b1548],
15	”	CD	NUMBER	”	dep	124	SENT_19	[p1l277t1524r322b1548],
16	d	NN	O	d	dep	124	SENT_19	[p1l277t1524r322b1548],
17	'	''	O	'	_	0	SENT_19	[p1l339t1524r428b1567],
18	”	CD	NUMBER	”	dep	124	SENT_19	[p1l339t1524r428b1567],
19	l	NN	O	l	dep	124	SENT_19	[p1l339t1524r428b1567],
20	‘‘	CD	NUMBER	‘‘	dep	124	SENT_19	[p1l339t1524r428b1567],
21	‘“	CD	NUMBER	‘“	dep	124	SENT_19	[p1l339t1524r428b1567],
22	_	NN	O	_	dep	124	SENT_19	[p1l339t1524r428b1567],
23	“’	CD	NUMBER	“’	dep	124	SENT_19	[p1l339t1524r428b1567],
24	3	CD	NUMBER	3	dep	124	SENT_19	[p1l441t1524r487b1548],
25	“	NN	O	“	dep	124	SENT_19	[p1l441t1524r487b1548],
26	D'	NN	O	d'	dep	124	SENT_19	[p1l503t1526r554b1548],
27	5	CD	NUMBER	5	dep	124	SENT_19	[p1l503t1526r554b1548],
28	-	:	O	-	_	0	SENT_19	[p1l503t1526r554b1548],
29	Kim	NNP	PERSON	Kim	dep	124	SENT_19	[p1l570t1526r625b1552],
30	»	NNP	O	»	dep	124	SENT_19	[p1l570t1526r625b1552],
31	In	IN	O	in	dep	124	SENT_19	[p1l665t1533r699b1561],
32	this	DT	O	this	dep	124	SENT_19	[p1l710t1531r772b1561],
33	open	JJ	O	open	dep	124	SENT_19	[p1l784t1531r958b1570],
34	—	NN	O	—	dep	124	SENT_19	[p1l784t1531r958b1570],
35	label	NN	O	label	dep	124	SENT_19	[p1l784t1531r958b1570],
36	study	NN	O	study	dep	124	SENT_19	[p1l969t1531r1058b1570],
37	involving	VBG	O	involve	dep	124	SENT_19	[p1l1067t1531r1220b1570],
38	247	CD	NUMBER	247	dep	124	SENT_19	[p1l1230t1533r1287b1561],
39	patients	NNS	O	patient	dep	124	SENT_19	[p1l1297t1531r1430b1570],
40	with	IN	O	with	dep	124	SENT_19	[p1l1439t1531r1515b1562],
41	metastatic	JJ	O	metastatic	dep	124	SENT_19	[p1l1526t1531r1699b1561],
42	melanoma	NN	O	melanoma	dep	124	SENT_19	[p1l1710t1531r1887b1561],
43	and	CC	O	and	dep	124	SENT_19	[p1l1897t1531r1958b1561],
44	BRAF	NNP	PERSON	BRAF	dep	124	SENT_19	[p1l1968t1533r2062b1563],
45	Patel	NNP	PERSON	Patel	dep	124	SENT_19	[p1l93t1562r162b1590],
46	,	,	O	,	_	0	SENT_19	[p1l93t1562r162b1590],
47	and	CC	O	and	dep	124	SENT_19	[p1l177t1562r222b1585],
48	Weber	NNP	PERSON	Weber	dep	124	SENT_19	[p1l236t1562r321b1586],
49	contributed	VBD	O	contribute	dep	124	SENT_19	[p1l333t1562r484b1585],
50	equally	RB	O	equally	dep	124	SENT_19	[p1l498t1562r589b1593],
51	to	TO	O	to	dep	124	SENT_19	[p1l601t1566r626b1585],
52	. . . . .	CD	NUMBER	. . . . .	dep	124	SENT_19	[p1l1640t1581r1645b1587],[p1l866t1581r871b1587],
53	this	DT	O	this	dep	124	SENT_19	[p1l90t1599r137b1623],
54	a	DT	O	a	dep	124	SENT_19	[p1l148t1599r234b1623],
55	,	,	O	,	_	0	SENT_19	[p1l148t1599r234b1623],
56	,	,	O	,	_	0	SENT_19	[p1l148t1599r234b1623],
57	,	,	O	,	_	0	SENT_19	[p1l148t1599r234b1623],
58	C	NN	O	c	dep	124	SENT_19	[p1l148t1599r234b1623],
59	,	,	O	,	_	0	SENT_19	[p1l148t1599r234b1623],
60	e	SYM	O	e	dep	124	SENT_19	[p1l148t1599r234b1623],
61	_	SYM	O	_	dep	124	SENT_19	[p1l148t1599r234b1623],
62	V600	NN	O	v600	dep	124	SENT_19	[p1l664t1583r747b1612],
63	mutations	NNS	O	mutation	dep	124	SENT_19	[p1l764t1587r942b1618],
64	,	,	O	,	_	0	SENT_19	[p1l764t1587r942b1618],
65	we	PRP	O	we	dep	124	SENT_19	[p1l958t1591r1004b1612],
66	evaluated	VBD	O	evaluate	dep	124	SENT_19	[p1l1020t1581r1176b1612],
67	the	DT	O	the	dep	124	SENT_19	[p1l1192t1581r1244b1611],
68	pharmacokinetic	JJ	O	pharmacokinetic	dep	124	SENT_19	[p1l1259t1581r1544b1620],
69	activity	NN	O	activity	dep	124	SENT_19	[p1l1559t1587r1679b1620],
70	and	CC	O	and	dep	124	SENT_19	[p1l1694t1581r1755b1612],
71	safety	NN	O	safety	dep	124	SENT_19	[p1l1771t1580r1869b1620],
72	of	IN	O	of	dep	124	SENT_19	[p1l1884t1580r1923b1612],
73	oral	JJ	O	oral	dep	124	SENT_19	[p1l1932t1581r1996b1612],
74	dabrafenib	NN	O	dabrafenib	dep	124	SENT_19	[p1l2012t1581r2063b1612, p1l666t1631r805b1662],
75	(	NN	O	(	dep	124	SENT_19	[p1l824t1634r873b1666],
76	75	CD	NUMBER	75	dep	124	SENT_19	[p1l824t1634r873b1666],
77	or	CC	O	or	dep	124	SENT_19	[p1l892t1641r926b1662],
78	150	CD	NUMBER	150	dep	124	SENT_19	[p1l943t1633r1001b1662],
79	mg	NN	O	mg	dep	124	SENT_19	[p1l1019t1641r1073b1670],
80	twice	RB	O	twice	dep	124	SENT_19	[p1l1088t1631r1176b1662],
81	daily	JJ	SET	daily	dep	124	SENT_19	[p1l1194t1631r1283b1670],
82	)	NN	O	)	dep	124	SENT_19	[p1l1194t1631r1283b1670],
83	and	CC	O	and	dep	124	SENT_19	[p1l1302t1631r1363b1662],
84	trametinib	NN	O	trametinib	dep	124	SENT_19	[p1l1380t1631r1559b1662],
85	(	NN	O	(	dep	124	SENT_19	[p1l1578t1633r1615b1668],
86	1	CD	NUMBER	1	dep	124	SENT_19	[p1l1578t1633r1615b1668],
87	,	,	O	,	_	0	SENT_19	[p1l1578t1633r1615b1668],
88	1.5	CD	NUMBER	1.5	dep	124	SENT_19	[p1l1636t1633r1692b1668],
89	,	,	O	,	_	0	SENT_19	[p1l1636t1633r1692b1668],
90	or	CC	O	or	dep	124	SENT_19	[p1l1711t1641r1746b1662],
91	2	CD	NUMBER	2	dep	124	SENT_19	[p1l1762t1633r1780b1661],
92	mg	NN	O	mg	dep	124	SENT_19	[p1l1797t1641r1852b1670],
93	daily	JJ	SET	daily	dep	124	SENT_19	[p1l1867t1631r1957b1670],
94	)	NN	O	)	dep	124	SENT_19	[p1l1867t1631r1957b1670],
95	in	IN	O	in	dep	124	SENT_19	[p1l1975t1631r2008b1661],
96	85	CD	NUMBER	85	dep	124	SENT_19	[p1l2025t1633r2062b1662],
97	patients	NNS	O	patient	dep	124	SENT_19	[p1l665t1681r797b1720],
98	and	CC	O	and	dep	124	SENT_19	[p1l813t1680r875b1711],
99	then	RB	O	then	dep	124	SENT_19	[p1l890t1681r964b1711],
100	randomly	RB	O	randomly	dep	124	SENT_19	[p1l980t1681r1141b1720],
101	assigned	VBN	O	assign	dep	124	SENT_19	[p1l1154t1681r1299b1720],
102	162	CD	NUMBER	162	dep	124	SENT_19	[p1l1316t1683r1372b1711],
103	patients	NNS	O	patient	dep	124	SENT_19	[p1l1388t1681r1520b1720],
104	to	TO	O	to	dep	124	SENT_19	[p1l1537t1687r1568b1711],
105	receive	VB	O	receive	dep	124	SENT_19	[p1l1584t1681r1696b1712],
106	combination	NN	O	combination	dep	124	SENT_19	[p1l1712t1681r1924b1711],
107	therapy	NN	O	therapy	dep	124	SENT_19	[p1l1940t1681r2065b1720],
108	with	IN	O	with	dep	124	SENT_19	[p1l664t1731r739b1762],
109	dabrafenib	NN	O	dabrafenib	dep	124	SENT_19	[p1l753t1730r933b1762],
110	(	NN	O	(	dep	124	SENT_19	[p1l949t1733r1019b1766],
111	150	CD	NUMBER	150	dep	124	SENT_19	[p1l949t1733r1019b1766],
112	mg	NN	O	mg	dep	124	SENT_19	[p1l1033t1734r1097b1770],
113	)	NN	O	)	dep	124	SENT_19	[p1l1033t1734r1097b1770],
114	plus	CC	O	plus	dep	124	SENT_19	[p1l1112t1731r1180b1770],
115	trametinib	NN	O	trametinib	dep	124	SENT_19	[p1l1195t1731r1373b1762],
116	(	NN	O	(	dep	124	SENT_19	[p1l1389t1733r1418b1766],
117	1	CD	NUMBER	1	dep	124	SENT_19	[p1l1389t1733r1418b1766],
118	or	CC	O	or	dep	124	SENT_19	[p1l1432t1741r1466b1762],
119	2	CD	NUMBER	2	dep	124	SENT_19	[p1l1479t1733r1497b1761],
120	mg	NN	O	mg	dep	124	SENT_19	[p1l1511t1734r1576b1770],
121	)	NN	O	)	dep	124	SENT_19	[p1l1511t1734r1576b1770],
122	or	CC	O	or	dep	124	SENT_19	[p1l1592t1741r1626b1762],
123	dabrafenib	NN	O	dabrafenib	dep	124	SENT_19	[p1l1639t1730r1819b1762],
124	monotherapy	NN	O	monotherapy	_	0	SENT_19	[p1l1833t1731r2061b1770],
125	.	.	O	.	_	0	SENT_19	[p1l1833t1731r2061b1770],

1	N	NN	MISC	n	nn	3	SENT_20	[p1l93t1791r110b1810],
2	Englj	NNP	MISC	Englj	nn	3	SENT_20	[p1l120t1789r182b1817],
3	Med	NNP	O	Med	_	0	SENT_20	[p1l193t1789r243b1810],
4	2012	CD	DATE	2012	num	3	SENT_20	[p1l251t1790r475b1815],
5	;	:	O	;	_	0	SENT_20	[p1l251t1790r475b1815],
6	367:1694	CD	DURATION	367:1694	number	7	SENT_20	[p1l251t1790r475b1815],
7	-7023	CD	DURATION	-7023	dep	3	SENT_20	[p1l251t1790r475b1815],
8	.	.	O	.	_	0	SENT_20	[p1l251t1790r475b1815],

1	The	DT	O	the	det	4	SENT_21	[p1l664t1781r726b1811],
2	primary	JJ	O	primary	amod	4	SENT_21	[p1l738t1781r874b1820],
3	end	NN	O	end	nn	4	SENT_21	[p1l885t1781r944b1812],
4	points	NNS	O	point	nsubj	7	SENT_21	[p1l956t1781r1060b1820],
5	were	VBD	O	be	cop	7	SENT_21	[p1l1072t1791r1150b1812],
6	the	DT	O	the	det	7	SENT_21	[p1l1162t1781r1214b1811],
7	incidence	NN	O	incidence	_	0	SENT_21	[p1l1226t1781r1383b1812],
8	of	IN	O	of	_	0	SENT_21	[p1l1396t1781r1435b1812],
9	cutaneous	JJ	O	cutaneous	amod	13	SENT_21	[p1l1440t1787r1609b1812],
10	squamous	JJ	O	squamous	amod	13	SENT_21	[p1l1623t1781r1865b1820],
11	—	NN	O	—	nn	13	SENT_21	[p1l1623t1781r1865b1820],
12	cell	NN	O	cell	nn	13	SENT_21	[p1l1623t1781r1865b1820],
13	carcinoma	NN	O	carcinoma	prep_of	7	SENT_21	[p1l1877t1781r2061b1818],
14	,	,	O	,	_	0	SENT_21	[p1l1877t1781r2061b1818],
15	°	CD	NUMBER	°	number	16	SENT_21	[p1l92t1827r256b1854],
16	°	CD	NUMBER	°	conj_and	7	SENT_21	[p1l92t1827r256b1854],
17	"	``	O	"	punct	19	SENT_21	[p1l92t1827r256b1854],
18	1	CD	NUMBER	1	num	19	SENT_21	[p1l92t1827r256b1854],
19	°	NN	O	°	dep	16	SENT_21	[p1l92t1827r256b1854],
20	'	''	O	'	_	0	SENT_21	[p1l92t1827r256b1854],
21	1	CD	NUMBER	1	num	31	SENT_21	[p1l92t1827r256b1854],
22	°	CD	NUMBER	°	number	23	SENT_21	[p1l92t1827r256b1854],
23	55	CD	NUMBER	55	amod	31	SENT_21	[p1l92t1827r256b1854],
24	/	:	O	/	punct	27	SENT_21	[p1l92t1827r256b1854],
25	"	``	O	"	punct	27	SENT_21	[p1l259t1827r452b1854],
26	‘	CD	NUMBER	‘	num	27	SENT_21	[p1l259t1827r452b1854],
27	EJM	NN	O	ejm	dep	23	SENT_21	[p1l259t1827r452b1854],
28	°	CD	NUMBER	°	num	29	SENT_21	[p1l259t1827r452b1854],
29	“	NN	O	“	dep	27	SENT_21	[p1l259t1827r452b1854],
30	121	CD	NUMBER	121	dep	29	SENT_21	[p1l259t1827r452b1854],
31	°	NN	O	°	dep	16	SENT_21	[p1l259t1827r452b1854],
32	°	CD	NUMBER	°	number	33	SENT_21	[p1l259t1827r452b1854],
33	93	CD	NUMBER	93	num	34	SENT_21	[p1l259t1827r452b1854],
34	survival	NN	O	survival	npadvmod	35	SENT_21	[p1l666t1831r795b1862],
35	free	JJ	O	free	amod	31	SENT_21	[p1l810t1830r873b1861],
36	of	IN	O	of	_	0	SENT_21	[p1l889t1830r928b1861],
37	melanoma	NN	O	melanoma	nn	38	SENT_21	[p1l936t1831r1113b1861],
38	progression	NN	O	progression	prep_of	31	SENT_21	[p1l1128t1831r1335b1870],
39	,	,	O	,	_	0	SENT_21	[p1l1128t1831r1335b1870],
40	and	CC	O	and	_	0	SENT_21	[p1l1352t1831r1414b1861],
41	response	NN	O	response	conj_and	7	SENT_21	[p1l1429t1840r1586b1870],
42	.	.	O	.	_	0	SENT_21	[p1l1429t1840r1586b1870],

1	Secondary	JJ	O	secondary	amod	3	SENT_22	[p1l1604t1831r1777b1870],
2	end	NN	O	end	nn	3	SENT_22	[p1l1791t1830r1851b1861],
3	points	NNS	O	point	nsubj	5	SENT_22	[p1l1866t1831r1970b1870],
4	were	VBD	O	be	cop	5	SENT_22	[p1l1985t1841r2063b1862],
5	Copyright	NN	O	copyright	_	0	SENT_22	[p1l92t1866r185b1891],
6	©	CD	NUMBER	©	num	5	SENT_22	[p1l194t1868r215b1889],
7	2012	CD	DATE	2012	num	10	SENT_22	[p1l225t1867r274b1885],
8	Massachusetts	NNP	LOCATION	Massachusetts	nn	10	SENT_22	[p1l283t1866r423b1885],
9	Mm	NN	O	mm	nn	10	SENT_22	[p1l432t1866r509b1885],
10	“	NN	O	“	dep	5	SENT_22	[p1l432t1866r509b1885],
11	,	,	O	,	_	0	SENT_22	[p1l432t1866r509b1885],
12	Society	NNP	ORGANIZATION	Society	conj_and	5	SENT_22	[p1l517t1867r589b1891],
13	‘	CD	NUMBER	‘	num	12	SENT_22	[p1l517t1867r589b1891],
14	overall	JJ	O	overall	amod	15	SENT_22	[p1l666t1881r776b1912],
15	survival	NN	O	survival	dep	12	SENT_22	[p1l790t1881r919b1912],
16	and	CC	O	and	_	0	SENT_22	[p1l932t1881r993b1912],
17	pharmacokinetic	JJ	O	pharmacokinetic	amod	18	SENT_22	[p1l1006t1881r1290b1920],
18	activity	NN	O	activity	conj_and	5	SENT_22	[p1l1303t1881r1423b1920],
19	This	DT	O	this	det	20	SENT_22	[p1l90t1674r142b1698],
20	article	NN	O	article	nsubjpass	22	SENT_22	[p1l157t1674r231b1698],
21	was	VBD	O	be	auxpass	22	SENT_22	[p1l244t1682r290b1698],
22	published	VBN	O	publish	rcmod	18	SENT_22	[p1l307t1674r428b1705],
23	on	IN	O	on	_	0	SENT_22	[p1l443t1682r473b1698],
24	September	NNP	DATE	September	prep_on	22	SENT_22	[p1l490t1674r628b1705],
25	29,2012	CD	DATE	29,2012	num	24	SENT_22	[p1l91t1713r200b1740],
26	,	,	O	,	_	0	SENT_22	[p1l91t1713r200b1740],
27	atNE	NN	O	atne	nn	29	SENT_22	[p1l210t1714r368b1743],
28	}	CD	NUMBER	}	num	29	SENT_22	[p1l210t1714r368b1743],
29	M.org	NN	O	m.org	appos	24	SENT_22	[p1l210t1714r368b1743],
30	.	.	O	.	_	0	SENT_22	[p1l210t1714r368b1743],

1	R	NN	O	r	nn	2	SENT_23	[p1l667t1961r682b1980],
2	E	NN	O	e	nsubj	7	SENT_23	[p1l687t1961r700b1980],
3	s	VBZ	O	s	cop	7	SENT_23	[p1l705t1961r719b1980],
4	u	FW	O	u	nn	7	SENT_23	[p1l725t1961r741b1980],
5	LTS	FW	O	lts	nn	7	SENT_23	[p1l748t1961r795b1980],
6	Dose	NN	O	dose	nn	7	SENT_23	[p1l665t1999r894b2038],
7	—	NN	O	—	dep	13	SENT_23	[p1l665t1999r894b2038],
8	limiting	VBG	O	limit	partmod	7	SENT_23	[p1l665t1999r894b2038],
9	toxic	JJ	O	toxic	amod	10	SENT_23	[p1l904t1999r982b2030],
10	effects	NNS	O	effect	dobj	8	SENT_23	[p1l994t1999r1100b2029],
11	were	VBD	O	be	auxpass	13	SENT_23	[p1l1111t2009r1188b2030],
12	infrequently	RB	O	infrequently	advmod	13	SENT_23	[p1l1199t1999r1400b2038],
13	observed	VBN	O	observe	_	0	SENT_23	[p1l1410t1999r1555b2030],
14	in	IN	O	in	_	0	SENT_23	[p1l1566t1999r1598b2029],
15	patients	NNS	O	patient	prep_in	13	SENT_23	[p1l1609t1999r1738b2038],
16	receiving	VBG	O	receive	xcomp	13	SENT_23	[p1l1751t1999r1899b2038],
17	combination	NN	O	combination	nn	18	SENT_23	[p1l1909t1999r2063b2030, p1l665t2048r731b2079],
18	therapy	NN	O	therapy	dobj	16	SENT_23	[p1l742t2048r865b2087],
19	with	IN	O	with	_	0	SENT_23	[p1l873t2048r948b2079],
20	150	CD	NUMBER	150	num	21	SENT_23	[p1l960t2050r1018b2079],
21	mg	NN	O	mg	prep_with	16	SENT_23	[p1l1029t2058r1083b2087],
22	of	IN	O	of	_	0	SENT_23	[p1l1092t2048r1131b2079],
23	dabrafenib	NN	O	dabrafenib	prep_of	21	SENT_23	[p1l1135t2048r1313b2079],
24	and	CC	O	and	_	0	SENT_23	[p1l1324t2048r1385b2079],
25	2	CD	NUMBER	2	num	26	SENT_23	[p1l1396t2050r1415b2078],
26	mg	NN	O	mg	conj_and	21	SENT_23	[p1l1426t2058r1479b2087],
27	of	IN	O	of	_	0	SENT_23	[p1l1489t2048r1528b2079],
28	trametinib	NN	O	trametinib	prep_of	26	SENT_23	[p1l1532t2048r1708b2079],
29	(	CD	NUMBER	(	num	32	SENT_23	[p1l1721t2048r1941b2083],
30	combination	NN	O	combination	nn	32	SENT_23	[p1l1721t2048r1941b2083],
31	150/2	CD	NUMBER	150/2	num	32	SENT_23	[p1l1953t2050r2061b2083],
32	)	NN	O	)	nsubjpass	13	SENT_23	[p1l1953t2050r2061b2083],
33	.	.	O	.	_	0	SENT_23	[p1l1953t2050r2061b2083],

1	Cutaneous	JJ	O	cutaneous	amod	3	SENT_24	[p1l665t2099r841b2128],
2	squamous	JJ	O	squamous	amod	3	SENT_24	[p1l854t2097r1096b2136],
3	—	NN	O	—	_	0	SENT_24	[p1l854t2097r1096b2136],
4	cell	NN	O	cell	nn	5	SENT_24	[p1l854t2097r1096b2136],
5	carcinoma	NN	O	carcinoma	nsubjpass	7	SENT_24	[p1l1107t2097r1283b2128],
6	was	VBD	O	be	auxpass	7	SENT_24	[p1l1292t2107r1355b2128],
7	seen	VBN	O	see	rcmod	3	SENT_24	[p1l1367t2107r1440b2127],
8	in	IN	O	in	_	0	SENT_24	[p1l1451t2097r1484b2127],
9	7	CD	PERCENT	7	num	10	SENT_24	[p1l1495t2099r1547b2128],
10	%	NN	PERCENT	%	prep_in	7	SENT_24	[p1l1495t2099r1547b2128],
11	of	IN	O	of	_	0	SENT_24	[p1l1558t2097r1597b2128],
12	patients	NNS	O	patient	prep_of	10	SENT_24	[p1l1600t2097r1733b2136],
13	receiving	VBG	O	receive	partmod	12	SENT_24	[p1l1745t2097r1896b2136],
14	combination	NN	O	combination	dobj	13	SENT_24	[p1l1906t2097r2063b2128, p1l665t2146r731b2177],
15	150/2	CD	NUMBER	150/2	num	14	SENT_24	[p1l746t2148r834b2181],
16	and	CC	O	and	_	0	SENT_24	[p1l847t2146r908b2177],
17	in	IN	O	in	conj_and	14	SENT_24	[p1l921t2146r953b2176],
18	19	CD	NUMBER	19	num	19	SENT_24	[p1l968t2148r1039b2177],
19	°	CD	NUMBER	°	pobj	17	SENT_24	[p1l968t2148r1039b2177],
20	/	:	O	/	punct	3	SENT_24	[p1l968t2148r1039b2177],
21	o	NN	O	o	nsubj	22	SENT_24	[p1l968t2148r1039b2177],
22	receiving	VBG	O	receive	dep	3	SENT_24	[p1l1052t2146r1204b2185],
23	monotherapy	NN	O	monotherapy	nn	25	SENT_24	[p1l1215t2146r1438b2185],
24	(	CD	NUMBER	(	num	25	SENT_24	[p1l1451t2148r1605b2183],
25	P	NN	O	p	dobj	22	SENT_24	[p1l1451t2148r1605b2183],
26	=	JJ	O	=	advmod	22	SENT_24	[p1l1451t2148r1605b2183],
27	0.09	CD	NUMBER	0.09	num	28	SENT_24	[p1l1451t2148r1605b2183],
28	)	NN	O	)	dep	26	SENT_24	[p1l1451t2148r1605b2183],
29	,	,	O	,	_	0	SENT_24	[p1l1451t2148r1605b2183],
30	whereas	IN	O	whereas	mark	34	SENT_24	[p1l1619t2146r1755b2177],
31	pyrexia	NN	O	pyrexia	nsubj	34	SENT_24	[p1l1769t2146r1890b2185],
32	was	VBD	O	be	cop	34	SENT_24	[p1l1901t2156r1964b2177],
33	more	RBR	O	more	advmod	34	SENT_24	[p1l1978t2156r2063b2177],
34	common	JJ	O	common	advcl	22	SENT_24	[p1l666t2205r814b2226],
35	in	IN	O	in	prep	34	SENT_24	[p1l832t2195r864b2225],
36	the	DT	O	the	det	37	SENT_24	[p1l883t2195r934b2225],
37	combination	NN	O	combination	dep	47	SENT_24	[p1l953t2195r1165b2226],
38	150/2	CD	NUMBER	150/2	num	39	SENT_24	[p1l1185t2197r1273b2230],
39	group	NN	O	group	npadvmod	40	SENT_24	[p1l1292t2205r1390b2234],
40	than	IN	O	than	advmod	37	SENT_24	[p1l1409t2195r1485b2225],
41	in	IN	O	in	_	0	SENT_24	[p1l1503t2195r1536b2225],
42	the	DT	O	the	det	43	SENT_24	[p1l1554t2195r1606b2225],
43	monotherapy	NN	O	monotherapy	prep_in	37	SENT_24	[p1l1624t2195r1847b2234],
44	group	NN	O	group	dep	47	SENT_24	[p1l1864t2205r1962b2234],
45	(	CD	PERCENT	(	num	44	SENT_24	[p1l1983t2197r2064b2230],
46	71	CD	PERCENT	71	num	47	SENT_24	[p1l1983t2197r2064b2230],
47	%	NN	PERCENT	%	dep	53	SENT_24	[p1l1983t2197r2064b2230],
48	vs.	CC	O	vs.	prep	47	SENT_24	[p1l664t2254r706b2275],
49	26	CD	NUMBER	26	num	50	SENT_24	[p1l727t2246r817b2279],
50	°	CD	NUMBER	°	dep	48	SENT_24	[p1l727t2246r817b2279],
51	/	:	O	/	punct	53	SENT_24	[p1l727t2246r817b2279],
52	o	NN	O	o	nn	53	SENT_24	[p1l727t2246r817b2279],
53	)	NN	O	)	dep	35	SENT_24	[p1l727t2246r817b2279],
54	.	.	O	.	_	0	SENT_24	[p1l727t2246r817b2279],

1	Median	JJ	MISC	median	amod	2	SENT_25	[p1l837t2244r963b2275],
2	progression	NN	O	progression	_	0	SENT_25	[p1l981t2244r1256b2283],
3	—	CD	NUMBER	—	num	5	SENT_25	[p1l981t2244r1256b2283],
4	free	JJ	O	free	amod	5	SENT_25	[p1l981t2244r1256b2283],
5	survival	NN	O	survival	nsubj	13	SENT_25	[p1l1275t2244r1404b2275],
6	in	IN	O	in	_	0	SENT_25	[p1l1422t2244r1455b2274],
7	the	DT	O	the	det	10	SENT_25	[p1l1474t2244r1525b2274],
8	combination	NN	O	combination	nn	10	SENT_25	[p1l1545t2244r1756b2275],
9	150/2	CD	NUMBER	150/2	num	10	SENT_25	[p1l1776t2246r1865b2279],
10	group	NN	O	group	prep_in	5	SENT_25	[p1l1884t2254r1982b2283],
11	was	VBD	O	be	cop	13	SENT_25	[p1l1999t2254r2062b2275],
12	9.4	CD	DURATION	9.4	num	13	SENT_25	[p1l665t2295r713b2324],
13	months	NNS	NUMBER	month	rcmod	2	SENT_25	[p1l726t2293r862b2330],
14	,	,	O	,	_	0	SENT_25	[p1l726t2293r862b2330],
15	as	IN	O	as	_	0	SENT_25	[p1l877t2303r910b2323],
16	compared	VBN	O	compare	prepc_as	13	SENT_25	[p1l924t2293r1089b2332],
17	with	IN	O	with	pcomp	16	SENT_25	[p1l1100t2293r1176b2324],
18	5.8	CD	DURATION	5.8	num	19	SENT_25	[p1l1189t2295r1237b2324],
19	months	NNS	NUMBER	month	pobj	17	SENT_25	[p1l1251t2293r1378b2324],
20	in	IN	O	in	_	0	SENT_25	[p1l1391t2293r1424b2323],
21	the	DT	O	the	det	23	SENT_25	[p1l1436t2293r1488b2323],
22	monotherapy	NN	O	monotherapy	nn	23	SENT_25	[p1l1501t2293r1723b2332],
23	group	NN	O	group	prep_in	19	SENT_25	[p1l1734t2303r1832b2332],
24	(	CD	NUMBER	(	num	26	SENT_25	[p1l1847t2293r1974b2328],
25	hazard	NN	O	hazard	nn	26	SENT_25	[p1l1847t2293r1974b2328],
26	ratio	NN	O	ratio	dep	2	SENT_25	[p1l1986t2293r2063b2324],
27	for	IN	O	for	_	0	SENT_25	[p1l665t2342r713b2373],
28	progression	NN	O	progression	prep_for	26	SENT_25	[p1l724t2342r922b2381],
29	or	CC	O	or	_	0	SENT_25	[p1l935t2352r969b2373],
30	death	NN	O	death	conj_or	28	SENT_25	[p1l981t2342r1082b2379],
31	,	,	O	,	_	0	SENT_25	[p1l981t2342r1082b2379],
32	0.39	CD	NUMBER	0.39	appos	28	SENT_25	[p1l1097t2344r1174b2379],
33	;	:	O	;	_	0	SENT_25	[p1l1097t2344r1174b2379],
34	95	CD	NUMBER	95	number	35	SENT_25	[p1l1188t2344r1260b2373],
35	°	CD	NUMBER	°	dep	2	SENT_25	[p1l1188t2344r1260b2373],
36	/	:	O	/	punct	39	SENT_25	[p1l1188t2344r1260b2373],
37	o	NN	O	o	nn	39	SENT_25	[p1l1188t2344r1260b2373],
38	confidence	NN	O	confidence	nn	39	SENT_25	[p1l1272t2342r1455b2373],
39	interval	NN	O	interval	dep	35	SENT_25	[p1l1468t2342r1603b2379],
40	,	,	O	,	_	0	SENT_25	[p1l1468t2342r1603b2379],
41	0.25	CD	NUMBER	0.25	appos	39	SENT_25	[p1l1618t2344r1686b2373],
42	to	TO	O	to	_	0	SENT_25	[p1l1700t2349r1732b2373],
43	0.62	CD	NUMBER	0.62	prep_to	35	SENT_25	[p1l1745t2344r1823b2379],
44	;	:	O	;	_	0	SENT_25	[p1l1745t2344r1823b2379],
45	P	NN	O	p	dep	46	SENT_25	[p1l1836t2344r1987b2377],
46	<	JJR	O	<	dep	2	SENT_25	[p1l1836t2344r1987b2377],
47	0.001	CD	NUMBER	0.001	num	48	SENT_25	[p1l1836t2344r1987b2377],
48	)	NN	O	)	dep	46	SENT_25	[p1l1836t2344r1987b2377],
49	.	.	O	.	_	0	SENT_25	[p1l1836t2344r1987b2377],

1	The	DT	O	the	det	2	SENT_26	[p1l2000t2342r2063b2372],
2	rate	NN	O	rate	nsubj	14	SENT_26	[p1l665t2397r727b2421],
3	of	IN	O	of	_	0	SENT_26	[p1l743t2391r782b2422],
4	complete	JJ	O	complete	amod	7	SENT_26	[p1l790t2391r941b2430],
5	or	CC	O	or	_	0	SENT_26	[p1l957t2401r991b2422],
6	partial	JJ	O	partial	conj_or	4	SENT_26	[p1l1005t2391r1116b2430],
7	response	NN	O	response	prep_of	2	SENT_26	[p1l1131t2401r1279b2430],
8	with	IN	O	with	_	0	SENT_26	[p1l1293t2391r1369b2422],
9	combination	NN	O	combination	nn	11	SENT_26	[p1l1384t2391r1596b2422],
10	150/2	CD	NUMBER	150/2	num	11	SENT_26	[p1l1613t2393r1701b2426],
11	therapy	NN	O	therapy	prep_with	7	SENT_26	[p1l1717t2391r1842b2430],
12	was	VBD	O	be	cop	14	SENT_26	[p1l1854t2401r1917b2422],
13	76	CD	PERCENT	76	num	14	SENT_26	[p1l1933t2393r2012b2428],
14	%	NN	PERCENT	%	_	0	SENT_26	[p1l1933t2393r2012b2428],
15	,	,	O	,	_	0	SENT_26	[p1l1933t2393r2012b2428],
16	as	IN	O	as	_	0	SENT_26	[p1l2029t2401r2062b2421],
17	compared	VBN	O	compare	prepc_as	14	SENT_26	[p1l666t2440r831b2479],
18	With	IN	O	with	pcomp	17	SENT_26	[p1l842t2440r918b2471],
19	54	CD	NUMBER	54	number	20	SENT_26	[p1l932t2442r1003b2471],
20	°	CD	NUMBER	°	pobj	18	SENT_26	[p1l932t2442r1003b2471],
21	/	:	O	/	punct	29	SENT_26	[p1l932t2442r1003b2471],
22	o	NN	O	o	dep	29	SENT_26	[p1l932t2442r1003b2471],
23	with	IN	O	with	_	0	SENT_26	[p1l1015t2440r1091b2471],
24	monotherapy	NN	O	monotherapy	nn	26	SENT_26	[p1l1104t2440r1326b2479],
25	(	CD	NUMBER	(	num	26	SENT_26	[p1l1340t2442r1493b2475],
26	P	NN	O	p	prep_with	22	SENT_26	[p1l1340t2442r1493b2475],
27	=	JJ	O	=	amod	29	SENT_26	[p1l1340t2442r1493b2475],
28	0.03	CD	NUMBER	0.03	num	29	SENT_26	[p1l1340t2442r1493b2475],
29	)	NN	O	)	dep	20	SENT_26	[p1l1340t2442r1493b2475],
30	.	.	O	.	_	0	SENT_26	[p1l1340t2442r1493b2475],

1	co	NN	O	co	nn	3	SENT_27	[p1l666t2519r707b2539],
2	N	NN	O	n	nn	3	SENT_27	[p1l713t2519r730b2539],
3	c	NN	O	c	nsubj	11	SENT_27	[p1l736t2519r753b2539],
4	L	NN	O	l	nn	6	SENT_27	[p1l758t2519r770b2539],
5	u	NN	O	u	nn	6	SENT_27	[p1l775t2519r792b2539],
6	s	NNS	O	s	dep	3	SENT_27	[p1l797t2519r811b2539],
7	I	PRP	O	I	dep	3	SENT_27	[p1l817t2519r822b2539],
8	o	NN	O	o	nn	9	SENT_27	[p1l828t2519r849b2539],
9	N	NN	O	n	dep	7	SENT_27	[p1l855t2519r872b2539],
10	s	VBZ	O	s	cop	11	SENT_27	[p1l878t2519r892b2539],
11	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_27	[p1l665t2559r848b2590],
12	and	CC	O	and	_	0	SENT_27	[p1l860t2559r920b2590],
13	trametinib	NN	O	trametinib	nsubjpass	16	SENT_27	[p1l932t2559r1106b2590],
14	were	VBD	O	be	auxpass	16	SENT_27	[p1l1116t2570r1193b2590],
15	safely	RB	O	safely	advmod	16	SENT_27	[p1l1206t2559r1298b2598],
16	combined	VBN	O	combine	conj_and	11	SENT_27	[p1l1308t2559r1470b2590],
17	at	IN	O	at	_	0	SENT_27	[p1l1481t2566r1511b2590],
18	full	JJ	O	full	amod	20	SENT_27	[p1l1521t2559r1578b2590],
19	monotherapy	JJ	O	monotherapy	amod	20	SENT_27	[p1l1589t2559r1807b2598],
20	doses	NNS	O	dose	prep_at	16	SENT_27	[p1l1817t2559r1917b2590],
21	.	.	O	.	_	0	SENT_27	[p1l1817t2559r1917b2590],

1	The	DT	O	the	det	2	SENT_28	[p1l1929t2559r1990b2590],
2	rate	NN	O	rate	nsubjpass	6	SENT_28	[p1l2002t2566r2063b2590],
3	of	IN	O	of	_	0	SENT_28	[p1l666t2610r704b2641],
4	pyrexia	NN	O	pyrexia	prep_of	2	SENT_28	[p1l708t2611r829b2649],
5	was	VBD	O	be	auxpass	6	SENT_28	[p1l838t2621r901b2641],
6	increased	VBN	O	increase	_	0	SENT_28	[p1l913t2610r1072b2641],
7	with	IN	O	with	_	0	SENT_28	[p1l1081t2610r1157b2641],
8	combination	NN	O	combination	nn	9	SENT_28	[p1l1168t2610r1380b2641],
9	therapy	NN	O	therapy	prep_with	6	SENT_28	[p1l1392t2610r1521b2649],
10	,	,	O	,	_	0	SENT_28	[p1l1392t2610r1521b2649],
11	whereas	IN	O	whereas	mark	20	SENT_28	[p1l1533t2610r1669b2641],
12	the	DT	O	the	det	13	SENT_28	[p1l1682t2610r1733b2641],
13	rate	NN	O	rate	nsubjpass	20	SENT_28	[p1l1744t2617r1807b2641],
14	of	IN	O	of	_	0	SENT_28	[p1l1818t2610r1857b2641],
15	proliferative	JJ	O	proliferative	amod	17	SENT_28	[p1l1860t2610r2063b2649],
16	skin	NN	O	skin	nn	17	SENT_28	[p1l666t2661r735b2693],
17	lesions	NNS	O	lesion	prep_of	13	SENT_28	[p1l745t2661r857b2692],
18	was	VBD	O	be	auxpass	20	SENT_28	[p1l867t2672r929b2693],
19	nonsignificantly	RB	O	nonsignificantly	advmod	20	SENT_28	[p1l941t2661r1211b2701],
20	reduced	VBN	O	reduce	advcl	6	SENT_28	[p1l1220t2661r1357b2693],
21	.	.	O	.	_	0	SENT_28	[p1l1220t2661r1357b2693],

1	Progression-free	JJ	O	progression-free	amod	2	SENT_29	[p1l1370t2661r1638b2701],
2	survival	NN	O	survival	nsubjpass	5	SENT_29	[p1l1650t2662r1775b2693],
3	was	VBD	O	be	auxpass	5	SENT_29	[p1l1785t2672r1847b2693],
4	significantly	RB	O	significantly	advmod	5	SENT_29	[p1l1859t2661r2065b2701],
5	improved	VBN	O	improve	_	0	SENT_29	[p1l665t2713r831b2752],
6	.	.	O	.	_	0	SENT_29	[p1l665t2713r831b2752],

1	(	NN	O	(	nsubj	2	SENT_30	[p1l846t2713r982b2748],
2	Funded	VBN	O	fund	_	0	SENT_30	[p1l846t2713r982b2748],
3	by	IN	O	by	_	0	SENT_30	[p1l993t2713r1031b2752],
4	GlaXoSmithI	NN	O	glaxosmithus	nn	6	SENT_30	[p1l1040t2713r1339b2750],
5	(	CD	NUMBER	(	num	6	SENT_30	[p1l1040t2713r1339b2750],
6	line	NN	O	line	prep_by	2	SENT_30	[p1l1040t2713r1339b2750],
7	;	:	O	;	_	0	SENT_30	[p1l1040t2713r1339b2750],
8	ClinicalTrials	NNS	O	clinicaltrial	dep	6	SENT_30	[p1l1352t2713r1647b2752],
9	.	.	O	.	_	0	SENT_30	[p1l1352t2713r1647b2752],

1	gov	NN	O	gov	nn	2	SENT_31	[p1l1352t2713r1647b2752],
2	number	NN	O	number	_	0	SENT_31	[p1l1657t2713r1795b2750],
3	,	,	O	,	_	0	SENT_31	[p1l1657t2713r1795b2750],
4	NCT01072175	NN	O	nct01072175	appos	2	SENT_31	[p1l1807t2715r2061b2748],
5	.	.	O	.	_	0	SENT_31	[p1l1807t2715r2061b2748],
6	)	SYM	O	)	dep	2	SENT_31	[p1l1807t2715r2061b2748],

1	1594	CD	DATE	1594	num	4	SENT_32	[p1l92t2827r169b2851],
2	N	NN	O	n	nn	4	SENT_32	[p1l879t2838r892b2854],
3	ENGLJ	NN	O	englj	nn	4	SENT_32	[p1l907t2838r985b2860],
4	MED	NN	O	med	_	0	SENT_32	[p1l1000t2838r1052b2853],
5	367	CD	NUMBER	367	dep	4	SENT_32	[p1l1062t2832r1139b2860],
6	;	:	O	;	_	0	SENT_32	[p1l1062t2832r1139b2860],
7	18	CD	NUMBER	18	num	8	SENT_32	[p1l1062t2832r1139b2860],
8	NEJM.ORG	NN	O	nejm.org	dep	5	SENT_32	[p1l1175t2838r1299b2860],
9	NOVEMBER	NNP	DATE	NOVEMBER	dep	8	SENT_32	[p1l1335t2838r1470b2854],
10	1	CD	DATE	1	num	9	SENT_32	[p1l1481t2838r1497b2858],
11	,	,	DATE	,	_	0	SENT_32	[p1l1481t2838r1497b2858],
12	2012	CD	DATE	2012	num	9	SENT_32	[p1l1509t2838r1566b2854],

1	The	DT	O	the	det	4	SENT_33	[p1l879t2895r930b2919],
2	New	NNP	O	New	nn	4	SENT_33	[p1l939t2896r1001b2919],
3	England	NNP	O	England	nn	4	SENT_33	[p1l1010t2895r1121b2926],
4	Journal	NNP	O	Journal	_	0	SENT_33	[p1l1129t2895r1227b2919],
5	of	IN	O	of	_	0	SENT_33	[p1l1236t2895r1265b2919],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_33	[p1l1272t2895r1397b2919],

1	Copyright	NN	O	copyright	_	0	SENT_34	[p1l671t2977r806b3008],
2	©	CD	NUMBER	©	num	6	SENT_34	[p1l815t2977r838b3001],
3	2012	CD	DATE	2012	num	6	SENT_34	[p1l848t2977r913b3001],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_34	[p1l923t2977r1114b3001],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_34	[p1l1124t2977r1232b3001],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_34	[p1l1242t2977r1347b3008],
7	.	.	O	.	_	0	SENT_34	[p1l1242t2977r1347b3008],

1	All	DT	O	all	det	2	SENT_35	[p1l1358t2977r1400b3001],
2	rights	NNS	O	rights	nsubj	3	SENT_35	[p1l1409t2977r1483b3008],
3	reserved	VBN	O	reserve	_	0	SENT_35	[p1l1493t2977r1612b3001],
4	.	.	O	.	_	0	SENT_35	[p1l1493t2977r1612b3001],

1	BRAF	NNS	ORGANIZATION	braf	_	0	SENT_36	[p1l714t3083r798b3102],
2	AND	CC	O	and	_	0	SENT_36	[p1l810t3083r882b3102],
3	MEK	NN	O	mek	nn	4	SENT_36	[p1l896t3083r968b3103],
4	INHIBITION	NN	O	inhibition	conj_and	1	SENT_36	[p1l981t3083r1184b3102],
5	IN	IN	O	in	_	0	SENT_36	[p1l1200t3083r1237b3102],
6	MELANOMA	NN	O	melanoma	prep_in	1	SENT_36	[p1l1252t3083r1446b3102],

1	HARMACOLOGIC	JJ	O	harmacologic	amod	2	SENT_37	[p1l271t3315r1028b3372],
2	INHIBITION	NN	O	inhibition	_	0	SENT_37	[p1l1117t3315r1675b3372],
3	OF	IN	O	of	_	0	SENT_37	[p1l1765t3315r1880b3372],
4	THE	DT	O	the	prep_of	2	SENT_37	[p1l1961t3315r2149b3371],

1	mitogen	NN	O	mitogen	nsubj	3	SENT_38	[p1l267t3423r1045b3524],
2	—	CD	NUMBER	—	num	1	SENT_38	[p1l267t3423r1045b3524],
3	actiVated	VBN	O	activate	_	0	SENT_38	[p1l267t3423r1045b3524],
4	protein	NN	O	protein	nn	5	SENT_38	[p1l1100t3424r1414b3524],
5	kinase	NN	O	kinase	dobj	3	SENT_38	[p1l1470t3423r1751b3503],
6	(	CD	NUMBER	(	num	9	SENT_38	[p1l1812t3429r2144b3515],
7	MAPK	NN	O	mapk	nn	9	SENT_38	[p1l1812t3429r2144b3515],
8	)	NN	O	)	nn	9	SENT_38	[p1l1812t3429r2144b3515],
9	pathway	NN	O	pathway	nsubj	11	SENT_38	[p1l266t3553r629b3654],
10	has	VBZ	O	have	aux	11	SENT_38	[p1l664t3553r809b3632],
11	proved	VBN	O	prove	rcmod	5	SENT_38	[p1l848t3553r1140b3654],
12	to	TO	O	to	aux	16	SENT_38	[p1l1179t3569r1261b3632],
13	be	VB	O	be	cop	16	SENT_38	[p1l1302t3553r1400b3632],
14	a	DT	O	a	det	16	SENT_38	[p1l1438t3580r1483b3632],
15	major	JJ	O	major	amod	16	SENT_38	[p1l1520t3554r1772b3654],
16	advance	NN	O	advance	xcomp	11	SENT_38	[p1l1807t3553r2149b3632],
17	in	IN	O	in	_	0	SENT_38	[p1l10t3684r92b3761],
18	the	DT	O	the	det	19	SENT_38	[p1l123t3683r255b3762],
19	treatment	NN	O	treatment	prep_in	16	SENT_38	[p1l286t3700r704b3762],
20	of	IN	O	of	_	0	SENT_38	[p1l731t3683r831b3762],
21	metastatic	JJ	O	metastatic	amod	22	SENT_38	[p1l842t3684r1283b3762],
22	melanoma	NN	O	melanoma	prep_of	19	SENT_38	[p1l1313t3683r1787b3762],
23	.	.	O	.	_	0	SENT_38	[p1l1313t3683r1787b3762],

1	The	DT	O	the	det	2	SENT_39	[p1l1820t3683r1980b3762],
2	use	NN	O	use	nsubjpass	25	SENT_39	[p1l2011t3710r2150b3762],
3	of	IN	O	of	_	0	SENT_39	[p2l11t31r111b110],
4	vemurafenib	NN	O	vemurafenib	prep_of	2	SENT_39	[p2l118t31r663b110],
5	and	CC	O	and	_	0	SENT_39	[p2l694t31r853b110],
6	dabrafenib	NN	O	dabrafenib	prep_of	2	SENT_39	[p2l883t31r1373b127],
7	,	,	O	,	_	0	SENT_39	[p2l883t31r1373b127],
8	agents	NNS	O	agent	appos	2	SENT_39	[p2l1408t48r1686b132],
9	that	WDT	O	that	nsubj	10	SENT_39	[p2l1718t31r1892b110],
10	block	VBP	O	block	rcmod	8	SENT_39	[p2l1917t31r2154b111],
11	MAPK	NN	ORGANIZATION	mapk	nn	12	SENT_39	[p2l7t166r287b240],
12	signaling	NN	O	signaling	dobj	10	SENT_39	[p2l322t159r729b260],
13	in	IN	O	in	_	0	SENT_39	[p2l762t160r846b237],
14	patients	NNS	O	patient	prep_in	10	SENT_39	[p2l882t160r1226b260],
15	with	IN	O	with	_	0	SENT_39	[p2l1261t159r1458b238],
16	melanoma	NN	O	melanoma	prep_with	14	SENT_39	[p2l1495t159r1955b238],
17	and	CC	O	and	_	0	SENT_39	[p2l1990t159r2150b238],
18	the	DT	O	the	det	21	SENT_39	[p2l11t287r144b366],
19	BRAF	NN	MISC	braf	nn	21	SENT_39	[p2l188t294r433b371],
20	V600E	NN	MISC	v600e	nn	21	SENT_39	[p2l475t293r747b366],
21	mutation	NN	O	mutation	conj_and	16	SENT_39	[p2l794t288r1212b383],
22	,	,	O	,	_	0	SENT_39	[p2l794t288r1212b383],
23	has	VBZ	O	have	aux	25	SENT_39	[p2l1262t287r1408b366],
24	been	VBN	O	be	auxpass	25	SENT_39	[p2l1454t287r1657b366],
25	associated	VBN	O	associate	_	0	SENT_39	[p2l1701t287r2149b366],
26	with	IN	O	with	_	0	SENT_39	[p2l6t416r199b495],
27	prolonged	JJ	O	prolonged	amod	28	SENT_39	[p2l233t416r665b517],
28	survival	NN	O	survival	prep_with	25	SENT_39	[p2l702t416r1029b495],
29	and	CC	O	and	_	0	SENT_39	[p2l1063t416r1220b495],
30	progression	NN	O	progression	prep_with	25	SENT_39	[p2l1253t416r1951b517],
31	—	CD	NUMBER	—	num	33	SENT_39	[p2l1253t416r1951b517],
32	free	JJ	O	free	amod	33	SENT_39	[p2l1253t416r1951b517],
33	survival	NN	O	survival	dep	30	SENT_39	[p2l1988t442r2148b495, p2l6t544r225b640],
34	,	,	O	,	_	0	SENT_39	[p2l1988t442r2148b495, p2l6t544r225b640],
35	respectively	RB	O	respectively	advmod	30	SENT_39	[p2l275t544r793b645],
36	,	,	O	,	_	0	SENT_39	[p2l275t544r793b645],
37	in	IN	O	in	_	0	SENT_39	[p2l842t545r927b622],
38	randomized	VBN	O	randomize	prepc_in	25	SENT_39	[p2l971t544r1495b623],
39	phase	NN	O	phase	nsubj	41	SENT_39	[p2l1538t544r1789b645],
40	3	CD	NUMBER	3	num	41	SENT_39	[p2l1834t550r1878b623],
41	trials	NNS	O	trial	xcomp	38	SENT_39	[p2l1926t544r2148b623],
42	involving	VBG	O	involve	_	0	SENT_39	[p2l10t672r409b773],
43	patients	NNS	O	patient	prep_involving	41	SENT_39	[p2l437t673r781b773],
44	with	IN	O	with	_	0	SENT_39	[p2l812t672r1009b751],
45	previously	RB	DATE	previously	advmod	46	SENT_39	[p2l1040t672r1483b773],
46	untreated	JJ	O	untreated	amod	47	SENT_39	[p2l1511t672r1927b751],
47	melanoma	NN	O	melanoma	prep_with	43	SENT_39	[p2l1959t672r2148b751, p2l10t804r422b880],
48	.	.	O	.	_	0	SENT_39	[p2l1959t672r2148b751, p2l10t804r422b880],

1	”	NN	O	”	nn	2	SENT_40	[p2l1959t672r2148b751, p2l10t804r422b880],
2	Trametinib	NN	O	trametinib	nsubj	3	SENT_40	[p2l448t800r925b880],
3	mediates	VBZ	O	mediate	_	0	SENT_40	[p2l955t800r1335b880],
4	blockade	NN	O	blockade	dobj	3	SENT_40	[p2l1366t800r1741b880],
5	of	IN	O	of	_	0	SENT_40	[p2l1770t800r1870b880],
6	MAPK	NN	O	mapk	prep_of	4	SENT_40	[p2l1877t807r2153b882],

1	kinase	NN	O	kinase	nn	4	SENT_41	[p2l10t929r280b1009],
2	(	CD	NUMBER	(	num	4	SENT_41	[p2l310t936r593b1025],
3	MEK	NN	O	mek	nn	4	SENT_41	[p2l310t936r593b1025],
4	)	NN	O	)	nsubj	22	SENT_41	[p2l310t936r593b1025],
5	,	,	O	,	_	0	SENT_41	[p2l310t936r593b1025],
6	which	WDT	O	which	nsubjpass	18	SENT_41	[p2l619t929r875b1009],
7	is	VBZ	O	be	cop	8	SENT_41	[p2l900t930r964b1008],
8	downstream	JJ	O	downstream	rcmod	4	SENT_41	[p2l993t929r1517b1009],
9	of	IN	O	of	_	0	SENT_41	[p2l1543t929r1642b1008],
10	BRAF	NN	O	braf	prep_of	8	SENT_41	[p2l1647t936r1886b1013],
11	in	IN	O	in	_	0	SENT_41	[p2l1912t930r1994b1007],
12	the	DT	O	the	det	14	SENT_41	[p2l2020t929r2149b1008],
13	MAPK	NN	ORGANIZATION	mapk	nn	14	SENT_41	[p2l7t1065r287b1139],
14	pathway	NN	O	pathway	prep_in	10	SENT_41	[p2l312t1058r676b1159],
15	and	CC	O	and	_	0	SENT_41	[p2l701t1058r860b1137],
16	has	VBZ	O	have	aux	18	SENT_41	[p2l890t1058r1036b1137],
17	been	VBN	O	be	auxpass	18	SENT_41	[p2l1069t1058r1271b1137],
18	associated	VBN	O	associate	rcmod	4	SENT_41	[p2l1301t1058r1750b1137],
19	with	IN	O	with	_	0	SENT_41	[p2l1775t1058r1972b1138],
20	im	NN	O	im	nn	21	SENT_41	[p2l2002t1059r2148b1136],
21	—	NN	O	—	prep_with	18	SENT_41	[p2l2002t1059r2148b1136],
22	proved	VBD	O	prove	_	0	SENT_41	[p2l9t1186r300b1287],
23	progression	NN	O	progression	dobj	22	SENT_41	[p2l353t1186r1066b1287],
24	—	CD	NUMBER	—	num	23	SENT_41	[p2l353t1186r1066b1287],
25	free	JJ	O	free	amod	28	SENT_41	[p2l353t1186r1066b1287],
26	and	CC	O	and	_	0	SENT_41	[p2l1120t1186r1280b1265],
27	overall	JJ	O	overall	conj_and	25	SENT_41	[p2l1335t1186r1622b1265],
28	survival	NN	O	survival	dobj	40	SENT_41	[p2l1678t1186r2012b1265],
29	in	IN	O	in	_	0	SENT_41	[p2l2065t1187r2149b1264],
30	BRAF	NN	O	braf	nn	32	SENT_41	[p2l8t1321r254b1398],
31	V600	NN	O	v600	nn	32	SENT_41	[p2l298t1320r515b1393],
32	melanoma	NN	O	melanoma	prep_in	28	SENT_41	[p2l561t1314r1022b1393],
33	(	CD	NUMBER	(	nsubj	40	SENT_41	[p2l1071t1315r1590b1415],
34	comprising	VBG	O	comprise	partmod	33	SENT_41	[p2l1071t1315r1590b1415],
35	both	DT	O	both	preconj	39	SENT_41	[p2l1634t1314r1833b1393],
36	V6OOE	NN	O	v6ooe	nn	39	SENT_41	[p2l1875t1320r2147b1393],
37	and	CC	O	and	_	0	SENT_41	[p2l10t1443r169b1522],
38	V6OOK	NN	O	v6ook	nn	39	SENT_41	[p2l200t1449r487b1524],
39	mutations	NNS	O	mutation	dobj	34	SENT_41	[p2l519t1444r1100b1535],
40	)	VBP	O	)	rcmod	23	SENT_41	[p2l519t1444r1100b1535],
41	.7	CD	NUMBER	.7	number	42	SENT_41	[p2l519t1444r1100b1535],
42	»	CD	NUMBER	»	num	43	SENT_41	[p2l519t1444r1100b1535],
43	8	CD	NUMBER	8	dobj	40	SENT_41	[p2l519t1444r1100b1535],

1	In	IN	O	in	_	0	SENT_42	[p2l139t1579r226b1649],
2	spite	NN	O	spite	_	0	SENT_42	[p2l261t1572r451b1672],
3	of	IN	O	of	_	0	SENT_42	[p2l485t1571r583b1650],
4	these	DT	O	these	det	5	SENT_42	[p2l599t1571r815b1650],
5	advances	NNS	O	advance	prep_in_spite_of	19	SENT_42	[p2l848t1571r1240b1667],
6	,	,	O	,	_	0	SENT_42	[p2l848t1571r1240b1667],
7	50	CD	PERCENT	50	num	8	SENT_42	[p2l1281t1576r1464b1650],
8	%	NN	PERCENT	%	nsubj	19	SENT_42	[p2l1281t1576r1464b1650],
9	of	IN	O	of	_	0	SENT_42	[p2l1496t1571r1595b1650],
10	patients	NNS	O	patient	prep_of	8	SENT_42	[p2l1608t1572r1937b1672],
11	who	WP	O	who	nsubjpass	13	SENT_42	[p2l1968t1571r2148b1650],
12	are	VBP	O	be	auxpass	13	SENT_42	[p2l10t1726r140b1780],
13	treated	VBN	O	treat	rcmod	10	SENT_42	[p2l191t1700r491b1780],
14	with	IN	O	with	_	0	SENT_42	[p2l538t1700r734b1780],
15	BRAF	NN	O	braf	nn	18	SENT_42	[p2l784t1707r1030b1785],
16	or	CC	O	or	_	0	SENT_42	[p2l1083t1726r1172b1780],
17	MEK	NN	O	mek	nn	18	SENT_42	[p2l1218t1708r1433b1782],
18	inhibitors	NNS	O	inhibitor	prep_with	13	SENT_42	[p2l1480t1700r1905b1780],
19	have	VBP	O	have	_	0	SENT_42	[p2l1958t1700r2149b1780],
20	disease	NN	O	disease	nn	21	SENT_42	[p2l11t1829r310b1908],
21	progression	NN	O	progression	dobj	19	SENT_42	[p2l341t1830r834b1930],
22	within	IN	O	within	_	0	SENT_42	[p2l862t1829r1138b1909],
23	6	CD	DURATION	6	number	25	SENT_42	[p2l1170t1835r1217b1908],
24	to	TO	DURATION	to	dep	25	SENT_42	[p2l1250t1846r1330b1908],
25	7	CD	DURATION	7	num	26	SENT_42	[p2l1365t1837r1411b1908],
26	months	NNS	NUMBER	month	prep_within	21	SENT_42	[p2l1444t1829r1763b1908],
27	after	IN	O	after	_	0	SENT_42	[p2l1795t1829r1990b1908],
28	the	DT	O	the	det	29	SENT_42	[p2l2020t1829r2149b1908],
29	initiation	NN	O	initiation	prep_after	19	SENT_42	[p2l10t1959r412b2038],
30	of	IN	O	of	_	0	SENT_42	[p2l476t1958r577b2038],
31	treatment	NN	O	treatment	prep_of	29	SENT_42	[p2l622t1962r1169b2038],
32	.	.	O	.	_	0	SENT_42	[p2l622t1962r1169b2038],

1	“	NN	O	“	nn	3	SENT_43	[p2l622t1962r1169b2038],
2	Several	JJ	O	several	amod	3	SENT_43	[p2l1235t1958r1537b2039],
3	mechanisms	NNS	O	mechanism	nsubjpass	14	SENT_43	[p2l1600t1958r2147b2038],
4	mediating	VBG	O	mediate	partmod	3	SENT_43	[p2l10t2087r456b2188],
5	resistance	NN	O	resistance	dobj	4	SENT_43	[p2l484t2088r915b2166],
6	to	TO	O	to	_	0	SENT_43	[p2l947t2104r1030b2166],
7	BRAF	NN	O	braf	nn	8	SENT_43	[p2l1062t2094r1307b2171],
8	inhibitors	NNS	O	inhibitor	prep_to	4	SENT_43	[p2l1340t2087r1764b2166],
9	through	IN	O	through	_	0	SENT_43	[p2l1799t2087r2149b2188],
10	MAPK	NN	O	mapk	nn	11	SENT_43	[p2l7t2222r283b2296],
11	reactivation	NN	O	reactivation	prep_through	4	SENT_43	[p2l310t2216r805b2294],
12	have	VBP	O	have	aux	14	SENT_43	[p2l835t2215r1023b2294],
13	been	VBN	O	be	auxpass	14	SENT_43	[p2l1054t2215r1253b2294],
14	described	VBN	O	describe	_	0	SENT_43	[p2l1285t2215r1712b2311],
15	,	,	O	,	_	0	SENT_43	[p2l1285t2215r1712b2311],
16	including	VBG	O	include	_	0	SENT_43	[p2l1748t2215r2153b2316],
17	the	DT	O	the	det	20	SENT_43	[p2l11t2343r140b2422],
18	up	RP	O	up	advmod	19	SENT_43	[p2l176t2343r743b2444],
19	—	CD	NUMBER	—	nn	20	SENT_43	[p2l176t2343r743b2444],
20	regulation	NN	O	regulation	prep_including	14	SENT_43	[p2l176t2343r743b2444],
21	of	IN	O	of	_	0	SENT_43	[p2l780t2343r878b2422],
22	bypass	NN	O	bypass	nn	23	SENT_43	[p2l896t2343r1174b2444],
23	pathways	NNS	O	pathway	prep_of	20	SENT_43	[p2l1210t2343r1597b2444],
24	mediated	VBN	O	mediate	partmod	23	SENT_43	[p2l1635t2343r2022b2422],
25	by	IN	O	by	_	0	SENT_43	[p2l2058t2343r2154b2444],
26	cancer	NN	O	cancer	nn	28	SENT_43	[p2l11t2497r288b2550],
27	Osaka	NNP	LOCATION	Osaka	nn	28	SENT_43	[p2l319t2471r585b2551],
28	thyroid	NN	O	thyroid	agent	24	SENT_43	[p2l617t2471r920b2572],
29	kinase	NN	O	kinase	nn	31	SENT_43	[p2l954t2471r1230b2551],
30	(	CD	NUMBER	(	num	31	SENT_43	[p2l1268t2477r1577b2567],
31	COT	NNP	O	COT	dep	28	SENT_43	[p2l1268t2477r1577b2567],
32	)	CD	NUMBER	)	number	33	SENT_43	[p2l1268t2477r1577b2567],
33	,9	CD	NUMBER	,9	num	34	SENT_43	[p2l1268t2477r1577b2567],
34	development	NN	O	development	dep	28	SENT_43	[p2l1612t2471r2154b2572],
35	of	IN	O	of	_	0	SENT_43	[p2l11t2599r110b2678],
36	de	FW	O	de	nn	38	SENT_43	[p2l132t2599r227b2678],
37	novo	FW	O	novo	nn	38	SENT_43	[p2l267t2625r468b2679],
38	NRAS	NNS	O	nra	prep_of	34	SENT_43	[p2l508t2605r765b2683],
39	or	CC	O	or	_	0	SENT_43	[p2l809t2625r897b2678],
40	MEK	NN	O	mek	nn	41	SENT_43	[p2l931t2607r1144b2680],
41	mutations	NNS	O	mutation	prep_of	34	SENT_43	[p2l1181t2600r1801b2695],
42	,1	CD	NUMBER	,1	number	43	SENT_43	[p2l1181t2600r1801b2695],
43	°	CD	NUMBER	°	num	44	SENT_43	[p2l1181t2600r1801b2695],
44	’11	CD	NUMBER	’11	dep	41	SENT_43	[p2l1181t2600r1801b2695],
45	and	CC	O	and	_	0	SENT_43	[p2l1841t2599r1998b2678],
46	dimerization	NN	O	dimerization	nn	49	SENT_43	[p2l2038t2599r2148b2678, p2l10t2729r483b2807],
47	or	CC	O	or	_	0	SENT_43	[p2l534t2754r624b2807],
48	variant	JJ	O	variant	conj_or	46	SENT_43	[p2l667t2729r973b2807],
49	splicing	NN	O	splicing	agent	24	SENT_43	[p2l1020t2728r1361b2829],
50	of	IN	O	of	_	0	SENT_43	[p2l1409t2728r1510b2807],
51	mutant	JJ	O	mutant	amod	53	SENT_43	[p2l1542t2745r1858b2807],
52	BRAF	NN	O	braf	nn	53	SENT_43	[p2l1903t2735r2148b2812],
53	V600	NN	O	v600	prep_of	49	SENT_43	[p2l6t2861r318b2935],
54	.	.	O	.	_	0	SENT_43	[p2l6t2861r318b2935],

1	”	NN	O	”	nsubj	18	SENT_44	[p2l6t2861r318b2935],
2	In	IN	O	in	dep	8	SENT_44	[p2l354t2864r443b2934],
3	addition	NN	O	addition	pobj	2	SENT_44	[p2l479t2856r853b2952],
4	,	,	O	,	_	0	SENT_44	[p2l479t2856r853b2952],
5	MAPK	NN	O	mapk	nn	6	SENT_44	[p2l892t2856r1722b2957],
6	—	NN	O	—	appos	3	SENT_44	[p2l892t2856r1722b2957],
7	independent	JJ	O	independent	amod	8	SENT_44	[p2l892t2856r1722b2957],
8	signaling	NN	O	signaling	rcmod	1	SENT_44	[p2l1755t2856r2153b2957],
9	through	IN	O	through	dep	8	SENT_44	[p2l11t2984r348b3085],
10	receptor	NN	O	receptor	nn	12	SENT_44	[p2l379t3001r723b3085],
11	tyrosine	NN	O	tyrosine	nn	12	SENT_44	[p2l751t2985r1084b3085],
12	kinases	NNS	O	kinase	pobj	9	SENT_44	[p2l1115t2984r1448b3080],
13	,	,	O	,	_	0	SENT_44	[p2l1115t2984r1448b3080],
14	such	JJ	O	such	_	0	SENT_44	[p2l1487t2984r1675b3063],
15	as	IN	O	as	_	0	SENT_44	[p2l1705t3011r1789b3063],
16	platelet	NN	O	platelet	nn	17	SENT_44	[p2l1821t2984r2148b3085],
17	—	NN	O	—	prep_such_as	8	SENT_44	[p2l1821t2984r2148b3085],
18	derived	VBN	O	derive	_	0	SENT_44	[p2l11t3112r322b3191],
19	growth	NN	O	growth	nn	21	SENT_44	[p2l372t3112r689b3213],
20	factor	NN	O	factor	nn	21	SENT_44	[p2l740t3112r992b3191],
21	receptor	NN	O	receptor	dobj	18	SENT_44	[p2l1041t3129r1399b3213],
22	,8,1	CD	NUMBER	,8,1	number	23	SENT_44	[p2l1443t3116r1603b3212],
23	°	CD	NUMBER	°	num	25	SENT_44	[p2l1443t3116r1603b3212],
24	insulin	NN	O	insulin	nn	25	SENT_44	[p2l1653t3112r2149b3192],
25	—	NN	O	—	dobj	41	SENT_44	[p2l1653t3112r2149b3192],
26	like	IN	O	like	_	0	SENT_44	[p2l1653t3112r2149b3192],
27	growth	NN	O	growth	nn	28	SENT_44	[p2l10t3240r321b3341],
28	factor	NN	O	factor	prep_like	25	SENT_44	[p2l349t3240r595b3319],
29	1	CD	NUMBER	1	num	30	SENT_44	[p2l623t3246r668b3318],
30	receptor	NN	O	receptor	nsubjpass	41	SENT_44	[p2l696t3245r1140b3341],
31	,	,	O	,	_	0	SENT_44	[p2l696t3245r1140b3341],
32	”	NN	O	”	appos	30	SENT_44	[p2l696t3245r1140b3341],
33	and	CC	O	and	_	0	SENT_44	[p2l1168t3240r1325b3319],
34	hepatocyte	NN	O	hepatocyte	nn	37	SENT_44	[p2l1353t3240r1811b3341],
35	growth	NN	O	growth	nn	37	SENT_44	[p2l1838t3240r2149b3341],
36	factor	NN	O	factor	nn	37	SENT_44	[p2l10t3368r262b3447],
37	receptor	NN	O	receptor	appos	30	SENT_44	[p2l300t3385r676b3469],
38	,	,	O	,	_	0	SENT_44	[p2l300t3385r676b3469],
39	have	VBP	O	have	aux	41	SENT_44	[p2l722t3368r914b3447],
40	been	VBN	O	be	auxpass	41	SENT_44	[p2l955t3368r1158b3447],
41	associated	VBN	O	associate	rcmod	21	SENT_44	[p2l1198t3368r1646b3447],
42	with	IN	O	with	_	0	SENT_44	[p2l1682t3368r1879b3447],
43	resistance	NN	O	resistance	prep_with	41	SENT_44	[p2l1920t3369r2148b3447, p2l11t3501r342b3575],
44	.	.	O	.	_	0	SENT_44	[p2l1920t3369r2148b3447, p2l11t3501r342b3575],

1	“	NNP	O	“	nn	4	SENT_45	[p2l1920t3369r2148b3447, p2l11t3501r342b3575],
2	New	NNP	O	New	nn	4	SENT_45	[p2l371t3504r569b3576],
3	therapeutic	JJ	O	therapeutic	amod	4	SENT_45	[p2l598t3496r1087b3597],
4	strategies	NNS	O	strategy	nsubjpass	6	SENT_45	[p2l1120t3497r1533b3597],
5	are	VBP	O	be	auxpass	6	SENT_45	[p2l1566t3522r1696b3575],
6	needed	VBN	O	need	_	0	SENT_45	[p2l1728t3496r2033b3575],
7	to	TO	O	to	aux	8	SENT_45	[p2l2066t3513r2148b3575],
8	address	VB	O	address	xcomp	6	SENT_45	[p2l10t3625r336b3704],
9	these	DT	O	these	det	11	SENT_45	[p2l379t3625r604b3704],
10	resistance	NN	O	resistance	nn	11	SENT_45	[p2l644t3626r1076b3704],
11	mechanisms	NNS	O	mechanism	dobj	8	SENT_45	[p2l1116t3625r1688b3704],
12	.	.	O	.	_	0	SENT_45	[p2l1116t3625r1688b3704],

1	In	IN	O	in	_	0	SENT_46	[p3l139t39r228b109],
2	preclinical	JJ	O	preclinical	amod	3	SENT_46	[p3l258t31r717b132],
3	models	NNS	O	model	prep_in	13	SENT_46	[p3l748t31r1084b127],
4	,	,	O	,	_	0	SENT_46	[p3l748t31r1084b127],
5	rapid	JJ	O	rapid	amod	6	SENT_46	[p3l1122t31r1342b132],
6	recovery	NN	O	recovery	nsubjpass	13	SENT_46	[p3l1373t57r1735b132],
7	of	IN	O	of	_	0	SENT_46	[p3l1763t31r1863b110],
8	MAPK	NN	O	mapk	nn	10	SENT_46	[p3l1873t38r2153b112],
9	pathway	NN	O	pathway	nn	10	SENT_46	[p3l9t159r360b260],
10	signaling	NN	O	signaling	prep_of	6	SENT_46	[p3l387t159r776b260],
11	has	VBZ	O	have	aux	13	SENT_46	[p3l803t159r944b238],
12	been	VBN	O	be	auxpass	13	SENT_46	[p3l977t159r1173b238],
13	associated	VBN	O	associate	_	0	SENT_46	[p3l1203t159r1632b238],
14	with	IN	O	with	_	0	SENT_46	[p3l1657t159r1847b239],
15	BRAF	NN	O	braf	nn	18	SENT_46	[p3l1877t166r2148b243],
16	—	NN	O	—	nn	18	SENT_46	[p3l1877t166r2148b243],
17	inhibitor	NN	O	inhibitor	nn	18	SENT_46	[p3l10t287r377b366],
18	resistance	NN	O	resistance	prep_with	13	SENT_46	[p3l404t288r838b383],
19	,	,	O	,	_	0	SENT_46	[p3l404t288r838b383],
20	and	CC	O	and	_	0	SENT_46	[p3l873t287r1028b366],
21	complete	JJ	O	complete	amod	22	SENT_46	[p3l1059t287r1435b388],
22	inhibition	NN	O	inhibition	nsubjpass	28	SENT_46	[p3l1465t287r1877b366],
23	of	IN	O	of	_	0	SENT_46	[p3l1909t287r2007b366],
24	the	DT	O	the	det	26	SENT_46	[p3l2020t287r2149b366],
25	MAPK	NN	ORGANIZATION	mapk	nn	26	SENT_46	[p3l7t422r287b496],
26	pathway	NN	O	pathway	prep_of	22	SENT_46	[p3l319t415r682b516],
27	is	VBZ	O	be	auxpass	28	SENT_46	[p3l714t416r781b494],
28	needed	VBN	O	need	conj_and	13	SENT_46	[p3l820t415r1126b494],
29	to	TO	O	to	aux	30	SENT_46	[p3l1163t432r1245b494],
30	induce	VB	O	induce	xcomp	28	SENT_46	[p3l1283t415r1568b494],
31	cell	NN	O	cell	nn	32	SENT_46	[p3l1606t415r1753b494],
32	death	NN	O	death	dobj	30	SENT_46	[p3l1791t415r2029b494],
33	in	IN	O	in	_	0	SENT_46	[p3l2066t416r2150b493],
34	BRAF	NN	O	braf	nn	36	SENT_46	[p3l8t550r248b627],
35	V600	NN	O	v600	nn	36	SENT_46	[p3l273t549r483b622],
36	melanoma	NN	O	melanoma	prep_in	30	SENT_46	[p3l512t543r1140b622],
37	.15	CD	NUMBER	.15	number	38	SENT_46	[p3l512t543r1140b622],
38	’15	CD	NUMBER	’15	nsubjpass	74	SENT_46	[p3l512t543r1140b622],
39	This	DT	O	this	nsubjpass	42	SENT_46	[p3l1166t543r1348b622],
40	can	MD	O	can	aux	42	SENT_46	[p3l1379t569r1524b622],
41	be	VB	O	be	auxpass	42	SENT_46	[p3l1553t543r1647b622],
42	achieved	VBN	O	achieve	rcmod	38	SENT_46	[p3l1675t543r2030b622],
43	by	IN	O	by	_	0	SENT_46	[p3l2059t543r2154b644],
44	combining	VBG	O	combine	agent	42	SENT_46	[p3l11t671r483b772],
45	a	DT	O	a	det	47	SENT_46	[p3l518t698r563b750],
46	BRAF	NN	O	braf	nn	47	SENT_46	[p3l597t678r843b755],
47	inhibitor	NN	O	inhibitor	dobj	44	SENT_46	[p3l882t671r1267b750],
48	with	IN	O	with	_	0	SENT_46	[p3l1297t671r1494b750],
49	a	DT	O	a	det	51	SENT_46	[p3l1532t698r1577b750],
50	MEK	NN	O	mek	nn	51	SENT_46	[p3l1610t679r1825b752],
51	inhibitor	NN	O	inhibitor	nn	71	SENT_46	[p3l1859t671r2148b750, p3l11t803r323b878],
52	.15	CD	NUMBER	.15	npadvmod	53	SENT_46	[p3l1859t671r2148b750, p3l11t803r323b878],
53	>	JJR	O	>	amod	71	SENT_46	[p3l1859t671r2148b750, p3l11t803r323b878],
54	16	CD	NUMBER	16	dep	53	SENT_46	[p3l1859t671r2148b750, p3l11t803r323b878],
55	The	DT	O	the	det	56	SENT_46	[p3l361t799r522b878],
56	emergence	NN	O	emergence	npadvmod	61	SENT_46	[p3l563t825r1028b900],
57	of	IN	O	of	_	0	SENT_46	[p3l1069t799r1170b878],
58	cutaneous	JJ	O	cutaneous	amod	60	SENT_46	[p3l1192t816r1630b878],
59	squamouscell	NN	O	squamouscell	nn	60	SENT_46	[p3l1674t825r2148b900, p3l11t927r154b1006],
60	carcinoma	NN	O	carcinoma	prep_of	56	SENT_46	[p3l189t928r637b1006],
61	early	RB	O	early	advmod	62	SENT_46	[p3l670t927r873b1028],
62	in	IN	O	in	dep	54	SENT_46	[p3l902t928r985b1005],
63	the	DT	O	the	det	64	SENT_46	[p3l1020t927r1151b1006],
64	course	NN	O	course	pobj	62	SENT_46	[p3l1186t953r1462b1006],
65	of	IN	O	of	_	0	SENT_46	[p3l1498t927r1598b1006],
66	BRAF	NN	O	braf	nn	69	SENT_46	[p3l1612t927r2148b1011],
67	—	CD	NUMBER	—	num	69	SENT_46	[p3l1612t927r2148b1011],
68	inhib	NN	O	inhib	nn	69	SENT_46	[p3l1612t927r2148b1011],
69	—	NN	O	—	prep_of	64	SENT_46	[p3l1612t927r2148b1011],
70	itor	NN	O	itor	nn	71	SENT_46	[p3l10t1056r158b1134],
71	therapy	NN	O	therapy	prep_with	44	SENT_46	[p3l185t1055r509b1156],
72	has	VBZ	O	have	aux	74	SENT_46	[p3l535t1055r680b1134],
73	been	VBN	O	be	auxpass	74	SENT_46	[p3l713t1055r916b1134],
74	associated	VBN	O	associate	rcmod	36	SENT_46	[p3l946t1055r1394b1134],
75	with	IN	O	with	_	0	SENT_46	[p3l1419t1055r1616b1134],
76	paradoxical	JJ	O	paradoxical	amod	79	SENT_46	[p3l1645t1055r2150b1156],
77	MAPK	NN	O	mapk	nn	79	SENT_46	[p3l7t1190r287b1264],
78	pathway	NN	O	pathway	nn	79	SENT_46	[p3l335t1183r698b1284],
79	activation	NN	O	activation	prep_with	74	SENT_46	[p3l747t1184r1167b1262],
80	during	IN	O	during	_	0	SENT_46	[p3l1220t1183r1512b1284],
81	BRAF	NN	O	braf	nn	82	SENT_46	[p3l1560t1190r1806b1267],
82	inhibition	NN	O	inhibition	prep_during	74	SENT_46	[p3l1859t1183r2148b1262, p3l11t1312r281b1390],
83	.	.	O	.	_	0	SENT_46	[p3l1859t1183r2148b1262, p3l11t1312r281b1390],

1	“	NN	O	“	npadvmod	20	SENT_47	[p3l1859t1183r2148b1262, p3l11t1312r281b1390],
2	In	IN	O	in	_	0	SENT_47	[p3l326t1319r415b1389],
3	an	DT	O	a	det	5	SENT_47	[p3l461t1337r564b1390],
4	experimental	JJ	O	experimental	amod	5	SENT_47	[p3l611t1311r1183b1412],
5	model	NN	O	model	prep_in	20	SENT_47	[p3l1228t1311r1498b1390],
6	of	IN	O	of	_	0	SENT_47	[p3l1544t1311r1645b1390],
7	squamouscell	NN	O	squamouscell	nn	8	SENT_47	[p3l1674t1337r2148b1412, p3l11t1439r154b1518],
8	carcinoma	NN	O	carcinoma	prep_of	5	SENT_47	[p3l186t1440r655b1535],
9	,	,	O	,	_	0	SENT_47	[p3l186t1440r655b1535],
10	the	DT	O	the	det	11	SENT_47	[p3l692t1439r824b1518],
11	addition	NN	O	addition	nsubj	20	SENT_47	[p3l855t1439r1207b1518],
12	of	IN	O	of	_	0	SENT_47	[p3l1239t1439r1339b1518],
13	a	DT	O	a	det	15	SENT_47	[p3l1350t1466r1395b1518],
14	MEK	NN	O	mek	nn	15	SENT_47	[p3l1422t1447r1635b1520],
15	inhibitor	NN	O	inhibitor	prep_of	11	SENT_47	[p3l1662t1439r2039b1518],
16	to	TO	O	to	_	0	SENT_47	[p3l2068t1456r2149b1518],
17	a	DT	O	a	det	19	SENT_47	[p3l10t1596r54b1649],
18	BRAF	NN	O	braf	nn	19	SENT_47	[p3l90t1576r336b1654],
19	inhibitor	NN	O	inhibitor	prep_to	15	SENT_47	[p3l377t1569r762b1649],
20	reduced	VBD	O	reduce	_	0	SENT_47	[p3l799t1569r1139b1649],
21	this	DT	O	this	det	22	SENT_47	[p3l1179t1569r1339b1649],
22	effect	NN	O	effect	dobj	20	SENT_47	[p3l1382t1569r1723b1649],
23	.	.	O	.	_	0	SENT_47	[p3l1382t1569r1723b1649],

1	“	NN	O	“	_	0	SENT_48	[p3l1382t1569r1723b1649],

1	In	IN	O	in	_	0	SENT_49	[p3l138t1706r227b1776],
2	an	DT	O	a	det	3	SENT_49	[p3l268t1724r371b1777],
3	attempt	NN	O	attempt	prep_in	24	SENT_49	[p3l413t1715r743b1799],
4	to	TO	O	to	aux	5	SENT_49	[p3l781t1715r862b1777],
5	delay	VB	O	delay	infmod	3	SENT_49	[p3l906t1698r1124b1799],
6	resistance	NN	O	resistance	dobj	5	SENT_49	[p3l1162t1699r1583b1777],
7	to	TO	O	to	_	0	SENT_49	[p3l1626t1715r1707b1777],
8	BRAF	NN	O	braf	nn	9	SENT_49	[p3l1749t1705r1992b1782],
9	inhibition	NN	O	inhibition	prep_to	5	SENT_49	[p3l2034t1699r2148b1776, p3l10t1826r352b1905],
10	and	CC	O	and	_	0	SENT_49	[p3l401t1826r560b1905],
11	explore	VB	O	explore	conj_and	5	SENT_49	[p3l612t1826r925b1927],
12	the	DT	O	the	det	13	SENT_49	[p3l977t1826r1110b1905],
13	safety	NN	O	safety	dobj	11	SENT_49	[p3l1163t1826r1418b1927],
14	of	IN	O	of	_	0	SENT_49	[p3l1465t1826r1566b1905],
15	combination	NN	O	combination	nn	16	SENT_49	[p3l1599t1826r2149b1905],
16	therapy	NN	O	therapy	prep_of	13	SENT_49	[p3l11t1954r335b2055],
17	with	IN	O	with	_	0	SENT_49	[p3l362t1954r559b2034],
18	BRAF	NN	ORGANIZATION	braf	nn	21	SENT_49	[p3l593t1961r839b2038],
19	and	CC	O	and	_	0	SENT_49	[p3l876t1954r1035b2033],
20	MEK	NN	O	mek	conj_and	18	SENT_49	[p3l1068t1962r1283b2035],
21	inhibition	NN	O	inhibition	prep_with	11	SENT_49	[p3l1315t1954r1770b2050],
22	,	,	O	,	_	0	SENT_49	[p3l1315t1954r1770b2050],
23	we	PRP	O	we	nsubj	24	SENT_49	[p3l1808t1981r1926b2033],
24	conducted	VBD	O	conduct	_	0	SENT_49	[p3l1963t1980r2148b2033, p3l11t2082r297b2161],
25	a	DT	O	a	det	26	SENT_49	[p3l341t2109r386b2161],
26	phase	NN	O	phase	nsubj	32	SENT_49	[p3l427t2082r677b2183],
27	1	CD	NUMBER	1	num	26	SENT_49	[p3l725t2088r769b2160],
28	and	CC	O	and	_	0	SENT_49	[p3l813t2082r972b2161],
29	2	CD	NUMBER	2	num	30	SENT_49	[p3l1016t2088r1063b2160],
30	study	NN	O	study	nsubj	32	SENT_49	[p3l1110t2082r1341b2183],
31	to	TO	O	to	aux	32	SENT_49	[p3l1381t2099r1463b2161],
32	investigate	VB	O	investigate	xcomp	24	SENT_49	[p3l1508t2083r1971b2183],
33	the	DT	O	the	det	34	SENT_49	[p3l2016t2082r2149b2161],
34	combination	NN	O	combination	dobj	32	SENT_49	[p3l11t2211r540b2291],
35	of	IN	O	of	_	0	SENT_49	[p3l573t2211r671b2291],
36	the	DT	O	the	det	39	SENT_49	[p3l685t2211r815b2291],
37	BRAF	NN	MISC	braf	nn	39	SENT_49	[p3l845t2218r1084b2296],
38	inhibitor	NN	O	inhibitor	nn	39	SENT_49	[p3l1117t2211r1485b2291],
39	dabrafenib	NN	O	dabrafenib	prep_of	34	SENT_49	[p3l1514t2211r1962b2291],
40	and	CC	O	and	_	0	SENT_49	[p3l1995t2211r2149b2291],
41	the	DT	O	the	det	44	SENT_49	[p3l10t2340r144b2419],
42	MEK	NN	O	mek	nn	44	SENT_49	[p3l197t2348r412b2421],
43	inhibitor	NN	O	inhibitor	nn	44	SENT_49	[p3l462t2340r848b2419],
44	trametinib	NN	O	trametinib	conj_and	34	SENT_49	[p3l900t2340r1362b2419],
45	in	IN	O	in	_	0	SENT_49	[p3l1418t2341r1503b2418],
46	patients	NNS	O	patient	prep_in	44	SENT_49	[p3l1556t2341r1900b2441],
47	with	IN	O	with	_	0	SENT_49	[p3l1952t2340r2149b2419],
48	metastatic	JJ	O	metastatic	amod	51	SENT_49	[p3l10t2470r460b2549],
49	BRAF	NN	O	braf	nn	51	SENT_49	[p3l498t2476r744b2554],
50	V600	NN	O	v600	nn	51	SENT_49	[p3l782t2475r998b2549],
51	melanoma	NN	O	melanoma	prep_with	32	SENT_49	[p3l1039t2469r1521b2549],
52	.	.	O	.	_	0	SENT_49	[p3l1039t2469r1521b2549],

1	METHODS	NNS	O	method	_	0	SENT_50	[p3l800t2719r1342b2778],

1	PATIENTS	NNS	O	patient	npadvmod	15	SENT_51	[p3l16t2968r383b3018],
2	From	IN	O	from	_	0	SENT_51	[p3l9t3074r237b3145],
3	March	NNP	DATE	March	prep_from	15	SENT_51	[p3l261t3067r537b3145],
4	26	CD	DATE	26	num	3	SENT_51	[p3l565t3073r687b3162],
5	,	,	DATE	,	_	0	SENT_51	[p3l565t3073r687b3162],
6	2010	CD	DATE	2010	num	3	SENT_51	[p3l720t3073r942b3162],
7	,	,	O	,	_	0	SENT_51	[p3l720t3073r942b3162],
8	to	TO	O	to	_	0	SENT_51	[p3l976t3084r1057b3145],
9	July	NNP	DATE	July	prep_to	3	SENT_51	[p3l1076t3067r1243b3166],
10	7	CD	DATE	7	num	9	SENT_51	[p3l1267t3074r1326b3162],
11	,	,	DATE	,	_	0	SENT_51	[p3l1267t3074r1326b3162],
12	2011	CD	DATE	2011	num	9	SENT_51	[p3l1359t3073r1585b3162],
13	,	,	O	,	_	0	SENT_51	[p3l1359t3073r1585b3162],
14	we	PRP	O	we	nsubj	15	SENT_51	[p3l1613t3093r1731b3146],
15	screened	VBD	O	screen	_	0	SENT_51	[p3l1761t3067r2134b3145],
16	443	CD	NUMBER	443	num	17	SENT_51	[p3l9t3200r160b3273],
17	patients	NNS	O	patient	dobj	15	SENT_51	[p3l194t3195r536b3294],
18	at	IN	O	at	_	0	SENT_51	[p3l570t3211r649b3272],
19	16	CD	NUMBER	16	num	20	SENT_51	[p3l680t3200r773b3273],
20	centers	NNS	O	center	prep_at	15	SENT_51	[p3l808t3211r1110b3272],
21	for	IN	O	for	_	0	SENT_51	[p3l1145t3193r1267b3273],
22	participation	NN	O	participation	prep_for	20	SENT_51	[p3l1296t3195r1852b3294],
23	in	IN	O	in	_	0	SENT_51	[p3l1885t3195r1968b3272],
24	the	DT	O	the	det	25	SENT_51	[p3l2001t3194r2133b3272],
25	study	NN	O	study	prep_in	15	SENT_51	[p3l12t3323r255b3423],
26	.	.	O	.	_	0	SENT_51	[p3l12t3323r255b3423],

1	Patients	NNS	O	patient	nsubj	23	SENT_52	[p3l298t3324r638b3401],
2	18	CD	DURATION	18	num	3	SENT_52	[p3l683t3329r777b3402],
3	years	NNS	NUMBER	year	npadvmod	1	SENT_52	[p3l814t3349r1033b3423],
4	of	IN	O	of	_	0	SENT_52	[p3l1075t3322r1175b3402],
5	age	NN	O	age	prep_of	1	SENT_52	[p3l1196t3349r1338b3424],
6	or	CC	O	or	_	0	SENT_52	[p3l1379t3349r1467b3402],
7	older	JJR	O	older	conj_or	5	SENT_52	[p3l1505t3323r1721b3402],
8	who	WP	O	who	nsubj	11	SENT_52	[p3l1753t3323r1936b3402],
9	had	VBD	O	have	aux	11	SENT_52	[p3l1977t3323r2133b3402],
10	histologically	RB	O	histologically	advmod	11	SENT_52	[p3l11t3451r594b3552],
11	confirmed	VBN	O	confirm	rcmod	1	SENT_52	[p3l653t3450r1107b3530],
12	metastatic	JJ	O	metastatic	amod	13	SENT_52	[p3l1169t3452r1617b3529],
13	melanoma	NN	O	melanoma	dobj	11	SENT_52	[p3l1678t3451r2135b3530],
14	with	IN	O	with	_	0	SENT_52	[p3l7t3579r202b3658],
15	either	CC	O	either	preconj	17	SENT_52	[p3l248t3579r495b3657],
16	BRAF	NN	O	braf	nn	17	SENT_52	[p3l535t3585r779b3662],
17	V600E	NN	O	v600e	prep_with	11	SENT_52	[p3l822t3585r1092b3658],
18	or	CC	O	or	_	0	SENT_52	[p3l1139t3605r1228b3658],
19	BRAF	NN	O	braf	nn	21	SENT_52	[p3l1268t3585r1512b3662],
20	V600K	NN	O	v600k	nn	21	SENT_52	[p3l1556t3585r1841b3659],
21	mutations	NNS	O	mutation	prep_with	11	SENT_52	[p3l1882t3596r2132b3658, p3l12t3708r223b3786],
22	were	VBD	O	be	cop	23	SENT_52	[p3l257t3733r459b3786],
23	eligible	JJ	O	eligible	_	0	SENT_52	[p3l497t3707r808b3808],
24	for	IN	O	for	_	0	SENT_52	[p3l845t3706r968b3786],
25	inclusion	NN	O	inclusion	prep_for	23	SENT_52	[p3l1001t3707r1417b3786],
26	.	.	O	.	_	0	SENT_52	[p3l1001t3707r1417b3786],

1	BRAF	NN	ORGANIZATION	braf	nn	3	SENT_53	[p3l1459t3714r1702b3790],
2	mutation	NN	O	mutation	nn	3	SENT_53	[p3l1741t3708r2134b3786],
3	status	NN	O	status	nsubjpass	5	SENT_53	[p4l12t38r253b100],
4	was	VBD	O	be	auxpass	5	SENT_53	[p4l280t47r438b100],
5	determined	VBN	O	determine	_	0	SENT_53	[p4l471t21r946b100],
6	locally	RB	O	locally	advmod	5	SENT_53	[p4l974t21r1254b121],
7	.	.	O	.	_	0	SENT_53	[p4l974t21r1254b121],

1	Eligible	JJ	O	eligible	amod	2	SENT_54	[p4l1288t21r1595b122],
2	patients	NNS	O	patient	nsubj	3	SENT_54	[p4l1623t22r1950b121],
3	had	VBD	O	have	_	0	SENT_54	[p4l1981t21r2133b100],
4	measurable	JJ	O	measurable	amod	5	SENT_54	[p4l11t149r503b228],
5	disease	NN	O	disease	dobj	3	SENT_54	[p4l543t149r877b244],
6	,	,	O	,	_	0	SENT_54	[p4l543t149r877b244],
7	an	DT	O	a	det	11	SENT_54	[p4l921t175r1024b226],
8	Eastern	NNP	ORGANIZATION	Eastern	nn	11	SENT_54	[p4l1062t156r1385b227],
9	Cooperative	NNP	ORGANIZATION	Cooperative	nn	11	SENT_54	[p4l1424t150r1934b248],
10	Oncology	NNP	ORGANIZATION	Oncology	nn	11	SENT_54	[p4l1974t155r2132b227, p4l12t277r295b378],
11	Group	NNP	ORGANIZATION	Group	dep	17	SENT_54	[p4l321t283r590b377],
12	(	CD	NUMBER	(	num	17	SENT_54	[p4l627t283r949b368],
13	ECOG	NNP	O	ECOG	nn	17	SENT_54	[p4l627t283r949b368],
14	)	CD	NUMBER	)	num	17	SENT_54	[p4l627t283r949b368],
15	performance	NN	O	performance	nn	17	SENT_54	[p4l983t276r1538b377],
16	status	NN	O	status	nn	17	SENT_54	[p4l1570t294r1822b356],
17	ofO	NN	O	ofo	conj_or	3	SENT_54	[p4l1856t276r2015b356],
18	or	CC	O	or	_	0	SENT_54	[p4l2048t303r2137b356],
19	1	CD	NUMBER	1	num	20	SENT_54	[p4l15t411r59b483],
20	(	NN	O	(	nsubj	23	SENT_54	[p4l93t405r310b496],
21	with	IN	O	with	_	0	SENT_54	[p4l93t405r310b496],
22	o	NN	O	o	prep_with	20	SENT_54	[p4l339t411r386b484],
23	indicating	VBG	O	indicate	conj_or	3	SENT_54	[p4l415t405r856b506],
24	asymptomatic	JJ	O	asymptomatic	amod	38	SENT_54	[p4l881t406r1489b505],
25	and	CC	O	and	_	0	SENT_54	[p4l1517t405r1675b484],
26	1	CD	NUMBER	1	number	27	SENT_54	[p4l1707t411r1751b483],
27	ambulatory	JJ	O	ambulatory	amod	38	SENT_54	[p4l1779t405r2132b484, p4l12t550r180b632],
28	but	CC	O	but	_	0	SENT_54	[p4l213t533r350b612],
29	restricted	JJ	O	restricted	conj_but	27	SENT_54	[p4l381t533r778b611],
30	in	IN	O	in	_	0	SENT_54	[p4l813t534r896b610],
31	strenuous	JJ	O	strenuous	amod	33	SENT_54	[p4l933t549r1342b612],
32	activity	NN	O	activity	nn	33	SENT_54	[p4l1379t534r1726b632],
33	)	NN	O	)	prep_in	29	SENT_54	[p4l1379t534r1726b632],
34	,	,	O	,	_	0	SENT_54	[p4l1379t534r1726b632],
35	and	CC	O	and	_	0	SENT_54	[p4l1767t533r1923b611],
36	adequate	JJ	O	adequate	conj_and	24	SENT_54	[p4l1958t533r2132b611, p4l12t678r239b761],
37	organ	NN	O	organ	nn	38	SENT_54	[p4l271t687r521b762],
38	function	NN	O	function	dobj	23	SENT_54	[p4l553t660r942b740],
39	.	.	O	.	_	0	SENT_54	[p4l553t660r942b740],

1	Patients	NNS	O	patient	nsubjpass	16	SENT_55	[p4l979t662r1319b739],
2	with	IN	O	with	_	0	SENT_55	[p4l1348t661r1543b740],
3	treated	JJ	O	treated	amod	5	SENT_55	[p4l1577t661r1875b740],
4	brain	NN	O	brain	nn	5	SENT_55	[p4l1908t661r2133b740],
5	metastases	NNS	O	metastase	prep_with	1	SENT_55	[p4l11t805r473b866],
6	and	CC	O	and	_	0	SENT_55	[p4l502t788r657b867],
7	at	IN	O	at	advmod	1	SENT_55	[p4l684t805r762b866],
8	least	JJS	O	least	pobj	7	SENT_55	[p4l783t788r978b866],
9	a	DT	O	a	det	11	SENT_55	[p4l1000t814r1044b866],
10	3-month	JJ	DURATION	3-month	amod	11	SENT_55	[p4l1071t788r1434b867],
11	history	NN	O	history	conj_and	1	SENT_55	[p4l1461t788r1759b888],
12	of	IN	O	of	_	0	SENT_55	[p4l1782t787r1881b867],
13	stable	JJ	O	stable	amod	14	SENT_55	[p4l1891t788r2133b867],
14	disease	NN	O	disease	prep_of	11	SENT_55	[p4l12t917r322b996],
15	were	VBD	O	be	auxpass	16	SENT_55	[p4l359t943r561b996],
16	allowed	VBN	O	allow	_	0	SENT_55	[p4l602t917r936b996],
17	to	TO	O	to	aux	18	SENT_55	[p4l978t934r1059b996],
18	enroll	VB	O	enroll	xcomp	16	SENT_55	[p4l1103t917r1376b996],
19	.	.	O	.	_	0	SENT_55	[p4l1103t917r1376b996],

1	Additional	JJ	O	additional	amod	3	SENT_56	[p4l1419t917r1876b996],
2	eligibility	NN	O	eligibility	nn	3	SENT_56	[p4l1918t917r2132b1018, p4l12t1045r233b1144],
3	criteria	NNS	O	criterion	nsubjpass	5	SENT_56	[p4l269t1046r573b1123],
4	are	VBP	O	be	auxpass	5	SENT_56	[p4l611t1071r740b1123],
5	provided	VBN	O	provide	_	0	SENT_56	[p4l778t1045r1153b1144],
6	in	IN	O	in	_	0	SENT_56	[p4l1192t1046r1275b1122],
7	the	DT	O	the	det	9	SENT_56	[p4l1316t1045r1449b1123],
8	Supplementary	NNP	O	Supplementary	nn	9	SENT_56	[p4l1491t1045r2138b1144],
9	Appendix	NNP	O	Appendix	prep_in	5	SENT_56	[p4l7t1172r446b1272],
10	,	,	O	,	_	0	SENT_56	[p4l7t1172r446b1272],
11	available	JJ	O	available	amod	22	SENT_56	[p4l491t1172r862b1252],
12	with	IN	O	with	_	0	SENT_56	[p4l898t1172r1093b1252],
13	the	DT	O	the	det	15	SENT_56	[p4l1135t1172r1267b1250],
14	full	JJ	O	full	amod	15	SENT_56	[p4l1308t1171r1457b1252],
15	text	NN	O	text	prep_with	11	SENT_56	[p4l1497t1189r1657b1250],
16	of	IN	O	of	_	0	SENT_56	[p4l1694t1171r1793b1251],
17	this	DT	O	this	det	18	SENT_56	[p4l1816t1172r1975b1250],
18	article	NN	O	article	prep_of	15	SENT_56	[p4l2017t1198r2132b1250, p4l12t1301r188b1379],
19	at	IN	O	at	_	0	SENT_56	[p4l234t1318r313b1379],
20	NE	NN	O	ne	prep_at	18	SENT_56	[p4l352t1309r795b1402],
21	)	CD	NUMBER	)	num	20	SENT_56	[p4l352t1309r795b1402],
22	M.org	NN	O	m.org	appos	9	SENT_56	[p4l352t1309r795b1402],
23	.	.	O	.	_	0	SENT_56	[p4l352t1309r795b1402],

1	All	DT	O	all	det	2	SENT_57	[p4l844t1301r969b1379],
2	patients	NNS	O	patient	nsubj	3	SENT_57	[p4l1014t1302r1355b1401],
3	provided	VBD	O	provide	_	0	SENT_57	[p4l1402t1301r1777b1401],
4	written	VBN	O	write	amod	6	SENT_57	[p4l1819t1302r2133b1380],
5	informed	VBN	O	inform	amod	6	SENT_57	[p4l11t1428r412b1508],
6	consent	NN	O	consent	dobj	3	SENT_57	[p4l447t1446r803b1508],
7	.	.	O	.	_	0	SENT_57	[p4l447t1446r803b1508],

1	STUDY	NN	O	study	nn	2	SENT_58	[p4l11t1702r267b1752],
2	DESIGN	NN	O	design	nsubj	11	SENT_58	[p4l303t1702r599b1752],
3	AND	CC	O	and	_	0	SENT_58	[p4l637t1703r807b1751],
4	TREATMENT	NN	O	treatment	conj_and	2	SENT_58	[p4l838t1703r1307b1751],
5	This	DT	O	this	nsubj	11	SENT_58	[p4l7t1801r195b1879],
6	was	VBD	O	be	cop	11	SENT_58	[p4l231t1827r393b1880],
7	an	DT	O	a	det	11	SENT_58	[p4l434t1827r536b1879],
8	open	JJ	O	open	amod	11	SENT_58	[p4l575t1801r1022b1901],
9	—	NN	O	—	nn	11	SENT_58	[p4l575t1801r1022b1901],
10	label	NN	O	label	nn	11	SENT_58	[p4l575t1801r1022b1901],
11	study	NN	O	study	_	0	SENT_58	[p4l1062t1801r1292b1901],
12	designed	VBN	O	design	partmod	11	SENT_58	[p4l1326t1801r1708b1902],
13	to	TO	O	to	aux	14	SENT_58	[p4l1747t1818r1828b1880],
14	assess	VB	O	assess	xcomp	12	SENT_58	[p4l1867t1827r2131b1880],
15	the	DT	O	the	det	16	SENT_58	[p4l12t1928r144b2006],
16	safety	NN	O	safety	dobj	14	SENT_58	[p4l183t1927r449b2028],
17	,	,	O	,	_	0	SENT_58	[p4l183t1927r449b2028],
18	pharmacokinetic	JJ	O	pharmacokinetic	amod	19	SENT_58	[p4l490t1928r1225b2028],
19	activity	NN	O	activity	conj_and	16	SENT_58	[p4l1260t1929r1583b2028],
20	,	,	O	,	_	0	SENT_58	[p4l1260t1929r1583b2028],
21	and	CC	O	and	_	0	SENT_58	[p4l1625t1928r1783b2007],
22	clinical	JJ	O	clinical	amod	23	SENT_58	[p4l1821t1928r2134b2006],
23	activity	NN	O	activity	dobj	14	SENT_58	[p4l11t2057r320b2156],
24	of	IN	O	of	_	0	SENT_58	[p4l359t2055r459b2135],
25	combination	NN	O	combination	nn	26	SENT_58	[p4l484t2056r1031b2135],
26	therapy	NN	O	therapy	prep_of	23	SENT_58	[p4l1074t2056r1396b2156],
27	with	IN	O	with	_	0	SENT_58	[p4l1430t2056r1625b2136],
28	dabrafenib	NN	O	dabrafenib	prep_with	14	SENT_58	[p4l1668t2055r2132b2135],
29	plus	CC	O	plus	prep	28	SENT_58	[p4l9t2184r185b2284],
30	trametinib	NN	O	trametinib	dep	29	SENT_58	[p4l218t2184r699b2263],
31	.	.	O	.	_	0	SENT_58	[p4l218t2184r699b2263],

1	The	DT	O	the	det	2	SENT_59	[p4l732t2184r892b2262],
2	study	NN	O	study	nsubjpass	4	SENT_59	[p4l925t2184r1155b2284],
3	was	VBD	O	be	auxpass	4	SENT_59	[p4l1175t2210r1338b2264],
4	conducted	VBN	O	conduct	_	0	SENT_59	[p4l1372t2184r1813b2264],
5	in	IN	O	in	_	0	SENT_59	[p4l1843t2185r1926b2262],
6	four	CD	NUMBER	four	num	7	SENT_59	[p4l1956t2183r2137b2264],
7	parts	NNS	O	part	prep_in	4	SENT_59	[p4l10t2330r220b2413],
8	(	CD	NUMBER	(	num	9	SENT_59	[p4l254t2314r425b2414],
9	Fig	NN	O	fig	dep	7	SENT_59	[p4l254t2314r425b2414],
10	.	.	O	.	_	0	SENT_59	[p4l254t2314r425b2414],

1	1	CD	NUMBER	1	_	0	SENT_60	[p4l462t2319r506b2391],
2	in	IN	O	in	_	0	SENT_60	[p4l534t2314r615b2391],
3	the	DT	O	the	det	6	SENT_60	[p4l643t2313r772b2392],
4	Supplementary	NNP	O	Supplementary	nn	6	SENT_60	[p4l802t2313r1422b2413],
5	Appendix	NNP	O	Appendix	nn	6	SENT_60	[p4l1442t2313r1888b2413],
6	)	NNP	O	)	prep_in	1	SENT_60	[p4l1442t2313r1888b2413],
7	,	,	O	,	_	0	SENT_60	[p4l1442t2313r1888b2413],
8	three	CD	NUMBER	three	nsubjpass	12	SENT_60	[p4l1922t2313r2133b2392],
9	of	IN	O	of	_	0	SENT_60	[p4l12t2439r112b2519],
10	which	WDT	O	which	prep_of	8	SENT_60	[p4l121t2440r384b2520],
11	are	VBP	O	be	auxpass	12	SENT_60	[p4l416t2466r545b2518],
12	reported	VBN	O	report	rcmod	6	SENT_60	[p4l577t2440r944b2540],
13	here	RB	O	here	advmod	12	SENT_60	[p4l976t2440r1181b2519],
14	.	.	O	.	_	0	SENT_60	[p4l976t2440r1181b2519],

1	Part	NNP	O	Part	nn	2	SENT_61	[p4l1217t2447r1395b2518],
2	A	NNP	O	A	nsubj	3	SENT_61	[p4l1418t2448r1484b2518],
3	confirmed	VBD	O	confirm	_	0	SENT_61	[p4l1515t2439r1968b2519],
4	the	DT	O	the	det	5	SENT_61	[p4l2001t2440r2133b2518],
5	absence	NN	O	absence	nsubj	24	SENT_61	[p4l11t2569r348b2648],
6	of	IN	O	of	_	0	SENT_61	[p4l391t2568r491b2648],
7	a	DT	O	a	det	11	SENT_61	[p4l515t2595r559b2647],
8	drug	NN	O	drug	nn	11	SENT_61	[p4l601t2569r1069b2670],
9	—	NN	O	—	nn	11	SENT_61	[p4l601t2569r1069b2670],
10	drug	NN	O	drug	nn	11	SENT_61	[p4l601t2569r1069b2670],
11	interaction	NN	O	interaction	prep_of	5	SENT_61	[p4l1107t2570r1575b2648],
12	between	IN	O	between	_	0	SENT_61	[p4l1619t2569r1976b2648],
13	repeated	JJ	O	repeated	amod	14	SENT_61	[p4l2019t2595r2132b2648, p4l10t2697r294b2797],
14	doses	NNS	O	dose	prep_between	11	SENT_61	[p4l336t2697r572b2776],
15	of	IN	O	of	_	0	SENT_61	[p4l616t2696r715b2776],
16	trametinib	NN	O	trametinib	prep_of	14	SENT_61	[p4l738t2697r1198b2776],
17	and	CC	O	and	_	0	SENT_61	[p4l1239t2697r1397b2776],
18	a	DT	O	a	det	20	SENT_61	[p4l1437t2723r1482b2775],
19	single	JJ	O	single	amod	20	SENT_61	[p4l1522t2697r1774b2798],
20	dose	NN	O	dose	conj_and	14	SENT_61	[p4l1816t2697r2010b2776],
21	of	IN	O	of	_	0	SENT_61	[p4l2052t2696r2152b2776],
22	dabrafenib	NN	O	dabrafenib	prep_of	20	SENT_61	[p4l12t2824r475b2904],
23	(	CD	NUMBER	(	num	22	SENT_61	[p4l520t2832r677b2916],
24	see	VBP	O	see	ccomp	3	SENT_61	[p4l520t2832r677b2916],
25	the	DT	O	the	det	27	SENT_61	[p4l715t2825r848b2904],
26	Pharmacokinetics	NNPS	O	Pharmacokinetics	nn	27	SENT_61	[p4l885t2825r1658b2905],
27	Section	NNP	O	Section	dobj	24	SENT_61	[p4l1700t2826r2013b2904],
28	in	IN	O	in	_	0	SENT_61	[p4l2050t2826r2134b2903],
29	Methods	NNS	O	method	prep_in	27	SENT_61	[p4l8t2954r384b3032],
30	in	IN	O	in	_	0	SENT_61	[p4l417t2955r501b3031],
31	the	DT	O	the	det	34	SENT_61	[p4l533t2954r666b3032],
32	Supplementary	NNP	O	Supplementary	nn	34	SENT_61	[p4l701t2954r1347b3053],
33	Appendix	NNP	O	Appendix	nn	34	SENT_61	[p4l1371t2954r1837b3053],
34	)	NN	O	)	prep_in	29	SENT_61	[p4l1371t2954r1837b3053],
35	.	.	O	.	_	0	SENT_61	[p4l1371t2954r1837b3053],

1	Part	NN	O	part	nn	2	SENT_62	[p4l1873t2960r2050b3032],
2	B	NN	O	b	nsubj	3	SENT_62	[p4l2076t2960r2132b3032],
3	evaluated	VBD	O	evaluate	_	0	SENT_62	[p4l12t3081r405b3161],
4	the	DT	O	the	det	8	SENT_62	[p4l440t3081r571b3159],
5	side	NN	O	side	nn	8	SENT_62	[p4l608t3080r1044b3160],
6	—	NN	O	—	nn	8	SENT_62	[p4l608t3080r1044b3160],
7	effect	NN	O	effect	nn	8	SENT_62	[p4l608t3080r1044b3160],
8	profile	NN	O	profile	dobj	3	SENT_62	[p4l1073t3080r1377b3181],
9	,	,	O	,	_	0	SENT_62	[p4l1073t3080r1377b3181],
10	safety	NN	O	safety	dobj	3	SENT_62	[p4l1418t3080r1678b3181],
11	,	,	O	,	_	0	SENT_62	[p4l1418t3080r1678b3181],
12	and	CC	O	and	_	0	SENT_62	[p4l1717t3081r1873b3160],
13	pharmacokinetic	JJ	O	pharmacokinetic	amod	14	SENT_62	[p4l1907t3081r2132b3181, p4l11t3210r530b3289],
14	activity	NN	O	activity	dobj	3	SENT_62	[p4l559t3211r861b3310],
15	of	IN	O	of	_	0	SENT_62	[p4l888t3209r987b3289],
16	escalating	VBG	O	escalate	amod	17	SENT_62	[p4l1000t3210r1429b3311],
17	doses	NNS	O	dose	prep_of	14	SENT_62	[p4l1457t3210r1689b3289],
18	of	IN	O	of	_	0	SENT_62	[p4l1722t3209r1822b3289],
19	dabraf	NN	O	dabraf	nn	20	SENT_62	[p4l1834t3209r2132b3289],
20	enib	NN	O	enib	prep_of	17	SENT_62	[p4l12t3338r190b3417],
21	(	CD	NUMBER	(	number	22	SENT_62	[p4l230t3345r355b3429],
22	75	CD	NUMBER	75	dep	20	SENT_62	[p4l230t3345r355b3429],
23	and	CC	O	and	_	0	SENT_62	[p4l391t3338r549b3417],
24	150	CD	NUMBER	150	num	25	SENT_62	[p4l586t3344r735b3417],
25	mg	NN	O	mg	npadvmod	26	SENT_62	[p4l769t3364r909b3439],
26	twice	RB	O	twice	advmod	20	SENT_62	[p4l939t3339r1166b3417],
27	daily	JJ	SET	daily	amod	28	SENT_62	[p4l1201t3338r1431b3438],
28	)	NN	O	)	conj_and	20	SENT_62	[p4l1201t3338r1431b3438],
29	in	IN	O	in	_	0	SENT_62	[p4l1469t3339r1552b3416],
30	combination	NN	O	combination	prep_in	28	SENT_62	[p4l1587t3338r2133b3417],
31	with	IN	O	with	_	0	SENT_62	[p4l7t3466r198b3545],
32	trametinib	NN	O	trametinib	nn	33	SENT_62	[p4l230t3466r679b3545],
33	(	NN	O	(	prep_with	17	SENT_62	[p4l715t3472r810b3562],
34	1	CD	NUMBER	1	num	33	SENT_62	[p4l715t3472r810b3562],
35	,	,	O	,	_	0	SENT_62	[p4l715t3472r810b3562],
36	1.5	CD	NUMBER	1.5	conj_and	17	SENT_62	[p4l849t3472r990b3562],
37	,	,	O	,	_	0	SENT_62	[p4l849t3472r990b3562],
38	and	CC	NUMBER	and	_	0	SENT_62	[p4l1026t3466r1181b3545],
39	2	CD	NUMBER	2	num	40	SENT_62	[p4l1212t3472r1258b3544],
40	mg	NN	O	mg	npadvmod	41	SENT_62	[p4l1290t3492r1428b3567],
41	once	RB	DATE	once	advmod	17	SENT_62	[p4l1456t3492r1649b3545],
42	daily	JJ	SET	daily	amod	43	SENT_62	[p4l1681t3466r1929b3566],
43	)	NN	O	)	conj_and	17	SENT_62	[p4l1681t3466r1929b3566],
44	.	.	O	.	_	0	SENT_62	[p4l1681t3466r1929b3566],

1	Part	NN	O	part	nn	2	SENT_63	[p4l1965t3472r2138b3544],
2	B	NN	O	b	_	0	SENT_63	[p4l10t3600r65b3672],
3	also	RB	O	also	advmod	4	SENT_63	[p4l107t3594r278b3672],
4	included	VBD	O	include	partmod	2	SENT_63	[p4l319t3594r686b3673],
5	two	CD	NUMBER	two	num	7	SENT_63	[p4l727t3611r884b3673],
6	additional	JJ	O	additional	amod	7	SENT_63	[p4l925t3594r1361b3672],
7	cohorts	NNS	O	cohort	dobj	4	SENT_63	[p4l1402t3594r1747b3672],
8	:	:	O	:	_	0	SENT_63	[p4l1402t3594r1747b3672],
9	patients	NNS	O	patient	dep	2	SENT_63	[p4l1790t3595r2132b3693],
10	with	IN	O	with	_	0	SENT_63	[p4l7t3722r202b3801],
11	metastatic	JJ	O	metastatic	amod	12	SENT_63	[p4l231t3723r678b3800],
12	melanoma	NN	O	melanoma	prep_with	9	SENT_63	[p4l707t3722r1164b3801],
13	and	CC	O	and	_	0	SENT_63	[p4l1191t3722r1349b3801],
14	a	DT	O	a	det	17	SENT_63	[p4l1378t3748r1422b3800],
15	BRAF	NN	O	braf	nn	17	SENT_63	[p4l1449t3728r1692b3805],
16	V600	NN	O	v600	nn	17	SENT_63	[p4l1720t3728r1934b3801],
17	mutation	NN	O	mutation	conj_and	12	SENT_63	[p4l1965t3748r2132b3801, p5l12t38r264b116],

1	who	WP	O	who	nsubj	2	SENT_64	[p5l290t37r473b116],
2	had	VBD	O	have	_	0	SENT_64	[p5l505t37r661b116],
3	disease	NN	O	disease	nn	4	SENT_64	[p5l692t37r1003b116],
4	progression	NN	O	progression	dobj	2	SENT_64	[p5l1032t38r1543b138],
5	during	IN	O	during	_	0	SENT_64	[p5l1574t37r1863b138],
6	previous	JJ	O	previous	amod	7	SENT_64	[p5l1889t38r2132b137, p5l12t191r157b244],
7	treatment	NN	O	treatment	prep_during	2	SENT_64	[p5l189t181r612b243],
8	with	IN	O	with	_	0	SENT_64	[p5l632t165r826b244],
9	a	DT	O	a	det	11	SENT_64	[p5l855t191r900b242],
10	BRAF	NN	O	braf	nn	11	SENT_64	[p5l925t171r1169b248],
11	inhibitor	NN	O	inhibitor	prep_with	7	SENT_64	[p5l1199t165r1581b243],
12	and	CC	O	and	_	0	SENT_64	[p5l1605t165r1763b243],
13	patients	NNS	O	patient	conj_and	11	SENT_64	[p5l1791t166r2132b264],
14	with	IN	O	with	_	0	SENT_64	[p5l7t293r199b372],
15	colorectal	JJ	O	colorectal	amod	16	SENT_64	[p5l227t293r638b372],
16	cancer	NN	O	cancer	prep_with	2	SENT_64	[p5l666t319r941b371],
17	and	CC	O	and	_	0	SENT_64	[p5l965t293r1120b372],
18	a	DT	O	a	det	21	SENT_64	[p5l1147t319r1191b371],
19	BRAF	NN	MISC	braf	nn	21	SENT_64	[p5l1215t299r1456b376],
20	V600	NN	MISC	v600	nn	21	SENT_64	[p5l1481t299r1693b372],
21	mutation	NN	O	mutation	prep_with	2	SENT_64	[p5l1721t294r2129b372],
22	.	.	O	.	_	0	SENT_64	[p5l1721t294r2129b372],

1	(	NN	O	(	_	0	SENT_65	[p5l16t420r358b511],
2	Results	NNS	O	result	dobj	5	SENT_65	[p5l16t420r358b511],
3	for	IN	O	for	_	0	SENT_65	[p5l392t419r515b499],
4	the	DT	O	the	prep_for	2	SENT_65	[p5l545t420r678b498],
5	latter	JJ	O	latter	dep	1	SENT_65	[p5l708t420r936b498],
6	two	CD	NUMBER	two	num	7	SENT_65	[p5l965t437r1123b500],
7	cohorts	NNS	O	cohort	nsubjpass	10	SENT_65	[p5l1157t420r1478b499],
8	are	VBP	O	be	auxpass	10	SENT_65	[p5l1511t446r1640b498],
9	not	RB	O	not	neg	10	SENT_65	[p5l1672t437r1814b499],
10	reported	VBN	O	report	ccomp	5	SENT_65	[p5l1841t437r2132b520, p5l12t549r109b627],
11	here	RB	O	here	advmod	10	SENT_65	[p5l143t549r376b639],
12	.	.	O	.	_	0	SENT_65	[p5l143t549r376b639],
13	)	SYM	O	)	dep	1	SENT_65	[p5l143t549r376b639],

1	Part	NN	O	part	nn	2	SENT_66	[p5l139t683r316b755],
2	C	NN	O	c	nsubj	7	SENT_66	[p5l350t683r408b755],
3	was	VBD	O	be	cop	7	SENT_66	[p5l445t703r608b756],
4	a	DT	O	a	det	7	SENT_66	[p5l649t703r693b754],
5	phase	NN	O	phase	nn	7	SENT_66	[p5l729t677r978b776],
6	2	CD	NUMBER	2	num	7	SENT_66	[p5l1018t683r1065b754],
7	study	NN	O	study	_	0	SENT_66	[p5l1107t677r1337b776],
8	in	IN	O	in	_	0	SENT_66	[p5l1371t678r1454b754],
9	which	WDT	O	which	rel	13	SENT_66	[p5l1489t677r1751b756],
10	patients	NNS	O	patient	nsubjpass	13	SENT_66	[p5l1789t678r2131b776],
11	were	VBD	O	be	auxpass	13	SENT_66	[p5l7t831r205b884],
12	randomly	RB	O	randomly	advmod	13	SENT_66	[p5l240t805r648b905],
13	assigned	VBN	O	assign	rcmod	7	SENT_66	[p5l678t805r1043b906],
14	in	IN	O	in	_	0	SENT_66	[p5l1077t806r1160b883],
15	a	DT	O	a	det	17	SENT_66	[p5l1194t831r1239b883],
16	1:1:1	CD	NUMBER	1:1:1	num	17	SENT_66	[p5l1275t811r1469b884],
17	ratio	NN	O	ratio	prep_in	13	SENT_66	[p5l1504t806r1697b884],
18	to	TO	O	to	aux	19	SENT_66	[p5l1734t822r1814b884],
19	receive	VB	O	receive	xcomp	13	SENT_66	[p5l1850t806r2133b884],
20	150	CD	NUMBER	150	num	21	SENT_66	[p5l15t939r161b1012],
21	mg	NN	O	mg	dobj	19	SENT_66	[p5l200t959r338b1034],
22	of	IN	O	of	_	0	SENT_66	[p5l374t932r473b1012],
23	dabrafenib	NN	O	dabrafenib	prep_of	21	SENT_66	[p5l494t932r948b1012],
24	twice	RB	O	twice	advmod	25	SENT_66	[p5l989t934r1212b1012],
25	daily	RB	SET	daily	advmod	19	SENT_66	[p5l1251t933r1454b1033],
26	plus	CC	O	plus	_	0	SENT_66	[p5l1487t933r1659b1033],
27	once	RB	DATE	once	advmod	7	SENT_66	[p5l1702t933r2138b1033],
28	—	RB	O	—	advmod	29	SENT_66	[p5l1702t933r2138b1033],
29	daily	JJ	SET	daily	amod	30	SENT_66	[p5l1702t933r2138b1033],
30	trametinib	NN	O	trametinib	dep	7	SENT_66	[p5l12t1061r482b1157],
31	,	,	O	,	_	0	SENT_66	[p5l12t1061r482b1157],
32	at	IN	O	at	_	0	SENT_66	[p5l521t1078r599b1139],
33	a	DT	O	a	det	34	SENT_66	[p5l627t1087r671b1139],
34	dose	NN	O	dose	prep_at	30	SENT_66	[p5l705t1061r896b1140],
35	of	IN	O	of	_	0	SENT_66	[p5l931t1060r1029b1140],
36	either	CC	O	either	preconj	40	SENT_66	[p5l1046t1061r1287b1140],
37	1	CD	NUMBER	1	num	40	SENT_66	[p5l1321t1067r1365b1139],
38	mg	NN	O	mg	nn	40	SENT_66	[p5l1400t1087r1538b1162],
39	(	NN	O	(	nn	40	SENT_66	[p5l1574t1061r2133b1152],
40	combination	NN	O	combination	prep_of	34	SENT_66	[p5l1574t1061r2133b1152],
41	150/1	CD	NUMBER	150/1	number	42	SENT_66	[p5l15t1194r263b1280],
42	)	CD	NUMBER	)	dep	40	SENT_66	[p5l15t1194r263b1280],
43	or	CC	O	or	_	0	SENT_66	[p5l302t1215r390b1268],
44	2	CD	NUMBER	2	num	47	SENT_66	[p5l420t1195r467b1267],
45	mg	NN	O	mg	nn	47	SENT_66	[p5l502t1215r639b1290],
46	(	NN	O	(	nn	47	SENT_66	[p5l674t1189r1234b1280],
47	combination	NN	O	combination	prep_of	34	SENT_66	[p5l674t1189r1234b1280],
48	150/2	CD	NUMBER	150/2	num	49	SENT_66	[p5l1271t1194r1543b1285],
49	)	NN	O	)	dep	30	SENT_66	[p5l1271t1194r1543b1285],
50	,	,	O	,	_	0	SENT_66	[p5l1271t1194r1543b1285],
51	or	CC	O	or	_	0	SENT_66	[p5l1583t1215r1671b1268],
52	150	CD	NUMBER	150	num	53	SENT_66	[p5l1704t1195r1850b1268],
53	mg	NN	O	mg	conj_or	7	SENT_66	[p5l1885t1215r2022b1290],
54	of	IN	O	of	_	0	SENT_66	[p5l2054t1188r2152b1268],
55	dabrafenib	NN	O	dabrafenib	nn	56	SENT_66	[p5l12t1315r466b1395],
56	monotherapy	NN	O	monotherapy	prep_of	53	SENT_66	[p5l498t1316r1061b1416],
57	twice	RB	O	twice	advmod	58	SENT_66	[p5l1088t1317r1310b1396],
58	daily	RB	SET	daily	advmod	56	SENT_66	[p5l1342t1316r1556b1416],
59	.	.	O	.	_	0	SENT_66	[p5l1342t1316r1556b1416],

1	Patients	NNS	O	patient	nsubj	13	SENT_67	[p5l1592t1317r1924b1394],
2	who	WP	O	who	nsubj	3	SENT_67	[p5l1952t1316r2132b1396],
3	had	VBD	O	have	rcmod	1	SENT_67	[p5l11t1445r166b1524],
4	disease	NN	O	disease	nn	5	SENT_67	[p5l208t1445r511b1524],
5	progression	NN	O	progression	dobj	3	SENT_67	[p5l551t1446r1052b1546],
6	while	IN	O	while	_	0	SENT_67	[p5l1089t1445r1320b1524],
7	receiving	VBG	O	receive	prepc_while	3	SENT_67	[p5l1362t1446r1744b1546],
8	dabrafe	JJ	O	dabrafe	amod	11	SENT_67	[p5l1783t1444r2132b1524],
9	—	NN	O	—	nn	11	SENT_67	[p5l1783t1444r2132b1524],
10	nib	NN	O	nib	nn	11	SENT_67	[p5l11t1573r145b1651],
11	monotherapy	NN	O	monotherapy	dobj	7	SENT_67	[p5l180t1573r743b1672],
12	could	MD	O	could	aux	13	SENT_67	[p5l773t1573r1003b1652],
13	cross	VB	O	cross	_	0	SENT_67	[p5l1036t1599r1250b1651],
14	over	IN	O	over	prt	13	SENT_67	[p5l1285t1599r1461b1652],
15	to	TO	O	to	aux	16	SENT_67	[p5l1491t1590r1572b1651],
16	receive	VB	O	receive	xcomp	13	SENT_67	[p5l1606t1574r1889b1652],
17	combination	NN	O	combination	dobj	16	SENT_67	[p5l1922t1599r2132b1651, p5l12t1700r356b1779],
18	150/2	CD	NUMBER	150/2	num	17	SENT_67	[p5l389t1706r629b1790],
19	.	.	O	.	_	0	SENT_67	[p5l389t1706r629b1790],

1	Primary	JJ	O	primary	amod	3	SENT_68	[p5l662t1701r999b1800],
2	end	NN	O	end	nn	3	SENT_68	[p5l1024t1700r1173b1779],
3	points	NNS	O	point	_	0	SENT_68	[p5l1200t1701r1458b1800],
4	for	IN	O	for	_	0	SENT_68	[p5l1489t1699r1609b1779],
5	this	DT	O	this	det	6	SENT_68	[p5l1635t1700r1787b1778],
6	portion	NN	O	portion	prep_for	3	SENT_68	[p5l1818t1701r2133b1800],

1	N	NN	O	n	nn	3	SENT_69	[p5l543t1865r557b1880],
2	ENGLJ	NN	O	englj	nn	3	SENT_69	[p5l572t1865r650b1887],
3	MED	NN	O	med	_	0	SENT_69	[p5l664t1865r716b1880],
4	7	CD	NUMBER	7	dep	3	SENT_69	[p5l757t1859r804b1886],
5	;	:	O	;	_	0	SENT_69	[p5l757t1859r804b1886],
6	18	CD	NUMBER	18	num	8	SENT_69	[p5l757t1859r804b1886],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_69	[p5l839t1865r963b1887],
8	NOVEMBERL2012	NN	O	novemberl2012	dep	4	SENT_69	[p5l1000t1865r1231b1885],
9	1595	CD	DATE	1595	dep	8	SENT_69	[p5l1940t1854r2015b1878],

1	e	LS	O	e	dep	4	SENT_70	[p5l739t1906r753b1922],
2	New	NNP	O	New	nn	4	SENT_70	[p5l762t1899r824b1922],
3	England	NNP	O	England	nn	4	SENT_70	[p5l833t1898r944b1929],
4	Journal	NNP	O	Journal	_	0	SENT_70	[p5l953t1898r1050b1922],
5	of	IN	O	of	prep	4	SENT_70	[p5l1060t1898r1089b1922],
6	Medicine	NNP	O	Medicine	dep	4	SENT_70	[p5l1095t1898r1220b1922],

1	Copyright	NN	O	copyright	_	0	SENT_71	[p5l494t1980r629b2011],
2	©	CD	NUMBER	©	num	6	SENT_71	[p5l638t1980r661b2004],
3	2012	CD	DATE	2012	num	6	SENT_71	[p5l672t1980r736b2004],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_71	[p5l746t1980r937b2004],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_71	[p5l947t1980r1055b2004],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_71	[p5l1066t1980r1170b2011],
7	.	.	O	.	_	0	SENT_71	[p5l1066t1980r1170b2011],

1	All	DT	O	all	det	2	SENT_72	[p5l1182t1980r1223b2004],
2	rights	NNS	O	rights	nsubj	3	SENT_72	[p5l1232t1980r1307b2011],
3	reserved	VBN	O	reserve	_	0	SENT_72	[p5l1316t1980r1435b2004],
4	.	.	O	.	_	0	SENT_72	[p5l1316t1980r1435b2004],

1	The	DT	O	the	det	4	SENT_73	[p5l673t2086r718b2107],
2	NEW	NNP	O	NEW	nn	4	SENT_73	[p5l737t2088r822b2107],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_73	[p5l841t2088r1029b2107],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_73	[p5l1048t2088r1227b2114],
5	of	IN	O	of	_	0	SENT_73	[p5l1247t2086r1275b2113],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_73	[p5l1287t2088r1486b2107],

1	of	IN	O	of	_	0	SENT_74	[p5l20t2308r121b2388],
2	the	DT	O	the	det	3	SENT_74	[p5l164t2309r297b2387],
3	study	NN	O	study	prep_of	4	SENT_74	[p5l359t2309r590b2409],
4	were	VBD	O	be	_	0	SENT_74	[p5l641t2335r844b2389],
5	the	DT	O	the	det	6	SENT_74	[p5l905t2309r1038b2387],
6	incidence	NN	O	incidence	nsubj	4	SENT_74	[p5l1099t2309r1505b2388],
7	of	IN	O	of	_	0	SENT_74	[p5l1567t2308r1667b2388],
8	cutaneous	JJ	O	cutaneous	amod	12	SENT_74	[p5l1710t2326r2147b2389],
9	squamous	JJ	O	squamous	amod	12	SENT_74	[p5l21t2438r622b2538],
10	—	NN	O	—	nn	12	SENT_74	[p5l21t2438r622b2538],
11	cell	NN	O	cell	nn	12	SENT_74	[p5l21t2438r622b2538],
12	carcinoma	NN	O	carcinoma	prep_of	6	SENT_74	[p5l659t2439r1116b2534],
13	,	,	O	,	_	0	SENT_74	[p5l659t2439r1116b2534],
14	progression	NN	O	progression	nsubj	4	SENT_74	[p5l1157t2437r1835b2539],
15	—	CD	NUMBER	—	num	17	SENT_74	[p5l1157t2437r1835b2539],
16	free	JJ	O	free	amod	17	SENT_74	[p5l1157t2437r1835b2539],
17	survival	NN	O	survival	dep	14	SENT_74	[p5l1875t2439r2147b2517, p5l19t2565r115b2661],
18	,	,	O	,	_	0	SENT_74	[p5l1875t2439r2147b2517, p5l19t2565r115b2661],
19	response	NN	O	response	nn	20	SENT_74	[p5l159t2591r533b2665],
20	rate	NN	O	rate	conj_and	6	SENT_74	[p5l571t2582r750b2661],
21	,	,	O	,	_	0	SENT_74	[p5l571t2582r750b2661],
22	duration	NN	O	duration	nsubj	4	SENT_74	[p5l795t2565r1155b2644],
23	of	IN	O	of	_	0	SENT_74	[p5l1194t2564r1293b2644],
24	response	NN	O	response	prep_of	22	SENT_74	[p5l1313t2591r1709b2665],
25	,	,	O	,	_	0	SENT_74	[p5l1313t2591r1709b2665],
26	and	CC	O	and	_	0	SENT_74	[p5l1753t2565r1909b2644],
27	safety	NN	O	safety	conj_and	6	SENT_74	[p5l1948t2564r2147b2643, p5l20t2711r111b2794],
28	.	.	O	.	_	0	SENT_74	[p5l1948t2564r2147b2643, p5l20t2711r111b2794],

1	Secondary	JJ	O	secondary	amod	3	SENT_75	[p5l165t2694r611b2794],
2	end	NN	O	end	nn	3	SENT_75	[p5l654t2694r807b2773],
3	points	NNS	O	point	nsubj	6	SENT_75	[p5l852t2695r1121b2794],
4	were	VBD	O	be	cop	6	SENT_75	[p5l1165t2720r1368b2773],
5	pharmacokinetic	JJ	O	pharmacokinetic	amod	6	SENT_75	[p5l1412t2694r2149b2794],
6	activity	NN	O	activity	_	0	SENT_75	[p5l19t2824r315b2923],
7	and	CC	O	and	_	0	SENT_75	[p5l338t2823r492b2902],
8	overall	JJ	O	overall	amod	9	SENT_75	[p5l522t2823r795b2902],
9	survival	NN	O	survival	conj_and	6	SENT_75	[p5l825t2823r1163b2903],
10	.	.	O	.	_	0	SENT_75	[p5l825t2823r1163b2903],

1	In	IN	O	in	_	0	SENT_76	[p5l1196t2831r1283b2901],
2	part	NN	O	part	nn	3	SENT_76	[p5l1310t2840r1483b2923],
3	C	NN	O	c	prep_in	9	SENT_76	[p5l1507t2829r1565b2902],
4	only	RB	O	only	advmod	9	SENT_76	[p5l1597t2823r1786b2923],
5	,	,	O	,	_	0	SENT_76	[p5l1597t2823r1786b2923],
6	patients	NNS	O	patient	nsubj	9	SENT_76	[p5l1819t2824r2146b2923],
7	could	MD	O	could	aux	9	SENT_76	[p5l20t2952r251b3031],
8	have	VB	O	have	aux	9	SENT_76	[p5l284t2952r472b3031],
9	undergone	VBN	O	undergo	_	0	SENT_76	[p5l505t2952r957b3053],
10	no	DT	O	no	det	16	SENT_76	[p5l991t2978r1095b3031],
11	more	JJR	O	more	mwe	12	SENT_76	[p5l1130t2978r1347b3031],
12	than	IN	O	than	quantmod	13	SENT_76	[p5l1381t2952r1575b3030],
13	one	CD	NUMBER	one	num	16	SENT_76	[p5l1609t2978r1758b3031],
14	previous	JJ	O	previous	amod	16	SENT_76	[p5l1791t2953r2146b3052],
15	chemotherapy	NN	O	chemotherapy	nn	16	SENT_76	[p5l20t3080r622b3180],
16	regimen	NN	O	regimen	dobj	9	SENT_76	[p5l646t3081r997b3181],
17	for	IN	O	for	_	0	SENT_76	[p5l1028t3079r1149b3159],
18	advanced	JJ	O	advanced	amod	21	SENT_76	[p5l1175t3080r1565b3159],
19	or	CC	O	or	_	0	SENT_76	[p5l1595t3106r1684b3159],
20	metastatic	JJ	O	metastatic	conj_or	18	SENT_76	[p5l1710t3081r2149b3158],
21	melanoma	NN	O	melanoma	prep_for	16	SENT_76	[p5l20t3208r491b3304],
22	,	,	O	,	_	0	SENT_76	[p5l20t3208r491b3304],
23	but	CC	O	but	_	0	SENT_76	[p5l530t3208r668b3287],
24	those	DT	O	those	nsubj	35	SENT_76	[p5l695t3208r923b3287],
25	who	WP	O	who	nsubj	28	SENT_76	[p5l951t3208r1132b3288],
26	had	VBD	O	have	aux	28	SENT_76	[p5l1166t3208r1320b3287],
27	previously	RB	DATE	previously	advmod	28	SENT_76	[p5l1351t3208r1782b3308],
28	received	VBN	O	receive	rcmod	24	SENT_76	[p5l1810t3208r2148b3287],
29	BRAF	NN	O	braf	nn	32	SENT_76	[p5l19t3343r263b3420],
30	or	CC	O	or	_	0	SENT_76	[p5l305t3363r394b3416],
31	MEK	NN	O	mek	conj_or	29	SENT_76	[p5l427t3345r641b3418],
32	inhibitors	NNS	O	inhibitor	dobj	28	SENT_76	[p5l677t3337r1100b3416],
33	were	VBD	O	be	cop	35	SENT_76	[p5l1137t3363r1340b3416],
34	not	RB	O	not	neg	35	SENT_76	[p5l1379t3354r1522b3416],
35	eligible	JJ	O	eligible	conj_but	9	SENT_76	[p5l1558t3337r1892b3438],
36	.	.	O	.	_	0	SENT_76	[p5l1558t3337r1892b3438],

1	sru	NN	O	sru	nn	3	SENT_77	[p5l20t3612r163b3662],
2	DY	NNP	O	DY	nn	3	SENT_77	[p5l182t3613r276b3661],
3	OVERSIGHT	NNP	O	OVERSIGHT	nsubjpass	7	SENT_77	[p5l309t3612r771b3662],
4	The	NNP	O	The	nn	5	SENT_77	[p5l16t3711r175b3789],
5	protocol	NN	O	protocol	dep	3	SENT_77	[p5l206t3711r560b3811],
6	was	VBD	O	be	auxpass	7	SENT_77	[p5l587t3737r747b3791],
7	approved	VBN	O	approve	_	0	SENT_77	[p5l781t3711r1164b3811],
8	by	IN	O	by	_	0	SENT_77	[p5l1196t3711r1292b3811],
9	the	DT	O	the	det	11	SENT_77	[p5l1320t3711r1451b3789],
10	institutional	JJ	O	institutional	amod	11	SENT_77	[p5l1482t3711r2004b3790],
11	reView	NN	O	review	agent	7	SENT_77	[p5l2035t3737r2147b3789, p6l15t25r211b103],

1	board	NN	O	board	nsubj	9	SENT_78	[p6l240t24r489b103],
2	at	IN	O	at	_	0	SENT_78	[p6l522t41r601b102],
3	each	DT	O	each	det	5	SENT_78	[p6l629t24r822b103],
4	participating	VBG	O	participate	amod	5	SENT_78	[p6l854t25r1416b125],
5	center	NN	O	center	prep_at	1	SENT_78	[p6l1448t41r1711b103],
6	and	CC	O	and	_	0	SENT_78	[p6l1740t24r1899b103],
7	com	NN	O	com	nn	8	SENT_78	[p6l1933t50r2147b103],
8	—	NN	O	—	prep_at	1	SENT_78	[p6l1933t50r2147b103],
9	plied	VBD	O	ply	_	0	SENT_78	[p6l19t152r231b252],
10	with	IN	O	with	_	0	SENT_78	[p6l286t152r482b231],
11	country	NN	O	country	nn	13	SENT_78	[p6l543t151r1241b252],
12	—	CD	NUMBER	—	num	13	SENT_78	[p6l543t151r1241b252],
13	specif1c	NN	O	specif1c	prep_with	9	SENT_78	[p6l543t151r1241b252],
14	regulatory	JJ	O	regulatory	amod	15	SENT_78	[p6l1301t152r1751b253],
15	requirements	NNS	O	requirement	dobj	9	SENT_78	[p6l1806t153r2147b252, p6l20t297r306b359],
16	.	.	O	.	_	0	SENT_78	[p6l1806t153r2147b252, p6l20t297r306b359],

1	The	DT	O	the	det	2	SENT_79	[p6l355t280r516b358],
2	study	NN	O	study	nsubjpass	4	SENT_79	[p6l565t280r795b380],
3	Was	VBD	O	be	auxpass	4	SENT_79	[p6l834t306r997b360],
4	conducted	VBN	O	conduct	_	0	SENT_79	[p6l1047t280r1490b359],
5	in	IN	O	in	_	0	SENT_79	[p6l1536t281r1619b358],
6	accordance	NN	O	accordance	prep_in	4	SENT_79	[p6l1665t280r2148b359],
7	With	IN	O	with	_	0	SENT_79	[p6l15t408r208b488],
8	the	DT	O	the	det	9	SENT_79	[p6l242t408r372b486],
9	provisions	NNS	O	provision	prep_with	4	SENT_79	[p6l404t409r838b508],
10	of	IN	O	of	_	0	SENT_79	[p6l875t407r974b487],
11	the	DT	O	the	det	12	SENT_79	[p6l989t408r1120b486],
12	Declaration	NN	O	declaration	prep_of	9	SENT_79	[p6l1152t408r1644b487],
13	of	IN	O	of	_	0	SENT_79	[p6l1678t407r1777b487],
14	Helsinki	NNP	LOCATION	Helsinki	prep_of	12	SENT_79	[p6l1792t408r2149b488],
15	and	CC	O	and	_	0	SENT_79	[p6l19t537r176b616],
16	Good	JJ	O	good	amod	19	SENT_79	[p6l215t537r450b616],
17	Clinical	JJ	O	clinical	amod	19	SENT_79	[p6l490t537r815b616],
18	Practice	NN	O	practice	nn	19	SENT_79	[p6l853t538r1184b615],
19	guidelines	NNS	O	guideline	prep_of	12	SENT_79	[p6l1224t537r1684b638],
20	.	.	O	.	_	0	SENT_79	[p6l1224t537r1684b638],

1	The	DT	O	the	det	2	SENT_80	[p6l1726t537r1884b615],
2	study	NN	O	study	nsubjpass	4	SENT_80	[p6l1926t537r2152b637],
3	was	VBD	O	be	auxpass	4	SENT_80	[p6l15t691r176b744],
4	designed	VBN	O	design	_	0	SENT_80	[p6l230t665r613b766],
5	by	IN	O	by	_	0	SENT_80	[p6l666t665r763b765],
6	the	DT	O	the	det	8	SENT_80	[p6l812t665r944b744],
7	academic	JJ	O	academic	amod	8	SENT_80	[p6l997t665r1398b744],
8	authors	NNS	O	author	agent	4	SENT_80	[p6l1449t665r1773b744],
9	in	IN	O	in	_	0	SENT_80	[p6l1827t666r1910b743],
10	conjunction	NN	O	conjunction	prep_in	8	SENT_80	[p6l1963t691r2147b744, p6l6t793r374b892],
11	With	IN	O	with	_	0	SENT_80	[p6l440t792r636b872],
12	representatives	NNS	O	representative	prep_with	4	SENT_80	[p6l706t793r1351b892],
13	of	IN	O	of	_	0	SENT_80	[p6l1424t791r1524b871],
14	the	DT	O	the	det	15	SENT_80	[p6l1576t792r1709b870],
15	sponsor	NN	O	sponsor	prep_of	12	SENT_80	[p6l1781t818r2143b892],
16	,	,	O	,	_	0	SENT_80	[p6l1781t818r2143b892],
17	GlaXoSmithKline	NNP	ORGANIZATION	GlaXoSmithKline	appos	15	SENT_80	[p6l20t921r792b1002],
18	.	.	O	.	_	0	SENT_80	[p6l20t921r792b1002],

1	The	DT	O	the	det	2	SENT_81	[p6l828t921r989b999],
2	data	NNS	O	datum	nsubjpass	9	SENT_81	[p6l1024t921r1207b1000],
3	were	VBD	O	be	auxpass	4	SENT_81	[p6l1235t947r1437b1000],
4	collected	VBN	O	collect	_	0	SENT_81	[p6l1472t921r1853b1000],
5	by	IN	O	by	_	0	SENT_81	[p6l1888t921r1985b1021],
6	the	DT	O	the	det	7	SENT_81	[p6l2015t921r2148b999],
7	sponsor	NN	O	sponsor	agent	4	SENT_81	[p6l21t1076r366b1150],
8	and	CC	O	and	_	0	SENT_81	[p6l407t1050r565b1129],
9	analyzed	VBN	O	analyze	conj_and	4	SENT_81	[p6l608t1050r988b1150],
10	in	IN	O	in	_	0	SENT_81	[p6l1032t1051r1116b1128],
11	collaboration	NN	O	collaboration	prep_in	9	SENT_81	[p6l1161t1050r1734b1129],
12	with	IN	O	with	_	0	SENT_81	[p6l1774t1050r1970b1129],
13	the	DT	O	the	det	14	SENT_81	[p6l2015t1050r2148b1128],
14	authors	NNS	O	author	prep_with	9	SENT_81	[p6l19t1178r367b1258],
15	.	.	O	.	_	0	SENT_81	[p6l19t1178r367b1258],

1	The	DT	O	the	det	2	SENT_82	[p6l407t1178r568b1256],
2	authors	NNS	O	author	nsubj	3	SENT_82	[p6l606t1178r929b1258],
3	vouch	VBP	O	vouch	_	0	SENT_82	[p6l964t1178r1218b1258],
4	for	IN	O	for	_	0	SENT_82	[p6l1255t1177r1379b1257],
5	the	DT	O	the	det	6	SENT_82	[p6l1414t1178r1548b1256],
6	accuracy	NN	O	accuracy	prep_for	3	SENT_82	[p6l1585t1204r1958b1278],
7	and	CC	O	and	_	0	SENT_82	[p6l1990t1178r2148b1257],
8	completeness	NN	O	completeness	prep_for	3	SENT_82	[p6l21t1306r600b1406],
9	of	IN	O	of	_	0	SENT_82	[p6l645t1305r745b1385],
10	the	DT	O	the	det	11	SENT_82	[p6l769t1306r902b1384],
11	data	NNS	O	datum	prep_of	6	SENT_82	[p6l945t1306r1129b1385],
12	and	CC	O	and	_	0	SENT_82	[p6l1169t1306r1327b1385],
13	the	DT	O	the	det	14	SENT_82	[p6l1369t1306r1502b1384],
14	fidelity	NN	O	fidelity	conj_and	6	SENT_82	[p6l1545t1305r1853b1406],
15	of	IN	O	of	_	0	SENT_82	[p6l1890t1305r1990b1385],
16	the	DT	O	the	det	17	SENT_82	[p6l2015t1306r2148b1384],
17	study	NN	O	study	prep_of	14	SENT_82	[p6l21t1435r252b1535],
18	to	TO	O	to	_	0	SENT_82	[p6l283t1452r364b1514],
19	the	DT	O	the	det	20	SENT_82	[p6l400t1435r534b1513],
20	protocol	NN	O	protocol	prep_to	3	SENT_82	[p6l567t1435r952b1535],
21	,	,	O	,	_	0	SENT_82	[p6l567t1435r952b1535],
22	which	WDT	O	which	nsubj	24	SENT_82	[p6l987t1435r1250b1515],
23	is	VBZ	O	be	cop	24	SENT_82	[p6l1285t1436r1350b1513],
24	available	JJ	O	available	rcmod	20	SENT_82	[p6l1387t1435r1759b1514],
25	at	IN	O	at	_	0	SENT_82	[p6l1793t1452r1872b1513],
26	N	NN	O	n	nn	27	SENT_82	[p6l1900t1443r1975b1514],
27	EJM	NN	O	ejm	prep_at	24	SENT_82	[p6l1978t1443r2147b1526],
28	.	.	O	.	_	0	SENT_82	[p6l24t1590r211b1665],

1	org	NN	O	org	_	0	SENT_83	[p6l24t1590r211b1665],
2	.	.	O	.	_	0	SENT_83	[p6l24t1590r211b1665],

1	The	DT	O	the	det	2	SENT_84	[p6l261t1564r422b1643],
2	manuscript	NN	O	manuscript	nsubjpass	4	SENT_84	[p6l470t1565r965b1664],
3	was	VBD	O	be	auxpass	4	SENT_84	[p6l1003t1590r1165b1643],
4	prepared	VBN	O	prepare	_	0	SENT_84	[p6l1214t1564r1598b1664],
5	by	IN	O	by	_	0	SENT_84	[p6l1646t1564r1743b1664],
6	the	DT	O	the	det	10	SENT_84	[p6l1787t1564r1920b1642],
7	first	JJ	ORDINAL	first	amod	10	SENT_84	[p6l1968t1563r2153b1642],
8	and	CC	O	and	_	0	SENT_84	[p6l19t1692r177b1771],
9	last	JJ	O	last	amod	10	SENT_84	[p6l215t1692r369b1770],
10	authors	NNS	O	author	agent	4	SENT_84	[p6l403t1692r750b1788],
11	,	,	O	,	_	0	SENT_84	[p6l403t1692r750b1788],
12	but	CC	O	but	_	0	SENT_84	[p6l796t1692r936b1771],
13	all	PDT	O	all	predet	15	SENT_84	[p6l969t1692r1073b1770],
14	the	DT	O	the	det	15	SENT_84	[p6l1113t1692r1245b1770],
15	authors	NNS	O	author	nsubj	16	SENT_84	[p6l1284t1692r1607b1771],
16	contributed	VBD	O	contribute	conj_but	4	SENT_84	[p6l1650t1692r2148b1771],
17	to	TO	O	to	_	0	SENT_84	[p6l20t1837r102b1899],
18	subsequent	JJ	O	subsequent	amod	19	SENT_84	[p6l142t1820r629b1920],
19	drafts	NNS	O	draft	prep_to	16	SENT_84	[p6l662t1819r940b1899],
20	.	.	O	.	_	0	SENT_84	[p6l662t1819r940b1899],

1	All	DT	O	all	det	2	SENT_85	[p6l980t1820r1104b1898],
2	authors	NNS	O	author	nsubj	3	SENT_85	[p6l1141t1820r1464b1900],
3	made	VBD	O	make	_	0	SENT_85	[p6l1504t1820r1736b1899],
4	the	DT	O	the	det	5	SENT_85	[p6l1774t1820r1907b1898],
5	decision	NN	O	decision	dobj	3	SENT_85	[p6l1945t1820r2147b1899, p6l21t1949r197b2027],
6	to	TO	O	to	aux	7	SENT_85	[p6l249t1965r331b2027],
7	submit	VB	O	submit	infmod	5	SENT_85	[p6l386t1948r685b2028],
8	the	DT	O	the	det	9	SENT_85	[p6l733t1948r866b2026],
9	manuscript	NN	O	manuscript	dobj	7	SENT_85	[p6l918t1949r1412b2048],
10	for	IN	O	for	_	0	SENT_85	[p6l1460t1947r1583b2027],
11	publication	NN	O	publication	prep_for	9	SENT_85	[p6l1630t1948r2143b2048],
12	.	.	O	.	_	0	SENT_85	[p6l1630t1948r2143b2048],

1	Editorial	NN	O	editorial	nn	2	SENT_86	[p6l19t2077r393b2156],
2	support	NN	O	support	nsubjpass	9	SENT_86	[p6l425t2094r759b2177],
3	that	WDT	O	that	nsubj	6	SENT_86	[p6l784t2077r957b2155],
4	did	VBD	O	do	aux	6	SENT_86	[p6l983t2077r1118b2156],
5	not	RB	O	not	neg	6	SENT_86	[p6l1148t2094r1292b2156],
6	involve	VB	O	involve	rcmod	2	SENT_86	[p6l1316t2077r1612b2156],
7	writing	VBG	O	write	xcomp	6	SENT_86	[p6l1638t2078r1961b2178],
8	was	VBD	O	be	auxpass	9	SENT_86	[p6l1983t2103r2146b2156],
9	provided	VBN	O	provide	_	0	SENT_86	[p6l19t2204r394b2304],
10	by	IN	O	by	_	0	SENT_86	[p6l433t2204r530b2304],
11	MediTech	NNP	ORGANIZATION	MediTech	nn	12	SENT_86	[p6l561t2204r980b2283],
12	Media	NNP	ORGANIZATION	Media	agent	9	SENT_86	[p6l1015t2204r1305b2300],
13	,	,	O	,	_	0	SENT_86	[p6l1015t2204r1305b2300],
14	which	WDT	O	which	nsubjpass	16	SENT_86	[p6l1344t2204r1607b2284],
15	was	VBD	O	be	auxpass	16	SENT_86	[p6l1641t2230r1804b2284],
16	funded	VBN	O	fund	rcmod	12	SENT_86	[p6l1844t2203r2148b2284],
17	by	IN	O	by	_	0	SENT_86	[p6l20t2333r118b2433],
18	the	DT	O	the	det	19	SENT_86	[p6l148t2333r282b2411],
19	sponsor	NN	O	sponsor	agent	16	SENT_86	[p6l318t2359r680b2433],
20	.	.	O	.	_	0	SENT_86	[p6l318t2359r680b2433],

1	STATISTICAL	JJ	O	statistical	amod	2	SENT_87	[p6l20t2608r511b2658],
2	ANALYSIS	NN	O	analysis	npadvmod	12	SENT_87	[p6l540t2608r917b2658],
3	For	IN	O	for	_	0	SENT_87	[p6l19t2714r159b2785],
4	parts	NNS	O	part	prep_for	12	SENT_87	[p6l191t2723r406b2806],
5	A	DT	O	a	dep	4	SENT_87	[p6l440t2714r506b2784],
6	and	CC	O	and	_	0	SENT_87	[p6l538t2706r694b2785],
7	B	NN	O	b	dep	4	SENT_87	[p6l729t2713r808b2802],
8	,	,	O	,	_	0	SENT_87	[p6l729t2713r808b2802],
9	we	PRP	O	we	nsubj	12	SENT_87	[p6l845t2732r962b2786],
10	did	VBD	O	do	aux	12	SENT_87	[p6l999t2706r1131b2785],
11	not	RB	O	not	neg	12	SENT_87	[p6l1167t2723r1308b2785],
12	test	VB	O	test	_	0	SENT_87	[p6l1339t2723r1491b2784],
13	any	DT	O	any	det	15	SENT_87	[p6l1521t2732r1670b2806],
14	formal	JJ	O	formal	amod	15	SENT_87	[p6l1701t2705r1986b2785],
15	hypotheses	NNS	O	hypothesis	dobj	12	SENT_87	[p6l2021t2706r2147b2806, p6l19t2835r406b2935],
16	;	:	O	;	_	0	SENT_87	[p6l2021t2706r2147b2806, p6l19t2835r406b2935],
17	all	DT	O	all	det	18	SENT_87	[p6l440t2835r541b2913],
18	analyses	NNS	O	analysis	nsubj	20	SENT_87	[p6l571t2835r916b2935],
19	were	VBD	O	be	cop	20	SENT_87	[p6l945t2861r1141b2915],
20	descriptive	JJ	O	descriptive	parataxis	12	SENT_87	[p6l1173t2835r1633b2935],
21	.	.	O	.	_	0	SENT_87	[p6l1173t2835r1633b2935],

1	The	DT	O	the	det	3	SENT_88	[p6l1666t2835r1823b2913],
2	sample	NN	O	sample	nn	3	SENT_88	[p6l1856t2835r2148b2935],
3	size	NN	O	size	nsubjpass	8	SENT_88	[p6l21t2964r183b3041],
4	for	IN	O	for	_	0	SENT_88	[p6l225t2962r348b3042],
5	part	NN	O	part	nn	6	SENT_88	[p6l385t2980r565b3063],
6	C	NN	O	c	prep_for	3	SENT_88	[p6l601t2969r658b3042],
7	was	VBD	O	be	auxpass	8	SENT_88	[p6l698t2989r860b3043],
8	based	VBN	O	base	_	0	SENT_88	[p6l905t2963r1149b3042],
9	on	IN	O	on	_	0	SENT_88	[p6l1191t2989r1297b3042],
10	the	DT	O	the	det	11	SENT_88	[p6l1338t2963r1472b3041],
11	demonstration	NN	O	demonstration	prep_on	8	SENT_88	[p6l1514t2963r2148b3042],
12	of	IN	O	of	_	0	SENT_88	[p6l20t3090r121b3170],
13	a	DT	O	a	det	14	SENT_88	[p6l129t3117r174b3169],
14	reduction	NN	O	reduction	prep_of	11	SENT_88	[p6l200t3091r610b3171],
15	in	IN	O	in	_	0	SENT_88	[p6l637t3092r720b3169],
16	the	DT	O	the	det	17	SENT_88	[p6l748t3091r881b3169],
17	rate	NN	O	rate	prep_in	14	SENT_88	[p6l909t3108r1069b3169],
18	of	IN	O	of	_	0	SENT_88	[p6l1098t3090r1198b3170],
19	cutaneous	JJ	O	cutaneous	amod	21	SENT_88	[p6l1208t3108r1644b3171],
20	squamouscell	NN	O	squamouscell	nn	21	SENT_88	[p6l1675t3117r2147b3191, p6l20t3220r167b3298],
21	carcinoma	NN	O	carcinoma	prep_of	17	SENT_88	[p6l199t3221r653b3299],
22	from	IN	O	from	_	0	SENT_88	[p6l682t3219r893b3299],
23	20	CD	PERCENT	20	num	24	SENT_88	[p6l925t3226r1112b3299],
24	%	NN	PERCENT	%	prep_from	8	SENT_88	[p6l925t3226r1112b3299],
25	with	IN	O	with	_	0	SENT_88	[p6l1139t3220r1335b3299],
26	dabrafenib	NN	O	dabrafenib	nn	27	SENT_88	[p6l1367t3219r1831b3299],
27	monotherapy	NN	O	monotherapy	prep_with	24	SENT_88	[p6l1864t3246r2147b3299, p6l20t3348r343b3448],
28	to	TO	O	to	_	0	SENT_88	[p6l378t3365r460b3427],
29	3	CD	PERCENT	3	num	30	SENT_88	[p6l503t3353r635b3427],
30	%	NN	PERCENT	%	prep_to	8	SENT_88	[p6l503t3353r635b3427],
31	with	IN	O	with	_	0	SENT_88	[p6l669t3348r865b3428],
32	combination	NN	O	combination	nn	33	SENT_88	[p6l906t3348r1453b3427],
33	therapy	NN	O	therapy	prep_with	30	SENT_88	[p6l1493t3348r1829b3448],
34	,	,	O	,	_	0	SENT_88	[p6l1493t3348r1829b3448],
35	with	IN	O	with	_	0	SENT_88	[p6l1870t3348r2065b3428],
36	a	DT	O	a	det	37	SENT_88	[p6l2105t3374r2149b3426],
37	power	NN	O	power	prep_with	8	SENT_88	[p6l19t3502r287b3576],
38	of	IN	O	of	_	0	SENT_88	[p6l324t3475r425b3555],
39	82	CD	PERCENT	82	num	40	SENT_88	[p6l447t3482r632b3555],
40	%	NN	PERCENT	%	prep_of	37	SENT_88	[p6l447t3482r632b3555],
41	and	CC	O	and	_	0	SENT_88	[p6l671t3476r829b3555],
42	a	DT	O	a	det	46	SENT_88	[p6l869t3502r913b3554],
43	type	NN	O	type	nn	46	SENT_88	[p6l952t3493r1134b3576],
44	I	CD	NUMBER	i	num	46	SENT_88	[p6l1172t3484r1203b3554],
45	error	NN	O	error	nn	46	SENT_88	[p6l1242t3502r1456b3555],
46	rate	NN	O	rate	prep_with	8	SENT_88	[p6l1492t3493r1653b3554],
47	of	IN	O	of	_	0	SENT_88	[p6l1694t3475r1794b3555],
48	5	CD	PERCENT	5	num	49	SENT_88	[p6l1818t3481r1973b3556],
49	%	NN	PERCENT	%	prep_of	46	SENT_88	[p6l1818t3481r1973b3556],
50	.	.	O	.	_	0	SENT_88	[p6l1818t3481r1973b3556],

1	We	PRP	O	we	nsubj	2	SENT_89	[p6l2015t3484r2148b3554],
2	based	VBD	O	base	_	0	SENT_89	[p6l20t3604r266b3683],
3	the	DT	O	the	det	4	SENT_89	[p6l306t3604r439b3682],
4	choice	NN	O	choice	dobj	2	SENT_89	[p6l480t3604r751b3683],
5	of	IN	O	of	_	0	SENT_89	[p6l791t3603r892b3683],
6	this	DT	O	this	det	9	SENT_89	[p6l914t3604r1073b3682],
7	primary	JJ	O	primary	amod	9	SENT_89	[p6l1114t3605r1465b3704],
8	end	NN	O	end	nn	9	SENT_89	[p6l1501t3604r1655b3683],
9	point	NN	O	point	prep_of	4	SENT_89	[p6l1694t3605r1924b3704],
10	on	IN	O	on	_	0	SENT_89	[p6l1960t3630r2066b3683],
11	a	DT	O	a	det	14	SENT_89	[p6l2105t3630r2150b3682],
12	preclinical	JJ	O	preclinical	amod	14	SENT_89	[p7l19t22r454b122],
13	scientiﬁc	NN	O	scientiﬁc	nn	14	SENT_89	[p7l480t21r855b101],
14	hypothesis	NN	O	hypothesis	prep_on	9	SENT_89	[p7l879t22r1323b122],
15	that	IN	O	that	complm	20	SENT_89	[p7l1351t22r1517b100],
16	this	DT	O	this	det	18	SENT_89	[p7l1537t22r1690b100],
17	drug	NN	O	drug	nn	18	SENT_89	[p7l1719t22r1917b123],
18	combination	NN	O	combination	nsubj	20	SENT_89	[p7l1939t48r2147b101, p7l20t149r366b228],
19	Would	MD	O	would	aux	20	SENT_89	[p7l399t149r665b229],
20	attenuate	VB	O	attenuate	ccomp	2	SENT_89	[p7l703t166r1100b229],
21	the	DT	O	the	det	22	SENT_89	[p7l1140t149r1273b227],
22	development	NN	O	development	dobj	20	SENT_89	[p7l1313t149r1864b249],
23	of	IN	O	of	_	0	SENT_89	[p7l1898t148r1998b228],
24	cutaneous	JJ	O	cutaneous	amod	28	SENT_89	[p7l2020t175r2147b228, p7l20t296r356b358],
25	squamous	JJ	O	squamous	amod	28	SENT_89	[p7l395t279r1020b379],
26	—	NN	O	—	nn	28	SENT_89	[p7l395t279r1020b379],
27	cell	NN	O	cell	nn	28	SENT_89	[p7l395t279r1020b379],
28	carcinoma	NN	O	carcinoma	prep_of	22	SENT_89	[p7l1055t280r1532b358],
29	.	.	O	.	_	0	SENT_89	[p7l1055t280r1532b358],

1	Efficacy	NN	O	efficacy	nn	2	SENT_90	[p7l148t406r490b507],
2	analyses	NNS	O	analysis	nsubjpass	4	SENT_90	[p7l519t407r871b507],
3	were	VBD	O	be	auxpass	4	SENT_90	[p7l903t433r1103b487],
4	performed	VBN	O	perform	_	0	SENT_90	[p7l1135t406r1584b507],
5	in	IN	O	in	_	0	SENT_90	[p7l1618t408r1700b485],
6	the	DT	O	the	det	7	SENT_90	[p7l1735t407r1866b485],
7	intention	NN	O	intention	prep_in	4	SENT_90	[p7l1901t408r2147b485, p7l20t536r523b614],
8	—	CD	NUMBER	—	number	10	SENT_90	[p7l1901t408r2147b485, p7l20t536r523b614],
9	to	TO	O	to	dep	10	SENT_90	[p7l1901t408r2147b485, p7l20t536r523b614],
10	—	CD	NUMBER	—	num	12	SENT_90	[p7l1901t408r2147b485, p7l20t536r523b614],
11	treat	NN	O	treat	nn	12	SENT_90	[p7l1901t408r2147b485, p7l20t536r523b614],
12	population	NN	O	population	dobj	32	SENT_90	[p7l547t535r1000b635],
13	in	IN	O	in	_	0	SENT_90	[p7l1030t536r1112b613],
14	part	NN	O	part	prep_in	12	SENT_90	[p7l1141t552r1315b635],
15	C.	FW	O	c.	dep	14	SENT_90	[p7l1341t541r1421b614],
16	The	DT	O	the	det	18	SENT_90	[p7l1454t535r1611b613],
17	prespecified	JJ	O	prespecified	amod	18	SENT_90	[p7l1641t534r2148b635],
18	rate	NN	O	rate	nsubj	32	SENT_90	[p7l20t681r180b743],
19	of	IN	O	of	_	0	SENT_90	[p7l222t663r322b743],
20	progression	NN	O	progression	nn	21	SENT_90	[p7l343t665r856b765],
21	events	NNS	O	event	prep_of	18	SENT_90	[p7l897t681r1161b743],
22	required	VBN	O	require	partmod	21	SENT_90	[p7l1205t664r1567b764],
23	for	IN	O	for	_	0	SENT_90	[p7l1608t663r1731b743],
24	the	DT	O	the	det	26	SENT_90	[p7l1770t664r1902b742],
25	final	JJ	O	final	amod	26	SENT_90	[p7l1944t663r2148b742],
26	analysis	NN	O	analysis	prep_for	22	SENT_90	[p7l19t792r353b892],
27	in	IN	O	in	_	0	SENT_90	[p7l388t793r470b870],
28	part	NN	O	part	nn	29	SENT_90	[p7l503t809r680b892],
29	C	NN	O	c	prep_in	26	SENT_90	[p7l708t798r767b871],
30	was	VBD	O	be	cop	32	SENT_90	[p7l798t818r959b872],
31	70	CD	PERCENT	70	num	32	SENT_90	[p7l996t797r1178b871],
32	%	NN	PERCENT	%	rcmod	7	SENT_90	[p7l996t797r1178b871],
33	across	IN	O	across	_	0	SENT_90	[p7l1211t818r1472b871],
34	the	DT	O	the	det	37	SENT_90	[p7l1509t792r1640b870],
35	three	CD	NUMBER	three	num	37	SENT_90	[p7l1674t792r1891b870],
36	study	NN	O	study	nn	37	SENT_90	[p7l1926t792r2152b892],
37	groups	NNS	O	group	prep_across	32	SENT_90	[p7l20t947r341b1022],
38	,	,	O	,	_	0	SENT_90	[p7l20t947r341b1022],
39	which	WDT	O	which	nsubjpass	41	SENT_90	[p7l377t921r640b1000],
40	was	VBD	O	be	auxpass	41	SENT_90	[p7l671t947r834b1000],
41	reached	VBN	O	reach	rcmod	37	SENT_90	[p7l870t921r1204b1000],
42	on	IN	O	on	_	0	SENT_90	[p7l1239t947r1345b1000],
43	May	NNP	DATE	May	prep_on	41	SENT_90	[p7l1377t929r1558b1021],
44	31	CD	DATE	31	num	43	SENT_90	[p7l1590t927r1708b1017],
45	,	,	DATE	,	_	0	SENT_90	[p7l1590t927r1708b1017],
46	2012	CD	DATE	2012	num	43	SENT_90	[p7l1749t927r1978b1000],
47	.	.	O	.	_	0	SENT_90	[p7l1749t927r1978b1000],

1	We	PRP	O	we	nsubj	2	SENT_91	[p7l2014t929r2148b999],
2	used	VBD	O	use	_	0	SENT_91	[p7l20t1049r214b1128],
3	Kaplan	NNP	PERSON	Kaplan	dobj	2	SENT_91	[p7l249t1049r842b1149],
4	.	.	O	.	_	0	SENT_91	[p7l249t1049r842b1149],

1	—	NN	O	—	_	0	SENT_92	[p7l249t1049r842b1149],
2	.	.	O	.	_	0	SENT_92	[p7l249t1049r842b1149],

1	Meier	JJR	PERSON	meier	amod	2	SENT_93	[p7l249t1049r842b1149],
2	methods	NNS	O	method	nsubj	21	SENT_93	[p7l874t1049r1242b1128],
3	to	TO	O	to	aux	4	SENT_93	[p7l1281t1066r1361b1128],
4	estimate	VB	O	estimate	infmod	2	SENT_93	[p7l1399t1050r1757b1127],
5	progression-free	JJ	O	progression-free	amod	6	SENT_93	[p7l1792t1075r2147b1150, p7l21t1176r377b1256],
6	survival	NN	O	survival	dobj	4	SENT_93	[p7l412t1177r729b1256],
7	and	CC	O	and	_	0	SENT_93	[p7l761t1177r914b1256],
8	compared	VBN	O	compare	dobj	4	SENT_93	[p7l948t1177r1360b1277],
9	the	DT	O	the	det	10	SENT_93	[p7l1393t1177r1522b1255],
10	results	NNS	O	result	dep	8	SENT_93	[p7l1554t1177r1825b1256],
11	among	IN	O	among	_	0	SENT_93	[p7l1859t1203r2152b1278],
12	the	DT	O	the	det	15	SENT_93	[p7l20t1305r154b1383],
13	three	CD	NUMBER	three	num	15	SENT_93	[p7l193t1305r413b1384],
14	study	NN	O	study	nn	15	SENT_93	[p7l453t1305r684b1405],
15	groups	NNS	O	group	prep_among	10	SENT_93	[p7l718t1331r1014b1406],
16	with	IN	O	with	_	0	SENT_93	[p7l1051t1305r1246b1384],
17	a	DT	O	a	det	20	SENT_93	[p7l1284t1331r1329b1383],
18	log	NN	O	log	nn	20	SENT_93	[p7l1365t1305r1735b1406],
19	—	CD	NUMBER	—	num	20	SENT_93	[p7l1365t1305r1735b1406],
20	rank	NN	O	rank	prep_with	15	SENT_93	[p7l1365t1305r1735b1406],
21	test	NN	O	test	_	0	SENT_93	[p7l1770t1322r1945b1384],
22	.	.	O	.	_	0	SENT_93	[p7l1770t1322r1945b1384],

1	The	DT	O	the	det	4	SENT_94	[p7l1986t1305r2147b1384],
2	statistical	JJ	O	statistical	amod	4	SENT_94	[p7l21t1433r438b1511],
3	analysis	NN	O	analysis	nn	4	SENT_94	[p7l474t1433r814b1533],
4	plan	NN	O	plan	nsubj	6	SENT_94	[p7l852t1433r1041b1533],
5	is	VBZ	O	be	cop	6	SENT_94	[p7l1077t1434r1143b1511],
6	available	JJ	O	available	_	0	SENT_94	[p7l1180t1433r1553b1512],
7	at	IN	O	at	_	0	SENT_94	[p7l1589t1450r1668b1511],
8	NEJM.org	NN	O	nejm.org	prep_at	6	SENT_94	[p7l1698t1441r2142b1534],
9	.	.	O	.	_	0	SENT_94	[p7l1698t1441r2142b1534],

1	RESULTS	NNS	O	result	_	0	SENT_95	[p7l840t1783r1318b1841],

1	PATIENTS	NNS	O	patient	_	0	SENT_96	[p7l16t2028r385b2079],

1	We	PRP	O	we	nsubj	2	SENT_97	[p7l7t2137r140b2208],
2	enrolled	VBD	O	enrol	_	0	SENT_97	[p7l173t2130r520b2208],
3	247	CD	NUMBER	247	num	4	SENT_97	[p7l552t2135r698b2208],
4	patients	NNS	O	patient	dobj	2	SENT_97	[p7l730t2131r1066b2230],
5	with	IN	O	with	_	0	SENT_97	[p7l1097t2130r1290b2209],
6	metastatic	JJ	O	metastatic	amod	7	SENT_97	[p7l1323t2131r1764b2208],
7	melanoma	NN	O	melanoma	prep_with	4	SENT_97	[p7l1796t2130r2145b2208, p7l11t2285r143b2337],
8	who	WP	O	who	nsubj	11	SENT_97	[p7l169t2259r350b2338],
9	had	VBD	O	have	aux	11	SENT_97	[p7l383t2259r538b2337],
10	not	RB	O	not	neg	11	SENT_97	[p7l569t2275r711b2337],
11	received	VBN	O	receive	rcmod	4	SENT_97	[p7l738t2259r1077b2338],
12	previous	JJ	O	previous	amod	14	SENT_97	[p7l1107t2260r1464b2359],
13	BRAF-inhibitor	NN	O	braf-inhibitor	nn	14	SENT_97	[p7l1496t2259r2149b2342],
14	treatment	NN	O	treatment	dobj	11	SENT_97	[p7l11t2404r438b2466],
15	(	CD	NUMBER	(	num	16	SENT_97	[p7l481t2388r741b2479],
16	Table	NNP	O	Table	dep	14	SENT_97	[p7l481t2388r741b2479],
17	1	CD	NUMBER	1	num	16	SENT_97	[p7l788t2393r855b2484],
18	,	,	O	,	_	0	SENT_97	[p7l788t2393r855b2484],
19	and	CC	O	and	_	0	SENT_97	[p7l904t2388r1063b2466],
20	Table	NNP	O	Table	nn	21	SENT_97	[p7l1103t2388r1334b2466],
21	S3	NN	O	s3	dobj	11	SENT_97	[p7l1380t2393r1473b2467],
22	in	IN	O	in	_	0	SENT_97	[p7l1520t2389r1604b2465],
23	the	DT	O	the	det	26	SENT_97	[p7l1648t2388r1782b2466],
24	Supplementary	NNP	O	Supplementary	nn	26	SENT_97	[p7l1828t2388r2145b2488, p7l11t2533r373b2617],
25	Appendix	NNP	O	Appendix	nn	26	SENT_97	[p7l406t2517r877b2617],
26	)	NNP	O	)	prep_in	21	SENT_97	[p7l406t2517r877b2617],
27	:	:	O	:	_	0	SENT_97	[p7l406t2517r877b2617],
28	8	CD	NUMBER	8	num	29	SENT_97	[p7l923t2522r969b2595],
29	patients	NNS	O	patient	dobj	2	SENT_97	[p7l1012t2518r1355b2617],
30	in	IN	O	in	_	0	SENT_97	[p7l1398t2518r1482b2594],
31	part	NN	O	part	nn	32	SENT_97	[p7l1522t2533r1703b2617],
32	A	NN	O	a	prep_in	29	SENT_97	[p7l1735t2524r1823b2613],
33	,	,	O	,	_	0	SENT_97	[p7l1735t2524r1823b2613],
34	77	CD	NUMBER	77	num	35	SENT_97	[p7l1872t2524r1972b2595],
35	patients	NNS	O	patient	appos	32	SENT_97	[p7l2013t2543r2145b2617, p7l11t2646r249b2723],
36	in	IN	O	in	_	0	SENT_97	[p7l285t2645r369b2722],
37	part	NN	O	part	nn	38	SENT_97	[p7l403t2661r583b2745],
38	B	NN	O	b	prep_in	35	SENT_97	[p7l612t2651r667b2723],
39	(	CD	NUMBER	(	num	38	SENT_97	[p7l709t2645r1150b2746],
40	including	VBG	O	include	_	0	SENT_97	[p7l709t2645r1150b2746],
41	24	CD	NUMBER	24	prep_including	35	SENT_97	[p7l1182t2650r1281b2723],
42	receiving	VBG	O	receive	partmod	41	SENT_97	[p7l1315t2646r1708b2746],
43	combination	NN	O	combination	nn	45	SENT_97	[p7l1740t2645r2145b2723, p7l11t2775r181b2852],
44	150/2	CD	NUMBER	150/2	num	45	SENT_97	[p7l221t2779r502b2869],
45	)	NN	O	)	dobj	42	SENT_97	[p7l221t2779r502b2869],
46	,	,	O	,	_	0	SENT_97	[p7l221t2779r502b2869],
47	and	CC	O	and	_	0	SENT_97	[p7l543t2774r702b2852],
48	162	CD	NUMBER	162	dobj	2	SENT_97	[p7l741t2779r886b2852],
49	in	IN	O	in	_	0	SENT_97	[p7l922t2775r1006b2851],
50	part	NN	O	part	nn	51	SENT_97	[p7l1040t2790r1221b2874],
51	C	NN	O	c	prep_in	48	SENT_97	[p7l1252t2779r1311b2852],
52	(	CD	NUMBER	(	num	51	SENT_97	[p7l1353t2774r1573b2865],
53	With	IN	O	with	_	0	SENT_97	[p7l1353t2774r1573b2865],
54	54	CD	NUMBER	54	prep_with	48	SENT_97	[p7l1610t2779r1710b2852],
55	per	IN	O	per	_	0	SENT_97	[p7l1745t2800r1886b2874],
56	study	NN	O	study	nn	57	SENT_97	[p7l1920t2774r2152b2874],
57	group	NN	O	group	prep_per	54	SENT_97	[p7l11t2909r308b3004],
58	)	CD	NUMBER	)	num	57	SENT_97	[p7l11t2909r308b3004],
59	.	.	O	.	_	0	SENT_97	[p7l11t2909r308b3004],

1	Rates	NNS	O	rate	nsubj	22	SENT_98	[p7l344t2909r576b2986],
2	of	IN	O	of	_	0	SENT_98	[p7l610t2901r710b2981],
3	poor	JJ	O	poor	amod	5	SENT_98	[p7l721t2927r922b3003],
4	prognostic	JJ	O	prognostic	amod	5	SENT_98	[p7l949t2903r1407b3004],
5	features	NNS	O	feature	prep_of	1	SENT_98	[p7l1438t2901r1799b2999],
6	,	,	O	,	_	0	SENT_98	[p7l1438t2901r1799b2999],
7	such	JJ	O	such	_	0	SENT_98	[p7l1837t2902r2029b2982],
8	as	IN	O	as	_	0	SENT_98	[p7l2060t2928r2144b2981],
9	M1c	NN	O	m1c	nn	10	SENT_98	[p7l8t3037r185b3110],
10	disease	NN	O	disease	prep_such_as	1	SENT_98	[p7l215t3032r535b3128],
11	,	,	O	,	_	0	SENT_98	[p7l215t3032r535b3128],
12	brain	NN	O	brain	nn	13	SENT_98	[p7l572t3032r790b3110],
13	metastases	NNS	O	metastase	conj_and	10	SENT_98	[p7l821t3048r1299b3128],
14	,	,	O	,	_	0	SENT_98	[p7l821t3048r1299b3128],
15	and	CC	O	and	_	0	SENT_98	[p7l1334t3032r1488b3110],
16	elevated	JJ	O	elevated	amod	19	SENT_98	[p7l1519t3032r1848b3111],
17	lactate	NN	O	lactate	nn	19	SENT_98	[p7l1878t3032r2146b3110],
18	dehydrogenase	NN	O	dehydrogenase	nn	19	SENT_98	[p7l11t3160r632b3261],
19	levels	NNS	O	level	conj_and	10	SENT_98	[p7l662t3160r906b3256],
20	,	,	O	,	_	0	SENT_98	[p7l662t3160r906b3256],
21	were	VBD	O	be	cop	22	SENT_98	[p7l939t3186r1135b3239],
22	similar	JJ	O	similar	_	0	SENT_98	[p7l1169t3160r1464b3238],
23	in	IN	O	in	_	0	SENT_98	[p7l1491t3161r1573b3237],
24	the	DT	O	the	det	25	SENT_98	[p7l1605t3160r1735b3238],
25	cohort	NN	O	cohort	prep_in	22	SENT_98	[p7l1767t3160r2040b3238],
26	in	IN	O	in	_	0	SENT_98	[p7l2066t3161r2147b3237],
27	part	NN	O	part	nn	28	SENT_98	[p7l9t3304r186b3389],
28	B	NN	O	b	prep_in	25	SENT_98	[p7l209t3295r265b3367],
29	and	CC	O	and	_	0	SENT_98	[p7l295t3288r452b3367],
30	each	DT	O	each	nsubj	40	SENT_98	[p7l482t3288r672b3367],
31	of	IN	O	of	_	0	SENT_98	[p7l701t3287r801b3367],
32	the	DT	O	the	det	34	SENT_98	[p7l812t3288r943b3367],
33	study	NN	O	study	nn	34	SENT_98	[p7l974t3288r1201b3389],
34	groups	NNS	O	group	prep_of	30	SENT_98	[p7l1225t3314r1517b3390],
35	in	IN	O	in	_	0	SENT_98	[p7l1547t3289r1630b3365],
36	part	NN	O	part	nn	37	SENT_98	[p7l1658t3305r1835b3389],
37	C.	NNP	O	C.	prep_in	34	SENT_98	[p7l1859t3293r1942b3367],
38	One	CD	NUMBER	one	num	37	SENT_98	[p7l1976t3293r2147b3367],
39	patient	NN	O	patient	nsubj	40	SENT_98	[p7l9t3419r300b3518],
40	had	VBD	O	have	conj_and	22	SENT_98	[p7l324t3418r477b3496],
41	a	DT	O	a	det	44	SENT_98	[p7l504t3444r549b3496],
42	BRAF	NN	MISC	braf	nn	44	SENT_98	[p7l574t3424r813b3501],
43	V6OOR	NN	MISC	v6oor	nn	44	SENT_98	[p7l839t3423r1123b3501],
44	mutation	NN	O	mutation	dobj	40	SENT_98	[p7l1141t3419r1542b3514],
45	,	,	O	,	_	0	SENT_98	[p7l1141t3419r1542b3514],
46	and	CC	O	and	_	0	SENT_98	[p7l1575t3418r1730b3496],
47	all	DT	O	all	det	48	SENT_98	[p7l1757t3418r1858b3496],
48	others	NNS	O	other	nsubj	49	SENT_98	[p7l1887t3418r2145b3496],
49	had	VBD	O	have	conj_and	22	SENT_98	[p7l11t3546r168b3625],
50	a	DT	O	a	det	54	SENT_98	[p7l204t3572r249b3625],
51	V6OOE	NN	O	v6ooe	nn	54	SENT_98	[p7l279t3551r551b3625],
52	or	CC	O	or	_	0	SENT_98	[p7l590t3571r679b3625],
53	V6OOK	NN	O	v6ook	nn	54	SENT_98	[p7l709t3551r996b3627],
54	mutation	NN	O	mutation	dobj	49	SENT_98	[p7l1029t3547r1447b3626],
55	.	.	O	.	_	0	SENT_98	[p7l1029t3547r1447b3626],

1	After	IN	O	after	_	0	SENT_99	[p7l1485t3545r1709b3625],
2	a	DT	O	a	det	3	SENT_99	[p7l1743t3572r1787b3625],
3	median	JJ	O	median	prep_after	4	SENT_99	[p7l1822t3546r2147b3625],
4	follow	VBP	O	follow	_	0	SENT_99	[p7l11t3674r421b3775],
5	—	CD	NUMBER	—	npadvmod	6	SENT_99	[p7l11t3674r421b3775],
6	up	IN	O	up	advmod	4	SENT_99	[p7l11t3674r421b3775],
7	of	IN	O	of	_	0	SENT_99	[p7l456t3674r556b3753],
8	14.1	CD	DURATION	14.1	num	9	SENT_99	[p7l574t3680r743b3753],
9	months	NNS	NUMBER	month	prep_of	4	SENT_99	[p7l777t3675r1105b3753],
10	in	IN	O	in	_	0	SENT_99	[p7l1139t3676r1223b3752],
11	part	NN	O	part	prep_in	9	SENT_99	[p7l1254t3692r1434b3775],
12	C	NN	O	c	nsubj	4	SENT_99	[p7l1462t3680r1545b3770],
13	,	,	O	,	_	0	SENT_99	[p7l1462t3680r1545b3770],
14	49	CD	NUMBER	49	appos	12	SENT_99	[p7l1582t3680r1682b3753],
15	of	IN	O	of	_	0	SENT_99	[p7l1716t3674r1817b3753],
16	the	DT	O	the	det	17	SENT_99	[p7l1831t3675r1965b3753],
17	162	CD	NUMBER	162	prep_of	14	SENT_99	[p7l2001t3680r2145b3753],

1	patients	NNS	O	patient	nsubj	2	SENT_100	[p8l9t22r337b121],
2	continued	VBD	O	continue	_	0	SENT_100	[p8l369t21r783b100],
3	to	TO	O	to	aux	4	SENT_100	[p8l812t38r891b99],
4	receive	VB	O	receive	xcomp	2	SENT_100	[p8l921t22r1199b100],
5	treatment	NN	O	treatment	nn	8	SENT_100	[p8l1227t37r1636b99],
6	(	NN	O	(	nn	8	SENT_100	[p8l1664t26r1786b112],
7	23	CD	NUMBER	23	num	8	SENT_100	[p8l1664t26r1786b112],
8	patients	NNS	O	patient	dobj	4	SENT_100	[p8l1817t22r2144b121],
9	in	IN	O	in	_	0	SENT_100	[p8l10t150r92b226],
10	each	DT	O	each	prep_in	4	SENT_100	[p8l120t149r307b228],
11	of	IN	O	of	_	0	SENT_100	[p8l334t148r433b228],
12	the	DT	O	the	dep	17	SENT_100	[p8l442t149r571b228],
13	two	CD	NUMBER	two	num	17	SENT_100	[p8l599t165r754b229],
14	combination	NN	O	combination	nn	17	SENT_100	[p8l783t149r1655b250],
15	—	NN	O	—	nn	17	SENT_100	[p8l783t149r1655b250],
16	therapy	NN	O	therapy	nn	17	SENT_100	[p8l783t149r1655b250],
17	groups	NNS	O	group	prep_of	10	SENT_100	[p8l1677t174r1964b251],
18	and	CC	O	and	_	0	SENT_100	[p8l1993t149r2147b228],
19	3	CD	NUMBER	3	num	20	SENT_100	[p8l12t283r55b357],
20	patients	NNS	O	patient	conj_and	17	SENT_100	[p8l92t279r436b378],
21	in	IN	O	in	_	0	SENT_100	[p8l472t278r556b355],
22	the	DT	O	the	det	24	SENT_100	[p8l592t278r725b356],
23	monotherapy	NN	O	monotherapy	nn	24	SENT_100	[p8l760t278r1338b378],
24	group	NN	O	group	prep_in	4	SENT_100	[p8l1368t284r1673b379],
25	)	CD	NUMBER	)	tmod	4	SENT_100	[p8l1368t284r1673b379],
26	.	.	O	.	_	0	SENT_100	[p8l1368t284r1673b379],

1	DOSE	NN	O	dose	nn	2	SENT_101	[p8l16t554r224b605],
2	ESCALATION	NN	O	escalation	nsubj	8	SENT_101	[p8l264t554r754b605],
3	IN	IN	O	in	_	0	SENT_101	[p8l800t555r876b604],
4	PART	NN	O	part	nn	7	SENT_101	[p8l922t554r1110b604],
5	B	NN	O	b	nn	7	SENT_101	[p8l1144t555r1182b604],
6	Dose	NN	O	dose	nn	7	SENT_101	[p8l9t662r219b734],
7	escalation	NN	O	escalation	prep_in	2	SENT_101	[p8l250t655r667b734],
8	began	VBD	O	begin	_	0	SENT_101	[p8l698t655r950b757],
9	with	IN	O	with	_	0	SENT_101	[p8l976t655r1166b735],
10	half	PDT	O	half	predet	11	SENT_101	[p8l1196t654r1377b734],
11	the	DT	O	the	prep_with	8	SENT_101	[p8l1389t655r1518b734],
12	recommended	VBN	O	recommend	amod	14	SENT_101	[p8l1548t655r2147b734],
13	monotherapy	NN	O	monotherapy	nn	14	SENT_101	[p8l11t784r588b884],
14	dose	NN	O	dose	dobj	8	SENT_101	[p8l630t784r825b862],
15	for	IN	O	for	_	0	SENT_101	[p8l870t783r994b862],
16	both	DT	O	both	preconj	17	SENT_101	[p8l1036t784r1235b862],
17	dabrafenib	NN	O	dabrafenib	prep_for	14	SENT_101	[p8l1281t783r1748b862],
18	and	CC	O	and	_	0	SENT_101	[p8l1793t784r1952b862],
19	trametinib	NN	O	trametinib	prep_for	14	SENT_101	[p8l1997t800r2145b862, p8l11t912r363b1009],
20	,	,	O	,	_	0	SENT_101	[p8l1997t800r2145b862, p8l11t912r363b1009],
21	with	IN	O	with	_	0	SENT_101	[p8l396t912r590b992],
22	no	DT	O	no	det	25	SENT_101	[p8l622t938r726b991],
23	dose-limiting	JJ	O	dose-limiting	amod	25	SENT_101	[p8l761t912r1335b1014],
24	toxic	JJ	O	toxic	amod	25	SENT_101	[p8l1365t913r1567b991],
25	effects	NNS	O	effect	prep_with	14	SENT_101	[p8l1599t911r1875b991],
26	at	IN	O	at	_	0	SENT_101	[p8l1909t929r1988b991],
27	the	DT	O	the	det	31	SENT_101	[p8l2015t912r2147b991],
28	first	JJ	ORDINAL	first	amod	31	SENT_101	[p8l11t1040r196b1120],
29	three	CD	NUMBER	three	num	31	SENT_101	[p8l224t1041r445b1120],
30	dose	NN	O	dose	nn	31	SENT_101	[p8l479t1041r674b1120],
31	levels	NNS	O	level	prep_at	25	SENT_101	[p8l706t1041r963b1121],
32	:	:	O	:	_	0	SENT_101	[p8l706t1041r963b1121],
33	75	CD	NUMBER	75	num	34	SENT_101	[p8l1001t1048r1095b1120],
34	mg	NN	O	mg	conj_and	14	SENT_101	[p8l1131t1067r1271b1143],
35	of	IN	O	of	_	0	SENT_101	[p8l1301t1040r1402b1120],
36	dabrafenib	NN	O	dabrafenib	prep_of	34	SENT_101	[p8l1417t1040r1883b1120],
37	twice	RB	O	twice	advmod	38	SENT_101	[p8l1918t1042r2147b1121],
38	daily	RB	SET	daily	advmod	36	SENT_101	[p8l12t1170r220b1271],
39	plus	CC	O	plus	_	0	SENT_101	[p8l248t1170r425b1271],
40	1	CD	NUMBER	1	num	41	SENT_101	[p8l464t1175r509b1247],
41	mg	NN	O	mg	conj_and	14	SENT_101	[p8l543t1196r683b1272],
42	of	IN	O	of	_	0	SENT_101	[p8l714t1169r815b1249],
43	trametinib	NN	O	trametinib	prep_of	41	SENT_101	[p8l830t1170r1292b1249],
44	once	RB	DATE	once	advmod	45	SENT_101	[p8l1328t1196r1526b1249],
45	daily	RB	SET	daily	advmod	43	SENT_101	[p8l1561t1170r1783b1271],
46	,	,	O	,	_	0	SENT_101	[p8l1561t1170r1783b1271],
47	150	CD	NUMBER	150	num	48	SENT_101	[p8l1826t1175r1976b1249],
48	mg	NN	O	mg	conj_and	14	SENT_101	[p8l2010t1196r2150b1272],
49	of	IN	O	of	_	0	SENT_101	[p8l12t1298r112b1378],
50	dabrafenib	NN	O	dabrafenib	prep_of	48	SENT_101	[p8l125t1298r591b1378],
51	twice	RB	O	twice	advmod	52	SENT_101	[p8l623t1300r851b1379],
52	daily	RB	SET	daily	advmod	50	SENT_101	[p8l883t1299r1092b1400],
53	plus	CC	O	plus	_	0	SENT_101	[p8l1117t1299r1292b1400],
54	1	CD	NUMBER	1	num	55	SENT_101	[p8l1328t1304r1373b1376],
55	mg	NN	O	mg	conj_and	14	SENT_101	[p8l1404t1325r1543b1401],
56	of	IN	O	of	_	0	SENT_101	[p8l1571t1298r1672b1378],
57	trametinib	NN	O	trametinib	prep_of	55	SENT_101	[p8l1684t1299r2145b1378],
58	once	RB	DATE	once	advmod	59	SENT_101	[p8l12t1454r210b1507],
59	daily	RB	SET	daily	advmod	57	SENT_101	[p8l246t1428r467b1529],
60	,	,	O	,	_	0	SENT_101	[p8l246t1428r467b1529],
61	and	CC	O	and	_	0	SENT_101	[p8l507t1428r665b1507],
62	150	CD	NUMBER	150	num	63	SENT_101	[p8l703t1434r852b1507],
63	mg	NN	O	mg	conj_and	14	SENT_101	[p8l887t1454r1027b1530],
64	of	IN	O	of	_	0	SENT_101	[p8l1059t1427r1160b1507],
65	dabrafenib	NN	O	dabrafenib	prep_of	63	SENT_101	[p8l1176t1427r1643b1507],
66	twice	RB	O	twice	advmod	67	SENT_101	[p8l1679t1429r1907b1508],
67	daily	RB	SET	daily	advmod	65	SENT_101	[p8l1943t1428r2152b1529],
68	plus	CC	O	plus	_	0	SENT_101	[p8l9t1557r186b1658],
69	1.5	CD	NUMBER	1.5	num	70	SENT_101	[p8l225t1562r346b1636],
70	mg	NN	O	mg	conj_plus	63	SENT_101	[p8l383t1583r523b1659],
71	of	IN	O	of	_	0	SENT_101	[p8l555t1556r655b1636],
72	trametinib	NN	O	trametinib	prep_of	70	SENT_101	[p8l671t1557r1133b1636],
73	once	RB	DATE	once	advmod	74	SENT_101	[p8l1169t1582r1367b1636],
74	daily	RB	SET	daily	advmod	72	SENT_101	[p8l1402t1557r1624b1658],
75	.	.	O	.	_	0	SENT_101	[p8l1402t1557r1624b1658],

1	Among	IN	O	among	_	0	SENT_102	[p8l1660t1564r1982b1659],
2	the	DT	O	the	det	4	SENT_102	[p8l2014t1557r2147b1636],
3	24	CD	NUMBER	24	num	4	SENT_102	[p8l11t1691r110b1764],
4	patients	NNS	O	patient	prep_among	33	SENT_102	[p8l144t1687r488b1786],
5	who	WP	O	who	nsubjpass	7	SENT_102	[p8l522t1686r706b1765],
6	were	VBD	O	be	auxpass	7	SENT_102	[p8l739t1712r942b1765],
7	treated	VBN	O	treat	rcmod	4	SENT_102	[p8l979t1686r1280b1764],
8	at	IN	O	at	_	0	SENT_102	[p8l1315t1702r1395b1764],
9	the	DT	O	the	det	13	SENT_102	[p8l1426t1686r1560b1764],
10	highest	JJS	O	highest	amod	13	SENT_102	[p8l1596t1686r1919b1787],
11	dose	NN	O	dose	nn	13	SENT_102	[p8l1951t1686r2146b1764],
12	level	NN	O	level	nn	13	SENT_102	[p8l10t1814r192b1894],
13	—	NN	O	—	prep_at	7	SENT_102	[p8l215t1860r323b1867],
14	150	CD	NUMBER	150	num	15	SENT_102	[p8l349t1819r494b1893],
15	mg	NN	O	mg	dep	13	SENT_102	[p8l522t1840r660b1916],
16	of	IN	O	of	_	0	SENT_102	[p8l684t1813r782b1893],
17	dabrafenib	NN	O	dabrafenib	prep_of	15	SENT_102	[p8l792t1813r1239b1893],
18	twice	RB	O	twice	advmod	19	SENT_102	[p8l1269t1815r1488b1894],
19	daily	RB	SET	daily	advmod	17	SENT_102	[p8l1517t1814r1717b1915],
20	plus	CC	O	plus	_	0	SENT_102	[p8l1738t1814r1908b1915],
21	2	CD	NUMBER	2	num	22	SENT_102	[p8l1937t1820r1985b1891],
22	mg	NN	O	mg	dep	13	SENT_102	[p8l2013t1840r2151b1916],
23	of	IN	O	of	_	0	SENT_102	[p8l12t1942r112b2021],
24	trametinib	NN	O	trametinib	prep_of	22	SENT_102	[p8l134t1943r596b2021],
25	once	RB	DATE	once	advmod	24	SENT_102	[p8l638t1968r837b2021],
26	daily	JJ	SET	daily	amod	28	SENT_102	[p8l878t1943r1086b2043],
27	(	NN	O	(	nn	28	SENT_102	[p8l1127t1943r1702b2034],
28	combination	NN	O	combination	dep	24	SENT_102	[p8l1127t1943r1702b2034],
29	150/2	CD	NUMBER	150/2	number	30	SENT_102	[p8l1745t1948r2001b2034],
30	)	CD	NUMBER	)	num	31	SENT_102	[p8l1745t1948r2001b2034],
31	—	NN	O	—	dep	28	SENT_102	[p8l2043t1988r2152b1995],
32	there	EX	O	there	expl	33	SENT_102	[p8l12t2071r225b2150],
33	was	VBD	O	be	_	0	SENT_102	[p8l252t2097r414b2151],
34	one	CD	NUMBER	one	num	37	SENT_102	[p8l447t2096r597b2150],
35	dose-limiting	JJ	O	dose-limiting	amod	37	SENT_102	[p8l629t2071r1203b2173],
36	toxic	JJ	O	toxic	amod	37	SENT_102	[p8l1231t2072r1434b2150],
37	effect	NN	O	effect	nsubj	33	SENT_102	[p8l1465t2070r1723b2150],
38	:	:	O	:	_	0	SENT_102	[p8l1465t2070r1723b2150],
39	recurrent	JJ	O	recurrent	amod	41	SENT_102	[p8l1758t2087r2152b2151],
40	neutrophilic	JJ	O	neutrophilic	amod	41	SENT_102	[p8l11t2201r543b2301],
41	panniculitis	NN	O	panniculitis	dep	37	SENT_102	[p8l569t2201r1113b2301],
42	,	,	O	,	_	0	SENT_102	[p8l569t2201r1113b2301],
43	which	WDT	O	which	nsubjpass	45	SENT_102	[p8l1143t2201r1407b2280],
44	was	VBD	O	be	auxpass	45	SENT_102	[p8l1431t2227r1595b2280],
45	treated	VBN	O	treat	rcmod	41	SENT_102	[p8l1626t2201r1926b2279],
46	with	IN	O	with	_	0	SENT_102	[p8l1950t2201r2147b2280],
47	glucocorticoids	NNS	O	glucocorticoid	prep_with	45	SENT_102	[p8l11t2329r677b2430],
48	and	CC	O	and	_	0	SENT_102	[p8l720t2329r879b2407],
49	an	DT	O	a	det	52	SENT_102	[p8l921t2354r1024b2407],
50	eventual	JJ	O	eventual	amod	52	SENT_102	[p8l1066t2329r1427b2408],
51	dose	NN	O	dose	nn	52	SENT_102	[p8l1470t2329r1665b2407],
52	reduction	NN	O	reduction	prep_with	45	SENT_102	[p8l1707t2329r2142b2408],
53	.	.	O	.	_	0	SENT_102	[p8l1707t2329r2142b2408],

1	The	DT	O	the	det	2	SENT_103	[p8l7t2458r165b2536],
2	maximum	NN	O	maximum	nsubj	3	SENT_103	[p8l194t2459r630b2537],
3	tolerated	VBD	O	tolerate	_	0	SENT_103	[p8l660t2458r1021b2536],
4	dose	NN	O	dose	nn	5	SENT_103	[p8l1051t2458r1240b2536],
5	combination	NN	O	combination	nsubjpass	8	SENT_103	[p8l1270t2458r1799b2536],
6	was	VBD	O	be	auxpass	8	SENT_103	[p8l1823t2484r1982b2537],
7	not	RB	O	not	neg	8	SENT_103	[p8l2014t2474r2153b2536],
8	reached	VBN	O	reach	ccomp	3	SENT_103	[p8l11t2587r345b2665],
9	in	IN	O	in	_	0	SENT_103	[p8l377t2588r461b2664],
10	this	DT	O	this	det	11	SENT_103	[p8l494t2587r655b2665],
11	study	NN	O	study	prep_in	8	SENT_103	[p8l691t2587r935b2687],
12	.	.	O	.	_	0	SENT_103	[p8l691t2587r935b2687],

1	The	DT	O	the	det	3	SENT_104	[p8l970t2587r1131b2665],
2	recommended	VBN	O	recommend	amod	3	SENT_104	[p8l1164t2587r1784b2665],
3	phase	NN	O	phase	nsubj	7	SENT_104	[p8l1815t2587r2066b2687],
4	2	CD	NUMBER	2	number	5	SENT_104	[p8l2098t2592r2146b2664],
5	dose	NN	O	dose	amod	3	SENT_104	[p8l12t2716r204b2794],
6	was	VBD	O	be	cop	7	SENT_104	[p8l231t2742r393b2796],
7	combination	NN	O	combination	_	0	SENT_104	[p8l428t2716r967b2794],
8	150/2	CD	NUMBER	150/2	num	7	SENT_104	[p8l1002t2721r1249b2811],
9	,	,	O	,	_	0	SENT_104	[p8l1002t2721r1249b2811],
10	which	WDT	O	which	nsubj	11	SENT_104	[p8l1282t2716r1542b2795],
11	combines	VBZ	O	combine	rcmod	7	SENT_104	[p8l1575t2716r1981b2794],
12	the	DT	O	the	det	15	SENT_104	[p8l2015t2716r2147b2794],
13	recommended	VBN	O	recommend	amod	15	SENT_104	[p8l11t2844r631b2923],
14	monotherapy	NN	O	monotherapy	nn	15	SENT_104	[p8l665t2844r1242b2945],
15	dose	NN	O	dose	dobj	11	SENT_104	[p8l1273t2844r1468b2923],
16	for	IN	O	for	_	0	SENT_104	[p8l1501t2843r1625b2923],
17	each	DT	O	each	det	18	SENT_104	[p8l1657t2844r1850b2923],
18	agent	NN	O	agent	prep_for	15	SENT_104	[p8l1883t2860r2141b2946],
19	.	.	O	.	_	0	SENT_104	[p8l1883t2860r2141b2946],

1	All	DT	O	all	det	3	SENT_105	[p8l7t2973r132b3050],
2	toxic	JJ	O	toxic	amod	3	SENT_105	[p8l160t2974r362b3051],
3	effects	NNS	O	effect	nsubjpass	8	SENT_105	[p8l391t2972r667b3051],
4	in	IN	O	in	_	0	SENT_105	[p8l696t2974r780b3050],
5	part	NN	O	part	nn	6	SENT_105	[p8l806t2989r983b3073],
6	B	NN	O	b	prep_in	3	SENT_105	[p8l1005t2980r1061b3051],
7	are	VBP	O	be	auxpass	8	SENT_105	[p8l1091t2999r1218b3051],
8	summarized	VBN	O	summarize	_	0	SENT_105	[p8l1249t2973r1785b3052],
9	in	IN	O	in	_	0	SENT_105	[p8l1813t2974r1895b3050],
10	Table	NNP	O	Table	nn	11	SENT_105	[p8l1920t2973r2147b3051],
11	S5	NNP	O	S5	prep_in	8	SENT_105	[p8l13t3107r105b3180],
12	in	IN	O	in	_	0	SENT_105	[p8l143t3102r227b3179],
13	the	DT	O	the	det	15	SENT_105	[p8l262t3102r395b3180],
14	Supplementary	NNP	O	Supplementary	nn	15	SENT_105	[p8l433t3102r1083b3202],
15	Appendix	NNP	O	Appendix	prep_in	11	SENT_105	[p8l1110t3102r1551b3202],
16	.	.	O	.	_	0	SENT_105	[p8l1110t3102r1551b3202],

1	SAFETY	NN	O	safety	_	0	SENT_106	[p8l11t3378r297b3429],
2	AND	CC	O	and	_	0	SENT_106	[p8l328t3379r498b3428],
3	SIDE-EFFECT	NN	O	side-effect	nn	4	SENT_106	[p8l532t3378r1037b3429],
4	PROFILE	NN	O	profile	conj_and	1	SENT_106	[p8l1073t3378r1395b3429],
5	In	IN	O	in	_	0	SENT_106	[p8l9t3486r98b3556],
6	part	NN	O	part	nn	7	SENT_106	[p8l132t3495r312b3579],
7	C	NN	O	c	prep_in	1	SENT_106	[p8l342t3484r425b3574],
8	,	,	O	,	_	0	SENT_106	[p8l342t3484r425b3574],
9	the	DT	O	the	det	10	SENT_106	[p8l467t3479r600b3557],
10	incidence	NN	O	incidence	appos	7	SENT_106	[p8l634t3479r1042b3557],
11	of	IN	O	of	_	0	SENT_106	[p8l1078t3478r1178b3557],
12	cutaneous	JJ	O	cutaneous	amod	14	SENT_106	[p8l1196t3495r1634b3558],
13	squamouscell	NN	O	squamouscell	nn	14	SENT_106	[p8l1672t3504r2145b3579, p8l11t3607r151b3685],
14	carcinoma	NN	O	carcinoma	prep_of	10	SENT_106	[p8l186t3608r625b3685],
15	(	CD	NUMBER	(	dep	10	SENT_106	[p8l661t3607r1083b3708],
16	including	VBG	O	include	dep	1	SENT_106	[p8l661t3607r1083b3708],
17	keratoacanthoma	NN	O	keratoacanthoma	nn	18	SENT_106	[p8l1114t3607r1865b3698],
18	)	NN	O	)	pobj	16	SENT_106	[p8l1114t3607r1865b3698],
19	in	IN	O	in	_	0	SENT_106	[p8l1904t3608r1985b3684],
20	patients	NNS	O	patient	prep_in	18	SENT_106	[p8l2018t3633r2145b3707, p9l11t22r238b100],

1	receiving	VBG	O	receive	csubj	6	SENT_107	[p9l273t22r649b123],
2	dabrafenib	JJ	O	dabrafenib	amod	3	SENT_107	[p9l679t20r1126b100],
3	monotherapy	NN	O	monotherapy	dobj	1	SENT_107	[p9l1161t21r1717b122],
4	was	VBD	O	be	cop	6	SENT_107	[p9l1741t47r1900b101],
5	19	CD	PERCENT	19	num	6	SENT_107	[p9l1939t26r2141b117],
6	%	NN	PERCENT	%	_	0	SENT_107	[p9l1939t26r2141b117],
7	,	,	O	,	_	0	SENT_107	[p9l1939t26r2141b117],
8	as	IN	O	as	_	0	SENT_107	[p9l10t176r96b228],
9	compared	VBN	O	compare	prepc_as	6	SENT_107	[p9l131t150r560b250],
10	with	IN	O	with	pcomp	9	SENT_107	[p9l589t150r785b229],
11	2	CD	PERCENT	2	num	12	SENT_107	[p9l818t155r954b229],
12	%	NN	PERCENT	%	pobj	10	SENT_107	[p9l818t155r954b229],
13	for	IN	O	for	_	0	SENT_107	[p9l986t149r1109b228],
14	combination	NN	O	combination	prep_for	12	SENT_107	[p9l1140t150r1690b228],
15	150/1	CD	NUMBER	150/1	num	14	SENT_107	[p9l1726t155r1956b240],
16	and	CC	O	and	_	0	SENT_107	[p9l1988t150r2147b228],
17	7	CD	NUMBER	7	number	18	SENT_107	[p9l12t283r145b357],
18	°	CD	NUMBER	°	conj_and	12	SENT_107	[p9l12t283r145b357],
19	/	:	O	/	punct	20	SENT_107	[p9l12t283r145b357],
20	o	NN	O	o	dep	18	SENT_107	[p9l12t283r145b357],
21	for	IN	O	for	_	0	SENT_107	[p9l176t277r299b356],
22	combination	NN	O	combination	prep_for	20	SENT_107	[p9l328t278r878b356],
23	150/2	CD	NUMBER	150/2	number	24	SENT_107	[p9l912t283r1141b368],
24	(	CD	NUMBER	(	num	25	SENT_107	[p9l1178t283r1583b369],
25	P	NN	O	p	dep	22	SENT_107	[p9l1178t283r1583b369],
26	=	JJ	O	=	amod	25	SENT_107	[p9l1178t283r1583b369],
27	0.004	CD	NUMBER	0.004	tmod	26	SENT_107	[p9l1178t283r1583b369],
28	and	CC	O	and	_	0	SENT_107	[p9l1613t278r1773b356],
29	P	NN	O	p	prep_for	20	SENT_107	[p9l1801t283r2141b373],
30	=	JJ	O	=	amod	29	SENT_107	[p9l1801t283r2141b373],
31	0.09	CD	NUMBER	0.09	tmod	30	SENT_107	[p9l1801t283r2141b373],
32	,	,	O	,	_	0	SENT_107	[p9l1801t283r2141b373],
33	respectively	RB	O	respectively	advmod	20	SENT_107	[p9l11t406r511b506],
34	)	CD	NUMBER	)	number	35	SENT_107	[p9l11t406r511b506],
35	(	CD	NUMBER	(	dep	20	SENT_107	[p9l548t406r798b497],
36	Table	NNP	O	Table	dep	35	SENT_107	[p9l548t406r798b497],
37	2	CD	NUMBER	2	number	38	SENT_107	[p9l825t411r921b497],
38	)	CD	NUMBER	)	num	18	SENT_107	[p9l825t411r921b497],
39	.	.	O	.	_	0	SENT_107	[p9l825t411r921b497],

1	The	DT	O	the	det	2	SENT_108	[p9l950t406r1107b484],
2	rates	NNS	O	rate	nsubj	13	SENT_108	[p9l1135t422r1330b484],
3	of	IN	O	of	_	0	SENT_108	[p9l1360t405r1459b484],
4	rash	NN	O	rash	prep_of	2	SENT_108	[p9l1467t406r1644b484],
5	in	IN	O	in	_	0	SENT_108	[p9l1671t407r1752b483],
6	the	DT	O	the	det	7	SENT_108	[p9l1780t406r1909b484],
7	combination	NN	O	combination	prep_in	4	SENT_108	[p9l1937t431r2145b484, p9l11t534r373b612],
8	150/1	CD	NUMBER	150/1	num	7	SENT_108	[p9l408t539r637b623],
9	and	CC	O	and	_	0	SENT_108	[p9l668t534r827b612],
10	150/2	CD	NUMBER	150/2	num	11	SENT_108	[p9l861t539r1090b623],
11	groups	NNS	O	group	conj_and	7	SENT_108	[p9l1122t559r1419b635],
12	were	VBD	O	be	cop	13	SENT_108	[p9l1448t560r1651b613],
13	lower	JJR	O	lower	_	0	SENT_108	[p9l1681t534r1921b613],
14	than	IN	O	than	mark	35	SENT_108	[p9l1949t534r2147b612],
15	the	DT	O	the	det	16	SENT_108	[p9l11t662r142b740],
16	rate	NN	O	rate	dep	23	SENT_108	[p9l172t678r329b740],
17	in	IN	O	in	_	0	SENT_108	[p9l359t663r441b739],
18	the	DT	O	the	det	19	SENT_108	[p9l470t662r602b740],
19	monotherapy	NN	O	monotherapy	prep_in	16	SENT_108	[p9l631t662r1198b762],
20	group	NN	O	group	dep	23	SENT_108	[p9l1222t687r1472b763],
21	(	CD	PERCENT	(	number	22	SENT_108	[p9l1508t667r1721b753],
22	20	CD	PERCENT	20	num	23	SENT_108	[p9l1508t667r1721b753],
23	%	NN	PERCENT	%	dep	30	SENT_108	[p9l1508t667r1721b753],
24	and	CC	O	and	_	0	SENT_108	[p9l1749t662r1905b740],
25	27	CD	PERCENT	27	num	26	SENT_108	[p9l1935t667r2141b757],
26	%	NN	PERCENT	%	conj_and	23	SENT_108	[p9l1935t667r2141b757],
27	,	,	O	,	_	0	SENT_108	[p9l1935t667r2141b757],
28	respectively	RB	O	respectively	advmod	26	SENT_108	[p9l11t791r528b891],
29	,	,	O	,	_	0	SENT_108	[p9l11t791r528b891],
30	vs.	FW	O	vs.	dep	35	SENT_108	[p9l566t817r676b870],
31	36	CD	NUMBER	36	num	32	SENT_108	[p9l718t796r951b886],
32	°	CD	NUMBER	°	pobj	30	SENT_108	[p9l718t796r951b886],
33	/	:	O	/	punct	35	SENT_108	[p9l718t796r951b886],
34	o	NN	O	o	nn	35	SENT_108	[p9l718t796r951b886],
35	)	NN	O	)	dep	13	SENT_108	[p9l718t796r951b886],
36	,	,	O	,	_	0	SENT_108	[p9l718t796r951b886],
37	but	CC	O	but	_	0	SENT_108	[p9l993t791r1134b870],
38	MEK	NN	O	mek	nn	41	SENT_108	[p9l1163t798r1378b872],
39	inhibitor	NN	O	inhibitor	nn	41	SENT_108	[p9l1410t791r2145b869],
40	—	NN	O	—	nn	41	SENT_108	[p9l1410t791r2145b869],
41	associ	NNS	O	assocus	nsubj	42	SENT_108	[p9l1410t791r2145b869],
42	—	VBP	O	—	conj_but	13	SENT_108	[p9l1410t791r2145b869],
43	ated	JJ	O	ated	amod	45	SENT_108	[p9l10t919r189b997],
44	acneiform	NN	O	acneiform	nn	45	SENT_108	[p9l225t918r663b997],
45	dermatitis	NN	O	dermatitis	nsubj	48	SENT_108	[p9l700t919r1142b997],
46	was	VBD	O	be	cop	48	SENT_108	[p9l1176t945r1339b998],
47	more	RBR	O	more	advmod	48	SENT_108	[p9l1378t944r1598b997],
48	prevalent	JJ	O	prevalent	ccomp	42	SENT_108	[p9l1633t919r2033b1019],
49	in	IN	O	in	prep	48	SENT_108	[p9l2063t920r2147b996],

1	1696	CD	DATE	1696	num	4	SENT_109	[p9l149t1077r225b1101],
2	N	NN	O	n	nn	4	SENT_109	[p9l935t1088r949b1103],
3	ENGLJ	NN	O	englj	nn	4	SENT_109	[p9l964t1088r1041b1110],
4	MED	NN	O	med	_	0	SENT_109	[p9l1056t1088r1108b1103],
5	367	CD	NUMBER	367	dep	4	SENT_109	[p9l1118t1082r1196b1110],
6	;	:	O	;	_	0	SENT_109	[p9l1118t1082r1196b1110],
7	18	CD	NUMBER	18	num	9	SENT_109	[p9l1118t1082r1196b1110],
8	NEjM.ORG	NN	O	nejm.org	nn	9	SENT_109	[p9l1231t1088r1355b1110],
9	NOVEMBER1	NN	O	november1	dep	5	SENT_109	[p9l1392t1088r1623b1108],
10	,2012	CD	NUMBER	,2012	dep	9	SENT_109	[p9l1392t1088r1623b1108],

1	The	DT	O	the	det	4	SENT_110	[p9l935t1121r986b1145],
2	New	NNP	O	New	nn	4	SENT_110	[p9l995t1122r1057b1145],
3	England	NNP	O	England	nn	4	SENT_110	[p9l1066t1121r1177b1152],
4	Joumal	NNP	O	Joumal	_	0	SENT_110	[p9l1186t1121r1283b1145],
5	of	IN	O	of	_	0	SENT_110	[p9l1293t1121r1322b1145],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_110	[p9l1329t1121r1454b1145],

1	Copyright	NN	O	copyright	_	0	SENT_111	[p9l728t1203r862b1234],
2	©	CD	NUMBER	©	num	6	SENT_111	[p9l871t1203r895b1227],
3	2012	CD	DATE	2012	num	6	SENT_111	[p9l905t1203r970b1227],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_111	[p9l979t1203r1170b1227],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_111	[p9l1180t1203r1288b1227],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_111	[p9l1299t1203r1404b1234],
7	.	.	O	.	_	0	SENT_111	[p9l1299t1203r1404b1234],

1	All	DT	O	all	det	2	SENT_112	[p9l1415t1203r1456b1227],
2	rights	NNS	O	rights	nsubj	3	SENT_112	[p9l1465t1203r1540b1234],
3	reserved	VBN	O	reserve	_	0	SENT_112	[p9l1550t1203r1668b1227],
4	.	.	O	.	_	0	SENT_112	[p9l1550t1203r1668b1227],

1	BRAF	NNS	ORGANIZATION	braf	_	0	SENT_113	[p9l713t1246r797b1265],
2	AND	CC	O	and	_	0	SENT_113	[p9l809t1246r881b1265],
3	MEK	NN	O	mek	nn	4	SENT_113	[p9l895t1246r967b1265],
4	INHIBITION	NN	O	inhibition	conj_and	1	SENT_113	[p9l980t1246r1183b1265],
5	IN	IN	O	in	_	0	SENT_113	[p9l1199t1246r1236b1265],
6	MELANOMA	NN	O	melanoma	prep_in	1	SENT_113	[p9l1251t1246r1445b1265],

1	Table	NNP	O	Table	_	0	SENT_114	[p9l261t1367r335b1392],
2	1	CD	NUMBER	1	dep	1	SENT_114	[p9l345t1370r367b1392],
3	.	.	O	.	_	0	SENT_114	[p9l345t1370r367b1392],

1	Characteristics	NNS	O	characteristic	_	0	SENT_115	[p9l376t1367r579b1393],
2	of	IN	O	of	_	0	SENT_115	[p9l589t1367r620b1393],
3	the	DT	O	the	det	4	SENT_115	[p9l622t1367r666b1393],
4	Patients	NNS	O	patient	prep_of	1	SENT_115	[p9l677t1368r785b1393],
5	at	IN	O	at	_	0	SENT_115	[p9l795t1371r820b1393],
6	Baseline	NNP	O	Baseline	prep_at	4	SENT_115	[p9l830t1367r944b1393],
7	in	IN	O	in	_	0	SENT_115	[p9l953t1368r976b1392],
8	Part	NNP	O	Part	nn	9	SENT_115	[p9l989t1370r1042b1393],
9	C	NNP	O	C	prep_in	1	SENT_115	[p9l1050t1369r1069b1393],
10	(	CD	NUMBER	(	num	13	SENT_115	[p9l1080t1368r1331b1401],
11	Intention-to-Treat	NNP	O	Intention-to-Treat	nn	13	SENT_115	[p9l1080t1368r1331b1401],
12	Population	NNP	O	Population	nn	13	SENT_115	[p9l1341t1367r1523b1401],
13	)	NN	O	)	dep	9	SENT_115	[p9l1341t1367r1523b1401],
14	.	.	O	.	_	0	SENT_115	[p9l1341t1367r1523b1401],

1	*	NN	O	*	_	0	SENT_116	[p9l1341t1367r1523b1401],

1	Dabrafenib	NNP	O	Dabrafenib	nn	3	SENT_117	[p9l956t1442r1106b1468],
2	Monotherapy	NNP	O	Monotherapy	nn	3	SENT_117	[p9l1119t1443r1301b1476],
3	Combination	NNP	O	Combination	_	0	SENT_117	[p9l1327t1443r1503b1468],
4	150/1	CD	NUMBER	150/1	num	5	SENT_117	[p9l1517t1444r1593b1476],
5	Combination	NN	O	combination	dep	3	SENT_117	[p9l1635t1443r1811b1468],
6	150/2	CD	NUMBER	150/2	dep	3	SENT_117	[p9l1824t1444r1901b1476],

1	Characteristic	JJ	O	characteristic	amod	3	SENT_118	[p9l261t1480r450b1505],
2	(	NN	O	(	nn	3	SENT_118	[p9l1077t1482r1107b1513],
3	N	NN	O	n	dep	27	SENT_118	[p9l1077t1482r1107b1513],
4	=	JJ	O	=	quantmod	6	SENT_118	[p9l1115t1493r1132b1501],
5	54	CD	NUMBER	54	number	6	SENT_118	[p9l1138t1482r1178b1513],
6	)	CD	NUMBER	)	num	18	SENT_118	[p9l1138t1482r1178b1513],
7	(	NN	O	(	nn	18	SENT_118	[p9l1410t1482r1440b1513],
8	N	NN	O	n	nn	18	SENT_118	[p9l1410t1482r1440b1513],
9	=	JJ	O	=	amod	18	SENT_118	[p9l1448t1493r1465b1501],
10	54	CD	NUMBER	54	number	11	SENT_118	[p9l1471t1482r1511b1513],
11	)	CD	NUMBER	)	num	18	SENT_118	[p9l1471t1482r1511b1513],
12	(	NN	O	(	nn	18	SENT_118	[p9l1718t1482r1748b1513],
13	N	NN	O	n	nn	18	SENT_118	[p9l1718t1482r1748b1513],
14	=	JJ	O	=	amod	18	SENT_118	[p9l1756t1493r1773b1501],
15	54	CD	NUMBER	54	number	16	SENT_118	[p9l1779t1482r1819b1513],
16	)	CD	NUMBER	)	num	18	SENT_118	[p9l1779t1482r1819b1513],
17	Median	JJ	O	median	amod	18	SENT_118	[p9l264t1538r363b1563],
18	age	NN	O	age	dep	3	SENT_118	[p9l375t1546r421b1571],
19	(	NN	O	(	nn	20	SENT_118	[p9l434t1540r528b1571],
20	range	NN	O	range	dep	18	SENT_118	[p9l434t1540r528b1571],
21	)	CD	NUMBER	)	number	22	SENT_118	[p9l434t1540r528b1571],
22	—	CD	NUMBER	—	dep	20	SENT_118	[p9l539t1553r573b1556],
23	yr	NN	DURATION	yr	dep	27	SENT_118	[p9l581t1547r605b1571],
24	50	CD	NUMBER	50	num	23	SENT_118	[p9l1055t1539r1086b1563],
25	(	CD	NUMBER	(	num	27	SENT_118	[p9l1098t1539r1198b1571],
26	18	CD	NUMBER	18	num	27	SENT_118	[p9l1098t1539r1198b1571],
27	—	NN	O	—	dep	33	SENT_118	[p9l1098t1539r1198b1571],
28	82	CD	NUMBER	82	number	29	SENT_118	[p9l1098t1539r1198b1571],
29	)	CD	NUMBER	)	dep	27	SENT_118	[p9l1098t1539r1198b1571],
30	49	CD	NUMBER	49	num	31	SENT_118	[p9l1387t1540r1418b1563],
31	(	NN	O	(	dep	29	SENT_118	[p9l1432t1539r1531b1571],
32	23-85	CD	NUMBER	23-85	num	33	SENT_118	[p9l1432t1539r1531b1571],
33	)	CD	NUMBER	)	dep	41	SENT_118	[p9l1432t1539r1531b1571],
34	58	CD	NUMBER	58	num	35	SENT_118	[p9l1696t1539r1726b1563],
35	(	NN	O	(	dep	33	SENT_118	[p9l1739t1540r1839b1571],
36	27	CD	NUMBER	27	number	37	SENT_118	[p9l1739t1540r1839b1571],
37	—	CD	NUMBER	—	dep	35	SENT_118	[p9l1739t1540r1839b1571],
38	79	CD	NUMBER	79	num	41	SENT_118	[p9l1739t1540r1839b1571],
39	)	NN	O	)	nn	41	SENT_118	[p9l1739t1540r1839b1571],
40	Male	NN	O	male	nn	41	SENT_118	[p9l264t1595r329b1621],
41	sex	NN	O	sex	dep	48	SENT_118	[p9l339t1604r422b1621],
42	—	JJ	O	—	amod	43	SENT_118	[p9l339t1604r422b1621],
43	no.	NN	O	no.	dep	41	SENT_118	[p9l433t1604r472b1620],
44	(	CD	PERCENT	(	num	45	SENT_118	[p9l486t1597r531b1628],
45	%	NN	PERCENT	%	dep	43	SENT_118	[p9l486t1597r531b1628],
46	)	CD	NUMBER	)	number	47	SENT_118	[p9l486t1597r531b1628],
47	29	CD	NUMBER	29	num	45	SENT_118	[p9l1075t1598r1106b1621],
48	(	NN	O	(	dep	52	SENT_118	[p9l1119t1597r1169b1628],
49	54	CD	NUMBER	54	num	48	SENT_118	[p9l1119t1597r1169b1628],
50	)	CD	NUMBER	)	num	52	SENT_118	[p9l1119t1597r1169b1628],
51	30	CD	NUMBER	30	num	52	SENT_118	[p9l1413t1597r1444b1621],
52	(	NN	O	(	dep	56	SENT_118	[p9l1457t1597r1506b1628],
53	56	CD	NUMBER	56	number	54	SENT_118	[p9l1457t1597r1506b1628],
54	)	CD	NUMBER	)	dep	52	SENT_118	[p9l1457t1597r1506b1628],
55	34	CD	NUMBER	34	dep	54	SENT_118	[p9l1726t1597r1756b1620],
56	(	NN	O	(	dep	61	SENT_118	[p9l1769t1597r1819b1628],
57	63	CD	NUMBER	63	num	56	SENT_118	[p9l1769t1597r1819b1628],
58	)	CD	NUMBER	)	num	61	SENT_118	[p9l1769t1597r1819b1628],
59	ECOG	NN	O	ecog	nn	61	SENT_118	[p9l264t1655r345b1678],
60	performance	NN	O	performance	nn	61	SENT_118	[p9l358t1653r531b1686],
61	status	NN	O	status	dep	65	SENT_118	[p9l541t1658r622b1678],
62	—	CD	NUMBER	—	num	63	SENT_118	[p9l631t1668r665b1671],
63	no.	NN	O	no.	dep	61	SENT_118	[p9l675t1662r715b1678],
64	(	CD	PERCENT	(	num	65	SENT_118	[p9l729t1654r773b1686],
65	%	NN	PERCENT	%	dep	67	SENT_118	[p9l729t1654r773b1686],
66	)	CD	NUMBER	)	num	67	SENT_118	[p9l729t1654r773b1686],
67	o	NN	O	o	dep	72	SENT_118	[p9l312t1712r327b1736],
68	34	CD	NUMBER	34	number	69	SENT_118	[p9l1076t1713r1106b1736],
69	(	CD	NUMBER	(	dep	67	SENT_118	[p9l1119t1713r1169b1744],
70	63	CD	NUMBER	63	num	71	SENT_118	[p9l1119t1713r1169b1744],
71	)	NN	O	)	dep	69	SENT_118	[p9l1119t1713r1169b1744],
72	1	CD	NUMBER	1	_	0	SENT_118	[p9l314t1771r325b1793],

1	Metastatic	JJ	O	metastatic	amod	2	SENT_119	[p9l264t1828r406b1851],
2	status	NN	O	status	dep	7	SENT_119	[p9l416t1831r496b1851],
3	—	CD	NUMBER	—	num	4	SENT_119	[p9l506t1841r540b1844],
4	no.	NN	O	no.	dep	2	SENT_119	[p9l550t1835r589b1851],
5	(	CD	PERCENT	(	num	6	SENT_119	[p9l603t1827r669b1859],
6	%	NN	PERCENT	%	dep	7	SENT_119	[p9l603t1827r669b1859],
7	)	NN	O	)	_	0	SENT_119	[p9l603t1827r669b1859],
8	'	''	O	'	_	0	SENT_119	[p9l603t1827r669b1859],
9	i	FW	O	i	nn	10	SENT_119	[p9l603t1827r669b1859],
10	‘	FW	O	‘	dep	7	SENT_119	[p9l603t1827r669b1859],

1	Mo	NN	PERSON	mo	_	0	SENT_120	[p9l314t1885r356b1909],
2	Mla	NNP	PERSON	Mla	nn	4	SENT_120	[p9l314t1943r371b1966],
3	Mlb	NNP	PERSON	Mlb	nn	4	SENT_120	[p9l314t1999r373b2024],
4	Mlc	NNP	PERSON	Mlc	dep	1	SENT_120	[p9l314t2059r371b2082],

1	History	NN	O	history	nn	3	SENT_121	[p9l264t2116r362b2147],
2	ofbrain	NN	O	ofbrain	nn	3	SENT_121	[p9l371t2114r474b2139],
3	metastases	NNS	O	metastase	nsubj	4	SENT_121	[p9l486t2119r639b2139],
4	—	VBP	O	—	_	0	SENT_121	[p9l648t2130r682b2132],
5	no.	RB	O	no.	advmod	4	SENT_121	[p9l692t2123r731b2139],
6	(	CD	PERCENT	(	num	7	SENT_121	[p9l745t2115r790b2147],
7	%	NN	PERCENT	%	dobj	4	SENT_121	[p9l745t2115r790b2147],
8	)	CD	NUMBER	)	num	10	SENT_121	[p9l745t2115r790b2147],
9	Elevated	JJ	O	elevated	amod	10	SENT_121	[p9l264t2172r375b2197],
10	lactate	NN	O	lactate	dep	16	SENT_121	[p9l387t2172r474b2197],
11	dehydrogenase	NN	O	dehydrogenase	nn	12	SENT_121	[p9l484t2172r691b2205],
12	level	NN	O	level	dep	10	SENT_121	[p9l702t2172r760b2197],
13	—	CD	NUMBER	—	num	14	SENT_121	[p9l770t2187r803b2190],
14	no.	NN	O	no.	dep	16	SENT_121	[p9l814t2180r853b2197],
15	(	CD	PERCENT	(	num	16	SENT_121	[p9l867t2173r933b2205],
16	%	NN	PERCENT	%	dep	26	SENT_121	[p9l867t2173r933b2205],
17	)	CD	NUMBER	)	dep	16	SENT_121	[p9l867t2173r933b2205],
18	:	:	O	:	_	0	SENT_121	[p9l867t2173r933b2205],
19	i	FW	O	i	dep	17	SENT_121	[p9l867t2173r933b2205],
20	;	:	O	;	_	0	SENT_121	[p9l867t2173r933b2205],
21	BRAF	NN	O	braf	nn	22	SENT_121	[p9l264t2231r336b2254],
22	mutation	NN	O	mutation	dep	17	SENT_121	[p9l348t2232r469b2254],
23	—	CD	NUMBER	—	num	24	SENT_121	[p9l479t2245r513b2247],
24	no.	NN	O	no.	dep	22	SENT_121	[p9l523t2238r563b2254],
25	(	CD	PERCENT	(	num	26	SENT_121	[p9l577t2230r621b2262],
26	%	NN	PERCENT	%	dep	31	SENT_121	[p9l577t2230r621b2262],
27	)	CD	NUMBER	)	num	28	SENT_121	[p9l577t2230r621b2262],
28	V600E	NN	O	v600e	dep	26	SENT_121	[p9l311t2289r397b2312],
29	V600K	CD	NUMBER	v600k	num	31	SENT_121	[p9l311t2346r399b2370],
30	Previous	JJ	O	previous	amod	31	SENT_121	[p9l264t2404r378b2427],
31	chemotherapy	NN	O	chemotherapy	dep	35	SENT_121	[p9l389t2402r584b2435],
32	—	CD	NUMBER	—	num	33	SENT_121	[p9l592t2418r626b2420],
33	no.	NN	O	no.	dep	31	SENT_121	[p9l636t2411r676b2427],
34	(	CD	PERCENT	(	num	35	SENT_121	[p9l690t2403r734b2435],
35	%	NN	PERCENT	%	dep	40	SENT_121	[p9l690t2403r734b2435],
36	)	CD	NUMBER	)	num	38	SENT_121	[p9l690t2403r734b2435],
37	Previous	JJ	O	previous	amod	38	SENT_121	[p9l264t2462r378b2485],
38	immunotherapy	NN	O	immunotherapy	dep	35	SENT_121	[p9l390t2460r650b2493],
39	—	CD	NUMBER	—	num	40	SENT_121	[p9l390t2460r650b2493],
40	no.	NN	O	no.	dep	43	SENT_121	[p9l660t2469r700b2485],
41	(	CD	PERCENT	(	num	42	SENT_121	[p9l714t2461r758b2493],
42	%	NN	PERCENT	%	dep	40	SENT_121	[p9l714t2461r758b2493],
43	)	CD	NUMBER	)	dep	7	SENT_121	[p9l714t2461r758b2493],

1	*	NN	O	*	nn	3	SENT_122	[p9l235t2547r250b2561],
2	Part	NN	O	part	nn	3	SENT_122	[p9l263t2547r315b2570],
3	C	NN	O	c	nsubj	8	SENT_122	[p9l326t2547r344b2570],
4	was	VBD	O	be	cop	8	SENT_122	[p9l354t2554r405b2570],
5	a	DT	O	a	det	8	SENT_122	[p9l417t2554r430b2570],
6	phase	NN	O	phase	nn	8	SENT_122	[p9l444t2545r522b2578],
7	2	CD	NUMBER	2	num	8	SENT_122	[p9l534t2547r547b2570],
8	study	NN	O	study	_	0	SENT_122	[p9l560t2545r633b2578],
9	in	IN	O	in	_	0	SENT_122	[p9l644t2547r666b2570],
10	which	WDT	O	which	rel	14	SENT_122	[p9l678t2545r756b2570],
11	patients	NNS	O	patient	nsubjpass	14	SENT_122	[p9l771t2547r878b2578],
12	were	VBD	O	be	auxpass	14	SENT_122	[p9l889t2554r952b2570],
13	randomly	RB	O	randomly	advmod	14	SENT_122	[p9l965t2545r1093b2578],
14	assigned	VBN	O	assign	rcmod	8	SENT_122	[p9l1104t2545r1222b2578],
15	to	TO	O	to	aux	16	SENT_122	[p9l1234t2550r1261b2570],
16	receive	VB	O	receive	xcomp	14	SENT_122	[p9l1274t2547r1366b2570],
17	150	CD	NUMBER	150	num	19	SENT_122	[p9l1380t2546r1426b2570],
18	mg	NN	O	mg	nn	19	SENT_122	[p9l1438t2554r1480b2578],
19	ofdabrafenib	NN	O	ofdabrafenib	dobj	16	SENT_122	[p9l1491t2544r1673b2570],
20	twice	RB	O	twice	advmod	21	SENT_122	[p9l1683t2547r1753b2570],
21	daily	JJ	SET	daily	dep	19	SENT_122	[p9l1765t2545r1827b2578],
22	plus	CC	O	plus	_	0	SENT_122	[p9l1839t2545r1893b2578],
23	once-daily	JJ	O	once-daily	amod	24	SENT_122	[p9l260t2582r398b2616],
24	trametinib	NN	O	trametinib	dobj	16	SENT_122	[p9l408t2582r550b2608],
25	at	IN	O	at	_	0	SENT_122	[p9l562t2587r586b2608],
26	a	DT	O	a	det	32	SENT_122	[p9l597t2591r610b2608],
27	dose	NN	O	dose	nn	32	SENT_122	[p9l622t2582r686b2608],
28	ofeither	NN	O	ofeither	nn	32	SENT_122	[p9l697t2582r811b2608],
29	1	CD	NUMBER	1	num	32	SENT_122	[p9l824t2585r835b2607],
30	mg	NN	O	mg	nn	32	SENT_122	[p9l849t2591r891b2616],
31	(	NN	O	(	nn	32	SENT_122	[p9l905t2582r1085b2616],
32	combination	NN	O	combination	prep_at	24	SENT_122	[p9l905t2582r1085b2616],
33	150/1	CD	NUMBER	150/1	number	34	SENT_122	[p9l1100t2584r1186b2616],
34	)	CD	NUMBER	)	dep	32	SENT_122	[p9l1100t2584r1186b2616],
35	or	CC	O	or	_	0	SENT_122	[p9l1200t2591r1228b2608],
36	2	CD	NUMBER	2	num	39	SENT_122	[p9l1238t2585r1252b2607],
37	mg	NN	O	mg	nn	39	SENT_122	[p9l1265t2591r1307b2616],
38	(	NN	O	(	nn	39	SENT_122	[p9l1321t2582r1593b2616],
39	combination150/2	NN	O	combination150/2	prep_at	24	SENT_122	[p9l1321t2582r1593b2616],
40	)	CD	NUMBER	)	dep	39	SENT_122	[p9l1321t2582r1593b2616],
41	or	CC	O	or	_	0	SENT_122	[p9l1607t2591r1635b2608],
42	150	CD	NUMBER	150	dep	39	SENT_122	[p9l1647t2584r1693b2608],
43	mg	NN	O	mg	nn	45	SENT_122	[p9l1706t2591r1748b2616],
44	ofdabrafenib	NN	O	ofdabrafenib	nn	45	SENT_122	[p9l1758t2582r1905b2608, p9l262t2619r302b2645],
45	monotherapy	NN	O	monotherapy	dep	40	SENT_122	[p9l315t2619r496b2653],
46	twice	RB	O	twice	advmod	47	SENT_122	[p9l506t2622r576b2645],
47	daily	RB	SET	daily	advmod	16	SENT_122	[p9l588t2619r656b2653],
48	.	.	O	.	_	0	SENT_122	[p9l588t2619r656b2653],

1	There	EX	O	there	expl	2	SENT_123	[p9l667t2619r745b2645],
2	were	VBD	O	be	dep	16	SENT_123	[p9l755t2628r819b2645],
3	no	DT	O	no	det	5	SENT_123	[p9l831t2628r864b2645],
4	signiﬁcant	JJ	O	signiﬁcant	amod	5	SENT_123	[p9l876t2619r1017b2653],
5	differences	NNS	O	difference	nsubj	2	SENT_123	[p9l1028t2619r1175b2645],
6	among	IN	O	among	_	0	SENT_123	[p9l1188t2628r1283b2653],
7	groups	NNS	O	group	prep_among	5	SENT_123	[p9l1294t2628r1388b2653],
8	except	IN	O	except	_	0	SENT_123	[p9l1400t2624r1486b2653],
9	that	DT	O	that	det	10	SENT_123	[p9l1496t2619r1549b2645],
10	patients	NNS	O	patient	prep_except	7	SENT_123	[p9l1562t2622r1669b2653],
11	in	IN	O	in	_	0	SENT_123	[p9l1682t2622r1704b2644],
12	the	DT	O	the	det	15	SENT_123	[p9l1716t2619r1758b2645],
13	combination	NN	O	combination	nn	15	SENT_123	[p9l1770t2619r1897b2645, p9l259t2659r311b2682],
14	150/2	CD	NUMBER	150/2	num	15	SENT_123	[p9l326t2658r401b2690],
15	group	NN	O	group	prep_in	10	SENT_123	[p9l414t2666r493b2690],
16	were	VBD	O	be	_	0	SENT_123	[p9l504t2666r567b2682],
17	older	JJR	O	older	acomp	16	SENT_123	[p9l579t2657r648b2682],
18	than	IN	O	than	_	0	SENT_123	[p9l657t2657r717b2682],
19	those	DT	O	those	prep_than	16	SENT_123	[p9l729t2657r804b2682],
20	in	IN	O	in	_	0	SENT_123	[p9l816t2659r838b2682],
21	the	DT	O	the	det	23	SENT_123	[p9l850t2657r893b2682],
22	monotherapy	NN	O	monotherapy	nn	23	SENT_123	[p9l905t2657r1087b2690],
23	group	NN	O	group	prep_in	19	SENT_123	[p9l1098t2666r1177b2690],
24	(	CD	NUMBER	(	num	25	SENT_123	[p9l1192t2658r1321b2690],
25	P	NN	O	p	npadvmod	26	SENT_123	[p9l1192t2658r1321b2690],
26	=	JJ	O	=	amod	23	SENT_123	[p9l1192t2658r1321b2690],
27	0.04	CD	NUMBER	0.04	num	28	SENT_123	[p9l1192t2658r1321b2690],
28	)	NN	O	)	nsubj	16	SENT_123	[p9l1192t2658r1321b2690],
29	.	.	O	.	_	0	SENT_123	[p9l1192t2658r1321b2690],

1	ECOG	NN	ORGANIZATION	ecog	nsubj	2	SENT_124	[p9l1336t2659r1417b2682],
2	denotes	VBZ	O	denote	_	0	SENT_124	[p9l1430t2657r1538b2682],
3	Eastern	NNP	ORGANIZATION	Eastern	nn	6	SENT_124	[p9l1552t2659r1650b2682],
4	Cooperative	NNP	ORGANIZATION	Cooperative	nn	6	SENT_124	[p9l1663t2659r1826b2690],
5	Oncology	NNP	ORGANIZATION	Oncology	nn	6	SENT_124	[p9l261t2694r391b2727],
6	Group	NNP	ORGANIZATION	Group	dobj	2	SENT_124	[p9l402t2696r496b2726],
7	.	.	O	.	_	0	SENT_124	[p9l402t2696r496b2726],

1	1	CD	NUMBER	1	dep	5	SENT_125	[p9l236t2733r252b2763],
2	'	''	O	'	_	0	SENT_125	[p9l236t2733r252b2763],
3	The	DT	O	the	det	4	SENT_125	[p9l259t2730r310b2755],
4	criteria	NNS	O	criterion	nsubj	5	SENT_125	[p9l321t2733r414b2755],
5	ofthe	VBP	O	ofthe	_	0	SENT_125	[p9l426t2730r504b2755],
6	American	JJ	ORGANIZATION	american	amod	8	SENT_125	[p9l514t2732r643b2755],
7	Joint	NNP	ORGANIZATION	Joint	nn	8	SENT_125	[p9l652t2733r719b2763],
8	Committee	NNP	ORGANIZATION	Committee	nsubj	14	SENT_125	[p9l730t2732r882b2755],
9	on	IN	O	on	_	0	SENT_125	[p9l894t2739r926b2755],
10	Cancer	NNP	O	Cancer	prep_on	8	SENT_125	[p9l939t2732r1033b2755],
11	for	IN	O	for	_	0	SENT_125	[p9l1043t2730r1081b2755],
12	distant	JJ	O	distant	amod	13	SENT_125	[p9l1091t2730r1185b2755],
13	metastasis	NN	O	metastasis	prep_for	10	SENT_125	[p9l1198t2733r1342b2755],
14	are	VBP	O	be	ccomp	5	SENT_125	[p9l1355t2739r1395b2755],
15	as	IN	O	as	mark	16	SENT_125	[p9l1407t2739r1434b2755],
16	follows	VBZ	O	follow	advcl	14	SENT_125	[p9l1446t2730r1549b2755],
17	:	:	O	:	_	0	SENT_125	[p9l1446t2730r1549b2755],
18	Mo	NN	DURATION	mo	nsubj	49	SENT_125	[p9l1564t2732r1613b2760],
19	,	,	O	,	_	0	SENT_125	[p9l1564t2732r1613b2760],
20	no	DT	O	no	det	22	SENT_125	[p9l1627t2739r1659b2755],
21	detectable	JJ	O	detectable	amod	22	SENT_125	[p9l1670t2730r1810b2755],
22	evidence	NN	O	evidence	appos	18	SENT_125	[p9l1821t2733r1867b2755, p9l260t2767r340b2792],
23	ofdistant	JJ	O	ofdistant	amod	24	SENT_125	[p9l352t2767r482b2792],
24	metastases	NNS	O	metastase	dep	22	SENT_125	[p9l494t2772r655b2797],
25	;	:	O	;	_	0	SENT_125	[p9l494t2772r655b2797],
26	Mla	NNP	O	Mla	appos	18	SENT_125	[p9l669t2770r734b2797],
27	,	,	O	,	_	0	SENT_125	[p9l669t2770r734b2797],
28	metastases	NNS	O	metastase	appos	26	SENT_125	[p9l748t2772r900b2792],
29	to	TO	O	to	_	0	SENT_125	[p9l911t2772r938b2792],
30	skin	NN	O	skin	prep_to	28	SENT_125	[p9l950t2767r1011b2797],
31	,	,	O	,	_	0	SENT_125	[p9l950t2767r1011b2797],
32	subcutaneous	JJ	O	subcutaneous	amod	33	SENT_125	[p9l1024t2767r1214b2792],
33	tissue	NN	O	tissue	prep_to	28	SENT_125	[p9l1226t2770r1313b2797],
34	,	,	O	,	_	0	SENT_125	[p9l1226t2770r1313b2797],
35	or	CC	O	or	_	0	SENT_125	[p9l1326t2776r1354b2792],
36	distant	JJ	O	distant	amod	38	SENT_125	[p9l1364t2767r1458b2792],
37	lymph	NN	O	lymph	nn	38	SENT_125	[p9l1470t2767r1551b2800],
38	nodes	NNS	O	node	conj_or	30	SENT_125	[p9l1565t2767r1653b2797],
39	;	:	O	;	_	0	SENT_125	[p9l1565t2767r1653b2797],
40	Mlb	NNP	O	Mlb	conj_and	22	SENT_125	[p9l1668t2767r1734b2797],
41	,	,	O	,	_	0	SENT_125	[p9l1668t2767r1734b2797],
42	metastases	NNS	O	metastase	appos	40	SENT_125	[p9l1748t2772r1900b2792],
43	to	TO	O	to	_	0	SENT_125	[p9l259t2809r286b2829],
44	lung	NN	O	lung	prep_to	42	SENT_125	[p9l299t2804r364b2837],
45	;	:	O	;	_	0	SENT_125	[p9l299t2804r364b2837],
46	and	CC	O	and	_	0	SENT_125	[p9l377t2804r425b2829],
47	Mlc	NNP	O	Mlc	conj_and	22	SENT_125	[p9l440t2806r503b2833],
48	,	,	O	,	_	0	SENT_125	[p9l440t2806r503b2833],
49	metastases	NNS	O	metastase	parataxis	16	SENT_125	[p9l517t2809r669b2829],
50	to	TO	O	to	_	0	SENT_125	[p9l680t2809r707b2829],
51	all	DT	O	all	det	54	SENT_125	[p9l719t2804r747b2829],
52	other	JJ	O	other	amod	54	SENT_125	[p9l760t2804r831b2829],
53	visceral	JJ	O	visceral	amod	54	SENT_125	[p9l841t2804r941b2829],
54	sites	NNS	O	site	prep_to	49	SENT_125	[p9l955t2806r1015b2829],
55	or	CC	O	or	_	0	SENT_125	[p9l1027t2813r1055b2829],
56	distant	JJ	O	distant	amod	57	SENT_125	[p9l1066t2804r1160b2829],
57	metastases	NNS	O	metastase	conj_or	49	SENT_125	[p9l1172t2809r1324b2829],
58	to	TO	O	to	_	0	SENT_125	[p9l1335t2809r1362b2829],
59	any	DT	O	any	det	60	SENT_125	[p9l1374t2813r1419b2837],
60	site	NN	O	site	prep_to	57	SENT_125	[p9l1431t2806r1477b2829],
61	combined	VBN	O	combine	partmod	60	SENT_125	[p9l1488t2804r1623b2829],
62	with	IN	O	with	_	0	SENT_125	[p9l1635t2804r1691b2829],
63	an	DT	O	a	det	68	SENT_125	[p9l1704t2813r1734b2829],
64	elevated	JJ	O	elevated	amod	68	SENT_125	[p9l1747t2804r1857b2829],
65	serum	NN	O	serum	nn	68	SENT_125	[p9l1871t2813r1907b2829, p9l262t2850r314b2866],
66	lactate	NN	O	lactate	nn	68	SENT_125	[p9l328t2841r416b2866],
67	dehydrogenase	NN	O	dehydrogenase	nn	68	SENT_125	[p9l427t2841r634b2874],
68	level	NN	O	level	prep_with	61	SENT_125	[p9l646t2841r712b2866],
69	.	.	O	.	_	0	SENT_125	[p9l646t2841r712b2866],

1	:3	CD	NUMBER	:3	_	0	SENT_126	[p9l236t2880r252b2911],
2	:	:	O	:	_	0	SENT_126	[p9l236t2880r252b2911],
3	The	DT	O	the	det	6	SENT_126	[p9l259t2877r310b2903],
4	lactate	NN	O	lactate	nn	6	SENT_126	[p9l322t2877r410b2903],
5	dehydrogenase	NN	O	dehydrogenase	nn	6	SENT_126	[p9l421t2877r628b2911],
6	level	NN	O	level	nsubjpass	8	SENT_126	[p9l640t2877r698b2903],
7	was	VBD	O	be	auxpass	8	SENT_126	[p9l709t2886r760b2903],
8	considered	VBN	O	consider	dep	1	SENT_126	[p9l773t2877r921b2903],
9	to	TO	O	to	aux	11	SENT_126	[p9l933t2882r960b2903],
10	be	VB	O	be	cop	11	SENT_126	[p9l973t2877r1002b2903],
11	elevated	JJ	O	elevated	xcomp	8	SENT_126	[p9l1014t2877r1124b2903],
12	if	IN	O	if	mark	22	SENT_126	[p9l1138t2877r1157b2902],
13	it	PRP	O	it	nsubj	22	SENT_126	[p9l1165t2880r1180b2903],
14	was	VBD	O	be	cop	22	SENT_126	[p9l1190t2886r1241b2903],
15	more	JJR	O	more	amod	22	SENT_126	[p9l1255t2886r1324b2903],
16	than	IN	O	than	_	0	SENT_126	[p9l1335t2877r1394b2903],
17	the	DT	O	the	det	20	SENT_126	[p9l1406t2877r1448b2903],
18	upper	JJ	O	upper	amod	20	SENT_126	[p9l1461t2886r1540b2911],
19	limit	NN	O	limit	nn	20	SENT_126	[p9l1551t2877r1611b2903],
20	ofthe	NN	O	ofthe	prep_than	15	SENT_126	[p9l1622t2877r1700b2903],
21	normal	JJ	O	normal	amod	22	SENT_126	[p9l1713t2877r1807b2903],
22	range	NN	O	range	advcl	11	SENT_126	[p9l1821t2886r1903b2911],
23	.	.	O	.	_	0	SENT_126	[p9l1821t2886r1903b2911],

1	the	DT	O	the	det	5	SENT_127	[p9l11t3133r144b3211],
2	combination	NN	O	combination	nn	5	SENT_127	[p9l188t3133r1100b3233],
3	—	NN	O	—	nn	5	SENT_127	[p9l188t3133r1100b3233],
4	therapy	NN	O	therapy	nn	5	SENT_127	[p9l188t3133r1100b3233],
5	groups	NNS	O	group	nsubj	6	SENT_127	[p9l1138t3159r1436b3234],
6	(	VBP	O	(	_	0	SENT_127	[p9l1487t3138r1694b3224],
7	11	CD	PERCENT	11	num	8	SENT_127	[p9l1487t3138r1694b3224],
8	%	NN	PERCENT	%	dobj	6	SENT_127	[p9l1487t3138r1694b3224],
9	and	CC	O	and	_	0	SENT_127	[p9l1735t3133r1894b3212],
10	16	CD	PERCENT	16	num	11	SENT_127	[p9l1941t3138r2144b3229],
11	%	NN	PERCENT	%	conj_and	8	SENT_127	[p9l1941t3138r2144b3229],
12	,	,	O	,	_	0	SENT_127	[p9l1941t3138r2144b3229],
13	respectively	RB	O	respectively	advmod	11	SENT_127	[p9l10t3261r528b3361],
14	,	,	O	,	_	0	SENT_127	[p9l10t3261r528b3361],
15	vs.	FW	O	vs.	dep	18	SENT_127	[p9l564t3287r674b3340],
16	4	CD	PERCENT	4	num	17	SENT_127	[p9l713t3266r896b3352],
17	%	NN	PERCENT	%	pobj	15	SENT_127	[p9l713t3266r896b3352],
18	)	CD	NUMBER	)	rcmod	11	SENT_127	[p9l713t3266r896b3352],
19	.	.	O	.	_	0	SENT_127	[p9l713t3266r896b3352],

1	Known	VBN	O	know	_	0	SENT_128	[p9l140t3398r454b3471],
2	MEK	NN	O	mek	nn	4	SENT_128	[p9l522t3398r737b3471],
3	inhibitor	NN	O	inhibitor	nn	4	SENT_128	[p9l804t3390r1694b3470],
4	—	NN	O	—	dep	1	SENT_128	[p9l804t3390r1694b3470],
5	associated	VBN	O	associate	partmod	4	SENT_128	[p9l804t3390r1694b3470],
6	toxic	JJ	O	toxic	amod	7	SENT_128	[p9l1765t3391r1972b3470],
7	effects	NNS	O	effect	dobj	5	SENT_128	[p9l2043t3389r2148b3469, p9l10t3518r234b3616],
8	,	,	O	,	_	0	SENT_128	[p9l2043t3389r2148b3469, p9l10t3518r234b3616],

1	including	VBG	O	include	_	0	SENT_129	[p9l276t3519r690b3621],
2	peripheral	JJ	O	peripheral	amod	3	SENT_129	[p9l723t3519r1169b3620],
3	edema	NN	O	edema	prep_including	16	SENT_129	[p9l1206t3519r1511b3616],
4	,	,	O	,	_	0	SENT_129	[p9l1206t3519r1511b3616],
5	hypertension	NN	O	hypertension	nsubj	16	SENT_129	[p9l1554t3519r2144b3620],
6	,	,	O	,	_	0	SENT_129	[p9l1554t3519r2144b3620],
7	decreased	VBD	O	decrease	partmod	5	SENT_129	[p9l11t3647r436b3726],
8	cardiac	JJ	O	cardiac	amod	10	SENT_129	[p9l490t3647r801b3726],
9	ejection	NN	O	ejection	nn	10	SENT_129	[p9l854t3648r1190b3747],
10	fraction	NN	O	fraction	dobj	7	SENT_129	[p9l1243t3646r1606b3743],
11	,	,	O	,	_	0	SENT_129	[p9l1243t3646r1606b3743],
12	and	CC	O	and	_	0	SENT_129	[p9l1664t3647r1823b3726],
13	ocular	JJ	O	ocular	amod	14	SENT_129	[p9l1877t3647r2152b3727],
14	events	NNS	O	event	conj_and	10	SENT_129	[p10l11t38r295b117],
15	,	,	O	,	_	0	SENT_129	[p10l11t38r295b117],
16	occurred	VBD	O	occur	_	0	SENT_129	[p10l336t21r711b101],
17	more	RBR	O	more	advmod	18	SENT_129	[p10l746t47r963b100],
18	frequently	RB	O	frequently	advmod	16	SENT_129	[p10l999t20r1433b121],
19	in	IN	O	in	_	0	SENT_129	[p10l1462t22r1546b99],
20	the	DT	O	the	det	22	SENT_129	[p10l1582t21r1713b99],
21	combination	NN	O	combination	nn	22	SENT_129	[p10l1749t21r2148b100, p10l11t150r542b250],
22	—	NN	O	—	prep_in	18	SENT_129	[p10l1749t21r2148b100, p10l11t150r542b250],
23	therapy	NN	O	therapy	nn	24	SENT_129	[p10l1749t21r2148b100, p10l11t150r542b250],
24	groups	NNS	O	group	dobj	16	SENT_129	[p10l601t176r899b251],
25	than	IN	O	than	advmod	16	SENT_129	[p10l967t150r1165b228],
26	in	IN	O	in	_	0	SENT_129	[p10l1228t151r1312b228],
27	the	DT	O	the	det	29	SENT_129	[p10l1377t150r1511b228],
28	monotherapy	JJ	O	monotherapy	amod	29	SENT_129	[p10l1575t150r2154b250],
29	group	NN	O	group	prep_in	16	SENT_129	[p10l10t304r276b379],
30	.	.	O	.	_	0	SENT_129	[p10l10t304r276b379],

1	Conversely	RB	O	conversely	advmod	7	SENT_130	[p10l313t278r773b378],
2	,	,	O	,	_	0	SENT_130	[p10l313t278r773b378],
3	known	JJ	O	known	amod	6	SENT_130	[p10l809t278r1101b357],
4	BRAF	NN	O	braf	nn	6	SENT_130	[p10l1131t284r1370b361],
5	inhibitor	NN	O	inhibitor	nn	6	SENT_130	[p10l1402t278r2149b357],
6	—	NN	O	—	nsubj	7	SENT_130	[p10l1402t278r2149b357],
7	induced	VBD	O	induce	_	0	SENT_130	[p10l1402t278r2149b357],
8	hyperproliferative	JJ	O	hyperproliferative	amod	10	SENT_130	[p10l10t404r765b505],
9	skin	NN	O	skin	nn	10	SENT_130	[p10l802t405r980b485],
10	lesions	NNS	O	lesion	nsubjpass	26	SENT_130	[p10l1014t405r1327b501],
11	,	,	O	,	_	0	SENT_130	[p10l1014t405r1327b501],
12	such	JJ	O	such	_	0	SENT_130	[p10l1369t405r1561b484],
13	as	IN	O	as	_	0	SENT_130	[p10l1595t431r1680b483],
14	cutaneous	JJ	O	cutaneous	amod	17	SENT_130	[p10l1717t422r2148b485],
15	squamous	JJ	O	squamous	amod	17	SENT_130	[p10l11t534r628b634],
16	—	NN	O	—	nn	17	SENT_130	[p10l11t534r628b634],
17	cell	NN	O	cell	prep_such_as	10	SENT_130	[p10l11t534r628b634],
18	carcinoma	NN	O	carcinoma	dep	17	SENT_130	[p10l669t535r1139b630],
19	,	,	O	,	_	0	SENT_130	[p10l669t535r1139b630],
20	papilloma	NN	O	papilloma	conj_and	18	SENT_130	[p10l1185t534r1635b634],
21	,	,	O	,	_	0	SENT_130	[p10l1185t534r1635b634],
22	and	CC	O	and	_	0	SENT_130	[p10l1682t534r1839b613],
23	hyperkeratosis	NN	O	hyperkeratosis	conj_and	18	SENT_130	[p10l1881t534r2148b634, p10l10t662r409b758],
24	,	,	O	,	_	0	SENT_130	[p10l1881t534r2148b634, p10l10t662r409b758],
25	were	VBD	O	be	auxpass	26	SENT_130	[p10l467t688r670b742],
26	observed	VBN	O	observe	ccomp	7	SENT_130	[p10l727t662r1111b741],
27	less	RBR	O	less	advmod	28	SENT_130	[p10l1166t662r1322b740],
28	frequently	RB	O	frequently	advmod	26	SENT_130	[p10l1381t661r1824b762],
29	in	IN	O	in	_	0	SENT_130	[p10l1875t663r1959b740],
30	the	DT	O	the	det	33	SENT_130	[p10l2015t662r2149b740],
31	combination	NN	O	combination	nn	33	SENT_130	[p10l11t791r923b891],
32	—	NN	O	—	nn	33	SENT_130	[p10l11t791r923b891],
33	therapy	NN	O	therapy	prep_in	28	SENT_130	[p10l11t791r923b891],
34	groups	NNS	O	group	npadvmod	35	SENT_130	[p10l964t817r1261b892],
35	than	IN	O	than	advmod	28	SENT_130	[p10l1310t791r1508b869],
36	in	IN	O	in	_	0	SENT_130	[p10l1554t792r1638b869],
37	the	DT	O	the	det	39	SENT_130	[p10l1684t791r1818b869],
38	monotherapy	JJ	O	monotherapy	amod	39	SENT_130	[p10l1864t817r2148b870, p10l11t919r335b1019],
39	group	NN	O	group	prep_in	26	SENT_130	[p10l370t945r647b1020],
40	.	.	O	.	_	0	SENT_130	[p10l370t945r647b1020],

1	The	DT	O	the	det	5	SENT_131	[p10l136t1046r299b1124],
2	most	RBS	O	most	advmod	3	SENT_131	[p10l336t1063r554b1125],
3	frequent	JJ	O	frequent	amod	5	SENT_131	[p10l586t1045r953b1146],
4	adverse	JJ	O	adverse	amod	5	SENT_131	[p10l985t1046r1301b1126],
5	events	NNS	O	event	nsubj	13	SENT_131	[p10l1340t1063r1605b1126],
6	observed	VBN	O	observe	partmod	5	SENT_131	[p10l1645t1046r2029b1126],
7	in	IN	O	in	_	0	SENT_131	[p10l2065t1047r2149b1124],
8	the	DT	O	the	det	11	SENT_131	[p10l11t1175r144b1253],
9	combination	NN	O	combination	nn	11	SENT_131	[p10l198t1175r749b1254],
10	150/2	CD	NUMBER	150/2	num	11	SENT_131	[p10l806t1180r1034b1265],
11	group	NN	O	group	prep_in	6	SENT_131	[p10l1088t1201r1343b1276],
12	were	VBD	O	be	cop	13	SENT_131	[p10l1393t1201r1596b1254],
13	pyrexia	NN	O	pyrexia	dep	31	SENT_131	[p10l1648t1176r1963b1275],
14	(	CD	NUMBER	(	num	13	SENT_131	[p10l2020t1175r2149b1266],
15	all	DT	O	all	det	16	SENT_131	[p10l2020t1175r2149b1266],
16	grades	NNS	O	grade	dep	13	SENT_131	[p10l10t1303r318b1404],
17	,	,	O	,	_	0	SENT_131	[p10l10t1303r318b1404],
18	71	CD	NUMBER	71	number	19	SENT_131	[p10l362t1308r565b1399],
19	°	CD	NUMBER	°	dep	31	SENT_131	[p10l362t1308r565b1399],
20	/	:	O	/	punct	21	SENT_131	[p10l362t1308r565b1399],
21	o	NN	O	o	dep	19	SENT_131	[p10l362t1308r565b1399],
22	;	:	O	;	_	0	SENT_131	[p10l362t1308r565b1399],
23	grade	NN	O	grade	dep	21	SENT_131	[p10l605t1303r846b1404],
24	3	CD	NUMBER	3	num	23	SENT_131	[p10l885t1309r954b1399],
25	,	,	O	,	_	0	SENT_131	[p10l885t1309r954b1399],
26	5	CD	PERCENT	5	number	27	SENT_131	[p10l999t1308r1154b1394],
27	%	NN	PERCENT	%	dep	21	SENT_131	[p10l999t1308r1154b1394],
28	)	CD	NUMBER	)	dep	19	SENT_131	[p10l999t1308r1154b1394],
29	and	CC	O	and	_	0	SENT_131	[p10l1197t1303r1356b1382],
30	chills	NNS	O	chill	dep	31	SENT_131	[p10l1393t1303r1625b1381],
31	(	VBP	O	(	_	0	SENT_131	[p10l1669t1303r1799b1394],
32	all	DT	O	all	det	33	SENT_131	[p10l1669t1303r1799b1394],
33	grades	NNS	O	grade	dobj	31	SENT_131	[p10l1835t1303r2144b1404],
34	,	,	O	,	_	0	SENT_131	[p10l1835t1303r2144b1404],
35	58	CD	PERCENT	58	number	36	SENT_131	[p10l12t1436r222b1527],
36	%	NN	PERCENT	%	amod	33	SENT_131	[p10l12t1436r222b1527],
37	;	:	O	;	_	0	SENT_131	[p10l12t1436r222b1527],
38	grade	NN	O	grade	nsubj	31	SENT_131	[p10l271t1431r512b1532],
39	3	CD	NUMBER	3	num	38	SENT_131	[p10l560t1437r629b1527],
40	,	,	O	,	_	0	SENT_131	[p10l560t1437r629b1527],
41	2	CD	PERCENT	2	num	42	SENT_131	[p10l682t1436r866b1522],
42	%	NN	PERCENT	%	appos	38	SENT_131	[p10l682t1436r866b1522],
43	)	CD	NUMBER	)	dep	42	SENT_131	[p10l682t1436r866b1522],
44	.	.	O	.	_	0	SENT_131	[p10l682t1436r866b1522],

1	Pyrexia	NNP	O	Pyrexia	_	0	SENT_132	[p10l916t1432r1234b1531],
2	that	WDT	O	that	nsubjpass	4	SENT_132	[p10l1279t1431r1452b1509],
3	was	VBD	O	be	auxpass	4	SENT_132	[p10l1489t1457r1653b1510],
4	associated	VBN	O	associate	rcmod	1	SENT_132	[p10l1701t1431r2149b1510],
5	with	IN	O	with	_	0	SENT_132	[p10l6t1559r199b1638],
6	severe	JJ	O	severe	amod	7	SENT_132	[p10l236t1585r490b1638],
7	chills	NNS	O	chill	prep_with	4	SENT_132	[p10l526t1559r753b1637],
8	or	CC	O	or	_	0	SENT_132	[p10l791t1585r879b1638],
9	hypotension	NN	O	hypotension	conj_or	7	SENT_132	[p10l912t1559r1434b1659],
10	or	CC	O	or	_	0	SENT_132	[p10l1470t1585r1559b1638],
11	that	IN	O	that	dep	16	SENT_132	[p10l1592t1559r1762b1637],
12	required	VBN	O	require	amod	13	SENT_132	[p10l1792t1559r2149b1659],
13	hospitalization	NN	O	hospitalization	nsubj	16	SENT_132	[p10l10t1687r664b1787],
14	was	VBD	O	be	cop	16	SENT_132	[p10l697t1713r861b1767],
15	more	RBR	O	more	advmod	16	SENT_132	[p10l900t1713r1122b1766],
16	frequent	JJ	O	frequent	rcmod	1	SENT_132	[p10l1159t1686r1526b1787],
17	in	IN	O	in	_	0	SENT_132	[p10l1558t1688r1642b1765],
18	the	DT	O	the	det	19	SENT_132	[p10l1679t1687r1813b1765],
19	combination	NN	O	combination	prep_in	16	SENT_132	[p10l1851t1687r2148b1766, p10l10t1817r283b1895],
20	150/1	CD	NUMBER	150/1	num	19	SENT_132	[p10l323t1821r548b1906],
21	and	CC	O	and	_	0	SENT_132	[p10l586t1816r742b1895],
22	combination	NN	O	combination	conj_and	19	SENT_132	[p10l780t1816r1320b1895],
23	150/2	CD	NUMBER	150/2	num	24	SENT_132	[p10l1361t1821r1585b1906],
24	groups	NNS	O	group	npadvmod	25	SENT_132	[p10l1622t1842r1915b1917],
25	than	IN	O	than	advmod	16	SENT_132	[p10l1955t1816r2149b1894],
26	in	IN	O	in	_	0	SENT_132	[p10l10t1945r93b2022],
27	the	DT	O	the	det	29	SENT_132	[p10l149t1944r282b2023],
28	monotherapy	NN	O	monotherapy	nn	29	SENT_132	[p10l337t1944r916b2044],
29	group	NN	O	group	prep_in	16	SENT_132	[p10l966t1970r1220b2045],
30	(	CD	PERCENT	(	number	35	SENT_132	[p10l1281t1949r1496b2035],
31	19	CD	PERCENT	19	number	35	SENT_132	[p10l1281t1949r1496b2035],
32	%	NN	PERCENT	%	dep	35	SENT_132	[p10l1281t1949r1496b2035],
33	and	CC	O	and	_	0	SENT_132	[p10l1549t1944r1708b2023],
34	25	CD	PERCENT	25	conj_and	35	SENT_132	[p10l1764t1949r1975b2040],
35	%	NN	PERCENT	%	amod	1	SENT_132	[p10l1764t1949r1975b2040],
36	,	,	O	,	_	0	SENT_132	[p10l1764t1949r1975b2040],
37	respectively	RB	O	respectively	dep	35	SENT_132	[p10l2035t1970r2148b2022, p10l11t2072r443b2172],
38	,	,	O	,	_	0	SENT_132	[p10l2035t1970r2148b2022, p10l11t2072r443b2172],
39	vs.	FW	O	vs.	prep	1	SENT_132	[p10l480t2098r590b2151],
40	2	CD	PERCENT	2	num	41	SENT_132	[p10l631t2077r816b2163],
41	%	NN	PERCENT	%	pobj	39	SENT_132	[p10l631t2077r816b2163],
42	)	CD	NUMBER	)	dep	41	SENT_132	[p10l631t2077r816b2163],
43	.	.	O	.	_	0	SENT_132	[p10l631t2077r816b2163],

1	Two	CD	NUMBER	two	num	2	SENT_133	[p10l854t2078r1032b2151],
2	patients	NNS	O	patient	nsubj	16	SENT_133	[p10l1068t2073r1412b2172],
3	in	IN	O	in	_	0	SENT_133	[p10l1450t2073r1534b2150],
4	the	DT	O	the	det	7	SENT_133	[p10l1570t2072r1704b2150],
5	combination	NN	O	combination	nn	7	SENT_133	[p10l1742t2072r2148b2151, p10l11t2202r181b2280],
6	150/1	CD	NUMBER	150/1	num	7	SENT_133	[p10l228t2206r459b2291],
7	group	NN	O	group	prep_in	2	SENT_133	[p10l503t2227r757b2302],
8	and	CC	O	and	_	0	SENT_133	[p10l802t2201r961b2280],
9	one	CD	NUMBER	one	num	10	SENT_133	[p10l1006t2227r1158b2280],
10	patient	NN	O	patient	prep_in	2	SENT_133	[p10l1201t2202r1505b2301],
11	in	IN	O	in	_	0	SENT_133	[p10l1544t2202r1628b2279],
12	the	DT	O	the	det	15	SENT_133	[p10l1673t2201r1806b2279],
13	combination	NN	O	combination	nn	15	SENT_133	[p10l1851t2201r2148b2280, p10l10t2330r288b2408],
14	150/2	CD	NUMBER	150/2	num	15	SENT_133	[p10l325t2334r554b2419],
15	group	NN	O	group	prep_in	10	SENT_133	[p10l588t2355r842b2430],
16	had	VBD	O	have	_	0	SENT_133	[p10l877t2329r1035b2408],
17	drug	NN	O	drug	dobj	16	SENT_133	[p10l1069t2329r1602b2430],
18	—	RB	O	—	advmod	19	SENT_133	[p10l1069t2329r1602b2430],
19	related	JJ	O	related	amod	20	SENT_133	[p10l1069t2329r1602b2430],
20	pyrexia	NN	O	pyrexia	dep	17	SENT_133	[p10l1634t2330r1949b2429],
21	that	WDT	O	that	nsubjpass	23	SENT_133	[p10l1981t2329r2154b2407],
22	was	VBD	O	be	auxpass	23	SENT_133	[p10l6t2483r169b2536],
23	associated	VBN	O	associate	rcmod	17	SENT_133	[p10l223t2457r671b2536],
24	with	IN	O	with	_	0	SENT_133	[p10l718t2457r915b2537],
25	hyponatremia	NN	O	hyponatremia	prep_with	23	SENT_133	[p10l967t2457r1574b2557],
26	or	CC	O	or	_	0	SENT_133	[p10l1625t2483r1715b2536],
27	renal	JJ	O	renal	amod	28	SENT_133	[p10l1764t2457r1982b2535],
28	insufficiency	NN	O	insufficiency	prep_with	23	SENT_133	[p10l2033t2458r2148b2535, p10l11t2584r499b2685],
29	.	.	O	.	_	0	SENT_133	[p10l2033t2458r2148b2535, p10l11t2584r499b2685],

1	Other	JJ	O	other	amod	3	SENT_134	[p10l140t2714r382b2793],
2	adverse	JJ	O	adverse	amod	3	SENT_134	[p10l410t2714r714b2793],
3	events	NNS	O	event	nsubj	26	SENT_134	[p10l747t2731r1024b2810],
4	,	,	O	,	_	0	SENT_134	[p10l747t2731r1024b2810],
5	in	IN	O	in	_	0	SENT_134	[p10l1062t2715r1143b2792],
6	addition	NN	O	addition	_	0	SENT_134	[p10l1175t2714r1518b2793],
7	to	TO	O	to	_	0	SENT_134	[p10l1552t2731r1631b2793],
8	pyrexia	NN	O	pyrexia	prep_in_addition_to	3	SENT_134	[p10l1663t2715r1965b2814],
9	and	CC	O	and	_	0	SENT_134	[p10l1995t2714r2150b2793],
10	chills	NNS	O	chill	prep_in_addition_to	3	SENT_134	[p10l11t2843r280b2939],
11	,	,	O	,	_	0	SENT_134	[p10l11t2843r280b2939],
12	that	WDT	O	that	nsubj	15	SENT_134	[p10l332t2843r513b2921],
13	were	VBD	O	be	cop	15	SENT_134	[p10l549t2869r759b2922],
14	more	JJR	O	more	dep	15	SENT_134	[p10l806t2869r1033b2922],
15	common	JJ	O	common	rcmod	3	SENT_134	[p10l1081t2869r1476b2922],
16	in	IN	O	in	_	0	SENT_134	[p10l1522t2844r1608b2921],
17	the	DT	O	the	det	18	SENT_134	[p10l1655t2843r1793b2921],
18	combination	NN	O	combination	prep_in	15	SENT_134	[p10l1840t2843r2148b2922, p10l10t2973r277b3051],
19	150/2	CD	NUMBER	150/2	num	20	SENT_134	[p10l309t2977r529b3062],
20	group	NN	O	group	npadvmod	21	SENT_134	[p10l558t2998r804b3073],
21	than	IN	O	than	advmod	15	SENT_134	[p10l834t2972r1026b3050],
22	in	IN	O	in	_	0	SENT_134	[p10l1054t2973r1135b3050],
23	the	DT	O	the	det	25	SENT_134	[p10l1164t2972r1293b3050],
24	monotherapy	NN	O	monotherapy	nn	25	SENT_134	[p10l1322t2972r1880b3072],
25	group	NN	O	group	prep_in	15	SENT_134	[p10l1903t2998r2149b3073],
26	included	VBD	O	include	_	0	SENT_134	[p10l10t3100r364b3180],
27	fatigue	NN	O	fatigue	nn	28	SENT_134	[p10l392t3099r678b3202],
28	(	NN	O	(	dobj	26	SENT_134	[p10l712t3101r820b3192],
29	in	IN	O	in	_	0	SENT_134	[p10l712t3101r820b3192],
30	53	CD	PERCENT	53	num	31	SENT_134	[p10l850t3106r1027b3180],
31	%	NN	PERCENT	%	prep_in	26	SENT_134	[p10l850t3106r1027b3180],
32	of	IN	O	of	_	0	SENT_134	[p10l1055t3099r1154b3180],
33	patients	NNS	O	patient	prep_of	31	SENT_134	[p10l1162t3101r1538b3201],
34	)	RB	O	)	advmod	33	SENT_134	[p10l1162t3101r1538b3201],
35	,	,	O	,	_	0	SENT_134	[p10l1162t3101r1538b3201],
36	nausea	NN	O	nausea	appos	31	SENT_134	[p10l1571t3126r1860b3180],
37	(	CD	PERCENT	(	number	38	SENT_134	[p10l1891t3106r2144b3197],
38	44	CD	PERCENT	44	num	39	SENT_134	[p10l1891t3106r2144b3197],
39	%	NN	PERCENT	%	dep	36	SENT_134	[p10l1891t3106r2144b3197],
40	)	CD	NUMBER	)	tmod	26	SENT_134	[p10l1891t3106r2144b3197],
41	,	,	O	,	_	0	SENT_134	[p10l1891t3106r2144b3197],
42	vomiting	VBG	O	vomit	partmod	26	SENT_134	[p10l6t3230r400b3330],
43	(	CD	PERCENT	(	number	44	SENT_134	[p10l461t3234r724b3325],
44	40	CD	PERCENT	40	num	45	SENT_134	[p10l461t3234r724b3325],
45	%	NN	PERCENT	%	dobj	42	SENT_134	[p10l461t3234r724b3325],
46	)	CD	NUMBER	)	dep	45	SENT_134	[p10l461t3234r724b3325],
47	,	,	O	,	_	0	SENT_134	[p10l461t3234r724b3325],
48	and	CC	O	and	_	0	SENT_134	[p10l787t3229r946b3308],
49	diarrhea	NN	O	diarrhea	dobj	42	SENT_134	[p10l1006t3229r1371b3308],
50	(	CD	PERCENT	(	number	51	SENT_134	[p10l1434t3234r1695b3325],
51	36	CD	PERCENT	36	num	52	SENT_134	[p10l1434t3234r1695b3325],
52	%	NN	PERCENT	%	dep	49	SENT_134	[p10l1434t3234r1695b3325],
53	)	CD	NUMBER	)	tmod	42	SENT_134	[p10l1434t3234r1695b3325],
54	,	,	O	,	_	0	SENT_134	[p10l1434t3234r1695b3325],
55	although	IN	O	although	mark	60	SENT_134	[p10l1760t3229r2149b3330],
56	the	DT	O	the	det	57	SENT_134	[p10l11t3357r144b3435],
57	symptoms	NNS	O	symptom	nsubj	60	SENT_134	[p10l179t3374r624b3457],
58	were	VBD	O	be	cop	60	SENT_134	[p10l655t3383r858b3436],
59	rarely	RB	O	rarely	advmod	60	SENT_134	[p10l890t3357r1136b3457],
60	grade	NN	O	grade	dep	53	SENT_134	[p10l1163t3357r1404b3458],
61	3	CD	NUMBER	3	num	60	SENT_134	[p10l1437t3363r1482b3436],
62	or	CC	O	or	_	0	SENT_134	[p10l1518t3383r1608b3436],
63	4	CD	NUMBER	4	conj_or	60	SENT_134	[p10l1635t3363r1707b3436],
64	.	.	O	.	_	0	SENT_134	[p10l1635t3363r1707b3436],

1	The	DT	O	the	nsubj	17	SENT_135	[p10l1742t3357r1903b3435],
2	most	RBS	O	most	advmod	1	SENT_135	[p10l1937t3374r2154b3436],
3	frequently	RB	O	frequently	advmod	4	SENT_135	[p10l10t3484r453b3586],
4	occurring	VBG	O	occur	partmod	1	SENT_135	[p10l490t3486r915b3587],
5	grade	NN	O	grade	dobj	4	SENT_135	[p10l952t3485r1192b3587],
6	3	CD	NUMBER	3	num	5	SENT_135	[p10l1234t3492r1278b3565],
7	or	CC	O	or	_	0	SENT_135	[p10l1323t3511r1412b3565],
8	4	CD	NUMBER	4	num	10	SENT_135	[p10l1448t3492r1499b3565],
9	toxic	JJ	O	toxic	amod	10	SENT_135	[p10l1539t3486r1747b3565],
10	effect	NN	O	effect	conj_or	5	SENT_135	[p10l1787t3484r2031b3564],
11	in	IN	O	in	_	0	SENT_135	[p10l2065t3486r2149b3563],
12	the	DT	O	the	det	15	SENT_135	[p10l11t3614r144b3693],
13	combination	NN	O	combination	nn	15	SENT_135	[p10l201t3614r751b3693],
14	150/2	CD	NUMBER	150/2	num	15	SENT_135	[p10l811t3619r1040b3704],
15	group	NN	O	group	prep_in	10	SENT_135	[p10l1097t3640r1351b3715],
16	was	VBD	O	be	cop	17	SENT_135	[p10l1404t3640r1568b3693],
17	neutropenia	NN	O	neutropenia	_	0	SENT_135	[p10l1626t3615r2151b3714],

1	(	NN	O	(	_	0	SENT_136	[p11l15t21r127b111],
2	in	IN	O	in	_	0	SENT_136	[p11l15t21r127b111],
3	11	CD	PERCENT	11	num	4	SENT_136	[p11l189t25r367b99],
4	%	NN	PERCENT	%	prep_in	1	SENT_136	[p11l189t25r367b99],
5	of	IN	O	of	_	0	SENT_136	[p11l427t19r527b99],
6	patients	NNS	O	patient	prep_of	4	SENT_136	[p11l566t21r962b120],
7	)	RB	O	)	advmod	6	SENT_136	[p11l566t21r962b120],
8	,	,	O	,	_	0	SENT_136	[p11l566t21r962b120],
9	with	IN	O	with	_	0	SENT_136	[p11l1023t20r1219b100],
10	one	CD	NUMBER	one	num	11	SENT_136	[p11l1279t46r1431b99],
11	case	NN	O	case	prep_with	1	SENT_136	[p11l1492t46r1673b98],
12	of	IN	O	of	_	0	SENT_136	[p11l1734t19r1834b99],
13	febrile	JJ	O	febrile	amod	14	SENT_136	[p11l1875t19r2149b99],
14	neutropenia	NN	O	neutropenia	prep_of	11	SENT_136	[p11l10t151r557b250],
15	.	.	O	.	_	0	SENT_136	[p11l10t151r557b250],

1	Dose	NN	O	dose	nn	2	SENT_137	[p11l139t285r352b357],
2	interruptions	NNS	O	interruption	nsubj	6	SENT_137	[p11l383t279r942b378],
3	and	CC	O	and	_	0	SENT_137	[p11l976t278r1132b357],
4	delays	NNS	O	delay	conj_and	2	SENT_137	[p11l1164t278r1420b378],
5	were	VBD	O	be	cop	6	SENT_137	[p11l1449t304r1649b358],
6	frequent	JJ	O	frequent	_	0	SENT_137	[p11l1681t277r2041b378],
7	in	IN	O	in	_	0	SENT_137	[p11l2066t279r2149b356],
8	all	DT	O	all	det	11	SENT_137	[p11l10t407r110b485],
9	three	CD	NUMBER	three	num	11	SENT_137	[p11l144t407r356b485],
10	study	NN	O	study	nn	11	SENT_137	[p11l391t407r614b507],
11	groups	NNS	O	group	prep_in	6	SENT_137	[p11l642t433r929b508],
12	(	VBP	O	(	rcmod	11	SENT_137	[p11l969t407r1218b498],
13	Table	NNP	O	Table	nn	14	SENT_137	[p11l969t407r1218b498],
14	S1	NN	O	s1	dobj	12	SENT_137	[p11l1254t413r1347b486],
15	in	IN	O	in	_	0	SENT_137	[p11l1380t408r1461b485],
16	the	DT	O	the	det	17	SENT_137	[p11l1495t407r1625b485],
17	SupplemenN	NN	O	supplemenn	prep_in	12	SENT_137	[p11l1660t407r2148b507, p11l543t576r557b591],

1	ENGLJ	NNP	MISC	ENGLJ	nn	2	SENT_138	[p11l572t576r650b598],
2	MED	NNP	MISC	MED	_	0	SENT_138	[p11l664t576r716b591],
3	367	CD	NUMBER	367	num	2	SENT_138	[p11l726t570r804b598],
4	;	:	O	;	_	0	SENT_138	[p11l726t570r804b598],
5	18	CD	NUMBER	18	num	7	SENT_138	[p11l726t570r804b598],
6	NEJM.ORG	NN	O	nejm.org	nn	7	SENT_138	[p11l839t576r963b598],
7	NOVEMBER1	NN	O	november1	dep	2	SENT_138	[p11l1000t576r1231b596],
8	,2012	CD	NUMBER	,2012	number	9	SENT_138	[p11l1000t576r1231b596],
9	1697	CD	DATE	1697	dep	7	SENT_138	[p11l1940t565r2016b589],

1	The	DT	O	the	det	4	SENT_139	[p11l702t609r753b633],
2	New	NNP	O	New	nn	4	SENT_139	[p11l762t610r824b633],
3	England	NNP	O	England	nn	4	SENT_139	[p11l833t609r944b640],
4	Journal	NNP	O	Journal	_	0	SENT_139	[p11l952t609r1050b633],
5	of	IN	O	of	_	0	SENT_139	[p11l1059t609r1088b633],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_139	[p11l1095t609r1220b633],

1	Copyright	NN	O	copyright	_	0	SENT_140	[p11l494t691r629b722],
2	©	CD	NUMBER	©	num	6	SENT_140	[p11l638t691r661b715],
3	2012	CD	DATE	2012	num	6	SENT_140	[p11l671t691r736b715],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_140	[p11l746t691r937b715],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_140	[p11l947t691r1055b715],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_140	[p11l1065t691r1170b722],
7	.	.	O	.	_	0	SENT_140	[p11l1065t691r1170b722],

1	All	DT	O	all	det	2	SENT_141	[p11l1181t691r1223b715],
2	rights	NNS	O	rights	nsubj	3	SENT_141	[p11l1232t691r1306b722],
3	reserved	VBN	O	reserve	_	0	SENT_141	[p11l1316t691r1435b715],
4	.	.	O	.	_	0	SENT_141	[p11l1316t691r1435b715],

1	The	DT	O	the	det	4	SENT_142	[p11l816t733r862b754],
2	NEW	NNP	O	NEW	nn	4	SENT_142	[p11l880t735r966b754],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_142	[p11l985t735r1173b754],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_142	[p11l1192t735r1372b761],
5	of	IN	O	of	_	0	SENT_142	[p11l1391t733r1419b760],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_142	[p11l1432t735r1630b754],

1	Table	NNP	O	Table	_	0	SENT_143	[p11l119t863r193b888],
2	2	CD	NUMBER	2	dep	1	SENT_143	[p11l202t866r224b888],
3	.	.	O	.	_	0	SENT_143	[p11l202t866r224b888],

1	Adverse	JJ	O	adverse	amod	2	SENT_144	[p11l234t863r344b888],
2	Events	NNS	O	event	nsubj	3	SENT_144	[p11l354t866r443b888],
3	Reported	VBN	O	report	_	0	SENT_144	[p11l455t863r575b896],
4	in	IN	O	in	_	0	SENT_144	[p11l586t864r609b888],
5	Part	NNP	O	Part	nn	6	SENT_144	[p11l621t866r675b888],
6	C.	NNP	O	C.	prep_in	3	SENT_144	[p11l683t865r727b888],
7	*	IN	O	*	prep	3	SENT_144	[p11l683t865r727b888],

1	Dabrafenib	NNP	O	Dabrafenib	nn	3	SENT_145	[p11l710t938r860b964],
2	Monotherapy	NNP	O	Monotherapy	nn	3	SENT_145	[p11l873t938r1055b971],
3	Combination	NNP	O	Combination	_	0	SENT_145	[p11l1231t938r1407b964],
4	150/1	CD	NUMBER	150/1	num	5	SENT_145	[p11l1421t940r1497b971],
5	Combination	NN	O	combination	dep	3	SENT_145	[p11l1714t938r1890b964],
6	150/2	CD	NUMBER	150/2	dep	3	SENT_145	[p11l1903t940r1981b971],

1	Adverse	JJ	O	adverse	amod	3	SENT_146	[p11l119t976r229b1001],
2	Event	NN	O	event	nn	3	SENT_146	[p11l241t978r316b1001],
3	(	NN	O	(	_	0	SENT_146	[p11l821t978r851b1009],
4	N	NN	O	n	prep	3	SENT_146	[p11l821t978r851b1009],
5	=	JJ	O	=	amod	6	SENT_146	[p11l859t988r876b997],
6	53	CD	NUMBER	53	dep	4	SENT_146	[p11l882t978r942b1009],
7	)	SYM	O	)	dep	3	SENT_146	[p11l882t978r942b1009],
8	-	:	O	-	_	0	SENT_146	[p11l882t978r942b1009],
9	(	SYM	O	(	dep	12	SENT_146	[p11l882t978r942b1009],
10	-	:	O	-	_	0	SENT_146	[p11l882t978r942b1009],
11	(	NN	O	(	nn	12	SENT_146	[p11l1314t978r1344b1009],
12	N	NN	O	n	dep	3	SENT_146	[p11l1314t978r1344b1009],
13	=	JJ	O	=	quantmod	15	SENT_146	[p11l1352t988r1369b997],
14	54	CD	NUMBER	54	number	15	SENT_146	[p11l1376t978r1415b1009],
15	)	CD	NUMBER	)	num	17	SENT_146	[p11l1376t978r1415b1009],
16	(	NN	O	(	nn	17	SENT_146	[p11l1787t978r1818b1009],
17	N	NN	O	n	npadvmod	18	SENT_146	[p11l1787t978r1818b1009],
18	=	JJ	O	=	amod	3	SENT_146	[p11l1825t988r1843b997],
19	55	CD	NUMBER	55	number	20	SENT_146	[p11l1849t978r1908b1009, p11l689t1034r771b1059],
20	)	CD	NUMBER	)	dep	3	SENT_146	[p11l1849t978r1908b1009, p11l689t1034r771b1059],
21	)	CD	NUMBER	)	num	22	SENT_146	[p11l1849t978r1908b1009, p11l689t1034r771b1059],
22	Grade	NNP	O	Grade	dep	20	SENT_146	[p11l1849t978r1908b1009, p11l689t1034r771b1059],

1	3	CD	NUMBER	3	dep	13	SENT_147	[p11l782t1036r794b1059],
2	or	CC	O	or	_	0	SENT_147	[p11l806t1042r834b1059],
3	4	CD	NUMBER	4	conj_or	1	SENT_147	[p11l842t1036r857b1058],
4	All	DT	O	all	det	6	SENT_147	[p11l918t1034r952b1058],
5	Grades	NNP	O	Grades	nn	6	SENT_147	[p11l963t1034r1059b1059],
6	Grade	NNP	O	Grade	dep	1	SENT_147	[p11l1173t1034r1255b1059],
7	3	CD	NUMBER	3	num	6	SENT_147	[p11l1265t1036r1277b1059],
8	or	CC	O	or	_	0	SENT_147	[p11l1289t1042r1317b1059],
9	4	CD	NUMBER	4	conj_or	1	SENT_147	[p11l1325t1036r1340b1058],
10	All	DT	O	all	dep	9	SENT_147	[p11l1402t1034r1435b1058],
11	Grades	NNP	O	Grades	nn	12	SENT_147	[p11l1447t1034r1543b1059],
12	Grade	NNP	O	Grade	dep	13	SENT_147	[p11l1656t1034r1738b1059],
13	3	CD	NUMBER	3	dep	21	SENT_147	[p11l1749t1036r1761b1059],
14	or	CC	O	or	_	0	SENT_147	[p11l1773t1042r1801b1059],
15	4	CD	NUMBER	4	conj_or	13	SENT_147	[p11l1809t1036r1824b1058],
16	All	DT	O	all	det	18	SENT_147	[p11l1885t1034r1918b1058],
17	Grades	NNS	O	grade	nn	18	SENT_147	[p11l1930t1034r2025b1059],
18	number	NN	O	number	dep	13	SENT_147	[p11l1178t1097r1281b1122],
19	of	IN	O	of	_	0	SENT_147	[p11l1288t1096r1319b1130],
20	patients	NNS	O	patient	prep_of	13	SENT_147	[p11l1319t1098r1423b1130],
21	(	CD	PERCENT	(	dep	22	SENT_147	[p11l1435t1099r1548b1130],
22	percent	NN	PERCENT	percent	dep	27	SENT_147	[p11l1435t1099r1548b1130],
23	)	CD	NUMBER	)	num	22	SENT_147	[p11l1435t1099r1548b1130],
24	Any	DT	O	any	det	27	SENT_147	[p11l119t1161r170b1192],
25	event	NN	O	event	nn	27	SENT_147	[p11l179t1164r252b1185],
26	53	CD	NUMBER	53	num	27	SENT_147	[p11l934t1161r962b1185],
27	(	NN	O	(	dep	33	SENT_147	[p11l977t1161r1043b1192],
28	100	CD	NUMBER	100	number	29	SENT_147	[p11l977t1161r1043b1192],
29	)	CD	NUMBER	)	dep	27	SENT_147	[p11l977t1161r1043b1192],
30	26	CD	NUMBER	26	num	31	SENT_147	[p11l1208t1161r1239b1185],
31	(	NN	O	(	dep	29	SENT_147	[p11l1252t1161r1302b1192],
32	48	CD	NUMBER	48	num	33	SENT_147	[p11l1252t1161r1302b1192],
33	)	CD	NUMBER	)	dep	46	SENT_147	[p11l1252t1161r1302b1192],
34	53	CD	NUMBER	53	num	35	SENT_147	[p11l1425t1161r1454b1185],
35	(	NN	O	(	dep	33	SENT_147	[p11l1469t1161r1519b1192],
36	98	CD	NUMBER	98	number	37	SENT_147	[p11l1469t1161r1519b1192],
37	)	CD	NUMBER	)	num	42	SENT_147	[p11l1469t1161r1519b1192],
38	Pyrexia	NNP	O	Pyrexia	nn	42	SENT_147	[p11l122t1219r213b1250],
39	14	CD	NUMBER	14	number	40	SENT_147	[p11l935t1219r964b1242],
40	(	CD	NUMBER	(	amod	42	SENT_147	[p11l977t1219r1027b1250],
41	26	CD	NUMBER	26	dep	40	SENT_147	[p11l977t1219r1027b1250],
42	)	NN	O	)	dep	35	SENT_147	[p11l977t1219r1027b1250],
43	5	CD	NUMBER	5	number	44	SENT_147	[p11l1225t1219r1238b1242],
44	(	CD	NUMBER	(	num	42	SENT_147	[p11l1252t1219r1285b1250],
45	9	CD	NUMBER	9	num	46	SENT_147	[p11l1252t1219r1285b1250],
46	)	NN	O	)	dep	52	SENT_147	[p11l1252t1219r1285b1250],
47	37	CD	NUMBER	37	number	48	SENT_147	[p11l1425t1219r1456b1242],
48	(	CD	NUMBER	(	dep	46	SENT_147	[p11l1469t1219r1519b1250],
49	69	CD	NUMBER	69	num	51	SENT_147	[p11l1469t1219r1519b1250],
50	)	CD	NUMBER	)	num	51	SENT_147	[p11l1469t1219r1519b1250],
51	Chills	NNS	O	chill	dep	48	SENT_147	[p11l120t1275r194b1300],
52	9	CD	NUMBER	9	dep	53	SENT_147	[p11l950t1277r964b1300],
53	(	NN	O	(	dep	56	SENT_147	[p11l977t1277r1027b1308],
54	17	CD	NUMBER	17	num	53	SENT_147	[p11l977t1277r1027b1308],
55	)	CD	NUMBER	)	num	56	SENT_147	[p11l977t1277r1027b1308],
56	27	CD	NUMBER	27	dep	62	SENT_147	[p11l1425t1277r1476b1308],
57	(	CD	NUMBER	(	num	58	SENT_147	[p11l1425t1277r1476b1308],
58	Fatigue	NNP	O	Fatigue	dep	56	SENT_147	[p11l122t1335r220b1365],
59	21	CD	NUMBER	21	num	58	SENT_147	[p11l933t1335r963b1357],
60	(	CD	NUMBER	(	number	61	SENT_147	[p11l977t1334r1027b1365],
61	40	CD	NUMBER	40	dep	58	SENT_147	[p11l977t1334r1027b1365],
62	)	NN	O	)	dep	65	SENT_147	[p11l977t1334r1027b1365],
63	31	CD	NUMBER	31	num	62	SENT_147	[p11l1425t1334r1455b1357],
64	(	CD	NUMBER	(	num	65	SENT_147	[p11l1469t1334r1476b1365],
65	Nausea	NN	O	nausea	dep	71	SENT_147	[p11l122t1392r223b1415],
66	11	CD	NUMBER	11	number	67	SENT_147	[p11l935t1392r1027b1423],
67	(	CD	NUMBER	(	dep	65	SENT_147	[p11l935t1392r1027b1423],
68	21	CD	NUMBER	21	num	69	SENT_147	[p11l935t1392r1027b1423],
69	)	NN	O	)	dep	67	SENT_147	[p11l935t1392r1027b1423],
70	25	CD	NUMBER	25	num	71	SENT_147	[p11l1425t1392r1454b1415],
71	(	CD	NUMBER	(	dep	77	SENT_147	[p11l1469t1392r1476b1423],
72	23	CD	NUMBER	23	num	73	SENT_147	[p11l1425t1450r1454b1473],
73	(	NN	O	(	dep	71	SENT_147	[p11l1469t1450r1476b1481],
74	14	CD	NUMBER	14	number	75	SENT_147	[p11l1427t1507r1456b1530],
75	(	CD	NUMBER	(	dep	73	SENT_147	[p11l1469t1507r1476b1538],
76	20	CD	NUMBER	20	num	77	SENT_147	[p11l1425t1565r1457b1588],
77	(	NN	O	(	_	0	SENT_147	[p11l1469t1565r1476b1596],

1	32	CD	NUMBER	32	_	0	SENT_148	[p11l1692t1161r1722b1184],
2	3	CD	NUMBER	3	number	3	SENT_148	[p11l1709t1219r1721b1242],
3	1	CD	NUMBER	1	num	5	SENT_148	[p11l1710t1277r1721b1299],
4	2	CD	NUMBER	2	number	5	SENT_148	[p11l1709t1335r1722b1357],
5	1	CD	NUMBER	1	dep	1	SENT_148	[p11l1710t1392r1721b1415],
6	1	CD	NUMBER	1	number	7	SENT_148	[p11l1710t1450r1721b1472],
7	1	CD	NUMBER	1	dep	1	SENT_148	[p11l1710t1507r1721b1530],
8	o	NN	O	o	nn	17	SENT_148	[p11l1708t1564r1723b1588],
9	o	NN	O	o	nn	17	SENT_148	[p11l1708t1622r1723b1646],
10	o	NN	O	o	nn	17	SENT_148	[p11l1708t1680r1723b1703],
11	O	NN	O	o	nn	17	SENT_148	[p11l1708t1737r1723b1761],
12	o	NN	O	o	nn	17	SENT_148	[p11l1708t1795r1723b1819],
13	O	NN	O	o	nn	17	SENT_148	[p11l1708t1853r1723b1876],
14	o	NN	O	o	nn	17	SENT_148	[p11l1708t1910r1723b1934],
15	1	CD	NUMBER	1	num	17	SENT_148	[p11l1711t1969r1722b1991],
16	o	NN	O	o	nn	17	SENT_148	[p11l1708t2025r1723b2049],
17	o	NN	O	o	dep	7	SENT_148	[p11l1708t2083r1723b2107],
18	o	NN	O	o	nn	20	SENT_148	[p11l1708t2141r1723b2164],
19	U1	NN	O	u1	nn	20	SENT_148	[p11l1745t1162r1758b1185],
20	oo	NN	O	oo	dep	7	SENT_148	[p11l1762t1161r1776b1185],
21	ya	PRP	O	ya	nsubj	22	SENT_148	[p11l1778t1161r1785b1192],
22	l	NN	O	l	rcmod	1	SENT_148	[p11l1745t1219r1759b1299],
23	\	CD	NUMBER	\	number	24	SENT_148	[p11l1745t1219r1759b1299],
24	)	CD	NUMBER	)	num	25	SENT_148	[p11l1745t1219r1759b1299],
25	U	NNP	O	U	dobj	22	SENT_148	[p11l1745t1219r1759b1299],
26	'	POS	O	'	_	0	SENT_148	[p11l1745t1219r1759b1299],
27	I	PRP	O	I	nsubj	28	SENT_148	[p11l1745t1219r1759b1299],
28	~	VBP	O	~	rcmod	25	SENT_148	[p11l1761t1219r1769b1308],
29	.	.	O	.	_	0	SENT_148	[p11l1761t1219r1769b1308],

1	a	DT	O	a	det	2	SENT_149	[p11l1761t1219r1769b1308],
2	~	NN	O	~	_	0	SENT_149	[p11l1761t1219r1769b1308],
3	.	.	O	.	_	0	SENT_149	[p11l1761t1219r1769b1308],

1	a	DT	O	a	det	2	SENT_150	[p11l1761t1219r1769b1308],
2	Ix	NN	O	ix	_	0	SENT_150	[p11l1745t1392r1759b1415],
3	)	CD	NUMBER	)	num	4	SENT_150	[p11l1745t1392r1759b1415],
4	~	NN	O	~	dep	2	SENT_150	[p11l1761t1392r1769b1423],
5	.	.	O	.	_	0	SENT_150	[p11l1761t1392r1769b1423],

1	a	DT	O	a	_	0	SENT_151	[p11l1761t1392r1769b1423],

1	Vomiting	VBG	O	vomit	_	0	SENT_152	[p11l119t1450r246b1481],
2	8	CD	NUMBER	8	number	3	SENT_152	[p11l950t1449r964b1473],
3	(	CD	NUMBER	(	num	5	SENT_152	[p11l977t1450r1027b1481],
4	15	CD	NUMBER	15	number	5	SENT_152	[p11l977t1450r1027b1481],
5	)	CD	NUMBER	)	dobj	1	SENT_152	[p11l977t1450r1027b1481],
6	Diarrhea	NNP	O	Diarrhea	dep	13	SENT_152	[p11l122t1505r237b1530],
7	15	CD	NUMBER	15	num	6	SENT_152	[p11l935t1507r963b1530],
8	(	CD	NUMBER	(	num	9	SENT_152	[p11l977t1507r1027b1538],
9	28	CD	NUMBER	28	dep	6	SENT_152	[p11l977t1507r1027b1538],
10	)	NN	O	)	dep	13	SENT_152	[p11l977t1507r1027b1538],
11	26	CD	NUMBER	26	num	10	SENT_152	[p11l1478t1507r1519b1538],
12	)	CD	NUMBER	)	num	13	SENT_152	[p11l1478t1507r1519b1538],
13	Headache	NNP	O	Headache	dep	47	SENT_152	[p11l122t1563r257b1588],
14	15	CD	NUMBER	15	num	13	SENT_152	[p11l935t1565r963b1588],
15	(	CD	NUMBER	(	number	16	SENT_152	[p11l977t1564r1027b1596],
16	28	CD	NUMBER	28	num	17	SENT_152	[p11l977t1564r1027b1596],
17	)	NN	O	)	dep	13	SENT_152	[p11l977t1564r1027b1596],
18	37	CD	NUMBER	37	num	19	SENT_152	[p11l1479t1565r1519b1596],
19	)	CD	NUMBER	)	dep	17	SENT_152	[p11l1479t1565r1519b1596],
20	Peripheral	JJ	O	peripheral	amod	45	SENT_152	[p11l122t1620r257b1653],
21	edema	NN	O	edema	nn	45	SENT_152	[p11l268t1620r359b1646],
22	9	CD	NUMBER	9	num	45	SENT_152	[p11l950t1623r964b1646],
23	(	NN	O	(	nn	45	SENT_152	[p11l977t1623r1027b1653],
24	17	CD	NUMBER	17	num	45	SENT_152	[p11l977t1623r1027b1653],
25	)	CD	NUMBER	)	num	45	SENT_152	[p11l977t1623r1027b1653],
26	13	CD	NUMBER	13	num	45	SENT_152	[p11l1427t1623r1454b1646],
27	(	NN	O	(	nn	45	SENT_152	[p11l1469t1623r1519b1653],
28	24	CD	NUMBER	24	num	45	SENT_152	[p11l1469t1623r1519b1653],
29	)	CD	NUMBER	)	num	45	SENT_152	[p11l1469t1623r1519b1653],
30	Cough	NN	O	cough	nn	45	SENT_152	[p11l120t1678r207b1711],
31	11	CD	NUMBER	11	num	45	SENT_152	[p11l935t1680r963b1703],
32	(	CD	NUMBER	(	num	45	SENT_152	[p11l977t1680r1027b1711],
33	21	CD	NUMBER	21	num	45	SENT_152	[p11l977t1680r1027b1711],
34	)	NN	O	)	nn	45	SENT_152	[p11l977t1680r1027b1711],
35	6	CD	NUMBER	6	num	45	SENT_152	[p11l1442t1680r1456b1703],
36	(	NN	O	(	nn	45	SENT_152	[p11l1469t1680r1519b1711],
37	11	CD	NUMBER	11	num	45	SENT_152	[p11l1469t1680r1519b1711],
38	)	CD	NUMBER	)	num	45	SENT_152	[p11l1469t1680r1519b1711],
39	Arthralgia	NNP	ORGANIZATION	Arthralgia	nn	45	SENT_152	[p11l119t1736r252b1769],
40	18	CD	NUMBER	18	num	45	SENT_152	[p11l935t1737r964b1761],
41	(	CD	NUMBER	(	num	45	SENT_152	[p11l977t1738r1027b1769],
42	34	CD	NUMBER	34	num	45	SENT_152	[p11l977t1738r1027b1769],
43	)	NN	O	)	nn	45	SENT_152	[p11l977t1738r1027b1769],
44	24	CD	NUMBER	24	num	45	SENT_152	[p11l1425t1738r1456b1761],
45	(	NN	O	(	rcmod	19	SENT_152	[p11l1469t1738r1519b1769],
46	44	CD	NUMBER	44	num	47	SENT_152	[p11l1469t1738r1519b1769],
47	)	CD	NUMBER	)	dep	52	SENT_152	[p11l1469t1738r1519b1769],
48	Rash	NNP	O	Rash	dep	47	SENT_152	[p11l122t1793r185b1819],
49	19	CD	NUMBER	19	num	48	SENT_152	[p11l935t1796r964b1819],
50	(	CD	NUMBER	(	number	51	SENT_152	[p11l977t1795r1027b1826],
51	36	CD	NUMBER	36	dep	48	SENT_152	[p11l977t1795r1027b1826],
52	)	NN	O	)	dep	58	SENT_152	[p11l977t1795r1027b1826],
53	11	CD	NUMBER	11	num	52	SENT_152	[p11l1427t1796r1455b1818],
54	(	CD	NUMBER	(	num	58	SENT_152	[p11l1469t1795r1519b1826],
55	20	CD	NUMBER	20	num	58	SENT_152	[p11l1469t1795r1519b1826],
56	)	NN	O	)	nn	58	SENT_152	[p11l1469t1795r1519b1826],
57	Night	NN	TIME	night	nn	58	SENT_152	[p11l122t1851r197b1884],
58	sweats	NNS	O	sweat	dep	63	SENT_152	[p11l207t1856r297b1876],
59	8	CD	NUMBER	8	number	60	SENT_152	[p11l1442t1853r1456b1876],
60	(	CD	NUMBER	(	dep	58	SENT_152	[p11l1469t1853r1519b1884],
61	15	CD	NUMBER	15	num	62	SENT_152	[p11l1469t1853r1519b1884],
62	)	NN	O	)	dep	60	SENT_152	[p11l1469t1853r1519b1884],
63	15	CD	NUMBER	15	dep	68	SENT_152	[p11l1427t1911r1456b1934],
64	(	CD	NUMBER	(	number	65	SENT_152	[p11l1469t1910r1519b1942],
65	30	CD	NUMBER	30	dep	63	SENT_152	[p11l1469t1910r1519b1942],
66	)	CD	NUMBER	)	num	67	SENT_152	[p11l1469t1910r1519b1942],
67	13	CD	NUMBER	13	dep	65	SENT_152	[p11l1427t1968r1455b1991],
68	(	NN	O	(	dep	72	SENT_152	[p11l1469t1968r1519b1999],
69	24	CD	NUMBER	24	num	68	SENT_152	[p11l1469t1968r1519b1999],
70	)	CD	NUMBER	)	num	72	SENT_152	[p11l1469t1968r1519b1999],
71	9	CD	NUMBER	9	num	72	SENT_152	[p11l1442t2026r1456b2049],
72	(	NN	O	(	dep	79	SENT_152	[p11l1469t2026r1519b2057],
73	17	CD	NUMBER	17	number	74	SENT_152	[p11l1469t2026r1519b2057],
74	)	CD	NUMBER	)	dep	72	SENT_152	[p11l1469t2026r1519b2057],
75	12	CD	NUMBER	12	num	76	SENT_152	[p11l1427t2084r1456b2106],
76	(	NN	O	(	dep	74	SENT_152	[p11l1469t2084r1519b2115],
77	22	CD	NUMBER	22	number	78	SENT_152	[p11l1469t2084r1519b2115],
78	)	CD	NUMBER	)	num	79	SENT_152	[p11l1469t2084r1519b2115],
79	Hyperkeratosis	NN	O	hyperkeratosis	dep	81	SENT_152	[p11l123t2139r326b2172],
80	3	CD	NUMBER	3	dep	79	SENT_152	[p11l1443t2141r1455b2164],
81	(	NN	O	(	dep	84	SENT_152	[p11l1470t2141r1503b2172],
82	6	CD	NUMBER	6	num	81	SENT_152	[p11l1470t2141r1503b2172],
83	)	CD	NUMBER	)	num	84	SENT_152	[p11l1470t2141r1503b2172],
84	Alopecia	NNP	ORGANIZATION	Alopecia	dep	5	SENT_152	[p11l120t2197r236b2230],
85	18	CD	NUMBER	18	num	84	SENT_152	[p11l936t2198r965b2222],
86	(	CD	NUMBER	(	number	87	SENT_152	[p11l978t2199r1027b2230],
87	34	CD	NUMBER	34	num	89	SENT_152	[p11l978t2199r1027b2230],
88	)	NN	O	)	nn	89	SENT_152	[p11l978t2199r1027b2230],
89	O	NN	O	o	dep	84	SENT_152	[p11l1225t2198r1240b2222],
90	5	CD	NUMBER	5	number	91	SENT_152	[p11l1443t2199r1455b2222],
91	(	CD	NUMBER	(	num	89	SENT_152	[p11l1470t2199r1503b2230],
92	9	CD	NUMBER	9	num	94	SENT_152	[p11l1470t2199r1503b2230],
93	)	NN	O	)	nn	94	SENT_152	[p11l1470t2199r1503b2230],
94	o	NN	O	o	dep	89	SENT_152	[p11l1708t2198r1723b2222],

1	Grade	NNP	O	Grade	dep	22	SENT_153	[p11l711t2254r793b2280],
2	3	CD	NUMBER	3	num	1	SENT_153	[p11l804t2257r836b2288],
3	:	:	O	:	_	0	SENT_153	[p11l804t2257r836b2288],
4	)	CD	NUMBER	)	dep	1	SENT_153	[p11l804t2257r836b2288],
5	:	:	O	:	_	0	SENT_153	[p11l804t2257r836b2288],
6	All	DT	O	all	det	8	SENT_153	[p11l919t2254r952b2279],
7	Grades	NNP	O	Grades	nn	8	SENT_153	[p11l964t2254r1060b2280],
8	Grade	NNP	O	Grade	dep	4	SENT_153	[p11l1195t2254r1277b2280],
9	3	CD	NUMBER	3	dep	8	SENT_153	[p11l1287t2257r1319b2287],
10	:	:	O	:	_	0	SENT_153	[p11l1287t2257r1319b2287],
11	All	DT	O	all	det	13	SENT_153	[p11l1403t2254r1436b2279],
12	Grades	NNP	O	Grades	nn	13	SENT_153	[p11l1448t2254r1543b2280],
13	Grade	NNP	O	Grade	dep	8	SENT_153	[p11l1678t2254r1760b2280],
14	3	CD	NUMBER	3	num	16	SENT_153	[p11l1771t2257r1803b2288],
15	:	:	O	:	_	0	SENT_153	[p11l1771t2257r1803b2288],
16	)	CD	NUMBER	)	dep	13	SENT_153	[p11l1771t2257r1803b2288],
17	:	:	O	:	_	0	SENT_153	[p11l1771t2257r1803b2288],
18	All	DT	O	all	det	20	SENT_153	[p11l1885t2254r1919b2279],
19	Grades	NNS	O	grade	nn	20	SENT_153	[p11l1930t2254r2026b2280],
20	zmzazazszmzmzs	NNS	O	zmzazazszmzmz	dep	8	SENT_153	[p11l1736t1161r1743b1538],
21	I	PRP	O	I	dep	20	SENT_153	[p11l1745t1450r1759b1530],
22	\	VBP	O	\	_	0	SENT_153	[p11l1745t1450r1759b1530],
23	)	CD	NUMBER	)	dobj	22	SENT_153	[p11l1745t1450r1759b1530],
24	I	PRP	O	I	nsubj	25	SENT_153	[p11l1745t1450r1759b1530],
25	\	VBP	O	\	rcmod	23	SENT_153	[p11l1745t1450r1759b1530],
26	)	CD	NUMBER	)	num	28	SENT_153	[p11l1745t1450r1759b1530],
27	-5	CD	NUMBER	-5	num	28	SENT_153	[p11l1744t1335r1759b1357],
28	~	NN	O	~	dobj	25	SENT_153	[p11l1761t1450r1769b1538],
29	.4	CD	NUMBER	.4	num	32	SENT_153	[p11l1761t1450r1769b1538],
30	~	NN	O	~	nn	32	SENT_153	[p11l1761t1450r1769b1538],
31	.4	CD	NUMBER	.4	num	32	SENT_153	[p11l1761t1450r1769b1538],
32	V4	NN	O	v4	nsubj	22	SENT_153	[p11l1761t1334r1769b1365],

1	Decreased	VBN	O	decrease	_	0	SENT_154	[p11l122t1909r262b1934],
2	appetite	NN	O	appetite	nn	4	SENT_154	[p11l274t1911r383b1941],
3	Myalgia	NN	PERSON	myalgium	nn	4	SENT_154	[p11l122t1966r225b1999],
4	r	NN	O	r	nsubj	7	SENT_154	[p11l1736t1968r1744b1999],
5	\	CD	NUMBER	\	num	7	SENT_154	[p11l1736t1968r1744b1999],
6	NJ	NNP	O	NJ	nn	7	SENT_154	[p11l1746t1969r1759b1991],
7	xx	NN	O	xx	xcomp	1	SENT_154	[p11l1762t1968r1769b1999],

1	Constipation	NN	O	constipation	_	0	SENT_155	[p11l121t2026r295b2057],
2	Elevated	JJ	O	elevated	amod	3	SENT_155	[p11l123t2082r233b2107],
3	blood	NN	O	blood	dep	1	SENT_155	[p11l246t2082r320b2107],
4	alkaline	NN	O	alkaline	nn	5	SENT_155	[p11l332t2082r434b2107],
5	phosphatase	NN	O	phosphatase	dep	1	SENT_155	[p11l445t2082r619b2114],

1	Owi-OOOOOO	JJ	O	owi-oooooo	_	0	SENT_156	[p11l1224t1680r1240b2164],

1	Cutaneous	JJ	O	cutaneous	nsubj	31	SENT_157	[p11l121t2319r267b2343],
2	squamous-cell	JJ	O	squamous-cell	amod	23	SENT_157	[p11l278t2317r474b2350],
3	carcinoma	NN	O	carcinoma	nn	23	SENT_157	[p11l486t2317r641b2350],
4	§	CD	NUMBER	§	num	23	SENT_157	[p11l486t2317r641b2350],
5	9	CD	NUMBER	9	num	23	SENT_157	[p11l742t2320r756b2343],
6	(	NN	O	(	nn	23	SENT_157	[p11l769t2319r819b2350],
7	17	CD	NUMBER	17	num	23	SENT_157	[p11l769t2319r819b2350],
8	)	CD	NUMBER	)	num	23	SENT_157	[p11l769t2319r819b2350],
9	10	CD	NUMBER	10	num	23	SENT_157	[p11l936t2319r965b2343],
10	(	NN	O	(	nn	23	SENT_157	[p11l978t2319r1027b2350],
11	19	CD	NUMBER	19	num	23	SENT_157	[p11l978t2319r1027b2350],
12	)	NN	O	)	nn	23	SENT_157	[p11l978t2319r1027b2350],
13	1	CD	NUMBER	1	num	23	SENT_157	[p11l1228t2320r1239b2342],
14	(	NN	O	(	nn	23	SENT_157	[p11l1253t2319r1286b2350],
15	2	CD	NUMBER	2	num	23	SENT_157	[p11l1253t2319r1286b2350],
16	)	CD	NUMBER	)	num	23	SENT_157	[p11l1253t2319r1286b2350],
17	3	CD	NUMBER	3	num	23	SENT_157	[p11l1710t2319r1722b2342],
18	(	NN	O	(	nn	23	SENT_157	[p11l1736t2319r1769b2350],
19	5	CD	NUMBER	5	num	23	SENT_157	[p11l1736t2319r1769b2350],
20	)	CD	NUMBER	)	num	23	SENT_157	[p11l1736t2319r1769b2350],
21	Skin	NN	O	skin	nn	23	SENT_157	[p11l121t2375r176b2400],
22	papilloma	NN	O	papilloma	nn	23	SENT_157	[p11l189t2375r323b2408],
23	o	NN	O	o	rcmod	1	SENT_157	[p11l741t2377r756b2400],
24	8	CD	NUMBER	8	num	25	SENT_157	[p11l951t2377r965b2400],
25	(	NN	O	(	dep	1	SENT_157	[p11l978t2377r1027b2408],
26	15	CD	NUMBER	15	number	27	SENT_157	[p11l978t2377r1027b2408],
27	)	CD	NUMBER	)	dep	25	SENT_157	[p11l978t2377r1027b2408],
28	O	NN	O	o	nn	30	SENT_157	[p11l1708t2377r1724b2400],
29	Hyperkeratosis	NN	O	hyperkeratosis	nn	30	SENT_157	[p11l123t2433r326b2465],
30	o	NN	O	o	dep	1	SENT_157	[p11l1708t2434r1724b2458],
31	Decreased	VBD	O	decrease	_	0	SENT_157	[p11l123t2490r262b2515],
32	ejection	NN	O	ejection	nn	33	SENT_157	[p11l274t2493r379b2523],
33	fraction	NN	O	fraction	dobj	31	SENT_157	[p11l390t2490r492b2515],

1	o	NN	O	o	_	0	SENT_158	[p11l1708t2492r1724b2515],
2	Cardiac	JJ	O	cardiac	amod	5	SENT_158	[p11l121t2548r223b2573],
3	failure	NN	O	failure	nn	5	SENT_158	[p11l232t2548r317b2573],
4	o	NN	O	o	nn	5	SENT_158	[p11l1708t2550r1724b2573],
5	Hypertension	NN	O	hypertension	dep	1	SENT_158	[p11l123t2608r304b2638],
6	1	CD	NUMBER	1	number	7	SENT_158	[p11l1711t2608r1722b2630],
7	1	CD	NUMBER	1	dep	5	SENT_158	[p11l1711t2665r1722b2688],

1	Chorioretinopathy	NNP	O	Chorioretinopathy	_	0	SENT_159	[p11l121t2663r369b2696],

1	*	NN	O	*	nsubj	6	SENT_160	[p11l94t2750r109b2765],
2	Listed	VBN	O	list	partmod	1	SENT_160	[p11l121t2748r199b2773],
3	are	VBP	O	be	cop	6	SENT_160	[p11l212t2757r252b2773],
4	all	DT	O	all	det	6	SENT_160	[p11l264t2748r292b2773],
5	adverse	JJ	O	adverse	amod	6	SENT_160	[p11l305t2748r409b2773],
6	events	NNS	O	event	_	0	SENT_160	[p11l420t2753r507b2773],
7	that	WDT	O	that	nsubjpass	9	SENT_160	[p11l518t2748r571b2773],
8	were	VBD	O	be	auxpass	9	SENT_160	[p11l582t2757r645b2773],
9	reported	VBN	O	report	rcmod	6	SENT_160	[p11l658t2748r771b2781],
10	in	IN	O	in	_	0	SENT_160	[p11l785t2750r806b2773],
11	more	JJR	O	more	mwe	12	SENT_160	[p11l820t2757r890b2773],
12	than	IN	O	than	quantmod	13	SENT_160	[p11l900t2748r960b2773],
13	20	CD	PERCENT	20	num	14	SENT_160	[p11l973t2749r1032b2774],
14	%	NN	PERCENT	%	prep_in	9	SENT_160	[p11l973t2749r1032b2774],
15	of	IN	O	of	_	0	SENT_160	[p11l1043t2748r1073b2773],
16	patients	NNS	O	patient	prep_of	14	SENT_160	[p11l1081t2750r1188b2781],
17	in	IN	O	in	_	0	SENT_160	[p11l1202t2750r1223b2773],
18	any	DT	O	any	det	19	SENT_160	[p11l1236t2757r1282b2781],
19	group	NN	O	group	prep_in	16	SENT_160	[p11l1293t2757r1380b2781],
20	,	,	O	,	_	0	SENT_160	[p11l1293t2757r1380b2781],
21	regardless	RB	O	regardless	advmod	6	SENT_160	[p11l1394t2748r1532b2781],
22	ofwhether	NN	O	ofwhether	nsubj	27	SENT_160	[p11l1544t2748r1690b2773],
23	a	DT	O	a	det	25	SENT_160	[p11l1700t2757r1713b2773],
24	causal	JJ	O	causal	amod	25	SENT_160	[p11l1725t2748r1809b2773],
25	relationship	NN	O	relationship	dep	22	SENT_160	[p11l1823t2748r1984b2781],
26	was	VBD	O	be	cop	27	SENT_160	[p11l1994t2757r2045b2773],
27	likely	JJ	O	likely	ccomp	6	SENT_160	[p11l121t2785r193b2818],
28	.	.	O	.	_	0	SENT_160	[p11l121t2785r193b2818],

1	In	IN	O	in	_	0	SENT_161	[p11l207t2787r230b2810],
2	addition	NN	O	addition	_	0	SENT_161	[p11l243t2785r353b2810],
3	to	TO	O	to	_	0	SENT_161	[p11l365t2790r392b2810],
4	these	DT	O	these	det	5	SENT_161	[p11l402t2785r476b2810],
5	events	NNS	O	event	prep_in_addition_to	8	SENT_161	[p11l487t2790r581b2815],
6	,	,	O	,	_	0	SENT_161	[p11l487t2790r581b2815],
7	there	EX	O	there	expl	8	SENT_161	[p11l593t2785r663b2810],
8	was	VBD	O	be	_	0	SENT_161	[p11l673t2794r724b2810],
9	one	CD	NUMBER	one	num	10	SENT_161	[p11l736t2794r786b2810],
10	death	NN	O	death	nsubj	8	SENT_161	[p11l797t2785r871b2810],
11	from	IN	O	from	_	0	SENT_161	[p11l883t2785r947b2810],
12	sepsis	NN	O	sepsis	prep_from	10	SENT_161	[p11l960t2787r1043b2818],
13	in	IN	O	in	_	0	SENT_161	[p11l1057t2787r1078b2810],
14	the	DT	O	the	det	17	SENT_161	[p11l1090t2785r1133b2810],
15	combination	NN	O	combination	nn	17	SENT_161	[p11l1144t2785r1316b2810],
16	150/1	CD	NUMBER	150/1	num	17	SENT_161	[p11l1330t2787r1405b2818],
17	group	NN	O	group	prep_in	12	SENT_161	[p11l1418t2794r1497b2818],
18	and	CC	O	and	_	0	SENT_161	[p11l1509t2785r1557b2810],
19	there	EX	O	there	expl	20	SENT_161	[p11l1569t2785r1639b2810],
20	were	VBD	O	be	conj_and	8	SENT_161	[p11l1649t2794r1713b2810],
21	three	CD	NUMBER	three	num	22	SENT_161	[p11l1723t2785r1792b2810],
22	deaths	NNS	O	death	nsubj	20	SENT_161	[p11l1804t2785r1893b2810],
23	in	IN	O	in	_	0	SENT_161	[p11l1907t2787r1928b2810],
24	the	DT	O	the	det	27	SENT_161	[p11l1940t2785r1983b2810],
25	combination	NN	O	combination	nn	27	SENT_161	[p11l1994t2794r2062b2810, p11l121t2822r230b2847],
26	150/2	CD	NUMBER	150/2	num	27	SENT_161	[p11l245t2824r320b2855],
27	group	NN	O	group	prep_in	22	SENT_161	[p11l332t2831r412b2855],
28	(	CD	NUMBER	(	number	29	SENT_161	[p11l426t2824r483b2855],
29	two	CD	NUMBER	two	dep	27	SENT_161	[p11l426t2824r483b2855],
30	from	IN	O	from	_	0	SENT_161	[p11l494t2822r558b2847],
31	brain	NN	O	brain	nn	32	SENT_161	[p11l572t2822r638b2847],
32	hemorrhage	NN	O	hemorrhage	prep_from	29	SENT_161	[p11l652t2822r817b2855],
33	and	CC	O	and	_	0	SENT_161	[p11l829t2822r877b2847],
34	one	CD	NUMBER	one	conj_and	27	SENT_161	[p11l890t2831r939b2847],
35	from	IN	O	from	_	0	SENT_161	[p11l950t2822r1013b2847],
36	pulmonary	JJ	O	pulmonary	amod	38	SENT_161	[p11l1028t2822r1174b2855],
37	embolism	NN	O	embolism	nn	38	SENT_161	[p11l1184t2822r1340b2855],
38	)	NN	O	)	prep_from	34	SENT_161	[p11l1184t2822r1340b2855],
39	.	.	O	.	_	0	SENT_161	[p11l1184t2822r1340b2855],

1	None	NN	O	none	nn	3	SENT_162	[p11l1355t2824r1427b2847],
2	ofthese	NN	O	ofthese	nn	3	SENT_162	[p11l1439t2822r1547b2847],
3	events	NNS	O	event	nsubjpass	5	SENT_162	[p11l1559t2827r1645b2847],
4	were	VBD	O	be	auxpass	5	SENT_162	[p11l1656t2831r1720b2847],
5	considered	VBN	O	consider	_	0	SENT_162	[p11l1731t2822r1880b2847],
6	to	TO	O	to	aux	8	SENT_162	[p11l1892t2827r1918b2847],
7	be	VB	O	be	auxpass	8	SENT_162	[p11l1931t2822r1961b2847],
8	related	VBN	O	relate	xcomp	5	SENT_162	[p11l1974t2822r2063b2847],
9	to	TO	O	to	_	0	SENT_162	[p11l118t2864r145b2884],
10	a	DT	O	a	det	12	SENT_162	[p11l157t2868r170b2884],
11	study	NN	O	study	nn	12	SENT_162	[p11l182t2859r255b2892],
12	drug	NN	O	drug	prep_to	8	SENT_162	[p11l265t2859r335b2892],
13	.	.	O	.	_	0	SENT_162	[p11l265t2859r335b2892],

1	Neutropenia	NN	O	neutropenia	nn	3	SENT_163	[p11l349t2861r519b2892],
2	(	CD	NUMBER	(	num	3	SENT_163	[p11l533t2859r618b2892],
3	grade	NN	O	grade	nsubj	8	SENT_163	[p11l533t2859r618b2892],
4	3	CD	NUMBER	3	dep	3	SENT_163	[p11l630t2861r642b2884],
5	or	CC	O	or	_	0	SENT_163	[p11l655t2868r683b2884],
6	4	CD	NUMBER	4	num	7	SENT_163	[p11l693t2861r717b2892],
7	)	NN	O	)	conj_or	3	SENT_163	[p11l693t2861r717b2892],
8	occurred	VBD	O	occur	_	0	SENT_163	[p11l731t2859r849b2884],
9	in	IN	O	in	_	0	SENT_163	[p11l863t2861r885b2884],
10	11	CD	PERCENT	11	num	11	SENT_163	[p11l900t2860r957b2885],
11	%	NN	PERCENT	%	prep_in	8	SENT_163	[p11l900t2860r957b2885],
12	of	IN	O	of	_	0	SENT_163	[p11l968t2859r998b2884],
13	patients	NNS	O	patient	prep_of	11	SENT_163	[p11l1006t2861r1113b2892],
14	in	IN	O	in	_	0	SENT_163	[p11l1127t2861r1148b2884],
15	the	DT	O	the	det	18	SENT_163	[p11l1160t2859r1203b2884],
16	combination	NN	O	combination	nn	18	SENT_163	[p11l1214t2859r1386b2884],
17	150/2	CD	NUMBER	150/2	num	18	SENT_163	[p11l1400t2861r1476b2892],
18	group	NN	O	group	prep_in	8	SENT_163	[p11l1488t2868r1575b2892],
19	,	,	O	,	_	0	SENT_163	[p11l1488t2868r1575b2892],
20	with	IN	O	with	_	0	SENT_163	[p11l1587t2859r1643b2884],
21	one	CD	NUMBER	one	num	22	SENT_163	[p11l1655t2868r1705b2884],
22	case	NN	O	case	npadvmod	23	SENT_163	[p11l1716t2868r1775b2884],
23	offebrile	JJ	O	offebrile	amod	24	SENT_163	[p11l1786t2859r1906b2884],
24	neutropenia	NN	O	neutropenia	prep_with	8	SENT_163	[p11l1919t2864r2049b2892, p11l121t2898r167b2921],
25	.	.	O	.	_	0	SENT_163	[p11l1919t2864r2049b2892, p11l121t2898r167b2921],

1	Acneiform	NN	O	acneiform	nn	2	SENT_164	[p11l178t2896r319b2921],
2	dermatitis	NN	O	dermatitis	nsubj	3	SENT_164	[p11l332t2896r469b2921],
3	occurred	VBD	O	occur	_	0	SENT_164	[p11l482t2896r600b2921],
4	in	IN	O	in	_	0	SENT_164	[p11l613t2898r635b2921],
5	11	CD	PERCENT	11	num	6	SENT_164	[p11l650t2897r707b2922],
6	%	NN	PERCENT	%	prep_in	3	SENT_164	[p11l650t2897r707b2922],
7	of	IN	O	of	_	0	SENT_164	[p11l719t2896r748b2921],
8	patients	NNS	O	patient	prep_of	6	SENT_164	[p11l756t2898r864b2929],
9	in	IN	O	in	_	0	SENT_164	[p11l877t2898r898b2921],
10	the	DT	O	the	det	13	SENT_164	[p11l910t2896r953b2921],
11	combination	NN	O	combination	nn	13	SENT_164	[p11l964t2896r1136b2921],
12	150/1	CD	NUMBER	150/1	num	13	SENT_164	[p11l1151t2898r1225b2929],
13	group	NN	O	group	prep_in	8	SENT_164	[p11l1238t2905r1325b2929],
14	,	,	O	,	_	0	SENT_164	[p11l1238t2905r1325b2929],
15	16	CD	PERCENT	16	num	16	SENT_164	[p11l1340t2897r1397b2922],
16	%	NN	PERCENT	%	prep_of	6	SENT_164	[p11l1340t2897r1397b2922],
17	in	IN	O	in	_	0	SENT_164	[p11l1410t2898r1431b2921],
18	the	DT	O	the	det	21	SENT_164	[p11l1443t2896r1486b2921],
19	combination	NN	O	combination	nn	21	SENT_164	[p11l1497t2896r1668b2921],
20	150/2	CD	NUMBER	150/2	num	21	SENT_164	[p11l1683t2898r1759b2929],
21	group	NN	O	group	prep_in	16	SENT_164	[p11l1771t2905r1858b2929],
22	,	,	O	,	_	0	SENT_164	[p11l1771t2905r1858b2929],
23	and	CC	O	and	_	0	SENT_164	[p11l1871t2896r1919b2921],
24	4	CD	PERCENT	4	num	25	SENT_164	[p11l1931t2897r1974b2922],
25	%	NN	PERCENT	%	prep_of	6	SENT_164	[p11l1931t2897r1974b2922],
26	in	IN	O	in	_	0	SENT_164	[p11l1987t2898r2008b2921],
27	the	DT	O	the	det	29	SENT_164	[p11l2020t2896r2063b2921],
28	monotherapy	JJ	O	monotherapy	amod	29	SENT_164	[p11l121t2933r302b2966],
29	group	NN	O	group	prep_in	25	SENT_164	[p11l313t2942r400b2966],
30	,	,	O	,	_	0	SENT_164	[p11l313t2942r400b2966],
31	with	IN	O	with	_	0	SENT_164	[p11l412t2933r467b2958],
32	no	DT	O	no	det	33	SENT_164	[p11l482t2942r514b2958],
33	grade	NN	O	grade	prep_with	3	SENT_164	[p11l526t2933r601b2966],
34	3	CD	NUMBER	3	num	37	SENT_164	[p11l613t2935r625b2958],
35	or	CC	O	or	_	0	SENT_164	[p11l638t2942r666b2958],
36	4	CD	NUMBER	4	num	37	SENT_164	[p11l676t2935r690b2958],
37	events	NNS	O	event	nsubj	38	SENT_164	[p11l702t2938r789b2958],
38	reported	VBD	O	report	rcmod	33	SENT_164	[p11l802t2933r924b2966],
39	.	.	O	.	_	0	SENT_164	[p11l802t2933r924b2966],

1	1	CD	NUMBER	1	number	2	SENT_165	[p11l95t2972r110b3003],
2	‘	CD	NUMBER	‘	num	4	SENT_165	[p11l95t2972r110b3003],
3	One	CD	NUMBER	one	num	4	SENT_165	[p11l119t2972r176b2995],
4	patient	NN	O	patient	nsubjpass	18	SENT_165	[p11l189t2972r283b3003],
5	who	WP	O	who	nsubjpass	7	SENT_165	[p11l293t2970r349b2995],
6	was	VBD	O	be	auxpass	7	SENT_165	[p11l360t2979r411b2995],
7	assigned	VBN	O	assign	rcmod	4	SENT_165	[p11l423t2970r542b3003],
8	to	TO	O	to	_	0	SENT_165	[p11l554t2975r580b2995],
9	the	DT	O	the	det	11	SENT_165	[p11l591t2970r633b2995],
10	monotherapy	NN	O	monotherapy	nn	11	SENT_165	[p11l646t2970r828b3003],
11	group	NN	O	group	prep_to	7	SENT_165	[p11l839t2979r918b3003],
12	received	VBD	O	receive	_	0	SENT_165	[p11l931t2970r1040b2995],
13	combination	NN	O	combination	dobj	12	SENT_165	[p11l1053t2970r1224b2995],
14	150/2	CD	NUMBER	150/2	num	13	SENT_165	[p11l1239t2972r1315b3003],
15	and	CC	O	and	_	0	SENT_165	[p11l1327t2970r1375b2995],
16	so	RB	O	so	advmod	18	SENT_165	[p11l1388t2979r1418b2995],
17	was	VBD	O	be	auxpass	18	SENT_165	[p11l1429t2979r1480b2995],
18	included	VBN	O	include	conj_and	12	SENT_165	[p11l1493t2970r1607b2995],
19	in	IN	O	in	_	0	SENT_165	[p11l1621t2972r1643b2995],
20	the	DT	O	the	det	24	SENT_165	[p11l1654t2970r1697b2995],
21	combination	NN	O	combination	nn	24	SENT_165	[p11l1708t2970r1880b2995],
22	150/2	CD	NUMBER	150/2	num	24	SENT_165	[p11l1895t2972r1970b3003],
23	safety	NN	O	safety	nn	24	SENT_165	[p11l1983t2970r2060b3003],
24	analyses	NNS	O	analysis	prep_in	18	SENT_165	[p11l120t3007r241b3040],
25	.	.	O	.	_	0	SENT_165	[p11l120t3007r241b3040],

1	3	CD	NUMBER	3	num	2	SENT_166	[p11l95t3046r110b3077],
2	)	NN	O	)	_	0	SENT_166	[p11l95t3046r110b3077],
3	:	:	O	:	_	0	SENT_166	[p11l95t3046r110b3077],
4	For	IN	O	for	_	0	SENT_166	[p11l121t3046r164b3069],
5	these	DT	O	these	det	6	SENT_166	[p11l174t3044r247b3069],
6	categories	NNS	O	category	prep_for	13	SENT_166	[p11l258t3046r405b3077],
7	,	,	O	,	_	0	SENT_166	[p11l258t3046r405b3077],
8	no	DT	O	no	det	9	SENT_166	[p11l419t3053r451b3069],
9	grade	NN	O	grade	nsubjpass	13	SENT_166	[p11l462t3044r538b3077],
10	4	CD	NUMBER	4	num	11	SENT_166	[p11l549t3046r563b3069],
11	events	NNS	O	event	dep	9	SENT_166	[p11l575t3049r662b3069],
12	were	VBD	O	be	auxpass	13	SENT_166	[p11l673t3053r736b3069],
13	reported	VBN	O	report	dep	2	SENT_166	[p11l749t3044r870b3077],
14	.	.	O	.	_	0	SENT_166	[p11l749t3044r870b3077],

1	§	NN	O	§	nn	2	SENT_167	[p11l94t3081r105b3114],
2	Keratoacanthoma	NN	O	keratoacanthoma	nsubjpass	4	SENT_167	[p11l121t3081r361b3106],
3	was	VBD	O	be	auxpass	4	SENT_167	[p11l372t3090r423b3106],
4	classiﬁed	VBN	O	classiﬁed	_	0	SENT_167	[p11l435t3081r560b3106],
5	as	IN	O	as	_	0	SENT_167	[p11l573t3090r600b3106],
6	cutaneous	JJ	O	cutaneous	amod	8	SENT_167	[p11l612t3086r753b3106],
7	squamous-cell	JJ	O	squamous-cell	amod	8	SENT_167	[p11l766t3081r962b3114],
8	carcinoma	NN	O	carcinoma	prep_as	4	SENT_167	[p11l975t3083r1125b3106],
9	.	.	O	.	_	0	SENT_167	[p11l975t3083r1125b3106],

1	tary	JJ	O	tary	amod	2	SENT_168	[p11l381t3224r445b3257],
2	Appendix	NN	O	appendix	_	0	SENT_168	[p11l455t3217r635b3257],
3	)	NN	O	)	dep	2	SENT_168	[p11l455t3217r635b3257],
4	.	.	O	.	_	0	SENT_168	[p11l455t3217r635b3257],

1	In	IN	O	in	_	0	SENT_169	[p11l651t3220r685b3248],
2	the	DT	O	the	det	5	SENT_169	[p11l700t3218r751b3248],
3	combination	NN	O	combination	nn	5	SENT_169	[p11l766t3218r977b3248],
4	150/2	CD	NUMBER	150/2	num	5	SENT_169	[p11l993t3220r1081b3253],
5	group	NN	O	group	prep_in	10	SENT_169	[p11l1095t3227r1202b3257],
6	,	,	O	,	_	0	SENT_169	[p11l1095t3227r1202b3257],
7	pyrexia	NN	O	pyrexia	nsubjpass	10	SENT_169	[p11l1243t3218r1359b3257],
8	and	CC	O	and	advmod	10	SENT_169	[p11l1370t3217r1430b3248],
9	were	VBD	O	be	auxpass	10	SENT_169	[p11l1439t3228r1515b3249],
10	attributed	VBN	O	attribute	_	0	SENT_169	[p11l1526t3217r1684b3249],
11	to	TO	O	to	_	0	SENT_169	[p11l1695t3224r1726b3248],
12	dabrafenib	NN	O	dabrafenib	prep_to	10	SENT_169	[p11l1738t3217r1919b3248],
13	.	.	O	.	_	0	SENT_169	[p11l1738t3217r1919b3248],

1	Re	NNP	O	Re	nn	3	SENT_170	[p11l1932t3220r2066b3250, p11l381t3270r419b3298],
2	—	CD	NUMBER	—	num	3	SENT_170	[p11l1932t3220r2066b3250, p11l381t3270r419b3298],
3	esca32	NN	O	esca32	nsubj	7	SENT_170	[p11l1932t3220r2066b3250, p11l381t3270r419b3298],
4	of	IN	O	of	_	0	SENT_170	[p11l434t3267r473b3298],
5	55	CD	NUMBER	55	num	6	SENT_170	[p11l482t3270r517b3298],
6	patients	NNS	O	patient	prep_of	3	SENT_170	[p11l533t3268r666b3306],
7	included	VBD	O	include	ccomp	20	SENT_170	[p11l681t3267r823b3298],
8	in	IN	O	in	mark	18	SENT_170	[p11l838t3268r871b3297],
9	the	DT	O	the	det	12	SENT_170	[p11l886t3268r937b3298],
10	safety	NN	O	safety	nn	12	SENT_170	[p11l953t3267r1051b3306],
11	analyses	NNS	O	analysis	nn	12	SENT_170	[p11l1064t3267r1203b3306],
12	lation	NN	O	lation	nsubj	18	SENT_170	[p11l1243t3267r1335b3298],
13	of	IN	O	of	_	0	SENT_170	[p11l1348t3267r1386b3298],
14	the	DT	O	the	det	16	SENT_170	[p11l1391t3267r1441b3298],
15	dabrafenib	NN	O	dabrafenib	nn	16	SENT_170	[p11l1453t3267r1626b3298],
16	dose	NN	O	dose	prep_of	12	SENT_170	[p11l1639t3267r1712b3298],
17	was	VBD	O	be	cop	18	SENT_170	[p11l1722t3278r1784b3298],
18	common	JJ	O	common	advcl	7	SENT_170	[p11l1797t3277r1949b3304],
19	,	,	O	,	_	0	SENT_170	[p11l1797t3277r1949b3304],
20	occur	VBP	O	occur	_	0	SENT_170	[p11l1964t3277r2066b3298, p11l383t3319r471b3352],
21	(	CD	PERCENT	(	number	22	SENT_170	[p11l1964t3277r2066b3298, p11l383t3319r471b3352],
22	58	CD	PERCENT	58	dep	23	SENT_170	[p11l1964t3277r2066b3298, p11l383t3319r471b3352],
23	%	NN	PERCENT	%	dep	24	SENT_170	[p11l1964t3277r2066b3298, p11l383t3319r471b3352],
24	)	NN	O	)	dobj	20	SENT_170	[p11l1964t3277r2066b3298, p11l383t3319r471b3352],
25	required	VBN	O	require	dep	20	SENT_170	[p11l487t3316r621b3356],
26	dose	NN	O	dose	nn	27	SENT_170	[p11l635t3316r708b3347],
27	reductions	NNS	O	reduction	dobj	25	SENT_170	[p11l721t3316r889b3348],
28	because	IN	O	because	_	0	SENT_170	[p11l903t3316r1029b3348],
29	of	IN	O	of	_	0	SENT_170	[p11l1042t3316r1080b3347],
30	adverse	JJ	O	adverse	amod	31	SENT_170	[p11l1087t3316r1204b3347],
31	ring	NN	O	ring	prep_because_of	25	SENT_170	[p11l1244t3317r1313b3356],
32	in	IN	O	in	_	0	SENT_170	[p11l1326t3317r1358b3347],
33	28	CD	NUMBER	28	prep_in	31	SENT_170	[p11l1372t3319r1411b3347],
34	of	IN	O	of	_	0	SENT_170	[p11l1426t3316r1465b3347],
35	30	CD	NUMBER	30	num	36	SENT_170	[p11l1473t3319r1511b3348],
36	patients	NNS	O	patient	prep_of	33	SENT_170	[p11l1525t3317r1658b3356],
37	(	IN	O	(	_	0	SENT_170	[p11l1675t3319r1775b3352],
38	93	CD	PERCENT	93	num	39	SENT_170	[p11l1675t3319r1775b3352],
39	%	NN	PERCENT	%	prep_(	25	SENT_170	[p11l1675t3319r1775b3352],
40	)	CD	NUMBER	)	nsubj	20	SENT_170	[p11l1675t3319r1775b3352],
41	.	.	O	.	_	0	SENT_170	[p11l1675t3319r1775b3352],

1	Despite	IN	O	despite	dep	7	SENT_171	[p11l1791t3317r1913b3356],
2	the	DT	O	the	det	4	SENT_171	[p11l1927t3316r1977b3347],
3	need	NN	O	need	nn	4	SENT_171	[p11l1991t3316r2067b3347],
4	events	NNS	O	event	pobj	1	SENT_171	[p11l381t3373r488b3403],
5	,	,	O	,	_	0	SENT_171	[p11l381t3373r488b3403],
6	the	DT	O	the	det	7	SENT_171	[p11l504t3367r553b3397],
7	majority	NN	O	majority	_	0	SENT_171	[p11l567t3367r701b3405],
8	of	IN	O	of	_	0	SENT_171	[p11l713t3366r751b3397],
9	which	WDT	O	which	nsubjpass	11	SENT_171	[p11l755t3367r854b3397],
10	were	VBD	O	be	auxpass	11	SENT_171	[p11l865t3377r941b3397],
11	associated	VBN	O	associate	prepc_of	7	SENT_171	[p11l954t3366r1119b3397],
12	with	IN	O	with	dep	11	SENT_171	[p11l1131t3366r1204b3397],
13	for	IN	O	for	_	0	SENT_171	[p11l1244t3366r1290b3397],
14	dose	NN	O	dose	nn	15	SENT_171	[p11l1304t3366r1376b3397],
15	modiﬁcations	NNS	O	modiﬁcations	prep_for	11	SENT_171	[p11l1391t3366r1624b3403],
16	,	,	O	,	_	0	SENT_171	[p11l1391t3366r1624b3403],
17	the	DT	O	the	det	20	SENT_171	[p11l1641t3367r1691b3397],
18	median	JJ	O	median	amod	20	SENT_171	[p11l1706t3366r1827b3397],
19	treatment	NN	O	treatment	nn	20	SENT_171	[p11l1842t3373r2000b3397],
20	du1593	NN	O	du1593	appos	15	SENT_171	[p11l2014t3366r2066b3397, p11l94t3480r170b3504],

1	NENGLj	NN	O	nenglj	_	0	SENT_172	[p11l881t3491r987b3513],
2	MED367	NN	O	med367	rcmod	1	SENT_172	[p11l1002t3485r1142b3513],
3	;	:	O	;	_	0	SENT_172	[p11l1002t3485r1142b3513],
4	18	CD	NUMBER	18	num	6	SENT_172	[p11l1002t3485r1142b3513],
5	NEjM.ORG	NN	O	nejm.org	nn	6	SENT_172	[p11l1177t3491r1301b3513],
6	NOVEMBER1	NN	O	november1	dep	2	SENT_172	[p11l1338t3491r1568b3511],
7	,20	CD	NUMBER	,20	dep	2	SENT_172	[p11l1338t3491r1568b3511],
8	'	''	O	'	_	0	SENT_172	[p11l1338t3491r1568b3511],
9	|	NN	O	|	dep	1	SENT_172	[p11l1338t3491r1568b3511],
10	2	CD	NUMBER	2	num	9	SENT_172	[p11l1338t3491r1568b3511],

1	The	DT	O	the	det	4	SENT_173	[p11l881t3548r932b3572],
2	New	NNP	O	New	nn	4	SENT_173	[p11l941t3549r1003b3572],
3	England	NNP	O	England	nn	4	SENT_173	[p11l1012t3548r1123b3579],
4	Journal	NNP	O	Journal	_	0	SENT_173	[p11l1132t3548r1229b3572],
5	of	IN	O	of	_	0	SENT_173	[p11l1239t3548r1268b3572],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_173	[p11l1274t3548r1399b3572],

1	Copyright	NN	O	copyright	_	0	SENT_174	[p11l673t3630r808b3661],
2	©	CD	NUMBER	©	num	6	SENT_174	[p11l817t3630r840b3654],
3	2012	CD	DATE	2012	num	6	SENT_174	[p11l851t3630r916b3654],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_174	[p11l925t3630r1116b3654],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_174	[p11l1126t3630r1234b3654],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_174	[p11l1245t3630r1349b3661],
7	.	.	O	.	_	0	SENT_174	[p11l1245t3630r1349b3661],

1	All	DT	O	all	det	2	SENT_175	[p11l1361t3630r1402b3654],
2	rights	NNS	O	rights	nsubj	3	SENT_175	[p11l1411t3630r1486b3661],
3	reserved	VBN	O	reserve	_	0	SENT_175	[p11l1495t3630r1614b3654],
4	.	.	O	.	_	0	SENT_175	[p11l1495t3630r1614b3654],

1	BRAF	NNS	ORGANIZATION	braf	_	0	SENT_176	[p11l714t3736r798b3755],
2	AND	CC	O	and	_	0	SENT_176	[p11l810t3736r882b3755],
3	MEK	NN	O	mek	nn	4	SENT_176	[p11l896t3736r968b3756],
4	INHIBITION	NN	O	inhibition	conj_and	1	SENT_176	[p11l981t3736r1184b3755],
5	IN	IN	O	in	_	0	SENT_176	[p11l1200t3736r1237b3755],
6	MELANOMA	NN	O	melanoma	prep_in	1	SENT_176	[p11l1252t3736r1446b3755],

1	ration	NN	O	ration	nsubj	4	SENT_177	[p12l11t164r263b243],
2	was	VBD	O	be	cop	4	SENT_177	[p12l293t189r454b243],
3	10.5	CD	DURATION	10.5	num	4	SENT_177	[p12l495t169r660b243],
4	months	NNS	NUMBER	month	_	0	SENT_177	[p12l699t163r1022b243],
5	in	IN	O	in	_	0	SENT_177	[p12l1059t164r1142b241],
6	the	DT	O	the	det	9	SENT_177	[p12l1177t163r1308b242],
7	combination	NN	O	combination	nn	9	SENT_177	[p12l1344t163r1883b243],
8	150/1	CD	NUMBER	150/1	num	9	SENT_177	[p12l1922t168r2147b253],
9	group	NN	O	group	prep_in	4	SENT_177	[p12l11t318r287b393],
10	,	,	O	,	_	0	SENT_177	[p12l11t318r287b393],
11	11.0	CD	DURATION	11.0	num	12	SENT_177	[p12l353t298r529b371],
12	months	NNS	NUMBER	month	conj_and	4	SENT_177	[p12l587t292r916b371],
13	in	IN	O	in	_	0	SENT_177	[p12l974t293r1059b370],
14	the	DT	O	the	det	17	SENT_177	[p12l1116t292r1250b370],
15	combination	NN	O	combination	nn	17	SENT_177	[p12l1308t292r1857b371],
16	150/2	CD	NUMBER	150/2	num	17	SENT_177	[p12l1918t297r2146b382],
17	group	NN	O	group	prep_in	12	SENT_177	[p12l11t446r276b521],
18	,	,	O	,	_	0	SENT_177	[p12l11t446r276b521],
19	and	CC	O	and	_	0	SENT_177	[p12l315t420r469b499],
20	6.1	CD	DURATION	6.1	num	21	SENT_177	[p12l503t426r625b499],
21	months	NNS	NUMBER	month	conj_and	4	SENT_177	[p12l659t420r977b499],
22	in	IN	O	in	_	0	SENT_177	[p12l1013t421r1094b498],
23	the	DT	O	the	det	25	SENT_177	[p12l1128t420r1257b498],
24	monotherapy	JJ	O	monotherapy	amod	25	SENT_177	[p12l1291t420r1847b520],
25	group	NN	O	group	prep_in	21	SENT_177	[p12l1876t446r2142b521],
26	.	.	O	.	_	0	SENT_177	[p12l1876t446r2142b521],

1	PHARMACOKINETIC	JJ	O	pharmacokinetic	amod	3	SENT_178	[p12l17t696r797b747],
2	ACTIVITY	NN	O	activity	nn	3	SENT_178	[p12l827t696r1186b747],
3	Repeat	NN	O	repeat	nsubj	7	SENT_178	[p12l10t795r525b895],
4	—	CD	NUMBER	—	num	6	SENT_178	[p12l10t795r525b895],
5	dose	NN	O	dose	nn	6	SENT_178	[p12l10t795r525b895],
6	trametinib	NN	O	trametinib	dep	3	SENT_178	[p12l555t795r1007b874],
7	had	VBD	O	have	conj_and	7	SENT_178	[p12l1039t795r1194b874],
8	no	DT	O	no	det	9	SENT_178	[p12l1223t821r1328b874],
9	effect	NN	O	effect	dobj	7	SENT_178	[p12l1360t794r1598b873],
10	on	IN	O	on	_	0	SENT_178	[p12l1624t821r1729b874],
11	the	DT	O	the	det	17	SENT_178	[p12l1759t795r1891b873],
12	pharmacokinetic	JJ	O	pharmacokinetic	amod	17	SENT_178	[p12l1919t795r2146b895, p12l11t924r522b1004],
13	activity	NN	O	activity	nn	17	SENT_178	[p12l546t925r842b1025],
14	ofsingle	NN	O	ofsingle	nn	17	SENT_178	[p12l864t923r1438b1026],
15	—	CD	NUMBER	—	num	17	SENT_178	[p12l864t923r1438b1026],
16	dose	NN	O	dose	nn	17	SENT_178	[p12l864t923r1438b1026],
17	dabrafenib	NN	O	dabrafenib	prep_on	9	SENT_178	[p12l1464t923r1931b1021],
18	,	,	O	,	_	0	SENT_178	[p12l1464t923r1931b1021],
19	with	IN	O	with	_	0	SENT_178	[p12l1957t924r2147b1004],
20	ratios	NNS	O	ratio	prep_with	17	SENT_178	[p12l11t1053r253b1131],
21	of	IN	O	of	_	0	SENT_178	[p12l286t1051r386b1131],
22	0.94	CD	NUMBER	0.94	number	24	SENT_178	[p12l398t1058r577b1131],
23	to	TO	O	to	dep	24	SENT_178	[p12l608t1069r690b1131],
24	1.03	CD	NUMBER	1.03	prep_of	20	SENT_178	[p12l724t1058r895b1131],
25	for	IN	O	for	_	0	SENT_178	[p12l928t1051r1052b1131],
26	the	DT	O	the	det	27	SENT_178	[p12l1079t1052r1213b1130],
27	comparison	NN	O	comparison	prep_for	7	SENT_178	[p12l1244t1053r1757b1152],
28	between	IN	O	between	_	0	SENT_178	[p12l1787t1052r2147b1132],
29	the	DT	O	the	det	30	SENT_178	[p12l12t1182r145b1260],
30	area	NN	O	area	prep_between	27	SENT_178	[p12l177t1208r358b1261],
31	under	IN	O	under	_	0	SENT_178	[p12l389t1182r641b1261],
32	the	DT	O	the	det	33	SENT_178	[p12l670t1182r804b1260],
33	time	NN	O	time	prep_under	7	SENT_178	[p12l837t1183r1695b1261],
34	—	JJ	O	—	amod	36	SENT_178	[p12l837t1183r1695b1261],
35	concentration	NN	O	concentration	nn	36	SENT_178	[p12l837t1183r1695b1261],
36	curve	NN	O	curve	npadvmod	43	SENT_178	[p12l1727t1208r1957b1261],
37	and	CC	O	and	_	0	SENT_178	[p12l1989t1182r2148b1261],
38	the	DT	O	the	det	40	SENT_178	[p12l12t1310r145b1388],
39	maximum	NN	O	maximum	nn	40	SENT_178	[p12l191t1311r640b1389],
40	concentration	NN	O	concentration	conj_and	36	SENT_178	[p12l687t1311r1286b1389],
41	for	IN	O	for	_	0	SENT_178	[p12l1332t1309r1456b1389],
42	dabrafenib	NN	O	dabrafenib	prep_for	40	SENT_178	[p12l1500t1309r1966b1389],
43	before	IN	O	before	advmod	33	SENT_178	[p12l2015t1310r2146b1389, p12l11t1436r176b1516],
44	and	CC	O	and	_	0	SENT_178	[p12l202t1437r358b1516],
45	after	IN	O	after	_	0	SENT_178	[p12l385t1436r584b1515],
46	trametinib	NN	O	trametinib	prep_after	7	SENT_178	[p12l608t1437r1060b1516],
47	exposure	NN	O	exposure	nn	50	SENT_178	[p12l1088t1463r1469b1537],
48	(	CD	NUMBER	(	num	50	SENT_178	[p12l1501t1437r1756b1528],
49	Table	NNP	O	Table	nn	50	SENT_178	[p12l1501t1437r1756b1528],
50	S2	NN	O	s2	dep	7	SENT_178	[p12l1784t1443r1879b1516],
51	in	IN	O	in	_	0	SENT_178	[p12l1906t1438r1989b1515],
52	the	DT	O	the	det	55	SENT_178	[p12l2016t1437r2148b1515],
53	Supplementary	NNP	O	Supplementary	nn	55	SENT_178	[p12l13t1566r651b1666],
54	Appendix	NNP	O	Appendix	nn	55	SENT_178	[p12l679t1566r1139b1666],
55	)	NN	O	)	prep_in	7	SENT_178	[p12l679t1566r1139b1666],
56	.	.	O	.	_	0	SENT_178	[p12l679t1566r1139b1666],

1	Pharmacokinetic	JJ	O	pharmacokinetic	amod	2	SENT_179	[p12l1179t1566r1900b1646],
2	analyses	NNS	O	analysis	nsubj	12	SENT_179	[p12l1935t1566r2146b1644, p12l7t1722r177b1796],
3	that	WDT	O	that	nsubjpass	5	SENT_179	[p12l209t1695r376b1774],
4	Were	VBD	O	be	auxpass	5	SENT_179	[p12l396t1721r593b1775],
5	performed	VBN	O	perform	rcmod	2	SENT_179	[p12l621t1694r1063b1796],
6	during	IN	O	during	_	0	SENT_179	[p12l1093t1695r1373b1797],
7	dose	NN	O	dose	nn	8	SENT_179	[p12l1400t1695r1589b1775],
8	escalation	NN	O	escalation	prep_during	5	SENT_179	[p12l1619t1695r2036b1775],
9	in	IN	O	in	_	0	SENT_179	[p12l2066t1696r2147b1773],
10	part	NN	O	part	nn	11	SENT_179	[p12l10t1841r187b1924],
11	B	NN	O	b	prep_in	8	SENT_179	[p12l212t1830r268b1902],
12	suggested	VBD	O	suggest	_	0	SENT_179	[p12l303t1824r724b1925],
13	that	IN	O	that	complm	15	SENT_179	[p12l755t1824r925b1902],
14	there	EX	O	there	expl	15	SENT_179	[p12l951t1824r1165b1903],
15	Was	VBD	O	be	ccomp	12	SENT_179	[p12l1192t1850r1353b1903],
16	a	DT	O	a	det	41	SENT_179	[p12l1386t1850r1430b1902],
17	modest	JJ	O	modest	amod	41	SENT_179	[p12l1460t1824r1775b1903],
18	increase	NN	O	increase	amod	41	SENT_179	[p12l1800t1825r2147b1902],
19	in	IN	O	in	_	0	SENT_179	[p12l11t1952r94b2029],
20	exposure	NN	O	exposure	prep_in	18	SENT_179	[p12l124t1977r512b2051],
21	to	TO	O	to	_	0	SENT_179	[p12l543t1968r624b2030],
22	dabrafenib	NN	O	dabrafenib	prep_to	18	SENT_179	[p12l656t1950r1145b2047],
23	,	,	O	,	_	0	SENT_179	[p12l656t1950r1145b2047],
24	as	IN	O	as	mark	22	SENT_179	[p12l1179t1977r1265b2029],
25	compared	VBN	O	compare	_	0	SENT_179	[p12l1297t1951r1726b2051],
26	with	IN	O	with	_	0	SENT_179	[p12l1751t1951r1947b2031],
27	previously	RB	DATE	previously	advmod	28	SENT_179	[p12l1975t1977r2146b2051, p12l7t2079r310b2179],
28	reported	VBN	O	report	amod	29	SENT_179	[p12l344t2079r712b2179],
29	data	NNS	O	datum	prep_compared_with	22	SENT_179	[p12l752t2079r958b2175],
30	,	,	O	,	_	0	SENT_179	[p12l752t2079r958b2175],
31	and	CC	O	and	_	0	SENT_179	[p12l1003t2079r1161b2158],
32	no	DT	O	no	det	34	SENT_179	[p12l1200t2105r1306b2158],
33	apparent	JJ	O	apparent	amod	34	SENT_179	[p12l1345t2096r1729b2179],
34	effect	NN	O	effect	conj_and	29	SENT_179	[p12l1763t2078r2006b2157],
35	on	IN	O	on	_	0	SENT_179	[p12l2041t2105r2148b2158],
36	trametinib	NN	O	trametinib	nn	38	SENT_179	[p12l12t2208r473b2287],
37	exposure5	NN	O	exposure5	nn	38	SENT_179	[p12l518t2213r999b2308],
38	’	NN	O	’	prep_on	34	SENT_179	[p12l518t2213r999b2308],
39	7	CD	NUMBER	7	number	40	SENT_179	[p12l518t2213r999b2308],
40	(	CD	NUMBER	(	num	41	SENT_179	[p12l1046t2209r1226b2309],
41	Fig	NN	O	fig	nsubj	15	SENT_179	[p12l1046t2209r1226b2309],
42	.	.	O	.	_	0	SENT_179	[p12l1046t2209r1226b2309],

1	82A	NN	O	82a	_	0	SENT_180	[p12l1277t2214r1443b2287],
2	and	CC	O	and	_	0	SENT_180	[p12l1482t2208r1641b2287],
3	S2B	NN	O	s2b	conj_and	1	SENT_180	[p12l1685t2214r1843b2287],
4	in	IN	O	in	_	0	SENT_180	[p12l1887t2209r1970b2286],
5	the	DT	O	the	det	8	SENT_180	[p12l2013t2208r2147b2286],
6	Supplementary	NNP	O	Supplementary	nn	8	SENT_180	[p12l13t2336r638b2436],
7	Appendix	NNP	O	Appendix	nn	8	SENT_180	[p12l664t2336r1113b2436],
8	)	NN	O	)	prep_in	1	SENT_180	[p12l664t2336r1113b2436],
9	.	.	O	.	_	0	SENT_180	[p12l664t2336r1113b2436],

1	These	DT	O	these	det	2	SENT_181	[p12l1149t2336r1394b2414],
2	data	NNS	O	datum	nsubj	3	SENT_181	[p12l1428t2336r1606b2415],
3	suggest	VBP	O	suggest	_	0	SENT_181	[p12l1640t2353r1957b2437],
4	that	IN	O	that	complm	7	SENT_181	[p12l1985t2336r2153b2414],
5	trametinib	NN	O	trametinib	nsubj	7	SENT_181	[p12l12t2463r473b2542],
6	may	MD	O	may	aux	7	SENT_181	[p12l507t2489r686b2563],
7	have	VB	O	have	ccomp	3	SENT_181	[p12l714t2463r905b2543],
8	a	DT	O	a	det	11	SENT_181	[p12l936t2489r981b2541],
9	minor	JJ	O	minor	amod	11	SENT_181	[p12l1012t2464r1279b2542],
10	inhibitory	JJ	O	inhibitory	amod	11	SENT_181	[p12l1308t2463r1742b2563],
11	effect	NN	O	effect	dobj	7	SENT_181	[p12l1770t2462r2013b2541],
12	on	IN	O	on	_	0	SENT_181	[p12l2041t2489r2147b2542],
13	dabrafenib	JJ	O	dabrafenib	amod	14	SENT_181	[p12l12t2591r478b2671],
14	clearance	NN	O	clearance	prep_on	11	SENT_181	[p12l516t2592r943b2671],
15	.	.	O	.	_	0	SENT_181	[p12l516t2592r943b2671],

1	EFFICACY	NN	O	efficacy	_	0	SENT_182	[p12l16t2852r386b2903],

1	Part	NN	O	part	nn	2	SENT_183	[p12l16t2980r179b3049],
2	C	NN	O	c	npadvmod	24	SENT_183	[p12l216t2979r276b3049],
3	At	IN	O	at	_	0	SENT_183	[p12l7t3105r107b3175],
4	the	DT	O	the	det	5	SENT_183	[p12l140t3097r273b3175],
5	time	NN	O	time	prep_at	24	SENT_183	[p12l312t3098r506b3175],
6	of	IN	O	of	_	0	SENT_183	[p12l544t3096r645b3176],
7	the	DT	O	the	det	10	SENT_183	[p12l664t3097r797b3175],
8	prespecified	JJ	O	prespecified	amod	10	SENT_183	[p12l834t3096r1366b3197],
9	efficacy	NN	O	efficacy	nn	10	SENT_183	[p12l1404t3096r1743b3197],
10	analysis	NN	O	analysis	prep_of	5	SENT_183	[p12l1775t3097r2141b3197],
11	,	,	O	,	_	0	SENT_183	[p12l1775t3097r2141b3197],
12	the	DT	O	the	det	13	SENT_183	[p12l12t3225r145b3303],
13	median	NN	O	median	nsubj	24	SENT_183	[p12l185t3225r511b3304],
14	follow	VB	O	follow	dep	13	SENT_183	[p12l551t3224r961b3325],
15	—	RB	O	—	advmod	14	SENT_183	[p12l551t3224r961b3325],
16	up	RP	O	up	prep	14	SENT_183	[p12l551t3224r961b3325],
17	for	IN	O	for	_	0	SENT_183	[p12l1003t3224r1127b3304],
18	patients	NNS	O	patient	prep_for	16	SENT_183	[p12l1162t3226r1506b3325],
19	in	IN	O	in	_	0	SENT_183	[p12l1548t3226r1631b3303],
20	part	NN	O	part	nn	21	SENT_183	[p12l1670t3242r1851b3325],
21	C	NN	O	c	prep_in	18	SENT_183	[p12l1886t3231r1944b3304],
22	was	VBD	O	be	cop	24	SENT_183	[p12l1982t3251r2145b3305],
23	14.1	CD	DURATION	14.1	num	24	SENT_183	[p12l15t3360r184b3433],
24	months	NNS	NUMBER	month	_	0	SENT_183	[p12l235t3354r564b3433],
25	(	JJ	O	(	amod	26	SENT_183	[p12l622t3361r913b3455],
26	range	NN	O	range	attr	24	SENT_183	[p12l622t3361r913b3455],
27	,	,	O	,	_	0	SENT_183	[p12l622t3361r913b3455],
28	10.8	CD	NUMBER	10.8	number	30	SENT_183	[p12l974t3360r1147b3433],
29	to	TO	O	to	dep	30	SENT_183	[p12l1200t3371r1282b3433],
30	17.6	CD	NUMBER	17.6	appos	26	SENT_183	[p12l1338t3360r1556b3445],
31	)	CD	NUMBER	)	dep	30	SENT_183	[p12l1338t3360r1556b3445],
32	.	.	O	.	_	0	SENT_183	[p12l1338t3360r1556b3445],

1	The	DT	O	the	det	6	SENT_184	[p12l1609t3354r1770b3432],
2	median	JJ	O	median	amod	6	SENT_184	[p12l1822t3354r2147b3433],
3	progression	NN	O	progression	nn	6	SENT_184	[p12l10t3481r722b3584],
4	—	CD	NUMBER	—	num	6	SENT_184	[p12l10t3481r722b3584],
5	free	JJ	O	free	amod	6	SENT_184	[p12l10t3481r722b3584],
6	survival	NN	O	survival	nsubj	16	SENT_184	[p12l756t3482r1090b3562],
7	for	IN	O	for	_	0	SENT_184	[p12l1121t3481r1245b3562],
8	patients	NNS	O	patient	prep_for	6	SENT_184	[p12l1273t3483r1616b3583],
9	in	IN	O	in	_	0	SENT_184	[p12l1649t3483r1733b3560],
10	the	DT	O	the	det	13	SENT_184	[p12l1765t3482r1899b3561],
11	combination	NN	O	combination	nn	13	SENT_184	[p12l1931t3508r2145b3562, p12l12t3611r373b3690],
12	150/2	CD	NUMBER	150/2	num	13	SENT_184	[p12l425t3616r654b3701],
13	group	NN	O	group	prep_in	8	SENT_184	[p12l703t3637r956b3712],
14	was	VBD	O	be	cop	16	SENT_184	[p12l1001t3637r1165b3690],
15	9.4	CD	DURATION	9.4	num	16	SENT_184	[p12l1216t3617r1339b3690],
16	months	NNS	NUMBER	month	_	0	SENT_184	[p12l1387t3611r1741b3707],
17	,	,	O	,	_	0	SENT_184	[p12l1387t3611r1741b3707],
18	as	IN	O	as	mark	19	SENT_184	[p12l1794t3637r1880b3689],
19	compared	VBN	O	compare	advcl	16	SENT_184	[p12l1931t3637r2145b3690, p13l9t20r254b120],

1	with	IN	O	with	dep	25	SENT_185	[p13l299t20r495b100],
2	5.8	CD	DURATION	5.8	num	3	SENT_185	[p13l547t26r671b99],
3	months	NNS	NUMBER	month	pobj	1	SENT_185	[p13l722t20r1051b99],
4	with	IN	O	with	_	0	SENT_185	[p13l1099t20r1295b100],
5	dabrafenib	NN	O	dabrafenib	nn	9	SENT_185	[p13l1345t19r1812b99],
6	monotherapy	NN	O	monotherapy	nn	9	SENT_185	[p13l1862t46r2145b99, p13l12t149r335b250],
7	(	NN	O	(	nn	9	SENT_185	[p13l385t149r712b241],
8	hazard	NN	O	hazard	nn	9	SENT_185	[p13l385t149r712b241],
9	ratio	NN	O	ratio	prep_with	3	SENT_185	[p13l761t150r960b229],
10	for	IN	O	for	_	0	SENT_185	[p13l1010t148r1134b229],
11	progression	NN	O	progression	prep_for	9	SENT_185	[p13l1179t150r1694b251],
12	or	CC	O	or	_	0	SENT_185	[p13l1744t175r1833b229],
13	death	NN	O	death	prep_for	9	SENT_185	[p13l1880t149r2142b246],
14	,	,	O	,	_	0	SENT_185	[p13l1880t149r2142b246],
15	0.39	CD	NUMBER	0.39	appos	9	SENT_185	[p13l11t283r212b373],
16	;	:	O	;	_	0	SENT_185	[p13l11t283r212b373],
17	95	CD	NUMBER	95	number	18	SENT_185	[p13l257t282r442b356],
18	°	CD	NUMBER	°	dep	15	SENT_185	[p13l257t282r442b356],
19	/	:	O	/	punct	25	SENT_185	[p13l257t282r442b356],
20	o	NN	O	o	nn	25	SENT_185	[p13l257t282r442b356],
21	confidence	NN	O	confidence	nn	25	SENT_185	[p13l482t276r957b356],
22	interval	NN	O	interval	nn	25	SENT_185	[p13l997t277r1325b356],
23	[	CD	NUMBER	[	num	25	SENT_185	[p13l1374t283r1550b373],
24	CI	NN	O	ci	nn	25	SENT_185	[p13l1374t283r1550b373],
25	]	NN	O	]	_	0	SENT_185	[p13l1374t283r1550b373],
26	,	,	O	,	_	0	SENT_185	[p13l1374t283r1550b373],
27	0.25	CD	NUMBER	0.25	num	29	SENT_185	[p13l1596t283r1773b356],
28	to	TO	O	to	dep	29	SENT_185	[p13l1818t294r1900b356],
29	0.62	CD	NUMBER	0.62	appos	25	SENT_185	[p13l1941t283r2143b373],
30	;	:	O	;	_	0	SENT_185	[p13l1941t283r2143b373],
31	P	NN	O	p	dep	32	SENT_185	[p13l9t412r376b497],
32	<	JJR	O	<	dep	25	SENT_185	[p13l9t412r376b497],
33	0.001	CD	NUMBER	0.001	num	34	SENT_185	[p13l9t412r376b497],
34	)	NN	O	)	dep	32	SENT_185	[p13l9t412r376b497],
35	(	CD	NUMBER	(	num	36	SENT_185	[p13l420t406r680b497],
36	Table	NNP	O	Table	dep	32	SENT_185	[p13l420t406r680b497],
37	3	CD	NUMBER	3	num	36	SENT_185	[p13l714t412r759b485],
38	and	CC	O	and	_	0	SENT_185	[p13l795t406r954b485],
39	Fig	NN	O	fig	dep	32	SENT_185	[p13l986t407r1138b507],
40	.	.	O	.	_	0	SENT_185	[p13l986t407r1138b507],

1	1A	NN	O	1a	_	0	SENT_186	[p13l1180t412r1344b497],
2	)	NN	O	)	dep	1	SENT_186	[p13l1180t412r1344b497],
3	.	.	O	.	_	0	SENT_186	[p13l1180t412r1344b497],

1	The	DT	O	the	det	2	SENT_187	[p13l1380t406r1542b484],
2	improvement	NN	O	improvement	_	0	SENT_187	[p13l1574t407r2152b506],
3	in	IN	O	in	_	0	SENT_187	[p13l11t535r94b612],
4	progression	NN	O	progression	prep_in	2	SENT_187	[p13l126t533r839b636],
5	—	CD	NUMBER	—	num	4	SENT_187	[p13l126t533r839b636],
6	free	JJ	O	free	amod	7	SENT_187	[p13l126t533r839b636],
7	survival	NN	O	survival	nsubj	17	SENT_187	[p13l875t534r1208b614],
8	as	IN	O	as	amod	7	SENT_187	[p13l1241t561r1327b613],
9	assessed	VBN	O	assess	partmod	7	SENT_187	[p13l1362t534r1734b614],
10	by	IN	O	by	_	0	SENT_187	[p13l1767t534r1865b635],
11	an	DT	O	a	det	14	SENT_187	[p13l1893t560r1997b613],
12	independent	JJ	O	independent	amod	14	SENT_187	[p13l2030t535r2145b612, p13l12t663r456b763],
13	review	NN	O	review	nn	14	SENT_187	[p13l481t664r756b743],
14	committee	NN	O	committee	agent	9	SENT_187	[p13l782t664r1238b742],
15	was	VBD	O	be	cop	17	SENT_187	[p13l1262t689r1424b743],
16	less	RBR	O	less	advmod	17	SENT_187	[p13l1454t663r1608b741],
17	pronounced	JJ	O	pronounced	rcmod	2	SENT_187	[p13l1637t663r2148b763],
18	(	NN	O	(	nn	20	SENT_187	[p13l16t792r343b883],
19	hazard	NN	O	hazard	nn	20	SENT_187	[p13l16t792r343b883],
20	ratio	NN	O	ratio	dep	2	SENT_187	[p13l376t793r596b888],
21	,	,	O	,	_	0	SENT_187	[p13l376t793r596b888],
22	0.55	CD	NUMBER	0.55	appos	20	SENT_187	[p13l634t798r833b888],
23	;	:	O	;	_	0	SENT_187	[p13l634t798r833b888],
24	95	CD	PERCENT	95	num	26	SENT_187	[p13l870t797r1055b871],
25	%	NN	PERCENT	%	nn	26	SENT_187	[p13l870t797r1055b871],
26	CI	NN	O	ci	dep	2	SENT_187	[p13l1087t798r1202b888],
27	,	,	O	,	_	0	SENT_187	[p13l1087t798r1202b888],
28	0.33	CD	NUMBER	0.33	number	30	SENT_187	[p13l1240t798r1413b871],
29	to	TO	O	to	dep	30	SENT_187	[p13l1450t809r1532b871],
30	0.93	CD	NUMBER	0.93	appos	26	SENT_187	[p13l1566t798r1764b888],
31	;	:	O	;	_	0	SENT_187	[p13l1566t798r1764b888],
32	P	NN	O	p	dep	2	SENT_187	[p13l1799t798r2141b883],
33	=	JJ	O	=	advmod	37	SENT_187	[p13l1799t798r2141b883],
34	0.02	CD	NUMBER	0.02	dep	33	SENT_187	[p13l1799t798r2141b883],
35	)	CD	NUMBER	)	number	36	SENT_187	[p13l1799t798r2141b883],
36	(	CD	NUMBER	(	num	37	SENT_187	[p13l16t922r192b1023],
37	Fig	NN	O	fig	rcmod	32	SENT_187	[p13l16t922r192b1023],
38	.	.	O	.	_	0	SENT_187	[p13l16t922r192b1023],

1	S4	NN	O	s4	_	0	SENT_188	[p13l230t928r328b1001],
2	in	IN	O	in	_	0	SENT_188	[p13l357t922r441b999],
3	the	DT	O	the	det	6	SENT_188	[p13l471t921r602b1000],
4	Supplementary	NNP	O	Supplementary	nn	6	SENT_188	[p13l635t921r1273b1022],
5	Appendix	NNP	O	Appendix	nn	6	SENT_188	[p13l1295t921r1753b1022],
6	)	NN	O	)	prep_in	1	SENT_188	[p13l1295t921r1753b1022],
7	.	.	O	.	_	0	SENT_188	[p13l1295t921r1753b1022],

1	This	DT	O	this	det	2	SENT_189	[p13l1786t921r1971b1000],
2	difference	NN	O	difference	nsubj	9	SENT_189	[p13l2005t920r2145b1001, p13l11t1049r314b1129],
3	in	IN	O	in	_	0	SENT_189	[p13l350t1051r434b1128],
4	the	DT	O	the	det	6	SENT_189	[p13l472t1050r606b1129],
5	hazard	NN	O	hazard	nn	6	SENT_189	[p13l643t1050r942b1130],
6	ratio	NN	O	ratio	prep_in	2	SENT_189	[p13l978t1051r1177b1130],
7	is	VBZ	O	be	cop	9	SENT_189	[p13l1215t1051r1281b1129],
8	largely	RB	O	largely	advmod	9	SENT_189	[p13l1319t1050r1612b1152],
9	attributable	JJ	O	attributable	_	0	SENT_189	[p13l1644t1050r2147b1130],
10	to	TO	O	to	_	0	SENT_189	[p13l12t1196r93b1259],
11	an	DT	O	a	det	12	SENT_189	[p13l135t1205r239b1258],
12	imbalance	NN	O	imbalance	prep_to	9	SENT_189	[p13l280t1179r729b1259],
13	in	IN	O	in	_	0	SENT_189	[p13l770t1180r854b1257],
14	informative	JJ	O	informative	prep_in	12	SENT_189	[p13l894t1178r1399b1259],
15	censoring	VBG	O	censor	amod	14	SENT_189	[p13l1441t1180r1887b1281],
16	,	,	O	,	_	0	SENT_189	[p13l1441t1180r1887b1281],
17	most	JJS	O	most	dobj	26	SENT_189	[p13l1935t1196r2152b1259],
18	commonly	RB	O	commonly	advmod	17	SENT_189	[p13l12t1308r459b1408],
19	in	IN	O	in	_	0	SENT_189	[p13l480t1309r562b1386],
20	cases	NNS	O	case	prep_in	17	SENT_189	[p13l588t1334r803b1386],
21	in	IN	O	in	_	0	SENT_189	[p13l831t1309r912b1386],
22	which	WDT	O	which	prep_in	17	SENT_189	[p13l934t1308r1190b1387],
23	new	JJ	O	new	amod	24	SENT_189	[p13l1216t1334r1390b1387],
24	lesions	NNS	O	lesion	nsubjpass	34	SENT_189	[p13l1412t1308r1694b1387],
25	were	VBD	O	be	auxpass	26	SENT_189	[p13l1718t1334r1914b1387],
26	identiﬁed	VBN	O	identiﬁed	rcmod	14	SENT_189	[p13l1940t1308r2145b1387, p13l12t1435r233b1515],
27	at	IN	O	at	_	0	SENT_189	[p13l265t1453r345b1514],
28	the	DT	O	the	det	30	SENT_189	[p13l374t1436r508b1514],
29	study	NN	O	study	nn	30	SENT_189	[p13l544t1436r776b1536],
30	center	NN	O	center	prep_at	26	SENT_189	[p13l806t1453r1071b1514],
31	but	CC	O	but	_	0	SENT_189	[p13l1103t1436r1243b1516],
32	were	VBD	O	be	auxpass	34	SENT_189	[p13l1269t1462r1472b1516],
33	not	RB	O	not	neg	34	SENT_189	[p13l1506t1453r1650b1515],
34	considered	VBN	O	consider	rcmod	14	SENT_189	[p13l1680t1436r2147b1515],
35	to	TO	O	to	aux	36	SENT_189	[p13l12t1582r93b1645],
36	constitute	VB	O	constitute	xcomp	34	SENT_189	[p13l125t1566r555b1645],
37	definitive	JJ	O	definitive	amod	38	SENT_189	[p13l586t1564r995b1645],
38	progression	NN	O	progression	dobj	36	SENT_189	[p13l1023t1566r1538b1667],
39	on	IN	O	on	_	0	SENT_189	[p13l1568t1591r1675b1645],
40	central	JJ	O	central	amod	41	SENT_189	[p13l1705t1565r2003b1644],
41	review	NN	O	review	prep_on	36	SENT_189	[p13l2032t1591r2145b1644, p13l7t1695r215b1773],
42	.	.	O	.	_	0	SENT_189	[p13l2032t1591r2145b1644, p13l7t1695r215b1773],

1	Less	RBR	O	less	_	0	SENT_190	[p13l252t1702r434b1772],
2	censoring	VBG	O	censor	nsubj	3	SENT_190	[p13l470t1695r890b1795],
3	occurred	VBD	O	occur	dep	1	SENT_190	[p13l921t1694r1294b1773],
4	in	IN	O	in	_	0	SENT_190	[p13l1326t1695r1409b1772],
5	the	DT	O	the	det	8	SENT_190	[p13l1443t1694r1574b1772],
6	combination	NN	O	combination	nn	8	SENT_190	[p13l1609t1694r2148b1773],
7	150/2	CD	NUMBER	150/2	num	8	SENT_190	[p13l15t1828r243b1912],
8	group	NN	O	group	prep_in	3	SENT_190	[p13l272t1848r549b1924],
9	,	,	O	,	_	0	SENT_190	[p13l272t1848r549b1924],
10	in	IN	O	in	_	0	SENT_190	[p13l582t1823r666b1900],
11	part	NN	O	part	prep_in	3	SENT_190	[p13l694t1839r874b1923],
12	because	IN	O	because	_	0	SENT_190	[p13l898t1822r1237b1902],
13	of	IN	O	of	prepc_because_of	3	SENT_190	[p13l1266t1821r1366b1902],
14	additional	JJ	O	additional	amod	15	SENT_190	[p13l1376t1822r1816b1902],
15	followup	NN	O	followup	pobj	3	SENT_190	[p13l1844t1821r2146b1902, p13l11t1977r113b2051],
16	beyond	IN	O	beyond	_	0	SENT_190	[p13l151t1951r450b2051],
17	investigator	NN	O	investigator	prep_beyond	3	SENT_190	[p13l486t1951r1358b2052],
18	—	CD	NUMBER	—	num	17	SENT_190	[p13l486t1951r1358b2052],
19	assessed	VBN	O	assess	partmod	17	SENT_190	[p13l486t1951r1358b2052],
20	progression	NN	O	progression	dobj	19	SENT_190	[p13l1393t1952r1906b2052],
21	.	.	O	.	_	0	SENT_190	[p13l1393t1952r1906b2052],

1	Such	JJ	O	such	nsubj	7	SENT_191	[p13l1950t1951r2147b2030],
2	follow	VBP	O	follow	dep	1	SENT_191	[p13l11t2077r422b2178],
3	—	CD	NUMBER	—	dobj	2	SENT_191	[p13l11t2077r422b2178],
4	up	RP	O	up	prt	2	SENT_191	[p13l11t2077r422b2178],
5	did	VBD	O	do	aux	7	SENT_191	[p13l455t2078r590b2157],
6	not	RB	O	not	neg	7	SENT_191	[p13l621t2095r765b2157],
7	occur	VB	O	occur	_	0	SENT_191	[p13l792t2104r1032b2158],
8	for	IN	O	for	_	0	SENT_191	[p13l1060t2077r1184b2157],
9	patients	NNS	O	patient	prep_for	7	SENT_191	[p13l1210t2079r1555b2178],
10	who	WP	O	who	nsubj	11	SENT_191	[p13l1583t2078r1767b2158],
11	had	VBD	O	have	rcmod	9	SENT_191	[p13l1800t2078r1957b2157],
12	disease	NN	O	disease	nn	13	SENT_191	[p13l1989t2078r2145b2157, p13l12t2233r193b2286],
13	progression	NN	O	progression	dobj	11	SENT_191	[p13l247t2208r762b2308],
14	while	IN	O	while	_	0	SENT_191	[p13l813t2207r1050b2286],
15	receiving	VBG	O	receive	prepc_while	11	SENT_191	[p13l1106t2208r1499b2308],
16	monotherapy	NN	O	monotherapy	dobj	15	SENT_191	[p13l1551t2207r2141b2307],
17	.	.	O	.	_	0	SENT_191	[p13l1551t2207r2141b2307],

1	These	DT	O	these	det	2	SENT_192	[p13l7t2335r260b2413],
2	patients	NNS	O	patient	nsubjpass	14	SENT_192	[p13l302t2336r646b2435],
3	crossed	VBD	O	cross	_	0	SENT_192	[p13l692t2335r1016b2414],
4	over	IN	O	over	prt	3	SENT_192	[p13l1060t2361r1239b2414],
5	to	TO	O	to	aux	6	SENT_192	[p13l1279t2352r1361b2414],
6	receive	VB	O	receive	xcomp	3	SENT_192	[p13l1405t2336r1696b2414],
7	combination	NN	O	combination	nn	8	SENT_192	[p13l1740t2335r2145b2414, p13l12t2465r182b2544],
8	therapy	NN	O	therapy	dobj	6	SENT_192	[p13l213t2464r537b2565],
9	and	CC	O	and	_	0	SENT_192	[p13l563t2464r721b2544],
10	could	MD	O	could	aux	14	SENT_192	[p13l753t2464r989b2544],
11	no	RB	O	no	advmod	12	SENT_192	[p13l1020t2490r1126b2544],
12	longer	RB	O	longer	advmod	14	SENT_192	[p13l1157t2464r1434b2566],
13	be	VB	O	be	auxpass	14	SENT_192	[p13l1462t2464r1560b2544],
14	evaluated	VBN	O	evaluate	conj_and	3	SENT_192	[p13l1591t2464r1996b2544],
15	for	IN	O	for	_	0	SENT_192	[p13l2027t2463r2151b2544],
16	disease	NN	O	disease	nn	17	SENT_192	[p13l12t2593r324b2672],
17	progression	NN	O	progression	prep_for	14	SENT_192	[p13l373t2594r887b2694],
18	while	IN	O	while	_	0	SENT_192	[p13l934t2593r1170b2672],
19	receiving	VBG	O	receive	prepc_while	14	SENT_192	[p13l1221t2594r1614b2694],
20	their	PRP$	O	they	poss	23	SENT_192	[p13l1661t2593r1866b2671],
21	originally	RB	O	originally	advmod	22	SENT_192	[p13l1914t2594r2145b2694, p13l11t2721r223b2821],
22	assigned	VBN	O	assign	amod	23	SENT_192	[p13l252t2721r629b2822],
23	therapy	NN	O	therapy	dobj	19	SENT_192	[p13l664t2721r1000b2821],
24	.	.	O	.	_	0	SENT_192	[p13l664t2721r1000b2821],

1	At	IN	O	at	_	0	SENT_193	[p13l137t2856r237b2926],
2	1	CD	DURATION	1	prep_at	15	SENT_193	[p13l272t2854r316b2926],
3	year	NN	NUMBER	year	tmod	15	SENT_193	[p13l350t2874r549b2948],
4	,	,	O	,	_	0	SENT_193	[p13l350t2874r549b2948],
5	41	CD	PERCENT	41	num	6	SENT_193	[p13l590t2854r769b2927],
6	%	NN	PERCENT	%	nsubj	19	SENT_193	[p13l590t2854r769b2927],
7	of	IN	O	of	_	0	SENT_193	[p13l805t2847r906b2927],
8	patients	NNS	O	patient	prep_of	6	SENT_193	[p13l923t2849r1266b2948],
9	in	IN	O	in	_	0	SENT_193	[p13l1305t2849r1389b2926],
10	the	DT	O	the	det	13	SENT_193	[p13l1426t2848r1560b2926],
11	combination	NN	O	combination	nn	13	SENT_193	[p13l1597t2848r2148b2927],
12	150/2	CD	NUMBER	150/2	num	13	SENT_193	[p13l15t2982r243b3067],
13	group	NN	O	group	prep_in	8	SENT_193	[p13l289t3003r543b3079],
14	were	VBD	O	be	cop	15	SENT_193	[p13l585t3003r787b3057],
15	alive	JJ	O	alive	_	0	SENT_193	[p13l832t2977r1026b3057],
16	and	CC	O	and	_	0	SENT_193	[p13l1070t2977r1230b3057],
17	progression	NN	O	progression	npadvmod	19	SENT_193	[p13l1273t2976r2009b3079],
18	—	CD	NUMBER	—	num	17	SENT_193	[p13l1273t2976r2009b3079],
19	free	JJ	O	free	conj_and	15	SENT_193	[p13l1273t2976r2009b3079],
20	,	,	O	,	_	0	SENT_193	[p13l1273t2976r2009b3079],
21	as	IN	O	as	_	0	SENT_193	[p13l2059t3004r2144b3056],
22	compared	VBN	O	compare	prepc_as	15	SENT_193	[p13l12t3106r438b3206],
23	with	IN	O	with	pcomp	22	SENT_193	[p13l489t3106r684b3185],
24	9	CD	PERCENT	9	num	25	SENT_193	[p13l739t3111r874b3185],
25	%	NN	PERCENT	%	pobj	23	SENT_193	[p13l739t3111r874b3185],
26	in	IN	O	in	_	0	SENT_193	[p13l928t3107r1012b3184],
27	the	DT	O	the	det	29	SENT_193	[p13l1067t3106r1199b3184],
28	monotherapy	NN	O	monotherapy	nn	29	SENT_193	[p13l1255t3106r1829b3206],
29	group	NN	O	group	prep_in	25	SENT_193	[p13l1880t3132r2132b3207],
30	(	CD	NUMBER	(	num	31	SENT_193	[p13l16t3240r434b3325],
31	P	NN	O	p	npadvmod	32	SENT_193	[p13l16t3240r434b3325],
32	<	JJR	O	<	amod	29	SENT_193	[p13l16t3240r434b3325],
33	0.001	CD	NUMBER	0.001	num	34	SENT_193	[p13l16t3240r434b3325],
34	)	NN	O	)	dep	25	SENT_193	[p13l16t3240r434b3325],
35	.	.	O	.	_	0	SENT_193	[p13l16t3240r434b3325],

1	Progression	NN	O	progression	npadvmod	3	SENT_194	[p13l487t3233r1194b3335],
2	—	CD	NUMBER	—	num	1	SENT_194	[p13l487t3233r1194b3335],
3	free	JJ	O	free	amod	4	SENT_194	[p13l487t3233r1194b3335],
4	survival	NN	O	survival	nsubjpass	7	SENT_194	[p13l1244t3234r1576b3313],
5	was	VBD	O	be	auxpass	7	SENT_194	[p13l1619t3260r1782b3313],
6	consistently	RB	O	consistently	advmod	7	SENT_194	[p13l1832t3235r2132b3313, p13l12t3362r254b3462],
7	improved	VBN	O	improve	_	0	SENT_194	[p13l298t3362r702b3462],
8	in	IN	O	in	_	0	SENT_194	[p13l752t3363r835b3440],
9	all	DT	O	all	det	11	SENT_194	[p13l884t3362r989b3440],
10	prognostic	JJ	O	prognostic	amod	11	SENT_194	[p13l1037t3363r1502b3463],
11	subgroups	NNS	O	subgroup	prep_in	7	SENT_194	[p13l1552t3362r1999b3463],
12	of	IN	O	of	_	0	SENT_194	[p13l2052t3361r2152b3441],
13	the	DT	O	the	det	16	SENT_194	[p13l12t3490r144b3569],
14	combination	NN	O	combination	nn	16	SENT_194	[p13l183t3490r729b3569],
15	150/2	CD	NUMBER	150/2	num	16	SENT_194	[p13l770t3495r997b3580],
16	group	NN	O	group	prep_of	11	SENT_194	[p13l1035t3516r1310b3591],
17	,	,	O	,	_	0	SENT_194	[p13l1035t3516r1310b3591],
18	as	IN	O	as	_	0	SENT_194	[p13l1352t3516r1438b3568],
19	compared	VBN	O	compare	prepc_as	7	SENT_194	[p13l1479t3490r1905b3590],
20	with	IN	O	with	pcomp	19	SENT_194	[p13l1938t3490r2133b3569],
21	monotherapy	NN	O	monotherapy	nn	23	SENT_194	[p13l11t3618r585b3718],
22	(	CD	NUMBER	(	num	23	SENT_194	[p13l645t3619r825b3719],
23	Fig	NN	O	fig	pobj	20	SENT_194	[p13l645t3619r825b3719],
24	.	.	O	.	_	0	SENT_194	[p13l645t3619r825b3719],

1	1B	NN	O	1b	_	0	SENT_195	[p13l894t3624r1051b3709],
2	)	NN	O	)	dep	1	SENT_195	[p13l894t3624r1051b3709],
3	.	.	O	.	_	0	SENT_195	[p13l894t3624r1051b3709],

1	Notably	RB	O	notably	advmod	17	SENT_196	[p13l1115t3618r1467b3718],
2	,	,	O	,	_	0	SENT_196	[p13l1115t3618r1467b3718],
3	both	DT	O	both	det	4	SENT_196	[p13l1534t3618r1731b3697],
4	patients	NNS	O	patient	nsubj	17	SENT_196	[p13l1790t3619r2131b3718],
5	with	IN	O	with	_	0	SENT_196	[p14l7t20r202b99],
6	the	DT	O	the	det	9	SENT_196	[p14l247t20r380b98],
7	BRAF	NN	O	braf	nn	9	SENT_196	[p14l423t26r667b103],
8	V600E	NN	O	v600e	nn	9	SENT_196	[p14l710t26r980b99],
9	mutation	NN	O	mutation	prep_with	4	SENT_196	[p14l1027t21r1419b99],
10	and	CC	O	and	_	0	SENT_196	[p14l1463t20r1621b99],
11	those	DT	O	those	nsubj	17	SENT_196	[p14l1667t20r1898b99],
12	with	IN	O	with	_	0	SENT_196	[p14l1939t20r2134b99],
13	the	DT	O	the	det	16	SENT_196	[p14l12t148r144b227],
14	BRAF	NN	O	braf	nn	16	SENT_196	[p14l194t155r438b231],
15	V600K	NN	O	v600k	nn	16	SENT_196	[p14l487t154r772b229],
16	mutation	NN	O	mutation	prep_with	11	SENT_196	[p14l821t149r1213b227],
17	had	VBD	O	have	_	0	SENT_196	[p14l1264t148r1421b227],
18	significant	JJ	O	significant	amod	19	SENT_196	[p14l1473t147r1942b249],
19	improvement	NN	O	improvement	dobj	17	SENT_196	[p14l1987t149r2132b226, p14l9t293r469b376],
20	in	IN	O	in	_	0	SENT_196	[p14l502t277r585b354],
21	progression	NN	O	progression	npadvmod	23	SENT_196	[p14l623t275r1332b377],
22	—	CD	NUMBER	—	num	21	SENT_196	[p14l623t275r1332b377],
23	free	JJ	O	free	amod	24	SENT_196	[p14l623t275r1332b377],
24	survival	NN	O	survival	prep_in	19	SENT_196	[p14l1373t276r1727b355],
25	.	.	O	.	_	0	SENT_196	[p14l1373t276r1727b355],

1	An	DT	O	a	det	2	SENT_197	[p14l136t411r260b481],
2	improvement	NN	O	improvement	nsubjpass	10	SENT_197	[p14l323t404r896b503],
3	in	IN	O	in	_	0	SENT_197	[p14l954t404r1037b481],
4	the	DT	O	the	det	8	SENT_197	[p14l1101t403r1233b481],
5	other	JJ	O	other	amod	8	SENT_197	[p14l1297t403r1524b482],
6	efficacy	NN	O	efficacy	nn	8	SENT_197	[p14l1586t402r1921b503],
7	end	NN	O	end	nn	8	SENT_197	[p14l1981t403r2134b482],
8	points	NNS	O	point	prep_in	2	SENT_197	[p14l9t533r279b631],
9	was	VBD	O	be	auxpass	10	SENT_197	[p14l329t558r492b611],
10	observed	VBN	O	observe	dep	58	SENT_197	[p14l547t532r928b611],
11	in	IN	O	in	_	0	SENT_197	[p14l980t533r1064b609],
12	the	DT	O	the	det	15	SENT_197	[p14l1117t532r1249b610],
13	combination	NN	O	combination	nn	15	SENT_197	[p14l1303t532r1849b610],
14	150/2	CD	NUMBER	150/2	num	15	SENT_197	[p14l1905t537r2133b621],
15	group	NN	O	group	prep_in	10	SENT_197	[p14l11t686r280b761],
16	,	,	O	,	_	0	SENT_197	[p14l11t686r280b761],
17	as	IN	O	as	_	0	SENT_197	[p14l316t686r401b738],
18	compared	VBN	O	compare	prepc_as	10	SENT_197	[p14l435t660r854b760],
19	with	IN	O	with	pcomp	18	SENT_197	[p14l881t660r1074b739],
20	the	DT	O	the	det	22	SENT_197	[p14l1106t660r1235b738],
21	monotherapy	JJ	O	monotherapy	amod	22	SENT_197	[p14l1267t660r1831b760],
22	group	NN	O	group	pobj	19	SENT_197	[p14l1858t686r2129b761],
23	:	:	O	:	_	0	SENT_197	[p14l1858t686r2129b761],
24	76	CD	PERCENT	76	num	25	SENT_197	[p14l12t792r190b867],
25	%	NN	PERCENT	%	nn	41	SENT_197	[p14l12t792r190b867],
26	versus	CC	O	versus	prep	25	SENT_197	[p14l225t813r491b867],
27	54	CD	PERCENT	54	num	28	SENT_197	[p14l534t793r717b866],
28	%	NN	PERCENT	%	dep	26	SENT_197	[p14l534t793r717b866],
29	for	IN	O	for	_	0	SENT_197	[p14l756t786r879b866],
30	the	DT	O	the	det	31	SENT_197	[p14l915t787r1048b865],
31	rate	NN	O	rate	prep_for	28	SENT_197	[p14l1088t804r1248b865],
32	of	IN	O	of	_	0	SENT_197	[p14l1288t786r1387b866],
33	complete	JJ	O	complete	amod	38	SENT_197	[p14l1409t787r1797b887],
34	or	CC	O	or	_	0	SENT_197	[p14l1837t813r1926b866],
35	partial	JJ	O	partial	conj_or	33	SENT_197	[p14l1961t813r2132b887, p14l12t916r147b993],
36	response	NN	O	response	nn	38	SENT_197	[p14l181t942r554b1015],
37	(	CD	NUMBER	(	num	38	SENT_197	[p14l593t922r976b1011],
38	P	NN	O	p	prep_of	31	SENT_197	[p14l593t922r976b1011],
39	=	JJ	O	=	amod	41	SENT_197	[p14l593t922r976b1011],
40	0.03	CD	NUMBER	0.03	tmod	39	SENT_197	[p14l593t922r976b1011],
41	)	NN	O	)	dobj	10	SENT_197	[p14l593t922r976b1011],
42	,	,	O	,	_	0	SENT_197	[p14l593t922r976b1011],
43	and	CC	O	and	_	0	SENT_197	[p14l1014t916r1170b994],
44	10.5	CD	DURATION	10.5	num	45	SENT_197	[p14l1208t922r1373b994],
45	months	NNS	NUMBER	month	nsubj	46	SENT_197	[p14l1410t916r1732b994],
46	(	VBP	O	(	conj_and	10	SENT_197	[p14l1773t921r1981b1006],
47	95	CD	PERCENT	95	number	48	SENT_197	[p14l1773t921r1981b1006],
48	%	NN	PERCENT	%	amod	49	SENT_197	[p14l1773t921r1981b1006],
49	CI	NN	O	ci	dobj	46	SENT_197	[p14l2014t922r2128b1011],
50	,	,	O	,	_	0	SENT_197	[p14l2014t922r2128b1011],
51	7.4	CD	NUMBER	7.4	number	54	SENT_197	[p14l12t1049r124b1121],
52	to	TO	O	to	dep	54	SENT_197	[p14l159t1060r239b1121],
53	14.9	CD	NUMBER	14.9	number	54	SENT_197	[p14l278t1049r468b1133],
54	)	CD	NUMBER	)	appos	49	SENT_197	[p14l278t1049r468b1133],
55	versus	CC	O	versus	prep	54	SENT_197	[p14l503t1069r764b1122],
56	5.6	CD	DURATION	5.6	num	57	SENT_197	[p14l803t1049r923b1121],
57	months	NNS	NUMBER	month	dep	55	SENT_197	[p14l959t1043r1280b1121],
58	(	VBP	O	(	_	0	SENT_197	[p14l1321t1048r1529b1133],
59	95	CD	PERCENT	95	num	60	SENT_197	[p14l1321t1048r1529b1133],
60	%	NN	PERCENT	%	dobj	58	SENT_197	[p14l1321t1048r1529b1133],
61	CI	NN	O	ci	nsubj	58	SENT_197	[p14l1562t1049r1675b1138],
62	,	,	O	,	_	0	SENT_197	[p14l1562t1049r1675b1138],
63	4.5	CD	NUMBER	4.5	number	66	SENT_197	[p14l1713t1049r1835b1121],
64	to	TO	O	to	dep	66	SENT_197	[p14l1873t1059r1954b1121],
65	7.4	CD	NUMBER	7.4	number	66	SENT_197	[p14l1991t1049r2128b1133],
66	)	CD	NUMBER	)	appos	61	SENT_197	[p14l1991t1049r2128b1133],
67	for	IN	O	for	_	0	SENT_197	[p14l11t1169r130b1249],
68	the	DT	O	the	det	70	SENT_197	[p14l160t1170r288b1248],
69	median	JJ	O	median	amod	70	SENT_197	[p14l322t1170r634b1249],
70	duration	NN	O	duration	prep_for	66	SENT_197	[p14l667t1170r1018b1250],
71	of	IN	O	of	_	0	SENT_197	[p14l1052t1169r1149b1249],
72	response	NN	O	response	prep_of	70	SENT_197	[p14l1164t1196r1550b1270],
73	.	.	O	.	_	0	SENT_197	[p14l1164t1196r1550b1270],

1	Median	JJ	O	median	amod	3	SENT_198	[p14l1586t1170r1900b1249],
2	overall	JJ	O	overall	amod	3	SENT_198	[p14l1934t1196r2132b1250, p14l11t1299r115b1377],
3	survival	NN	O	survival	nsubjpass	6	SENT_198	[p14l162t1299r493b1378],
4	was	VBD	O	be	auxpass	6	SENT_198	[p14l534t1325r697b1378],
5	not	RB	O	not	neg	6	SENT_198	[p14l745t1316r888b1378],
6	reached	VBN	O	reach	_	0	SENT_198	[p14l928t1299r1261b1378],
7	at	IN	O	at	_	0	SENT_198	[p14l1306t1316r1384b1377],
8	the	DT	O	the	det	9	SENT_198	[p14l1426t1299r1558b1378],
9	time	NN	O	time	prep_at	6	SENT_198	[p14l1605t1300r1797b1377],
10	of	IN	O	of	_	0	SENT_198	[p14l1844t1298r1944b1378],
11	this	DT	O	this	det	12	SENT_198	[p14l1972t1299r2131b1377],
12	analysis	NN	O	analysis	prep_of	9	SENT_198	[p14l11t1427r358b1527],
13	.	.	O	.	_	0	SENT_198	[p14l11t1427r358b1527],

1	The	DT	O	the	det	2	SENT_199	[p14l390t1427r546b1505],
2	percentage	NN	O	percentage	nsubj	13	SENT_199	[p14l575t1444r1025b1528],
3	of	IN	O	of	_	0	SENT_199	[p14l1056t1426r1154b1506],
4	patients	NNS	O	patient	prep_of	2	SENT_199	[p14l1164t1428r1490b1527],
5	who	WP	O	who	nsubj	7	SENT_199	[p14l1518t1427r1697b1506],
6	were	VBD	O	be	cop	7	SENT_199	[p14l1724t1453r1919b1506],
7	alive	JJ	O	alive	rcmod	4	SENT_199	[p14l1949t1427r2133b1506],
8	at	IN	O	at	_	0	SENT_199	[p14l11t1572r90b1633],
9	12	CD	DURATION	12	num	10	SENT_199	[p14l122t1561r220b1632],
10	months	NNS	NUMBER	month	prep_at	7	SENT_199	[p14l256t1555r583b1634],
11	was	VBD	O	be	cop	13	SENT_199	[p14l615t1581r777b1634],
12	79	CD	PERCENT	79	num	13	SENT_199	[p14l816t1560r1001b1634],
13	%	NN	PERCENT	%	_	0	SENT_199	[p14l816t1560r1001b1634],
14	in	IN	O	in	_	0	SENT_199	[p14l1035t1556r1118b1632],
15	the	DT	O	the	det	18	SENT_199	[p14l1153t1555r1285b1633],
16	combination	NN	O	combination	nn	18	SENT_199	[p14l1321t1555r1868b1634],
17	150/2	CD	NUMBER	150/2	num	18	SENT_199	[p14l1906t1560r2133b1644],
18	group	NN	O	group	prep_in	13	SENT_199	[p14l11t1709r263b1784],
19	and	CC	O	and	_	0	SENT_199	[p14l302t1683r460b1762],
20	70	CD	PERCENT	70	num	21	SENT_199	[p14l501t1688r684b1762],
21	%	NN	PERCENT	%	prep_in	13	SENT_199	[p14l501t1688r684b1762],
22	in	IN	O	in	_	0	SENT_199	[p14l722t1684r806b1761],
23	the	DT	O	the	det	25	SENT_199	[p14l845t1683r977b1761],
24	monotherapy	JJ	O	monotherapy	amod	25	SENT_199	[p14l1017t1683r1591b1783],
25	group	NN	O	group	prep_in	13	SENT_199	[p14l1624t1709r1899b1784],
26	,	,	O	,	_	0	SENT_199	[p14l1624t1709r1899b1784],
27	even	RB	O	even	advmod	37	SENT_199	[p14l1944t1709r2133b1762],
28	though	IN	O	though	dep	37	SENT_199	[p14l12t1811r309b1912],
29	80	CD	PERCENT	80	num	30	SENT_199	[p14l343t1817r526b1890],
30	%	NN	PERCENT	%	nsubj	37	SENT_199	[p14l343t1817r526b1890],
31	of	IN	O	of	_	0	SENT_199	[p14l559t1810r657b1890],
32	patients	NNS	O	patient	prep_of	30	SENT_199	[p14l671t1812r997b1911],
33	in	IN	O	in	_	0	SENT_199	[p14l1031t1812r1113b1889],
34	the	DT	O	the	det	36	SENT_199	[p14l1146t1811r1274b1890],
35	monotherapy	NN	O	monotherapy	nn	36	SENT_199	[p14l1308t1811r1861b1911],
36	group	NN	O	group	prep_in	32	SENT_199	[p14l1889t1837r2133b1912],
37	crossed	VBD	O	cross	dep	13	SENT_199	[p14l12t1939r321b2018],
38	over	IN	O	over	prep	37	SENT_199	[p14l352t1965r523b2018],
39	to	TO	O	to	pcomp	38	SENT_199	[p14l551t1956r630b2018],
40	the	DT	O	the	det	43	SENT_199	[p14l662t1939r790b2017],
41	combination	NN	O	combination	nn	43	SENT_199	[p14l821t1939r1346b2018],
42	150/2	CD	NUMBER	150/2	num	43	SENT_199	[p14l1379t1944r1597b2029],
43	group	NN	O	group	pobj	39	SENT_199	[p14l1628t1965r1872b2040],
44	at	IN	O	at	_	0	SENT_199	[p14l1903t1956r1979b2017],
45	the	DT	O	the	det	46	SENT_199	[p14l2005t1939r2133b2017],
46	time	NN	O	time	prep_at	37	SENT_199	[p14l12t2068r201b2146],
47	of	IN	O	of	_	0	SENT_199	[p14l232t2066r331b2146],
48	disease	NN	O	disease	nn	49	SENT_199	[p14l343t2067r647b2146],
49	progression	NN	O	progression	prep_of	46	SENT_199	[p14l675t2068r1176b2168],
50	(	CD	NUMBER	(	num	51	SENT_199	[p14l1210t2068r1386b2168],
51	Fig	NN	O	fig	dep	37	SENT_199	[p14l1210t2068r1386b2168],
52	.	.	O	.	_	0	SENT_199	[p14l1210t2068r1386b2168],

1	S3	NN	O	s3	_	0	SENT_200	[p14l1423t2073r1515b2146],
2	in	IN	O	in	_	0	SENT_200	[p14l1547t2068r1630b2145],
3	the	DT	O	the	det	6	SENT_200	[p14l1660t2067r1790b2146],
4	Supplementary	NNP	O	Supplementary	nn	6	SENT_200	[p14l1823t2067r2132b2167, p14l11t2212r364b2294],
5	Appendix	NNP	O	Appendix	nn	6	SENT_200	[p14l395t2195r861b2294],
6	)	NN	O	)	prep_in	1	SENT_200	[p14l395t2195r861b2294],
7	.	.	O	.	_	0	SENT_200	[p14l395t2195r861b2294],

1	Part	NN	O	part	nn	2	SENT_201	[p14l16t2461r177b2531],
2	B	NN	O	b	npadvmod	28	SENT_201	[p14l216t2461r265b2530],
3	For	IN	O	for	_	0	SENT_201	[p14l9t2587r152b2658],
4	all	DT	O	all	det	5	SENT_201	[p14l183t2580r287b2658],
5	patients	NNS	O	patient	prep_for	28	SENT_201	[p14l320t2581r662b2679],
6	with	IN	O	with	_	0	SENT_201	[p14l694t2580r889b2659],
7	a	DT	O	a	det	10	SENT_201	[p14l924t2606r968b2657],
8	BRAF	NN	MISC	braf	nn	10	SENT_201	[p14l1000t2586r1243b2663],
9	V600	NN	MISC	v600	nn	10	SENT_201	[p14l1276t2586r1491b2658],
10	mutation	NN	O	mutation	prep_with	5	SENT_201	[p14l1526t2581r1919b2659],
11	who	WP	O	who	nsubj	12	SENT_201	[p14l1949t2580r2132b2659],
12	participated	VBD	O	participate	rcmod	10	SENT_201	[p14l9t2707r515b2807],
13	in	IN	O	in	_	0	SENT_201	[p14l545t2708r627b2785],
14	the	DT	O	the	det	18	SENT_201	[p14l659t2707r789b2785],
15	dose	NN	O	dose	nn	18	SENT_201	[p14l821t2707r1476b2786],
16	—	NN	O	—	nn	18	SENT_201	[p14l821t2707r1476b2786],
17	escalation	NN	O	escalation	nn	18	SENT_201	[p14l821t2707r1476b2786],
18	phase	NN	O	phase	prep_in	12	SENT_201	[p14l1505t2707r1772b2807],
19	,	,	O	,	_	0	SENT_201	[p14l1505t2707r1772b2807],
20	efficacy	NN	O	efficacy	nn	22	SENT_201	[p14l1809t2706r2138b2807],
21	end	NN	O	end	nn	22	SENT_201	[p14l12t2836r165b2915],
22	points	NNS	O	point	nsubjpass	28	SENT_201	[p14l198t2837r467b2936],
23	according	VBG	O	accord	_	0	SENT_201	[p14l503t2836r930b2937],
24	to	TO	O	to	prepc_according_to	22	SENT_201	[p14l962t2853r1043b2915],
25	dose	NN	O	dose	nn	26	SENT_201	[p14l1080t2836r1274b2915],
26	cohort	NN	O	cohort	pobj	22	SENT_201	[p14l1310t2836r1591b2915],
27	are	VBP	O	be	auxpass	28	SENT_201	[p14l1620t2862r1749b2914],
28	listed	VBN	O	list	_	0	SENT_201	[p14l1783t2836r2017b2915],
29	in	IN	O	in	_	0	SENT_201	[p14l2050t2837r2133b2914],
30	Table	NNP	O	Table	nn	31	SENT_201	[p14l7t2964r237b3043],
31	S4	NNP	O	S4	prep_in	28	SENT_201	[p14l270t2970r368b3043],
32	in	IN	O	in	_	0	SENT_201	[p14l398t2965r482b3042],
33	the	DT	O	the	det	35	SENT_201	[p14l512t2964r644b3042],
34	Supplementary	NNP	O	Supplementary	nn	35	SENT_201	[p14l678t2964r1324b3064],
35	Appendix	NNP	O	Appendix	prep_in	31	SENT_201	[p14l1346t2964r1784b3064],
36	.	.	O	.	_	0	SENT_201	[p14l1346t2964r1784b3064],

1	Among	IN	O	among	_	0	SENT_202	[p14l1816t2972r2137b3065],
2	the	DT	O	the	det	3	SENT_202	[p14l12t3092r142b3170],
3	patients	NNS	O	patient	prep_among	19	SENT_202	[p14l172t3093r506b3191],
4	in	IN	O	in	_	0	SENT_202	[p14l540t3093r622b3169],
5	part	NN	O	part	nn	6	SENT_202	[p14l652t3109r829b3191],
6	B	NN	O	b	prep_in	3	SENT_202	[p14l853t3098r909b3170],
7	Who	WP	O	who	nsubjpass	9	SENT_202	[p14l939t3092r1119b3171],
8	were	VBD	O	be	auxpass	9	SENT_202	[p14l1148t3118r1346b3171],
9	treated	VBN	O	treat	rcmod	3	SENT_202	[p14l1379t3092r1671b3170],
10	with	IN	O	with	_	0	SENT_202	[p14l1698t3092r1890b3171],
11	combination	NN	O	combination	prep_with	9	SENT_202	[p14l1922t3118r2132b3170, p14l12t3219r356b3298],
12	150/2	CD	NUMBER	150/2	num	11	SENT_202	[p14l386t3225r626b3315],
13	,	,	O	,	_	0	SENT_202	[p14l386t3225r626b3315],
14	the	DT	O	the	det	16	SENT_202	[p14l658t3219r786b3297],
15	response	NN	O	response	nn	16	SENT_202	[p14l813t3245r1178b3319],
16	rate	NN	O	rate	nsubj	19	SENT_202	[p14l1205t3236r1359b3297],
17	was	VBD	O	be	cop	19	SENT_202	[p14l1381t3245r1538b3299],
18	63	CD	PERCENT	63	num	19	SENT_202	[p14l1568t3225r1768b3315],
19	%	NN	PERCENT	%	_	0	SENT_202	[p14l1568t3225r1768b3315],
20	,	,	O	,	_	0	SENT_202	[p14l1568t3225r1768b3315],
21	and	CC	O	and	_	0	SENT_202	[p14l1799t3219r1952b3298],
22	2	CD	TIME	2	nsubj	26	SENT_202	[p14l1979t3225r2026b3297],
23	of	IN	TIME	of	_	0	SENT_202	[p14l2054t3218r2152b3298],
24	15	CD	TIME	15	num	25	SENT_202	[p14l15t3354r109b3427],
25	responses	NNS	O	response	prep_of	22	SENT_202	[p14l155t3374r578b3448],
26	(	VBP	O	(	conj_and	19	SENT_202	[p14l628t3353r863b3439],
27	13	CD	PERCENT	13	num	28	SENT_202	[p14l628t3353r863b3439],
28	%	NN	PERCENT	%	dobj	26	SENT_202	[p14l628t3353r863b3439],
29	)	CD	NUMBER	)	nsubj	33	SENT_202	[p14l628t3353r863b3439],
30	were	VBD	O	be	cop	33	SENT_202	[p14l907t3374r1109b3427],
31	complete	JJ	O	complete	amod	33	SENT_202	[p14l1152t3348r1541b3448],
32	radiographic	JJ	O	radiographic	amod	33	SENT_202	[p14l1584t3348r2134b3449],
33	responses	NNS	O	response	rcmod	28	SENT_202	[p14l11t3501r459b3575],
34	.	.	O	.	_	0	SENT_202	[p14l11t3501r459b3575],

1	The	DT	O	the	det	3	SENT_203	[p14l494t3475r655b3553],
2	median	JJ	O	median	amod	3	SENT_203	[p14l688t3475r1011b3554],
3	duration	NN	O	duration	nsubj	8	SENT_203	[p14l1045t3475r1410b3555],
4	of	IN	O	of	_	0	SENT_203	[p14l1444t3474r1545b3554],
5	response	NN	O	response	prep_of	3	SENT_203	[p14l1559t3501r1939b3575],
6	was	VBD	O	be	cop	8	SENT_203	[p14l1969t3501r2130b3555],
7	11.3	CD	DURATION	11.3	number	8	SENT_203	[p14l15t3610r186b3683],
8	months	NNS	NUMBER	month	_	0	SENT_203	[p14l243t3604r594b3700],
9	,	,	O	,	_	0	SENT_203	[p14l243t3604r594b3700],
10	and	CC	O	and	_	0	SENT_203	[p14l653t3604r810b3683],
11	the	DT	O	the	det	16	SENT_203	[p14l864t3604r996b3682],
12	median	JJ	O	median	amod	16	SENT_203	[p14l1049t3604r1373b3683],
13	progression	NN	O	progression	nn	16	SENT_203	[p14l1424t3603r2133b3705],
14	—	CD	NUMBER	—	num	16	SENT_203	[p14l1424t3603r2133b3705],
15	free	JJ	O	free	amod	16	SENT_203	[p14l1424t3603r2133b3705],
16	survival	NN	O	survival	nsubj	19	SENT_203	[p14l12t3733r344b3812],
17	was	VBD	O	be	cop	19	SENT_203	[p14l374t3759r536b3812],
18	10.8	CD	DURATION	10.8	number	19	SENT_203	[p14l577t3739r749b3812],
19	months	NNS	NUMBER	month	conj_and	8	SENT_203	[p14l785t3733r1137b3812],
20	.	.	O	.	_	0	SENT_203	[p14l785t3733r1137b3812],

1	DISCUSSION	NN	O	discussion	_	0	SENT_204	[p15l733t213r1411b272],

1	BRAF-targeted	JJ	O	braf-targeted	dep	110	SENT_205	[p15l9t430r647b531],
2	therapy	NN	O	therapy	dep	110	SENT_205	[p15l683t430r1004b530],
3	has	VBZ	O	have	dep	110	SENT_205	[p15l1034t430r1178b508],
4	been	VBN	O	be	dep	110	SENT_205	[p15l1216t430r1417b509],
5	established	VBN	O	establish	dep	110	SENT_205	[p15l1453t430r1935b509],
6	as	IN	O	as	dep	110	SENT_205	[p15l1969t456r2054b508],
7	a	DT	O	a	dep	110	SENT_205	[p15l2090t456r2135b508],
8	treatment	NN	O	treatment	dep	110	SENT_205	[p15l12t574r435b635],
9	standard	NN	O	standard	dep	110	SENT_205	[p15l473t557r852b636],
10	for	IN	O	for	dep	110	SENT_205	[p15l893t556r1016b636],
11	patients	NNS	O	patient	dep	110	SENT_205	[p15l1053t558r1394b657],
12	who	WP	O	who	dep	110	SENT_205	[p15l1432t557r1616b637],
13	have	VBP	O	have	dep	110	SENT_205	[p15l1658t557r1848b636],
14	metastatic	JJ	O	metastatic	dep	110	SENT_205	[p15l1889t574r2132b635, p15l12t687r235b764],
15	melanoma	NN	O	melanoma	dep	110	SENT_205	[p15l266t686r715b765],
16	with	IN	O	with	dep	110	SENT_205	[p15l742t686r934b765],
17	activating	VBG	O	activate	dep	110	SENT_205	[p15l965t687r1377b787],
18	BRAF	NN	O	braf	dep	110	SENT_205	[p15l1405t692r1645b769],
19	mutations	NNS	O	mutation	dep	110	SENT_205	[p15l1679t687r2128b782],
20	,	,	O	,	_	0	SENT_205	[p15l1679t687r2128b782],
21	on	IN	O	on	dep	110	SENT_205	[p15l12t839r117b892],
22	the	DT	O	the	dep	110	SENT_205	[p15l151t813r282b891],
23	basis	NN	O	basis	dep	110	SENT_205	[p15l316t813r523b892],
24	of	IN	O	of	dep	110	SENT_205	[p15l560t812r659b892],
25	improvement	NN	O	improvement	dep	110	SENT_205	[p15l674t814r1237b913],
26	in	IN	O	in	dep	110	SENT_205	[p15l1265t814r1347b891],
27	the	DT	O	the	dep	110	SENT_205	[p15l1382t813r1512b891],
28	rate	NN	O	rate	dep	110	SENT_205	[p15l1547t830r1703b891],
29	of	IN	O	of	dep	110	SENT_205	[p15l1738t812r1837b892],
30	survival	NN	O	survival	dep	110	SENT_205	[p15l1854t814r2132b893, p15l11t942r105b1037],
31	,	,	O	,	_	0	SENT_205	[p15l1854t814r2132b893, p15l11t942r105b1037],
32	as	IN	O	as	dep	110	SENT_205	[p15l137t968r222b1020],
33	compared	VBN	O	compare	dep	110	SENT_205	[p15l252t942r670b1041],
34	with	IN	O	with	dep	110	SENT_205	[p15l693t942r886b1021],
35	conventional	JJ	O	conventional	dep	110	SENT_205	[p15l914t942r1453b1021],
36	chemotherapy	NN	O	chemotherapy	dep	110	SENT_205	[p15l1481t942r2134b1041],
37	.4	CD	NUMBER	.4	dep	110	SENT_205	[p15l1481t942r2134b1041],
38	However	RB	O	however	dep	110	SENT_205	[p15l11t1077r405b1165],
39	,	,	O	,	_	0	SENT_205	[p15l11t1077r405b1165],
40	clinical	JJ	O	clinical	dep	110	SENT_205	[p15l451t1069r764b1147],
41	evidence	NN	O	evidence	dep	110	SENT_205	[p15l804t1069r1169b1148],
42	of	IN	O	of	dep	110	SENT_205	[p15l1210t1068r1310b1148],
43	resistance	NN	O	resistance	dep	110	SENT_205	[p15l1331t1070r1760b1147],
44	appears	VBZ	O	appear	dep	110	SENT_205	[p15l1799t1095r2131b1169],
45	on	IN	O	on	dep	110	SENT_205	[p15l12t1224r118b1277],
46	average	JJ	O	average	dep	110	SENT_205	[p15l159t1224r477b1299],
47	6	CD	DURATION	6	dep	110	SENT_205	[p15l519t1204r566b1277],
48	to	TO	DURATION	to	dep	110	SENT_205	[p15l609t1215r691b1277],
49	7	CD	DURATION	7	dep	110	SENT_205	[p15l735t1206r781b1277],
50	months	NNS	NUMBER	month	dep	110	SENT_205	[p15l824t1198r1151b1277],
51	after	IN	O	after	dep	110	SENT_205	[p15l1195t1197r1396b1276],
52	the	DT	O	the	dep	110	SENT_205	[p15l1436t1198r1569b1277],
53	initiation	NN	O	initiation	dep	110	SENT_205	[p15l1610t1199r2009b1277],
54	of	IN	O	of	dep	110	SENT_205	[p15l2052t1197r2152b1277],
55	therapy	NN	O	therapy	dep	110	SENT_205	[p15l12t1325r495b1425],
56	.2	NN	NUMBER	.2	dep	110	SENT_205	[p15l12t1325r495b1425],
57	'	''	O	'	_	0	SENT_205	[p15l12t1325r495b1425],
58	4	CD	NUMBER	4	dep	110	SENT_205	[p15l12t1325r495b1425],
59	’	CD	NUMBER	’	dep	110	SENT_205	[p15l12t1325r495b1425],
60	6	CD	NUMBER	6	dep	110	SENT_205	[p15l12t1325r495b1425],
61	Several	JJ	O	several	dep	110	SENT_205	[p15l534t1325r826b1404],
62	mechanisms	NNS	O	mechanism	dep	110	SENT_205	[p15l862t1325r1395b1403],
63	of	IN	O	of	dep	110	SENT_205	[p15l1435t1324r1533b1404],
64	MAPK	NN	O	mapk	dep	110	SENT_205	[p15l1549t1325r2132b1425],
65	—	CD	NUMBER	—	dep	110	SENT_205	[p15l1549t1325r2132b1425],
66	depen	NN	O	depen	dep	110	SENT_205	[p15l1549t1325r2132b1425],
67	—	NN	O	—	dep	110	SENT_205	[p15l1549t1325r2132b1425],
68	dent	NN	O	dent	dep	110	SENT_205	[p15l12t1454r197b1533],
69	resistance	NN	O	resistance	dep	110	SENT_205	[p15l225t1455r653b1532],
70	to	TO	O	to	dep	110	SENT_205	[p15l688t1471r770b1533],
71	BRAF	NN	O	braf	dep	110	SENT_205	[p15l804t1460r1048b1538],
72	inhibitors	NNS	O	inhibitor	dep	110	SENT_205	[p15l1083t1454r1505b1533],
73	have	VBP	O	have	dep	110	SENT_205	[p15l1541t1454r1731b1533],
74	been	VBN	O	be	dep	110	SENT_205	[p15l1766t1454r1968b1533],
75	described	VBN	O	describe	dep	110	SENT_205	[p15l2002t1454r2132b1533, p15l12t1582r321b1660],
76	in	FW	O	in	dep	110	SENT_205	[p15l352t1583r435b1659],
77	vitro	FW	O	vitro	dep	110	SENT_205	[p15l463t1583r661b1661],
78	and	CC	O	and	dep	110	SENT_205	[p15l694t1582r852b1660],
79	corroborated	VBN	O	corroborate	dep	110	SENT_205	[p15l885t1582r1442b1660],
80	in	IN	O	in	dep	110	SENT_205	[p15l1473t1583r1556b1659],
81	tumor	NN	O	tumor	dep	110	SENT_205	[p15l1589t1598r1857b1661],
82	specimens	NNS	O	specimen	dep	110	SENT_205	[p15l1887t1583r2132b1681, p15l11t1735r238b1787],
83	obtained	VBN	O	obtain	dep	110	SENT_205	[p15l264t1709r642b1788],
84	from	IN	O	from	dep	110	SENT_205	[p15l665t1708r875b1788],
85	patients	NNS	O	patient	dep	110	SENT_205	[p15l896t1710r1677b1809],
86	.9	CD	NUMBER	.9	dep	110	SENT_205	[p15l896t1710r1677b1809],
87	>	JJR	O	>	dep	110	SENT_205	[p15l896t1710r1677b1809],
88	1	CD	NUMBER	1	dep	110	SENT_205	[p15l896t1710r1677b1809],
89	°	NN	O	°	dep	110	SENT_205	[p15l896t1710r1677b1809],
90	»	CD	NUMBER	»	dep	110	SENT_205	[p15l896t1710r1677b1809],
91	12	CD	NUMBER	12	dep	110	SENT_205	[p15l896t1710r1677b1809],
92	’	CD	NUMBER	’	dep	110	SENT_205	[p15l896t1710r1677b1809],
93	13	CD	NUMBER	13	dep	110	SENT_205	[p15l896t1710r1677b1809],
94	>	JJR	O	>	dep	110	SENT_205	[p15l896t1710r1677b1809],
95	18	CD	NUMBER	18	dep	110	SENT_205	[p15l896t1710r1677b1809],
96	Inhibition	NN	O	inhibition	dep	110	SENT_205	[p15l1699t1709r2133b1788],
97	of	IN	O	of	dep	110	SENT_205	[p15l12t1836r112b1916],
98	the	DT	O	the	dep	110	SENT_205	[p15l130t1837r263b1915],
99	MAPK	NN	ORGANIZATION	mapk	dep	110	SENT_205	[p15l296t1844r573b1918],
100	pathway	NN	O	pathway	dep	110	SENT_205	[p15l605t1837r966b1937],
101	downstream	RB	O	downstream	dep	110	SENT_205	[p15l999t1837r1538b1917],
102	of	IN	O	of	dep	110	SENT_205	[p15l1575t1836r1675b1916],
103	BRAF	NN	ORGANIZATION	braf	dep	110	SENT_205	[p15l1691t1844r1935b1921],
104	was	VBD	O	be	dep	110	SENT_205	[p15l1968t1863r2130b1917],
105	hypothesized	VBN	O	hypothesize	dep	110	SENT_205	[p15l11t1965r585b2065],
106	to	TO	O	to	dep	110	SENT_205	[p15l632t1982r714b2044],
107	suppress	VB	O	suppress	dep	110	SENT_205	[p15l764t1991r1134b2065],
108	mechanisms	NNS	O	mechanism	dep	110	SENT_205	[p15l1183t1965r1727b2043],
109	of	IN	O	of	dep	110	SENT_205	[p15l1777t1964r1876b2044],
110	resistance	NN	O	resistance	_	0	SENT_205	[p15l1905t1966r2132b2043, p15l12t2111r263b2173],
111	.	.	O	.	_	0	SENT_205	[p15l1905t1966r2132b2043, p15l12t2111r263b2173],

1	MEK	NN	O	mek	nn	2	SENT_206	[p15l319t2101r532b2174],
2	inhibition	NN	O	inhibition	nsubjpass	5	SENT_206	[p15l581t2094r1009b2173],
3	has	VBZ	O	have	aux	5	SENT_206	[p15l1062t2094r1205b2172],
4	been	VBN	O	be	auxpass	5	SENT_206	[p15l1261t2094r1462b2173],
5	validated	VBN	O	validate	_	0	SENT_206	[p15l1510t2094r1899b2173],
6	as	IN	O	as	advmod	5	SENT_206	[p15l1951t2120r2036b2172],
7	a	DT	O	a	dep	6	SENT_206	[p15l2090t2120r2134b2172],

1	NENGLJ	NNP	O	NENGLJ	nn	2	SENT_207	[p15l543t2260r650b2282],
2	MED	NNP	O	MED	_	0	SENT_207	[p15l664t2260r716b2275],
3	;	:	O	;	_	0	SENT_207	[p15l772t2254r804b2280],
4	18	CD	NUMBER	18	num	6	SENT_207	[p15l772t2254r804b2280],
5	NEJM.ORG	NN	O	nejm.org	nn	6	SENT_207	[p15l839t2260r963b2282],
6	NOVEMBERL2012	NN	O	novemberl2012	dep	2	SENT_207	[p15l1000t2260r1231b2280],
7	1699	CD	DATE	1699	dep	6	SENT_207	[p15l1940t2249r2016b2273],

1	T	NN	O	t	nn	2	SENT_208	[p15l702t2294r721b2317],
2	ew	NN	O	ew	_	0	SENT_208	[p15l786t2301r824b2317],
3	England	NNP	LOCATION	England	nn	4	SENT_208	[p15l833t2293r944b2324],
4	Journal	NNP	O	Journal	dep	2	SENT_208	[p15l952t2293r1050b2317],
5	of	IN	O	of	_	0	SENT_208	[p15l1059t2293r1088b2317],
6	Medicine	NNP	O	Medicine	nn	8	SENT_208	[p15l1095t2293r1220b2317],
7	al	NNP	O	al	nn	8	SENT_208	[p15l1033t2375r1055b2399],
8	S	NN	O	s	prep_of	4	SENT_208	[p15l1065t2375r1081b2399],

1	Copyright	NN	O	copyright	nn	5	SENT_209	[p15l494t2375r629b2406],
2	©	CD	NUMBER	©	num	5	SENT_209	[p15l638t2375r661b2399],
3	2012	CD	DATE	2012	num	5	SENT_209	[p15l671t2375r736b2399],
4	Massachusetts	NNP	LOCATION	Massachusetts	nn	5	SENT_209	[p15l746t2375r937b2399],
5	Medic	NNP	MISC	Medic	_	0	SENT_209	[p15l947t2375r1031b2399],
6	ociety	NN	O	ociety	dep	5	SENT_209	[p15l1083t2375r1170b2406],
7	.	.	O	.	_	0	SENT_209	[p15l1083t2375r1170b2406],

1	All	DT	O	all	det	2	SENT_210	[p15l1181t2375r1223b2399],
2	rights	NNS	O	rights	nsubj	3	SENT_210	[p15l1232t2375r1306b2406],
3	reserved	VBN	O	reserve	_	0	SENT_210	[p15l1316t2375r1435b2399],
4	.	.	O	.	_	0	SENT_210	[p15l1316t2375r1435b2399],

1	The	DT	O	the	det	4	SENT_211	[p15l671t2417r716b2438],
2	NEW	NNP	O	NEW	nn	4	SENT_211	[p15l735t2419r820b2438],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_211	[p15l839t2419r1027b2438],
4	IOURNAL	NNP	O	IOURNAL	_	0	SENT_211	[p15l1046t2419r1226b2445],
5	of	IN	O	of	_	0	SENT_211	[p15l1245t2417r1274b2444],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_211	[p15l1286t2419r1485b2438],

1	Table	NNP	O	Table	_	0	SENT_212	[p15l261t2547r335b2572],
2	3	CD	NUMBER	3	dep	1	SENT_212	[p15l344t2550r366b2572],
3	.	.	O	.	_	0	SENT_212	[p15l344t2550r366b2572],

1	Efficacy	NNP	O	Efficacy	nn	3	SENT_213	[p15l378t2547r481b2580],
2	End	NNP	O	End	nn	3	SENT_213	[p15l491t2547r541b2572],
3	Points	NNP	O	Points	nsubj	14	SENT_213	[p15l553t2548r636b2572],
4	in	IN	O	in	_	0	SENT_213	[p15l647t2548r670b2572],
5	Part	NNP	O	Part	nn	6	SENT_213	[p15l682t2550r735b2572],
6	C	NNP	O	C	prep_in	3	SENT_213	[p15l744t2549r770b2578],
7	,	,	O	,	_	0	SENT_213	[p15l744t2549r770b2578],
8	as	IN	O	as	mark	9	SENT_213	[p15l780t2556r809b2572],
9	Assessed	VBN	O	assess	dep	6	SENT_213	[p15l818t2547r944b2572],
10	by	IN	O	by	_	0	SENT_213	[p15l956t2547r985b2580],
11	the	DT	O	the	det	13	SENT_213	[p15l993t2547r1037b2572],
12	Site	NN	O	site	nn	13	SENT_213	[p15l1046t2548r1097b2572],
13	Investigators	NNS	O	investigator	prep_by	9	SENT_213	[p15l1107t2548r1283b2580],
14	(	VBP	O	(	_	0	SENT_213	[p15l1294t2548r1545b2580],
15	Intention-to-Treat	NNP	O	Intention-to-Treat	nn	16	SENT_213	[p15l1294t2548r1545b2580],
16	Popu	NNP	O	Popu	nsubj	19	SENT_213	[p15l1555t2547r1737b2580],
17	|	NN	O	|	nn	19	SENT_213	[p15l1555t2547r1737b2580],
18	ation	NN	O	ation	nn	19	SENT_213	[p15l1555t2547r1737b2580],
19	)	NN	O	)	xcomp	14	SENT_213	[p15l1555t2547r1737b2580],
20	.	.	O	.	_	0	SENT_213	[p15l1555t2547r1737b2580],

1	*	NN	O	*	_	0	SENT_214	[p15l1555t2547r1737b2580],

1	Dabrafenib	NNP	O	Dabrafenib	nn	3	SENT_215	[p15l965t2622r1114b2648],
2	Monotherapy	NNP	O	Monotherapy	nn	3	SENT_215	[p15l1127t2622r1309b2655],
3	Combination	NNP	O	Combination	_	0	SENT_215	[p15l1336t2622r1512b2648],
4	150/1	CD	NUMBER	150/1	num	5	SENT_215	[p15l1525t2624r1601b2655],
5	Combination	NN	O	combination	dep	3	SENT_215	[p15l1639t2622r1815b2648],
6	150/2	CD	NUMBER	150/2	dep	3	SENT_215	[p15l1828t2624r1905b2655],

1	End	NN	O	end	nn	2	SENT_216	[p15l263t2660r313b2685],
2	Point	NN	O	point	_	0	SENT_216	[p15l326t2661r396b2685],
3	(	CD	NUMBER	(	num	4	SENT_216	[p15l1085t2662r1115b2693],
4	N	NN	O	n	dep	2	SENT_216	[p15l1085t2662r1115b2693],
5	=	JJ	O	=	quantmod	7	SENT_216	[p15l1123t2662r1186b2693],
6	54	CD	NUMBER	54	number	7	SENT_216	[p15l1123t2662r1186b2693],
7	)	CD	NUMBER	)	num	19	SENT_216	[p15l1123t2662r1186b2693],
8	(	NN	O	(	nn	19	SENT_216	[p15l1418t2662r1449b2693],
9	N	NN	O	n	nn	19	SENT_216	[p15l1418t2662r1449b2693],
10	=	JJ	O	=	amod	19	SENT_216	[p15l1456t2662r1520b2693],
11	54	CD	NUMBER	54	number	12	SENT_216	[p15l1456t2662r1520b2693],
12	)	CD	NUMBER	)	num	19	SENT_216	[p15l1456t2662r1520b2693],
13	(	NN	O	(	nn	19	SENT_216	[p15l1722t2662r1752b2693],
14	N	NN	O	n	nn	19	SENT_216	[p15l1722t2662r1752b2693],
15	=	JJ	O	=	amod	19	SENT_216	[p15l1760t2662r1823b2693],
16	54	CD	NUMBER	54	number	17	SENT_216	[p15l1760t2662r1823b2693],
17	)	CD	NUMBER	)	num	19	SENT_216	[p15l1760t2662r1823b2693],
18	Progression-free	JJ	O	progression-free	amod	19	SENT_216	[p15l264t2717r486b2751],
19	survival	NN	O	survival	dep	4	SENT_216	[p15l497t2718r598b2743],
20	—	CD	NUMBER	—	num	21	SENT_216	[p15l608t2733r642b2735],
21	mo	NN	DURATION	mo	dep	2	SENT_216	[p15l652t2726r694b2743],

1	Median	JJ	O	median	amod	2	SENT_217	[p15l314t2781r413b2806],
2	(	NN	O	(	_	0	SENT_217	[p15l428t2782r496b2814],
3	95	CD	PERCENT	95	num	6	SENT_217	[p15l428t2782r496b2814],
4	%	NN	PERCENT	%	nn	6	SENT_217	[p15l428t2782r496b2814],
5	CI	NN	O	ci	nn	6	SENT_217	[p15l506t2782r543b2814],
6	)	NN	O	)	dep	2	SENT_217	[p15l506t2782r543b2814],
7	5.8	CD	NUMBER	5.8	number	8	SENT_217	[p15l1050t2782r1089b2806],
8	(	CD	NUMBER	(	dep	6	SENT_217	[p15l1102t2783r1219b2814],
9	4.5-7	CD	NUMBER	4.5-7	num	10	SENT_217	[p15l1102t2783r1219b2814],
10	.4	NN	NUMBER	.4	dep	2	SENT_217	[p15l1102t2783r1219b2814],
11	)	CD	NUMBER	)	number	12	SENT_217	[p15l1102t2783r1219b2814],
12	9.2	CD	NUMBER	9.2	num	13	SENT_217	[p15l1375t2783r1414b2806],
13	(	NN	O	(	dep	10	SENT_217	[p15l1427t2782r1560b2814],
14	5.4	CD	NUMBER	5.4	number	15	SENT_217	[p15l1427t2782r1560b2814],
15	—	CD	NUMBER	—	dep	2	SENT_217	[p15l1427t2782r1560b2814],
16	11	CD	NUMBER	11	dep	15	SENT_217	[p15l1427t2782r1560b2814],
17	.	.	O	.	_	0	SENT_217	[p15l1427t2782r1560b2814],

1	o	NN	O	o	dep	126	SENT_218	[p15l1427t2782r1560b2814],
2	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1427t2782r1560b2814],
3	9.4	CD	NUMBER	9.4	dep	126	SENT_218	[p15l1679t2783r1718b2806],
4	(	NN	O	(	dep	126	SENT_218	[p15l1731t2782r1864b2814],
5	8.6-16	CD	NUMBER	8.6-16	dep	126	SENT_218	[p15l1731t2782r1864b2814],
6	.7	CD	NUMBER	.7	dep	126	SENT_218	[p15l1731t2782r1864b2814],
7	)	NN	O	)	dep	126	SENT_218	[p15l1731t2782r1864b2814],
8	Hazard	NN	O	hazard	dep	126	SENT_218	[p15l314t2838r410b2863],
9	ratio	NN	O	ratio	dep	126	SENT_218	[p15l423t2841r482b2863],
10	for	IN	O	for	dep	126	SENT_218	[p15l492t2838r530b2863],
11	death	NN	O	death	dep	126	SENT_218	[p15l539t2838r613b2863],
12	or	CC	O	or	dep	126	SENT_218	[p15l624t2847r652b2863],
13	progression	NN	O	progression	dep	126	SENT_218	[p15l662t2841r822b2871],
14	(	CD	PERCENT	(	dep	126	SENT_218	[p15l836t2839r905b2871],
15	95	CD	PERCENT	95	dep	126	SENT_218	[p15l836t2839r905b2871],
16	%	NN	PERCENT	%	dep	126	SENT_218	[p15l836t2839r905b2871],
17	Cl	NN	O	cl	dep	126	SENT_218	[p15l915t2840r952b2871],
18	)	CD	NUMBER	)	dep	126	SENT_218	[p15l915t2840r952b2871],
19	Reference	NNP	O	Reference	dep	126	SENT_218	[p15l1071t2838r1202b2863],
20	0.56	CD	NUMBER	0.56	dep	126	SENT_218	[p15l1358t2840r1414b2864],
21	(	CD	NUMBER	(	dep	126	SENT_218	[p15l1427t2840r1474b2871],
22	0.3	CD	NUMBER	0.3	dep	126	SENT_218	[p15l1427t2840r1474b2871],
23	7-0	CD	NUMBER	7-0	dep	126	SENT_218	[p15l1480t2840r1577b2871],
24	.87	CD	NUMBER	.87	dep	126	SENT_218	[p15l1480t2840r1577b2871],
25	)	NN	O	)	dep	126	SENT_218	[p15l1480t2840r1577b2871],
26	0.39	CD	NUMBER	0.39	dep	126	SENT_218	[p15l1661t2840r1717b2864],
27	(	CD	NUMBER	(	dep	126	SENT_218	[p15l1731t2840r1880b2871],
28	0.25-0	CD	NUMBER	0.25-0	dep	126	SENT_218	[p15l1731t2840r1880b2871],
29	.62	CD	NUMBER	.62	dep	126	SENT_218	[p15l1731t2840r1880b2871],
30	)	NN	O	)	dep	126	SENT_218	[p15l1731t2840r1880b2871],
31	P	NN	O	p	dep	126	SENT_218	[p15l314t2898r328b2921],
32	value	NN	O	value	dep	126	SENT_218	[p15l337t2896r408b2921],
33	Reference	NNP	O	Reference	dep	126	SENT_218	[p15l1071t2896r1202b2921],
34	0.006	CD	NUMBER	0.006	dep	126	SENT_218	[p15l1432t2898r1505b2921],
35	<	JJR	O	<	dep	126	SENT_218	[p15l1727t2897r1817b2921],
36	0.001	CD	NUMBER	0.001	dep	126	SENT_218	[p15l1727t2897r1817b2921],
37	Progression-free	JJ	O	progression-free	dep	126	SENT_218	[p15l264t2953r486b2987],
38	survival	NN	O	survival	dep	126	SENT_218	[p15l497t2953r598b2979],
39	at	IN	O	at	dep	126	SENT_218	[p15l610t2958r634b2979],
40	12	CD	DURATION	12	dep	126	SENT_218	[p15l645t2956r674b2978],
41	mo	NN	DURATION	mo	dep	126	SENT_218	[p15l686t2962r728b2979],
42	(	NN	O	(	dep	126	SENT_218	[p15l741t2955r810b2986],
43	95	CD	PERCENT	95	dep	126	SENT_218	[p15l741t2955r810b2986],
44	%	NN	PERCENT	%	dep	126	SENT_218	[p15l741t2955r810b2986],
45	Cl	NN	O	cl	dep	126	SENT_218	[p15l820t2955r857b2986],
46	)	CD	PERCENT	)	dep	126	SENT_218	[p15l820t2955r857b2986],
47	—	CD	PERCENT	—	dep	126	SENT_218	[p15l868t2969r902b2971],
48	%	NN	PERCENT	%	dep	126	SENT_218	[p15l911t2955r937b2980],
49	9	CD	NUMBER	9	dep	126	SENT_218	[p15l1079t2956r1093b2979],
50	(	NN	O	(	dep	126	SENT_218	[p15l1106t2955r1189b2986],
51	3-20	CD	NUMBER	3-20	dep	126	SENT_218	[p15l1106t2955r1189b2986],
52	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1106t2955r1189b2986],
53	26	CD	NUMBER	26	dep	126	SENT_218	[p15l1396t2956r1427b2979],
54	(	NN	O	(	dep	126	SENT_218	[p15l1440t2956r1539b2986],
55	15-39	CD	NUMBER	15-39	dep	126	SENT_218	[p15l1440t2956r1539b2986],
56	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1440t2956r1539b2986],
57	41	CD	NUMBER	41	dep	126	SENT_218	[p15l1699t2956r1729b2978],
58	(	NN	O	(	dep	126	SENT_218	[p15l1743t2956r1843b2986],
59	27-54	CD	NUMBER	27-54	dep	126	SENT_218	[p15l1743t2956r1843b2986],
60	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1743t2956r1843b2986],
61	Best	NN	O	best	dep	126	SENT_218	[p15l264t3014r321b3036],
62	response	NN	O	response	dep	126	SENT_218	[p15l331t3020r454b3044],
63	—	CD	NUMBER	—	dep	126	SENT_218	[p15l463t3027r496b3029],
64	no.	NN	O	no.	dep	126	SENT_218	[p15l507t3020r546b3036],
65	(	CD	PERCENT	(	dep	126	SENT_218	[p15l560t3012r605b3044],
66	%	NN	PERCENT	%	dep	126	SENT_218	[p15l560t3012r605b3044],
67	)	CD	NUMBER	)	dep	126	SENT_218	[p15l560t3012r605b3044],
68	Complete	JJ	O	complete	dep	126	SENT_218	[p15l312t3069r443b3102],
69	response	NN	O	response	dep	126	SENT_218	[p15l455t3078r577b3102],
70	2	CD	NUMBER	2	dep	126	SENT_218	[p15l1104t3071r1118b3094],
71	(	CD	NUMBER	(	dep	126	SENT_218	[p15l1131t3071r1164b3102],
72	4	CD	NUMBER	4	dep	126	SENT_218	[p15l1131t3071r1164b3102],
73	)	NN	O	)	dep	126	SENT_218	[p15l1131t3071r1164b3102],
74	3	CD	NUMBER	3	dep	126	SENT_218	[p15l1438t3071r1450b3094],
75	(	NN	O	(	dep	126	SENT_218	[p15l1465t3071r1498b3102],
76	6	CD	NUMBER	6	dep	126	SENT_218	[p15l1465t3071r1498b3102],
77	)	NN	O	)	dep	126	SENT_218	[p15l1465t3071r1498b3102],
78	5	CD	NUMBER	5	dep	126	SENT_218	[p15l1742t3071r1754b3094],
79	(	CD	NUMBER	(	dep	126	SENT_218	[p15l1769t3071r1802b3102],
80	9	CD	NUMBER	9	dep	126	SENT_218	[p15l1769t3071r1802b3102],
81	)	NN	O	)	dep	126	SENT_218	[p15l1769t3071r1802b3102],
82	Partial	JJ	O	partial	dep	126	SENT_218	[p15l314t3127r396b3152],
83	response	NN	O	response	dep	126	SENT_218	[p15l409t3135r532b3159],
84	27	CD	NUMBER	27	dep	126	SENT_218	[p15l1087t3129r1118b3152],
85	(	NN	O	(	dep	126	SENT_218	[p15l1131t3128r1181b3159],
86	50	CD	NUMBER	50	dep	126	SENT_218	[p15l1131t3128r1181b3159],
87	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1131t3128r1181b3159],
88	24	CD	NUMBER	24	dep	126	SENT_218	[p15l1421t3129r1452b3151],
89	(	NN	O	(	dep	126	SENT_218	[p15l1465t3129r1514b3159],
90	44	CD	NUMBER	44	dep	126	SENT_218	[p15l1465t3129r1514b3159],
91	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1465t3129r1514b3159],
92	36	CD	NUMBER	36	dep	126	SENT_218	[p15l1725t3129r1756b3152],
93	(	NN	O	(	dep	126	SENT_218	[p15l1769t3129r1818b3159],
94	67	CD	NUMBER	67	dep	126	SENT_218	[p15l1769t3129r1818b3159],
95	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1769t3129r1818b3159],
96	Stable	JJ	O	stable	dep	126	SENT_218	[p15l312t3184r395b3209],
97	disease	NN	O	disease	dep	126	SENT_218	[p15l405t3184r506b3209],
98	22	CD	NUMBER	22	dep	126	SENT_218	[p15l1087t3187r1118b3209],
99	(	CD	NUMBER	(	dep	126	SENT_218	[p15l1131t3186r1181b3217],
100	41	CD	NUMBER	41	dep	126	SENT_218	[p15l1131t3186r1181b3217],
101	)	NN	O	)	dep	126	SENT_218	[p15l1131t3186r1181b3217],
102	24	CD	NUMBER	24	dep	126	SENT_218	[p15l1421t3187r1452b3209],
103	(	NN	O	(	dep	126	SENT_218	[p15l1465t3186r1514b3217],
104	44	CD	NUMBER	44	dep	126	SENT_218	[p15l1465t3186r1514b3217],
105	)	CD	NUMBER	)	dep	126	SENT_218	[p15l1465t3186r1514b3217],
106	Progressive	JJ	O	progressive	dep	126	SENT_218	[p15l314t3244r469b3275],
107	disease	NN	O	disease	dep	126	SENT_218	[p15l479t3242r580b3267],
108	3	CD	NUMBER	3	dep	126	SENT_218	[p15l1105t3244r1117b3267],
109	(	NN	O	(	dep	126	SENT_218	[p15l1131t3244r1164b3275],
110	6	CD	NUMBER	6	dep	126	SENT_218	[p15l1131t3244r1164b3275],
111	)	NN	O	)	dep	126	SENT_218	[p15l1131t3244r1164b3275],
112	2	CD	NUMBER	2	dep	126	SENT_218	[p15l1437t3244r1451b3267],
113	(	CD	NUMBER	(	dep	126	SENT_218	[p15l1465t3244r1498b3275],
114	4	CD	NUMBER	4	dep	126	SENT_218	[p15l1465t3244r1498b3275],
115	)	NN	O	)	dep	126	SENT_218	[p15l1465t3244r1498b3275],
116	o	NN	O	o	dep	126	SENT_218	[p15l1741t3243r1756b3267],
117	Could	MD	O	could	dep	126	SENT_218	[p15l312t3299r390b3325],
118	not	RB	O	not	dep	126	SENT_218	[p15l403t3304r446b3325],
119	be	VB	O	be	dep	126	SENT_218	[p15l457t3299r486b3325],
120	evaluated	VBN	O	evaluate	dep	126	SENT_218	[p15l496t3299r625b3325],
121	o	NN	O	o	dep	126	SENT_218	[p15l1103t3301r1118b3325],
122	1	CD	NUMBER	1	dep	126	SENT_218	[p15l1439t3302r1450b3324],
123	(	NN	O	(	dep	126	SENT_218	[p15l1465t3302r1498b3333],
124	2	CD	NUMBER	2	dep	126	SENT_218	[p15l1465t3302r1498b3333],
125	)	NN	O	)	dep	126	SENT_218	[p15l1465t3302r1498b3333],
126	o	NN	O	o	_	0	SENT_218	[p15l1741t3301r1756b3325],

1	Complete	JJ	O	complete	_	0	SENT_219	[p15l262t3357r393b3390],
2	or	CC	O	or	_	0	SENT_219	[p15l403t3366r431b3382],
3	partial	JJ	O	partial	amod	4	SENT_219	[p15l441t3357r524b3390],
4	response	NN	O	response	conj_or	1	SENT_219	[p15l537t3366r659b3390],

1	No.	NN	O	no.	dep	7	SENT_220	[p15l314t3417r360b3440],
2	of	IN	O	of	_	0	SENT_220	[p15l371t3415r401b3440],
3	patients	NNS	O	patient	prep_of	1	SENT_220	[p15l407t3417r514b3448],
4	29	CD	PERCENT	29	dep	7	SENT_220	[p15l1120t3417r1151b3440],
5	27	CD	PERCENT	27	number	6	SENT_220	[p15l1453t3417r1484b3440],
6	41	CD	PERCENT	41	num	7	SENT_220	[p15l1756t3417r1787b3440],
7	Percent	NN	PERCENT	percent	dep	13	SENT_220	[p15l314t3475r414b3498],
8	of	IN	O	of	_	0	SENT_220	[p15l424t3472r453b3498],
9	patients	NNS	O	patient	prep_of	7	SENT_220	[p15l460t3475r567b3505],
10	(	IN	O	(	_	0	SENT_220	[p15l581t3474r649b3505],
11	95	CD	PERCENT	95	num	12	SENT_220	[p15l581t3474r649b3505],
12	%	NN	PERCENT	%	prep_(	9	SENT_220	[p15l581t3474r649b3505],
13	CI	NN	O	ci	dep	16	SENT_220	[p15l660t3474r697b3505],
14	)	CD	NUMBER	)	num	13	SENT_220	[p15l660t3474r697b3505],
15	54	CD	NUMBER	54	num	16	SENT_220	[p15l1063t3475r1093b3498],
16	(	NN	O	(	dep	22	SENT_220	[p15l1106t3474r1206b3505],
17	40-67	CD	NUMBER	40-67	num	18	SENT_220	[p15l1106t3474r1206b3505],
18	)	CD	NUMBER	)	dep	16	SENT_220	[p15l1106t3474r1206b3505],
19	50	CD	NUMBER	50	number	20	SENT_220	[p15l1396t3474r1427b3498],
20	(	CD	NUMBER	(	dep	18	SENT_220	[p15l1440t3474r1539b3505],
21	36-64	CD	NUMBER	36-64	num	22	SENT_220	[p15l1440t3474r1539b3505],
22	)	NN	O	)	dep	29	SENT_220	[p15l1440t3474r1539b3505],
23	76	CD	NUMBER	76	number	24	SENT_220	[p15l1701t3475r1730b3498],
24	(	CD	NUMBER	(	dep	22	SENT_220	[p15l1743t3474r1843b3505],
25	62-86	CD	NUMBER	62-86	num	28	SENT_220	[p15l1743t3474r1843b3505],
26	)	NN	O	)	nn	28	SENT_220	[p15l1743t3474r1843b3505],
27	P	NN	O	p	nn	28	SENT_220	[p15l314t3532r328b3555],
28	value	NN	O	value	dep	24	SENT_220	[p15l337t3530r408b3555],
29	Reference	NNP	O	Reference	dep	31	SENT_220	[p15l1071t3530r1202b3555],
30	0.77	CD	NUMBER	0.77	num	31	SENT_220	[p15l1441t3532r1497b3555],
31	0.03	CD	NUMBER	0.03	_	0	SENT_220	[p15l1744t3532r1799b3555],

1	Duration	NN	O	duration	_	0	SENT_221	[p15l264t3590r381b3613],
2	of	IN	O	of	_	0	SENT_221	[p15l393t3588r422b3613],
3	response	NN	O	response	prep_of	1	SENT_221	[p15l429t3597r552b3621],
4	—	CD	NUMBER	—	num	5	SENT_221	[p15l560t3603r594b3606],
5	mo	NN	DURATION	mo	dep	1	SENT_221	[p15l604t3597r646b3613],

1	Median	JJ	O	median	amod	2	SENT_222	[p15l314t3645r413b3671],
2	5.6	CD	PERCENT	5.6	dep	10	SENT_222	[p15l1116t3647r1155b3671],
3	9.5	CD	PERCENT	9.5	number	4	SENT_222	[p15l1449t3648r1487b3671],
4	10.5	CD	PERCENT	10.5	dep	2	SENT_222	[p15l1746t3647r1799b3671],
5	95	CD	PERCENT	95	num	6	SENT_222	[p15l312t3704r371b3729],
6	%	NN	PERCENT	%	dep	4	SENT_222	[p15l312t3704r371b3729],
7	CI	NN	O	ci	dep	10	SENT_222	[p15l381t3705r407b3728],
8	4.5-7	CD	NUMBER	4.5-7	num	7	SENT_222	[p15l1086t3705r1184b3728],
9	.4	CD	NUMBER	.4	num	10	SENT_222	[p15l1086t3705r1184b3728],
10	7.4-NA	NN	O	7.4-na	dep	13	SENT_222	[p15l1420t3705r1520b3728],
11	7.4	CD	NUMBER	7.4	dep	10	SENT_222	[p15l1717t3705r1829b3728],
12	—	CD	NUMBER	—	num	13	SENT_222	[p15l1717t3705r1829b3728],
13	14.9	CD	NUMBER	14.9	_	0	SENT_222	[p15l1717t3705r1829b3728],

1	*	NN	O	*	nn	3	SENT_223	[p16l235t19r250b34],
2	Hazard	NN	O	hazard	nn	3	SENT_223	[p16l262t17r359b42],
3	ratios	NNS	O	ratio	nsubj	7	SENT_223	[p16l373t19r447b42],
4	and	CC	O	and	_	0	SENT_223	[p16l459t17r507b42],
5	P	NN	O	p	nn	6	SENT_223	[p16l522t19r537b42],
6	values	NNS	O	value	conj_and	3	SENT_223	[p16l547t17r632b42],
7	are	VBP	O	be	_	0	SENT_223	[p16l645t26r685b42],
8	for	IN	O	for	_	0	SENT_223	[p16l695t17r733b42],
9	the	DT	O	the	det	10	SENT_223	[p16l743t17r785b42],
10	comparison	NN	O	comparison	prep_for	7	SENT_223	[p16l797t19r958b50],
11	between	IN	O	between	_	0	SENT_223	[p16l972t17r1082b42],
12	each	DT	O	each	det	14	SENT_223	[p16l1095t17r1156b42],
13	combination-therapy	JJ	O	combination-therapy	amod	14	SENT_223	[p16l1169t17r1454b50],
14	group	NN	O	group	prep_between	10	SENT_223	[p16l1465t26r1544b50],
15	and	CC	O	and	_	0	SENT_223	[p16l1556t17r1604b42],
16	the	DT	O	the	det	18	SENT_223	[p16l1616t17r1659b42],
17	monotherapy	NN	O	monotherapy	nn	18	SENT_223	[p16l1671t17r1853b50],
18	group	NN	O	group	prep_between	10	SENT_223	[p16l261t63r347b87],
19	.	.	O	.	_	0	SENT_223	[p16l261t63r347b87],

1	NA	NNP	O	NA	nsubj	2	SENT_224	[p16l362t56r404b79],
2	denotes	VBZ	O	denote	_	0	SENT_224	[p16l414t54r522b79],
3	not	RB	O	not	neg	2	SENT_224	[p16l535t59r578b79],
4	achieved	VBN	O	achieve	dep	2	SENT_224	[p16l590t54r715b79],
5	.	.	O	.	_	0	SENT_224	[p16l590t54r715b79],

1	therapeutic	JJ	O	therapeutic	amod	2	SENT_225	[p16l12t308r497b407],
2	approach	NN	O	approach	_	0	SENT_225	[p16l527t308r921b407],
3	in	IN	O	in	_	0	SENT_225	[p16l951t309r1034b385],
4	the	DT	O	the	det	7	SENT_225	[p16l1065t308r1198b386],
5	same	JJ	O	same	amod	7	SENT_225	[p16l1230t334r1450b386],
6	patient	NN	O	patient	nn	7	SENT_225	[p16l1479t309r1782b407],
7	population	NN	O	population	prep_in	2	SENT_225	[p16l1805t308r2133b407, p16l12t437r246b532],
8	,	,	O	,	_	0	SENT_225	[p16l1805t308r2133b407, p16l12t437r246b532],
9	"	``	O	"	punct	10	SENT_225	[p16l1805t308r2133b407, p16l12t437r246b532],
10	3	CD	NUMBER	3	appos	2	SENT_225	[p16l1805t308r2133b407, p16l12t437r246b532],
11	providing	VBG	O	provide	partmod	10	SENT_225	[p16l291t436r709b537],
12	an	DT	O	a	det	13	SENT_225	[p16l751t462r853b514],
13	opportunity	NN	O	opportunity	dobj	11	SENT_225	[p16l900t437r1417b536],
14	to	TO	O	to	aux	15	SENT_225	[p16l1459t453r1541b515],
15	investigate	VB	O	investigate	infmod	13	SENT_225	[p16l1587t437r2046b537],
16	a	DT	O	a	det	17	SENT_225	[p16l2091t462r2135b514],
17	regimen	NN	O	regimen	dobj	15	SENT_225	[p16l12t565r362b665],
18	combining	VBG	O	combine	partmod	17	SENT_225	[p16l395t564r855b665],
19	a	DT	O	a	det	21	SENT_225	[p16l884t590r928b642],
20	BRAF	NN	O	braf	nn	21	SENT_225	[p16l957t570r1198b647],
21	inhibitor	NN	O	inhibitor	dobj	18	SENT_225	[p16l1231t564r1605b643],
22	with	IN	O	with	_	0	SENT_225	[p16l1630t564r1822b643],
23	a	DT	O	a	det	25	SENT_225	[p16l1854t590r1898b642],
24	MEK	NN	O	mek	nn	25	SENT_225	[p16l1926t572r2138b645],
25	inhibitor	NN	O	inhibitor	prep_with	18	SENT_225	[p16l11t693r411b772],
26	.	.	O	.	_	0	SENT_225	[p16l11t693r411b772],

1	We	PRP	O	we	nsubj	2	SENT_226	[p16l137t829r270b899],
2	showed	VBD	O	show	_	0	SENT_226	[p16l329t821r652b900],
3	that	IN	O	that	complm	10	SENT_226	[p16l710t821r883b899],
4	dabrafenib	NN	O	dabrafenib	nsubjpass	10	SENT_226	[p16l936t820r1400b900],
5	and	CC	O	and	_	0	SENT_226	[p16l1458t821r1616b900],
6	trametinib	NN	O	trametinib	conj_and	4	SENT_226	[p16l1674t821r2133b900],
7	could	MD	O	could	aux	10	SENT_226	[p16l12t949r247b1028],
8	be	VB	O	be	auxpass	10	SENT_226	[p16l292t949r388b1028],
9	safely	RB	O	safely	advmod	10	SENT_226	[p16l434t948r678b1049],
10	combined	VBN	O	combine	ccomp	2	SENT_226	[p16l719t949r1144b1028],
11	when	WRB	O	when	advmod	15	SENT_226	[p16l1183t949r1417b1028],
12	each	DT	O	each	det	13	SENT_226	[p16l1462t949r1654b1027],
13	agent	NN	O	agent	nsubjpass	15	SENT_226	[p16l1698t966r1934b1050],
14	was	VBD	O	be	auxpass	15	SENT_226	[p16l1969t975r2132b1028],
15	administered	VBN	O	administer	advcl	10	SENT_226	[p16l11t1077r569b1156],
16	at	IN	O	at	_	0	SENT_226	[p16l600t1094r678b1155],
17	its	PRP$	O	its	poss	22	SENT_226	[p16l704t1078r800b1155],
18	full	JJ	O	full	amod	22	SENT_226	[p16l834t1076r978b1156],
19	single	JJ	O	single	amod	22	SENT_226	[p16l1012t1077r1527b1178],
20	—	JJ	O	—	amod	22	SENT_226	[p16l1012t1077r1527b1178],
21	agent	NN	O	agent	nn	22	SENT_226	[p16l1012t1077r1527b1178],
22	dose	NN	O	dose	prep_at	15	SENT_226	[p16l1554t1077r1767b1156],
23	.	.	O	.	_	0	SENT_226	[p16l1554t1077r1767b1156],

1	In	IN	O	in	_	0	SENT_227	[p16l1802t1085r1890b1155],
2	comparison	NN	O	comparison	nsubj	5	SENT_227	[p16l1922t1103r2133b1156, p16l11t1206r330b1305],
3	With	IN	O	with	_	0	SENT_227	[p16l359t1205r552b1284],
4	patients	NNS	O	patient	prep_with	5	SENT_227	[p16l584t1206r918b1305],
5	receiving	VBG	O	receive	prepc_in	13	SENT_227	[p16l954t1206r1335b1306],
6	dabrafenib	JJ	O	dabrafenib	amod	7	SENT_227	[p16l1366t1204r1821b1284],
7	monotherapy	NN	O	monotherapy	dobj	5	SENT_227	[p16l1855t1231r2133b1284, p16l12t1333r347b1433],
8	,	,	O	,	_	0	SENT_227	[p16l1855t1231r2133b1284, p16l12t1333r347b1433],
9	patients	NNS	O	patient	nsubj	13	SENT_227	[p16l399t1334r740b1433],
10	receiving	VBG	O	receive	partmod	9	SENT_227	[p16l789t1334r1179b1434],
11	combination	NN	O	combination	nn	12	SENT_227	[p16l1223t1333r1770b1412],
12	therapy	NN	O	therapy	dobj	10	SENT_227	[p16l1818t1333r2139b1433],
13	had	VBD	O	have	_	0	SENT_227	[p16l12t1460r168b1539],
14	more	RBR	O	more	advmod	15	SENT_227	[p16l209t1486r428b1539],
15	frequent	JJ	O	frequent	amod	19	SENT_227	[p16l469t1459r833b1560],
16	and	CC	O	and	_	0	SENT_227	[p16l868t1460r1026b1539],
17	more	RBR	O	more	advmod	18	SENT_227	[p16l1066t1486r1285b1539],
18	severe	JJ	O	severe	conj_and	15	SENT_227	[p16l1328t1486r1586b1540],
19	pyrexia	NN	O	pyrexia	dobj	13	SENT_227	[p16l1625t1461r1938b1560],
20	and	CC	O	and	_	0	SENT_227	[p16l1976t1460r2134b1539],
21	chills	NNS	O	chill	conj_and	19	SENT_227	[p16l12t1589r267b1685],
22	;	:	O	;	_	0	SENT_227	[p16l12t1589r267b1685],
23	they	PRP	O	they	nsubj	25	SENT_227	[p16l316t1589r499b1689],
24	also	RB	O	also	advmod	25	SENT_227	[p16l537t1589r709b1668],
25	had	VBD	O	have	parataxis	13	SENT_227	[p16l754t1589r910b1668],
26	more	RBR	O	more	advmod	27	SENT_227	[p16l955t1615r1173b1668],
27	frequent	JJ	O	frequent	amod	30	SENT_227	[p16l1218t1588r1582b1689],
28	gastrointestinal	JJ	O	gastrointestinal	amod	30	SENT_227	[p16l1622t1590r2133b1690, p16l12t1717r206b1795],
29	toxic	JJ	O	toxic	amod	30	SENT_227	[p16l240t1718r442b1796],
30	effects	NNS	O	effect	dobj	25	SENT_227	[p16l476t1716r750b1795],
31	(	VBP	O	(	rcmod	30	SENT_227	[p16l791t1724r980b1818],
32	e.g.	FW	O	e.g.	dobj	31	SENT_227	[p16l791t1724r980b1818],
33	,	,	O	,	_	0	SENT_227	[p16l791t1724r980b1818],
34	nausea	NN	O	nausea	appos	32	SENT_227	[p16l1020t1743r1311b1796],
35	and	CC	O	and	_	0	SENT_227	[p16l1343t1717r1499b1796],
36	vomiting	VBG	O	vomit	amod	37	SENT_227	[p16l1529t1718r1961b1818],
37	)	NN	O	)	appos	32	SENT_227	[p16l1529t1718r1961b1818],
38	,	,	O	,	_	0	SENT_227	[p16l1529t1718r1961b1818],
39	but	CC	O	but	_	0	SENT_227	[p16l2001t1717r2139b1796],
40	most	JJS	O	most	nsubj	45	SENT_227	[p16l12t1862r228b1924],
41	of	IN	O	of	_	0	SENT_227	[p16l266t1844r366b1924],
42	these	DT	O	these	det	43	SENT_227	[p16l390t1845r613b1923],
43	events	NNS	O	event	prep_of	40	SENT_227	[p16l657t1862r920b1924],
44	were	VBD	O	be	cop	45	SENT_227	[p16l960t1871r1162b1924],
45	grade	NN	O	grade	conj_but	25	SENT_227	[p16l1204t1845r1443b1946],
46	1	CD	NUMBER	1	num	45	SENT_227	[p16l1488t1851r1532b1923],
47	or	CC	O	or	_	0	SENT_227	[p16l1575t1871r1665b1924],
48	2	CD	NUMBER	2	conj_or	45	SENT_227	[p16l1703t1851r1774b1924],
49	.	.	O	.	_	0	SENT_227	[p16l1703t1851r1774b1924],

1	Pyrexia	NNP	O	Pyrexia	nsubj	4	SENT_228	[p16l1821t1846r2136b1945],
2	was	VBD	O	be	cop	4	SENT_228	[p16l7t1999r168b2052],
3	generally	RB	O	generally	advmod	4	SENT_228	[p16l198t1973r584b2074],
4	manageable	JJ	O	manageable	_	0	SENT_228	[p16l608t1973r1115b2074],
5	with	IN	O	with	_	0	SENT_228	[p16l1139t1973r1332b2052],
6	antipyretic	JJ	O	antipyretic	amod	7	SENT_228	[p16l1359t1974r1808b2073],
7	agents	NNS	O	agent	prep_with	4	SENT_228	[p16l1835t1990r2129b2074],
8	.	.	O	.	_	0	SENT_228	[p16l1835t1990r2129b2074],

1	However	RB	O	however	advmod	5	SENT_229	[p16l11t2108r398b2196],
2	,	,	O	,	_	0	SENT_229	[p16l11t2108r398b2196],
3	recurrent	JJ	O	recurrent	amod	4	SENT_229	[p16l435t2117r826b2180],
4	fevers	NNS	O	fever	nsubj	5	SENT_229	[p16l852t2099r1092b2179],
5	required	VBD	O	require	_	0	SENT_229	[p16l1125t2100r1479b2200],
6	the	DT	O	the	det	7	SENT_229	[p16l1511t2100r1641b2178],
7	use	NN	O	use	dobj	5	SENT_229	[p16l1672t2126r1810b2179],
8	of	IN	O	of	_	0	SENT_229	[p16l1842t2099r1941b2179],
9	lowdose	NN	O	lowdose	nn	11	SENT_229	[p16l1952t2100r2133b2180, p16l12t2229r203b2308],
10	oral	JJ	O	oral	amod	11	SENT_229	[p16l239t2229r402b2308],
11	glucocorticoids	NNS	O	glucocorticoid	prep_of	7	SENT_229	[p16l436t2229r1106b2330],
12	.	.	O	.	_	0	SENT_229	[p16l436t2229r1106b2330],

1	The	DT	O	the	det	2	SENT_230	[p16l1144t2229r1302b2307],
2	definition	NN	O	definition	nsubj	10	SENT_230	[p16l1338t2228r1757b2308],
3	of	IN	O	of	_	0	SENT_230	[p16l1793t2228r1892b2308],
4	doselimiting	VBG	O	doselimit	prepc_of	2	SENT_230	[p16l1909t2229r2133b2308, p16l11t2357r363b2458],
5	toxic	JJ	O	toxic	amod	6	SENT_230	[p16l404t2358r611b2436],
6	effects	NNS	O	effect	dobj	4	SENT_230	[p16l655t2356r936b2435],
7	in	IN	O	in	_	0	SENT_230	[p16l982t2358r1066b2435],
8	this	DT	O	this	det	9	SENT_230	[p16l1111t2357r1270b2435],
9	protocol	NN	O	protocol	prep_in	4	SENT_230	[p16l1316t2357r1676b2457],
10	pertained	VBD	O	pertain	_	0	SENT_230	[p16l1720t2357r2134b2457],
11	only	RB	O	only	advmod	10	SENT_230	[p16l12t2485r197b2585],
12	to	TO	O	to	_	0	SENT_230	[p16l227t2502r309b2564],
13	toxic	JJ	O	toxic	amod	14	SENT_230	[p16l346t2486r552b2564],
14	effects	NNS	O	effect	prep_to	10	SENT_230	[p16l587t2484r868b2563],
15	observed	VBN	O	observe	partmod	14	SENT_230	[p16l906t2485r1287b2564],
16	during	IN	O	during	_	0	SENT_230	[p16l1323t2485r1612b2586],
17	the	DT	DURATION	the	det	19	SENT_230	[p16l1644t2485r1777b2563],
18	21	CD	DURATION	21	num	19	SENT_230	[p16l1812t2491r1911b2563],
19	days	NNS	NUMBER	day	prep_during	15	SENT_230	[p16l1948t2485r2132b2585],
20	of	IN	O	of	_	0	SENT_230	[p16l12t2612r113b2692],
21	treatment	NN	O	treatment	prep_of	19	SENT_230	[p16l145t2630r589b2692],
22	.	.	O	.	_	0	SENT_230	[p16l145t2630r589b2692],

1	The	DT	O	the	det	4	SENT_231	[p16l640t2613r801b2691],
2	combination	NN	O	combination	nn	4	SENT_231	[p16l852t2613r1398b2692],
3	150/2	CD	NUMBER	150/2	num	4	SENT_231	[p16l1451t2618r1678b2702],
4	dose	NN	O	dose	nsubjpass	6	SENT_231	[p16l1730t2613r1924b2692],
5	was	VBD	O	be	auxpass	6	SENT_231	[p16l1970t2639r2132b2692],
6	chosen	VBN	O	choose	_	0	SENT_231	[p16l12t2741r312b2820],
7	on	IN	O	on	_	0	SENT_231	[p16l360t2767r466b2820],
8	the	DT	O	the	det	9	SENT_231	[p16l514t2741r647b2819],
9	basis	NN	O	basis	prep_on	6	SENT_231	[p16l696t2741r906b2820],
10	of	IN	O	of	_	0	SENT_231	[p16l957t2740r1057b2820],
11	the	DT	O	the	det	13	SENT_231	[p16l1086t2741r1219b2819],
12	median	JJ	O	median	amod	13	SENT_231	[p16l1267t2741r1590b2820],
13	duration	NN	O	duration	prep_of	9	SENT_231	[p16l1639t2741r2004b2820],
14	of	IN	O	of	_	0	SENT_231	[p16l2053t2740r2152b2820],
15	therapy	NN	O	therapy	prep_of	13	SENT_231	[p16l12t2869r334b2969],
16	(	CD	NUMBER	(	num	15	SENT_231	[p16l387t2875r513b2960],
17	11	CD	DURATION	11	num	18	SENT_231	[p16l387t2875r513b2960],
18	months	NNS	NUMBER	month	tmod	13	SENT_231	[p16l566t2869r944b2960],
19	)	RB	O	)	advmod	6	SENT_231	[p16l566t2869r944b2960],
20	.	.	O	.	_	0	SENT_231	[p16l566t2869r944b2960],

1	It	PRP	O	it	nsubj	3	SENT_232	[p16l1001t2877r1066b2947],
2	is	VBZ	O	be	cop	3	SENT_232	[p16l1113t2870r1179b2947],
3	possible	JJ	O	possible	_	0	SENT_232	[p16l1233t2869r1583b2969],
4	that	IN	O	that	complm	12	SENT_232	[p16l1637t2869r1809b2947],
5	higher	JJR	O	higher	amod	6	SENT_232	[p16l1857t2869r2138b2970],
6	doses	NNS	O	dose	nsubjpass	12	SENT_232	[p16l12t2997r249b3076],
7	of	IN	O	of	prep	6	SENT_232	[p16l291t2996r390b3076],
8	either	CC	O	either	prep	6	SENT_232	[p16l411t2997r657b3075],
9	agent	NN	O	agent	dep	8	SENT_232	[p16l692t3014r928b3098],
10	could	MD	O	could	aux	12	SENT_232	[p16l963t2997r1196b3076],
11	be	VB	O	be	auxpass	12	SENT_232	[p16l1235t2997r1332b3076],
12	administered	VBN	O	administer	ccomp	3	SENT_232	[p16l1369t2997r1939b3076],
13	and	CC	O	and	_	0	SENT_232	[p16l1977t2997r2134b3076],
14	will	MD	O	will	aux	16	SENT_232	[p16l7t3126r169b3205],
15	be	VB	O	be	auxpass	16	SENT_232	[p16l215t3126r311b3205],
16	considered	VBN	O	consider	conj_and	12	SENT_232	[p16l357t3126r813b3205],
17	in	IN	O	in	_	0	SENT_232	[p16l858t3127r941b3204],
18	other	JJ	O	other	amod	19	SENT_232	[p16l986t3126r1211b3205],
19	cancers	NNS	O	cancer	prep_in	16	SENT_232	[p16l1254t3152r1569b3204],
20	with	IN	O	with	_	0	SENT_232	[p16l1613t3126r1805b3205],
21	activating	VBG	O	activate	prepc_with	16	SENT_232	[p16l1850t3127r2147b3205, p16l11t3256r150b3356],

1	BRAF	NN	O	braf	nn	2	SENT_233	[p16l183t3261r429b3338],
2	mutations	NNS	O	mutation	_	0	SENT_233	[p16l470t3256r932b3334],
3	.	.	O	.	_	0	SENT_233	[p16l470t3256r932b3334],

1	The	DT	O	the	det	2	SENT_234	[p16l138t3382r295b3460],
2	incidence	NN	O	incidence	nsubjpass	20	SENT_234	[p16l324t3382r715b3461],
3	of	IN	O	of	_	0	SENT_234	[p16l744t3381r843b3461],
4	acneiform	NN	O	acneiform	nn	5	SENT_234	[p16l852t3381r1274b3461],
5	dermatitis	NN	O	dermatitis	prep_of	2	SENT_234	[p16l1304t3382r1749b3478],
6	,	,	O	,	_	0	SENT_234	[p16l1304t3382r1749b3478],
7	the	DT	O	the	det	9	SENT_234	[p16l1784t3382r1913b3460],
8	most	RBS	O	most	advmod	9	SENT_234	[p16l1942t3399r2153b3461],
9	common	JJ	O	common	nsubj	13	SENT_234	[p16l12t3537r397b3591],
10	and	CC	O	and	_	0	SENT_234	[p16l428t3511r587b3591],
11	dose	NN	O	dose	nn	12	SENT_234	[p16l620t3511r1207b3613],
12	—	NN	O	—	conj_and	9	SENT_234	[p16l620t3511r1207b3613],
13	limiting	VBG	O	limit	parataxis	20	SENT_234	[p16l620t3511r1207b3613],
14	toxic	JJ	O	toxic	amod	15	SENT_234	[p16l1235t3512r1443b3591],
15	effect	NN	O	effect	dobj	13	SENT_234	[p16l1475t3510r1718b3590],
16	of	IN	O	of	_	0	SENT_234	[p16l1745t3510r1846b3591],
17	trametinib	NN	O	trametinib	prep_of	15	SENT_234	[p16l1860t3528r2147b3590, p16l12t3639r232b3735],
18	,	,	O	,	_	0	SENT_234	[p16l1860t3528r2147b3590, p16l12t3639r232b3735],
19	is	VBZ	O	be	auxpass	20	SENT_234	[p16l273t3640r338b3717],
20	reduced	VBN	O	reduce	_	0	SENT_234	[p16l377t3639r708b3718],
21	when	WRB	O	when	advmod	26	SENT_234	[p16l740t3639r972b3718],
22	dabrafenib	NN	O	dabrafenib	nsubjpass	26	SENT_234	[p16l1008t3638r1465b3718],
23	and	CC	O	and	_	0	SENT_234	[p16l1502t3639r1659b3718],
24	trametinib	NN	O	trametinib	nsubjpass	26	SENT_234	[p16l1695t3639r2147b3718],
25	are	VBP	O	be	auxpass	26	SENT_234	[p17l12t49r139b101],
26	coadministered	VBN	O	coadminister	advcl	20	SENT_234	[p17l172t23r854b102],
27	.	.	O	.	_	0	SENT_234	[p17l172t23r854b102],

1	In	IN	O	in	mark	13	SENT_235	[p17l891t31r979b101],
2	a	DT	O	a	det	7	SENT_235	[p17l1010t49r1055b101],
3	phase	NN	O	phase	nn	7	SENT_235	[p17l1084t23r1330b123],
4	3	CD	NUMBER	3	num	7	SENT_235	[p17l1363t29r1407b102],
5	trial	NN	O	trial	nn	7	SENT_235	[p17l1443t23r1681b119],
6	,8	CD	NUMBER	,8	num	7	SENT_235	[p17l1443t23r1681b119],
7	grade	NN	O	grade	nsubj	13	SENT_235	[p17l1714t23r1949b124],
8	3	CD	NUMBER	3	num	7	SENT_235	[p17l1983t29r2026b102],
9	or	CC	O	or	_	0	SENT_235	[p17l2063t49r2151b102],
10	4	CD	NUMBER	4	num	12	SENT_235	[p17l10t158r60b230],
11	acneiform	NN	O	acneiform	nn	12	SENT_235	[p17l93t150r532b230],
12	dermatitis	NN	O	dermatitis	nsubj	13	SENT_235	[p17l566t151r1008b230],
13	occurred	VBD	O	occur	_	0	SENT_235	[p17l1045t151r1426b230],
14	in	IN	O	in	_	0	SENT_235	[p17l1458t152r1542b229],
15	8	CD	PERCENT	8	num	16	SENT_235	[p17l1576t156r1710b230],
16	%	NN	PERCENT	%	prep_in	13	SENT_235	[p17l1576t156r1710b230],
17	of	IN	O	of	_	0	SENT_235	[p17l1744t150r1844b230],
18	trametinib	NN	O	trametinib	nn	19	SENT_235	[p17l1860t168r2147b229, p17l12t279r556b358],
19	—	NN	O	—	prep_of	16	SENT_235	[p17l1860t168r2147b229, p17l12t279r556b358],
20	treated	VBN	O	treat	partmod	19	SENT_235	[p17l1860t168r2147b229, p17l12t279r556b358],

1	patients	NNS	O	patient	_	0	SENT_236	[p17l595t280r964b379],
2	,	,	O	,	_	0	SENT_236	[p17l595t280r964b379],
3	whereas	IN	O	whereas	mark	11	SENT_236	[p17l1006t279r1360b359],
4	no	DT	O	no	det	5	SENT_236	[p17l1403t305r1509b358],
5	patient	NN	O	patient	nsubj	11	SENT_236	[p17l1550t280r1853b379],
6	in	IN	O	in	_	0	SENT_236	[p17l1889t280r1973b357],
7	the	DT	O	the	det	10	SENT_236	[p17l2014t279r2148b357],
8	combination	NN	O	combination	nn	10	SENT_236	[p17l12t408r563b487],
9	150/2	CD	NUMBER	150/2	num	10	SENT_236	[p17l602t413r830b498],
10	group	NN	O	group	prep_in	5	SENT_236	[p17l868t434r1121b509],
11	had	VBD	O	have	dep	1	SENT_236	[p17l1159t408r1316b487],
12	grade	NN	O	grade	dobj	11	SENT_236	[p17l1352t408r1592b509],
13	3	CD	NUMBER	3	num	19	SENT_236	[p17l1630t414r1674b487],
14	or	CC	O	or	_	0	SENT_236	[p17l1714t434r1803b487],
15	4	CD	NUMBER	4	conj_or	13	SENT_236	[p17l1835t414r1885b487],
16	acne	NN	O	acne	nn	19	SENT_236	[p17l1920t434r2147b487],
17	—	NN	O	—	nn	19	SENT_236	[p17l1920t434r2147b487],
18	iform	NN	O	iform	nn	19	SENT_236	[p17l11t534r245b614],
19	dermatitis	NN	O	dermatitis	dep	12	SENT_236	[p17l282t535r728b614],
20	.	.	O	.	_	0	SENT_236	[p17l282t535r728b614],

1	Proliferative	JJ	O	proliferative	amod	3	SENT_237	[p17l768t534r1267b614],
2	skin	NN	O	skin	nn	3	SENT_237	[p17l1305t535r1479b614],
3	lesions	NNS	O	lesion	nsubjpass	30	SENT_237	[p17l1515t535r1821b631],
4	,	,	O	,	_	0	SENT_237	[p17l1515t535r1821b631],
5	including	VBG	O	include	_	0	SENT_237	[p17l1862t535r2147b614, p17l11t665r147b765],
6	cutaneous	JJ	O	cutaneous	amod	10	SENT_237	[p17l183t681r603b743],
7	squamous	JJ	O	squamous	amod	10	SENT_237	[p17l645t664r1247b764],
8	—	NN	O	—	nn	10	SENT_237	[p17l645t664r1247b764],
9	cell	NN	O	cell	nn	10	SENT_237	[p17l645t664r1247b764],
10	carcinomas	NNS	O	carcinoma	prep_including	3	SENT_237	[p17l1286t665r1786b760],
11	,	,	O	,	_	0	SENT_237	[p17l1286t665r1786b760],
12	papillo	NN	O	papillo	conj_and	10	SENT_237	[p17l1828t664r2147b764],
13	—	CD	NUMBER	—	num	14	SENT_237	[p17l1828t664r2147b764],
14	mas	NNS	O	ma	dep	12	SENT_237	[p17l12t818r211b888],
15	,	,	O	,	_	0	SENT_237	[p17l12t818r211b888],
16	and	CC	O	and	_	0	SENT_237	[p17l269t792r428b871],
17	hyperkeratosis	NN	O	hyperkeratosis	conj_and	10	SENT_237	[p17l481t792r1136b892],
18	,	,	O	,	_	0	SENT_237	[p17l481t792r1136b892],
19	which	WDT	O	which	nsubjpass	22	SENT_237	[p17l1190t792r1454b872],
20	are	VBP	O	be	auxpass	22	SENT_237	[p17l1506t818r1636b870],
21	commonly	RB	O	commonly	advmod	22	SENT_237	[p17l1690t792r2152b892],
22	seen	VBN	O	see	rcmod	3	SENT_237	[p17l13t946r199b998],
23	with	IN	O	with	_	0	SENT_237	[p17l231t920r424b1000],
24	dabrafenib	NN	O	dabrafenib	nn	25	SENT_237	[p17l461t919r919b999],
25	monotherapy	NN	O	monotherapy	prep_with	22	SENT_237	[p17l956t920r1535b1020],
26	,	,	O	,	_	0	SENT_237	[p17l956t920r1535b1020],
27	were	VBD	O	be	auxpass	30	SENT_237	[p17l1573t946r1773b1000],
28	less	RBR	O	less	advmod	29	SENT_237	[p17l1808t920r1961b998],
29	frequently	RB	O	frequently	advmod	30	SENT_237	[p17l2000t919r2147b998, p17l12t1048r320b1148],
30	observed	VBN	O	observe	_	0	SENT_237	[p17l346t1048r713b1128],
31	with	IN	O	with	_	0	SENT_237	[p17l738t1048r928b1128],
32	dabrafenib	NN	O	dabrafenib	prep_with	30	SENT_237	[p17l958t1047r1907b1127],
33	—	NN	O	—	nn	36	SENT_237	[p17l958t1047r1907b1127],
34	trametinib	NN	O	trametinib	nn	36	SENT_237	[p17l958t1047r1907b1127],
35	combination	NN	O	combination	nn	36	SENT_237	[p17l1939t1074r2147b1127, p17l12t1177r359b1257],
36	therapy	NN	O	therapy	dep	30	SENT_237	[p17l387t1177r709b1278],
37	.	.	O	.	_	0	SENT_237	[p17l387t1177r709b1278],

1	In	IN	O	in	_	0	SENT_238	[p17l741t1185r828b1255],
2	light	NN	O	light	pobj	1	SENT_238	[p17l855t1177r1050b1279],
3	of	IN	O	of	_	0	SENT_238	[p17l1073t1176r1171b1257],
4	the	DT	O	the	det	5	SENT_238	[p17l1181t1177r1310b1256],
5	evidence	NN	O	evidence	prep_of	2	SENT_238	[p17l1339t1177r1691b1257],
6	that	IN	O	that	complm	11	SENT_238	[p17l1720t1177r1887b1256],
7	BRAF	NN	ORGANIZATION	braf	nn	10	SENT_238	[p17l1908t1184r2147b1261],
8	and	CC	O	and	_	0	SENT_238	[p17l11t1306r170b1386],
9	MEK	NN	O	mek	nn	10	SENT_238	[p17l203t1314r418b1387],
10	inhibitors	NNS	O	inhibitor	nsubj	11	SENT_238	[p17l449t1306r874b1386],
11	have	VBP	O	have	dep	5	SENT_238	[p17l912t1306r1103b1386],
12	different	JJ	O	different	amod	13	SENT_238	[p17l1139t1305r1518b1386],
13	effects	NNS	O	effect	dobj	11	SENT_238	[p17l1550t1305r1833b1385],
14	on	IN	O	on	_	0	SENT_238	[p17l1871t1332r1978b1386],
15	the	DT	O	the	prep_on	13	SENT_238	[p17l2014t1306r2148b1385],

1	MAPK	NN	O	mapk	nn	2	SENT_239	[p17l9t1441r288b1516],
2	pathway	NN	O	pathway	nsubj	21	SENT_239	[p17l339t1435r702b1535],
3	in	IN	O	in	_	0	SENT_239	[p17l752t1436r836b1513],
4	BRAF	NNP	O	BRAF	prep_in	2	SENT_239	[p17l890t1441r1135b1519],
5	wild	JJ	O	wild	amod	8	SENT_239	[p17l1188t1435r1596b1535],
6	—	NN	O	—	nn	8	SENT_239	[p17l1188t1435r1596b1535],
7	type	NN	O	type	nn	8	SENT_239	[p17l1188t1435r1596b1535],
8	cells	NNS	O	cell	dep	4	SENT_239	[p17l1653t1435r2039b1531],
9	,19	CD	NUMBER	,19	number	10	SENT_239	[p17l1653t1435r2039b1531],
10	'21	CD	NUMBER	'21	dep	8	SENT_239	[p17l1653t1435r2039b1531],
11	it	PRP	O	it	nsubj	13	SENT_239	[p17l2093t1436r2153b1513],
12	appears	VBZ	O	appear	cop	13	SENT_239	[p17l11t1589r346b1663],
13	likely	JJ	O	likely	rcmod	2	SENT_239	[p17l385t1563r617b1663],
14	that	IN	O	that	complm	16	SENT_239	[p17l651t1563r825b1641],
15	trametinib	NN	O	trametinib	nsubj	16	SENT_239	[p17l858t1563r1320b1642],
16	attenuates	VBZ	O	attenuate	ccomp	13	SENT_239	[p17l1358t1580r1800b1642],
17	dabraf	JJ	O	dabraf	amod	20	SENT_239	[p17l1840t1562r2147b1642],
18	—	NN	O	—	nn	20	SENT_239	[p17l1840t1562r2147b1642],
19	enib	NN	O	enib	nn	20	SENT_239	[p17l13t1691r577b1771],
20	—	NN	O	—	dobj	16	SENT_239	[p17l13t1691r577b1771],
21	induced	VBD	O	induce	_	0	SENT_239	[p17l13t1691r577b1771],
22	activation	NN	O	activation	dobj	21	SENT_239	[p17l633t1692r1052b1771],
23	of	IN	O	of	_	0	SENT_239	[p17l1109t1690r1210b1770],
24	the	DT	O	the	det	26	SENT_239	[p17l1248t1691r1382b1769],
25	MAPK	NN	O	mapk	nn	26	SENT_239	[p17l1436t1698r1714b1772],
26	pathway	NN	O	pathway	prep_of	22	SENT_239	[p17l1766t1691r2143b1791],
27	.	.	O	.	_	0	SENT_239	[p17l1766t1691r2143b1791],

1	The	DT	O	the	det	2	SENT_240	[p17l8t1820r170b1898],
2	mechanism	NN	O	mechanism	nsubjpass	8	SENT_240	[p17l216t1820r720b1898],
3	underlying	VBG	O	underlie	partmod	2	SENT_240	[p17l765t1820r1234b1921],
4	this	DT	O	this	det	5	SENT_240	[p17l1277t1820r1438b1898],
5	interaction	NN	O	interaction	dobj	3	SENT_240	[p17l1484t1821r1956b1899],
6	has	VBZ	O	have	aux	8	SENT_240	[p17l2001t1820r2145b1898],
7	been	VBN	O	be	auxpass	8	SENT_240	[p17l13t1947r215b2026],
8	described	VBN	O	describe	_	0	SENT_240	[p17l256t1947r670b2026],
9	in	IN	O	in	_	0	SENT_240	[p17l709t1948r794b2025],
10	a	DT	O	a	det	12	SENT_240	[p17l834t1973r878b2025],
11	mouse	NN	O	mouse	nn	12	SENT_240	[p17l917t1973r1199b2027],
12	model	NN	O	model	prep_in	8	SENT_240	[p17l1240t1947r1509b2026],
13	of	IN	O	of	_	0	SENT_240	[p17l1549t1946r1650b2026],
14	squamouscell	NN	O	squamouscell	nn	15	SENT_240	[p17l1674t1973r2147b2047, p17l13t2077r159b2155],
15	carcinoma	NN	O	carcinoma	prep_of	12	SENT_240	[p17l199t2078r754b2156],
16	.	.	O	.	_	0	SENT_240	[p17l199t2078r754b2156],

1	“	NN	O	“	_	0	SENT_241	[p17l199t2078r754b2156],

1	1700	CD	DATE	1700	num	4	SENT_242	[p17l149t2231r225b2253],
2	N	NN	O	n	nn	4	SENT_242	[p17l935t2241r949b2256],
3	ENGLJ	NN	O	englj	nn	4	SENT_242	[p17l964t2241r1041b2263],
4	MED3	NN	O	med3	_	0	SENT_242	[p17l1056t2241r1129b2263],
5	;	:	O	;	_	0	SENT_242	[p17l1164t2241r1177b2261],
6	1	CD	NUMBER	1	num	8	SENT_242	[p17l1164t2241r1177b2261],
7	NEjM.oRG	NN	O	nejm.org	nn	8	SENT_242	[p17l1231t2241r1355b2263],
8	NOVEMBER1	NN	O	november1	dep	4	SENT_242	[p17l1392t2241r1544b2257],
9	2012	CD	DATE	2012	dep	8	SENT_242	[p17l1565t2241r1623b2257],

1	The	DT	O	the	det	4	SENT_243	[p17l935t2274r986b2298],
2	New	NNP	O	New	nn	4	SENT_243	[p17l995t2275r1057b2298],
3	Englan	NNP	O	Englan	nn	4	SENT_243	[p17l1066t2274r1160b2305],
4	ournal	NN	O	ournal	_	0	SENT_243	[p17l1199t2274r1283b2298],
5	of	IN	O	of	_	0	SENT_243	[p17l1293t2274r1322b2298],
6	Medicine	NN	MISC	medicine	prep_of	4	SENT_243	[p17l1329t2274r1454b2298],

1	Co	NNP	O	Co	_	0	SENT_244	[p17l728t2356r765b2380],
2	right	JJ	O	right	dep	1	SENT_244	[p17l799t2356r862b2387],
3	©	CD	NUMBER	©	num	7	SENT_244	[p17l871t2356r895b2380],
4	2012	CD	DATE	2012	num	7	SENT_244	[p17l905t2356r970b2380],
5	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	7	SENT_244	[p17l979t2356r1170b2380],
6	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_244	[p17l1180t2356r1288b2380],
7	Society	NNP	ORGANIZATION	Society	dep	2	SENT_244	[p17l1299t2356r1404b2387],
8	.	.	O	.	_	0	SENT_244	[p17l1299t2356r1404b2387],

1	All	DT	O	all	det	2	SENT_245	[p17l1415t2356r1456b2380],
2	rights	NNS	O	rights	nsubj	3	SENT_245	[p17l1465t2356r1540b2387],
3	reserved	VBN	O	reserve	_	0	SENT_245	[p17l1550t2356r1668b2380],
4	.	.	O	.	_	0	SENT_245	[p17l1550t2356r1668b2380],

1	BRAF	NNS	O	braf	_	0	SENT_246	[p17l572t2399r656b2418],
2	AND	CC	O	and	_	0	SENT_246	[p17l668t2399r740b2418],
3	K	NN	O	k	nn	4	SENT_246	[p17l806t2399r826b2418],
4	INHIBITION	NN	O	inhibition	conj_and	1	SENT_246	[p17l839t2399r1042b2418],
5	IN	IN	O	in	_	0	SENT_246	[p17l1058t2399r1095b2418],
6	MELANOMA	NN	O	melanoma	prep_in	1	SENT_246	[p17l1110t2399r1304b2418],

1	A	DT	O	a	det	3	SENT_247	[p18l114t32r136b57],
2	Progression-free	JJ	O	progression-free	amod	3	SENT_247	[p18l160t34r368b65],
3	Survival	NN	O	survival	_	0	SENT_247	[p18l377t34r478b58],

1	Median	JJ	O	median	amod	7	SENT_248	[p18l1195t79r1289b102],
2	Hazard	NNP	O	Hazard	nn	7	SENT_248	[p18l1328t78r1418b102],
3	Ratio	NNP	O	Ratio	nn	7	SENT_248	[p18l1430t79r1493b102],
4	(	CD	PERCENT	(	num	7	SENT_248	[p18l1504t80r1568b109],
5	95	CD	PERCENT	95	num	7	SENT_248	[p18l1504t80r1568b109],
6	%	NN	PERCENT	%	nn	7	SENT_248	[p18l1504t80r1568b109],
7	Cl	NN	O	cl	dep	20	SENT_248	[p18l1578t80r1613b109],
8	)	CD	NUMBER	)	num	11	SENT_248	[p18l1578t80r1613b109],
9	P	NN	O	p	nn	11	SENT_248	[p18l1652t80r1667b101],
10	Value	NN	O	value	nn	11	SENT_248	[p18l1675t78r1746b102],
11	mo	NN	DURATION	mo	dep	7	SENT_248	[p18l1223t122r1261b138],
12	5.2	CD	NUMBER	5.2	number	13	SENT_248	[p18l1225t156r1259b176],
13	9.2	CD	NUMBER	9.2	dep	11	SENT_248	[p18l1225t189r1258b210],
14	0.56	CD	NUMBER	0.56	num	15	SENT_248	[p18l1371t189r1421b210],
15	(	CD	NUMBER	(	dep	13	SENT_248	[p18l1432t189r1566b216],
16	o.	NN	O	o.	dep	20	SENT_248	[p18l1432t189r1566b216],
17	37	CD	NUMBER	37	num	16	SENT_248	[p18l1432t189r1566b216],
18	—	CD	NUMBER	—	num	20	SENT_248	[p18l1432t189r1566b216],
19	o.	NN	O	o.	nn	20	SENT_248	[p18l1432t189r1566b216],
20	s7	NN	O	s7	dep	30	SENT_248	[p18l1432t189r1566b216],
21	)	CD	NUMBER	)	number	22	SENT_248	[p18l1432t189r1566b216],
22	0.006	CD	NUMBER	0.006	dep	20	SENT_248	[p18l1674t189r1738b210],
23	0.39	CD	NUMBER	0.39	num	24	SENT_248	[p18l1371t222r1420b243],
24	(	NN	O	(	dep	22	SENT_248	[p18l1432t222r1566b250],
25	0.25-0	CD	NUMBER	0.25-0	number	26	SENT_248	[p18l1432t222r1566b250],
26	.62	CD	NUMBER	.62	num	27	SENT_248	[p18l1432t222r1566b250],
27	)	NN	O	)	npadvmod	28	SENT_248	[p18l1432t222r1566b250],
28	<	JJR	O	<	amod	22	SENT_248	[p18l1658t222r1737b243],
29	o.	CD	NUMBER	o.	num	30	SENT_248	[p18l1658t222r1737b243],
30	oo1	NN	O	oo1	_	0	SENT_248	[p18l1658t222r1737b243],

1	—	NN	O	—	nn	2	SENT_249	[p18l579t583r617b586],
2	Combination	NN	O	combination	_	0	SENT_249	[p18l629t571r783b594],
3	150/2	CD	NUMBER	150/2	number	4	SENT_249	[p18l795t573r861b600],
4	—	CD	NUMBER	—	num	5	SENT_249	[p18l579t624r617b626],
5	Combination	NN	O	combination	dep	2	SENT_249	[p18l629t612r783b634],
6	150/1	CD	NUMBER	150/1	number	7	SENT_249	[p18l795t613r861b641],
7	—	CD	NUMBER	—	num	8	SENT_249	[p18l579t664r617b667],
8	Monotherapy	NN	O	monotherapy	dep	5	SENT_249	[p18l630t652r790b681],

1	Probability	NN	O	probability	_	0	SENT_250	[p18l425t526r455b661],
2	of	IN	O	of	_	0	SENT_250	[p18l424t488r448b517],
3	Progression-free	JJ	O	progression-free	amod	4	SENT_250	[p18l424t274r455b482],
4	Survival	NN	O	survival	prep_of	1	SENT_250	[p18l425t164r448b265],

1	I	PRP	O	I	dep	9	SENT_251	[p18l736t710r738b723],
2	I	PRP	O	I	dep	1	SENT_251	[p18l929t708r932b723],
3	I	PRP	O	I	dep	2	SENT_251	[p18l1122t710r1125b723],
4	I	PRP	O	I	dep	9	SENT_251	[p18l1316t710r1318b723],
5	3	CD	NUMBER	3	number	6	SENT_251	[p18l731t730r742b750],
6	6	CD	NUMBER	6	num	9	SENT_251	[p18l925t730r937b751],
7	9	CD	NUMBER	9	number	8	SENT_251	[p18l1118t730r1130b751],
8	12	CD	DURATION	12	amod	9	SENT_251	[p18l1305t730r1330b750],
9	Months	NNS	DURATION	month	_	0	SENT_251	[p18l937t779r1034b803],
10	since	IN	O	since	_	0	SENT_251	[p18l1044t779r1110b803],
11	Randomization	NN	O	randomization	prep_since	9	SENT_251	[p18l1121t779r1312b803],

1	No.	NN	O	no.	dep	7	SENT_252	[p18l148t836r192b857],
2	at	IN	O	at	_	0	SENT_252	[p18l202t838r225b857],
3	Risk	NN	O	risk	prep_at	1	SENT_252	[p18l236t834r287b857],
4	Monotherapy	NN	O	monotherapy	dep	7	SENT_252	[p18l148t869r307b897],
5	25	CD	NUMBER	25	num	4	SENT_252	[p18l917t873r943b893],
6	13	CD	NUMBER	13	num	7	SENT_252	[p18l1112t872r1136b893],
7	Combination	NN	O	combination	dep	11	SENT_252	[p18l147t902r301b924],
8	150/1	CD	NUMBER	150/1	number	9	SENT_252	[p18l313t903r379b931],
9	33	CD	NUMBER	33	dep	7	SENT_252	[p18l917t906r943b926],
10	26	CD	NUMBER	26	dep	9	SENT_252	[p18l1110t906r1137b926],
11	Combination	NN	O	combination	dep	14	SENT_252	[p18l147t935r301b957],
12	150/2	CD	NUMBER	150/2	num	11	SENT_252	[p18l313t937r379b964],
13	36	CD	NUMBER	36	num	14	SENT_252	[p18l917t939r944b959],
14	29	CD	NUMBER	29	_	0	SENT_252	[p18l1110t939r1137b960],

1	B	NN	O	b	nn	3	SENT_253	[p18l117t1024r135b1049],
2	Subgroup	NN	O	subgroup	nn	3	SENT_253	[p18l158t1026r283b1057],
3	Analyses	NNS	O	analysis	_	0	SENT_253	[p18l291t1026r404b1057],
4	Subgroup	NNP	O	Subgroup	nn	5	SENT_253	[p18l135t1074r260b1105],
5	No.	NN	O	no.	dep	3	SENT_253	[p18l440t1076r484b1098],
6	of	IN	O	of	_	0	SENT_253	[p18l494t1074r523b1098],
7	Patients	NNS	O	patient	prep_of	5	SENT_253	[p18l529t1075r630b1098],
8	Hazard	NNP	O	Hazard	nn	9	SENT_253	[p18l1041t1074r1132b1098],
9	Ratio	NNP	O	Ratio	dep	3	SENT_253	[p18l1144t1075r1207b1098],
10	(	CD	PERCENT	(	number	11	SENT_253	[p18l1218t1076r1282b1105],
11	95	CD	PERCENT	95	num	12	SENT_253	[p18l1218t1076r1282b1105],
12	%	NN	PERCENT	%	dep	9	SENT_253	[p18l1218t1076r1282b1105],
13	Cl	NN	O	cl	dep	3	SENT_253	[p18l1291t1076r1327b1105],
14	)	CD	NUMBER	)	num	13	SENT_253	[p18l1291t1076r1327b1105],
15	Overall	JJ	O	overall	advmod	18	SENT_253	[p18l135t1129r219b1151],
16	108	CD	NUMBER	108	num	17	SENT_253	[p18l522t1130r562b1151],
17	ljojl	NN	O	ljojl	dep	15	SENT_253	[p18l977t1131r1148b1151],
18	_	NN	O	_	rcmod	13	SENT_253	[p18l1186t1159r1188b1161],
19	0.39	CD	NUMBER	0.39	num	18	SENT_253	[p18l1502t1130r1551b1151],
20	(	CD	NUMBER	(	num	22	SENT_253	[p18l1564t1130r1697b1158],
21	0.25	CD	NUMBER	0.25	num	22	SENT_253	[p18l1564t1130r1697b1158],
22	—	NN	O	—	dep	3	SENT_253	[p18l1564t1130r1697b1158],
23	0.62	CD	NUMBER	0.62	number	24	SENT_253	[p18l1564t1130r1697b1158],
24	)	CD	NUMBER	)	num	26	SENT_253	[p18l1564t1130r1697b1158],
25	BRAF	NN	O	braf	nn	26	SENT_253	[p18l137t1172r200b1192],
26	V600E	NN	O	v600e	dep	22	SENT_253	[p18l163t1213r239b1234],
27	92	CD	NUMBER	92	num	28	SENT_253	[p18l535t1214r562b1234],
28	0.43	CD	NUMBER	0.43	dep	3	SENT_253	[p18l1502t1213r1550b1234],
29	(	CD	NUMBER	(	num	31	SENT_253	[p18l1564t1213r1697b1241],
30	0.27	CD	NUMBER	0.27	num	31	SENT_253	[p18l1564t1213r1697b1241],
31	—	NN	O	—	dep	28	SENT_253	[p18l1564t1213r1697b1241],
32	0.71	CD	NUMBER	0.71	num	34	SENT_253	[p18l1564t1213r1697b1241],
33	)	CD	NUMBER	)	num	34	SENT_253	[p18l1564t1213r1697b1241],
34	V60OK	NN	O	v60ok	dep	3	SENT_253	[p18l164t1255r240b1276],
35	16	CD	NUMBER	16	num	37	SENT_253	[p18l537t1255r562b1276],
36	0.19	CD	NUMBER	0.19	num	37	SENT_253	[p18l1502t1255r1551b1276],
37	(	NN	O	(	dep	34	SENT_253	[p18l1564t1255r1697b1283],
38	0.05	CD	NUMBER	0.05	num	39	SENT_253	[p18l1564t1255r1697b1283],
39	—	CD	NUMBER	—	dep	3	SENT_253	[p18l1564t1255r1697b1283],
40	0.66	CD	NUMBER	0.66	num	42	SENT_253	[p18l1564t1255r1697b1283],
41	)	JJ	O	)	amod	42	SENT_253	[p18l1564t1255r1697b1283],
42	Age	NN	O	age	dep	39	SENT_253	[p18l134t1297r179b1325],
43	<	JJR	O	<	dep	3	SENT_253	[p18l164t1339r206b1359],
44	55	CD	DURATION	55	num	45	SENT_253	[p18l164t1339r206b1359],
45	yr	NN	DURATION	yr	dep	43	SENT_253	[p18l216t1345r237b1366],
46	85	CD	NUMBER	85	number	47	SENT_253	[p18l535t1338r561b1359],
47	0.40	CD	NUMBER	0.40	dep	3	SENT_253	[p18l1502t1339r1552b1359],
48	(	CD	NUMBER	(	num	50	SENT_253	[p18l1564t1339r1697b1366],
49	024-059	CD	NUMBER	024-059	num	50	SENT_253	[p18l1564t1339r1697b1366],
50	)	NN	O	)	dep	47	SENT_253	[p18l1564t1339r1697b1366],
51	265	CD	DURATION	265	num	52	SENT_253	[p18l164t1381r206b1401],
52	yr	NN	DURATION	yr	dep	3	SENT_253	[p18l216t1387r237b1408],
53	23	CD	NUMBER	23	number	54	SENT_253	[p18l535t1380r561b1401],
54	0.41	CD	NUMBER	0.41	dep	52	SENT_253	[p18l1503t1380r1551b1401],
55	(	CD	NUMBER	(	num	57	SENT_253	[p18l1564t1380r1697b1408],
56	0.17	CD	NUMBER	0.17	num	57	SENT_253	[p18l1564t1380r1697b1408],
57	—	NN	O	—	dep	3	SENT_253	[p18l1564t1380r1697b1408],
58	1	CD	NUMBER	1	dep	57	SENT_253	[p18l1564t1380r1697b1408],
59	.	.	O	.	_	0	SENT_253	[p18l1564t1380r1697b1408],

1	o2	NN	O	o2	nn	4	SENT_254	[p18l1564t1380r1697b1408],
2	)	CD	NUMBER	)	num	4	SENT_254	[p18l1564t1380r1697b1408],
3	Sex	NN	O	sex	nn	4	SENT_254	[p18l136t1422r175b1443],
4	Male	NN	O	male	dep	15	SENT_254	[p18l166t1462r223b1484],
5	63	CD	NUMBER	63	number	6	SENT_254	[p18l536t1464r561b1484],
6	0.48	CD	NUMBER	0.48	num	7	SENT_254	[p18l1502t1464r1551b1484],
7	(	NN	O	(	dep	4	SENT_254	[p18l1564t1463r1697b1491],
8	0.26	CD	NUMBER	0.26	number	9	SENT_254	[p18l1564t1463r1697b1491],
9	—	CD	NUMBER	—	num	11	SENT_254	[p18l1564t1463r1697b1491],
10	0.88	CD	NUMBER	0.88	number	11	SENT_254	[p18l1564t1463r1697b1491],
11	)	CD	NUMBER	)	npadvmod	12	SENT_254	[p18l1564t1463r1697b1491],
12	Female	JJ	O	female	amod	7	SENT_254	[p18l166t1504r251b1526],
13	45	CD	NUMBER	45	dep	15	SENT_254	[p18l535t1506r561b1526],
14	0.27	CD	NUMBER	0.27	num	15	SENT_254	[p18l1502t1505r1552b1526],
15	(	NN	O	(	dep	18	SENT_254	[p18l1564t1505r1697b1533],
16	0.13	CD	NUMBER	0.13	num	17	SENT_254	[p18l1564t1505r1697b1533],
17	—	CD	NUMBER	—	dep	15	SENT_254	[p18l1564t1505r1697b1533],
18	o.	NN	O	o.	dep	23	SENT_254	[p18l1564t1505r1697b1533],
19	55	CD	NUMBER	55	num	18	SENT_254	[p18l1564t1505r1697b1533],
20	)	CD	NUMBER	)	num	23	SENT_254	[p18l1564t1505r1697b1533],
21	Baseline	NN	O	baseline	nn	23	SENT_254	[p18l137t1546r235b1568],
22	disease	NN	O	disease	nn	23	SENT_254	[p18l244t1546r332b1568],
23	stage	NN	O	stage	dep	38	SENT_254	[p18l342t1550r404b1575],
24	|	CD	NUMBER	|	number	25	SENT_254	[p18l166t1589r248b1613],
25	|	CD	NUMBER	|	num	27	SENT_254	[p18l166t1589r248b1613],
26	|	NN	O	|	nn	27	SENT_254	[p18l166t1589r248b1613],
27	cMo	NN	O	cmo	dep	23	SENT_254	[p18l166t1589r248b1613],
28	,	,	O	,	_	0	SENT_254	[p18l166t1589r248b1613],
29	|	CD	NUMBER	|	num	30	SENT_254	[p18l260t1589r342b1613],
30	VM1a	NN	O	vm1a	appos	27	SENT_254	[p18l260t1589r342b1613],
31	,	,	O	,	_	0	SENT_254	[p18l260t1589r342b1613],
32	or	CC	O	or	_	0	SENT_254	[p18l353t1595r377b1609],
33	|	NN	O	|	nn	34	SENT_254	[p18l387t1587r465b1610],
34	VMlb	NN	O	vmlb	dep	38	SENT_254	[p18l387t1587r465b1610],
35	0.28	CD	NUMBER	0.28	num	36	SENT_254	[p18l1502t1589r1551b1609],
36	(	CD	NUMBER	(	dep	34	SENT_254	[p18l1564t1589r1697b1616],
37	0.12	CD	NUMBER	0.12	dep	36	SENT_254	[p18l1564t1589r1697b1616],
38	—	NN	O	—	dep	41	SENT_254	[p18l1564t1589r1697b1616],
39	0.66	CD	NUMBER	0.66	num	38	SENT_254	[p18l1564t1589r1697b1616],
40	)	CD	NUMBER	)	num	41	SENT_254	[p18l1564t1589r1697b1616],
41	|	NN	O	|	dep	42	SENT_254	[p18l166t1631r242b1651],
42	VM1c	NN	O	vm1c	dep	45	SENT_254	[p18l166t1631r242b1651],
43	0.45	CD	NUMBER	0.45	num	42	SENT_254	[p18l1502t1630r1550b1651],
44	(	CD	NUMBER	(	num	45	SENT_254	[p18l1564t1630r1697b1658],
45	O.	NNP	O	O.	dep	52	SENT_254	[p18l1564t1630r1697b1658],
46	26	CD	NUMBER	26	num	45	SENT_254	[p18l1564t1630r1697b1658],
47	—	CD	NUMBER	—	number	48	SENT_254	[p18l1564t1630r1697b1658],
48	0.78	CD	NUMBER	0.78	dep	45	SENT_254	[p18l1564t1630r1697b1658],
49	)	CD	NUMBER	)	num	50	SENT_254	[p18l1564t1630r1697b1658],
50	Baseline	NN	O	baseline	dep	48	SENT_254	[p18l137t1671r235b1693],
51	LDH	NN	O	ldh	nn	52	SENT_254	[p18l246t1673r298b1692],
52	sULN	NN	O	suln	dep	56	SENT_254	[p18l164t1714r233b1735],
53	0.25	CD	NUMBER	0.25	num	54	SENT_254	[p18l1502t1714r1550b1734],
54	(	CD	NUMBER	(	dep	52	SENT_254	[p18l1564t1714r1697b1741],
55	0.12	CD	NUMBER	0.12	dep	54	SENT_254	[p18l1564t1714r1697b1741],
56	—	NN	O	—	dep	60	SENT_254	[p18l1564t1714r1697b1741],
57	0.50	CD	NUMBER	0.50	num	56	SENT_254	[p18l1564t1714r1697b1741],
58	)	CD	NUMBER	)	num	60	SENT_254	[p18l1564t1714r1697b1741],
59	>	JJR	O	>	amod	60	SENT_254	[p18l164t1756r233b1776],
60	ULN	NN	O	uln	dep	65	SENT_254	[p18l164t1756r233b1776],
61	0.63	CD	NUMBER	0.63	number	62	SENT_254	[p18l1503t1755r1550b1776],
62	(	CD	NUMBER	(	dep	60	SENT_254	[p18l1564t1755r1697b1783],
63	O.	NNP	O	O.	dep	62	SENT_254	[p18l1564t1755r1697b1783],
64	34	CD	NUMBER	34	num	63	SENT_254	[p18l1564t1755r1697b1783],
65	—	CD	NUMBER	—	dep	76	SENT_254	[p18l1564t1755r1697b1783],
66	1.16	CD	NUMBER	1.16	number	67	SENT_254	[p18l1564t1755r1697b1783],
67	)	CD	NUMBER	)	num	70	SENT_254	[p18l1564t1755r1697b1783],
68	No	DT	O	no	det	70	SENT_254	[p18l137t1798r171b1818],
69	brain	NN	O	brain	nn	70	SENT_254	[p18l181t1796r239b1818],
70	metastasis	NN	O	metastasis	dep	65	SENT_254	[p18l251t1798r378b1818],
71	0.38	CD	NUMBER	0.38	number	72	SENT_254	[p18l1502t1797r1551b1818],
72	(	CD	NUMBER	(	num	70	SENT_254	[p18l1564t1797r1697b1824],
73	0.24	CD	NUMBER	0.24	num	74	SENT_254	[p18l1564t1797r1697b1824],
74	—	NN	O	—	dep	70	SENT_254	[p18l1564t1797r1697b1824],
75	0.61	CD	NUMBER	0.61	num	76	SENT_254	[p18l1564t1797r1697b1824],
76	)	NN	O	)	_	0	SENT_254	[p18l1564t1797r1697b1824],

1	I	PRP	O	I	_	0	SENT_255	[p18l937t1827r940b1842],
2	I	PRP	O	I	dep	1	SENT_255	[p18l1487t1829r1489b1842],
3	0.2	CD	NUMBER	0.2	dep	2	SENT_255	[p18l921t1849r955b1870],
4	.	.	O	.	_	0	SENT_255	[p18l1230t1866r1234b1870],

1	.	.	O	.	_	0	SENT_256	[p18l1357t1866r1360b1870],

1	4.0	CD	NUMBER	4.0	num	3	SENT_257	[p18l1470t1849r1506b1870],
2	>	JJR	O	>	amod	3	SENT_257	[p18l1447t1887r1470b1899],
3	Combination	NN	O	combination	_	0	SENT_257	[p18l807t1922r972b1945],
4	Therapy	NN	O	therapy	nn	9	SENT_257	[p18l982t1922r1086b1952],
5	Monotherapy	NN	O	monotherapy	nn	9	SENT_257	[p18l1273t1922r1444b1952],
6	(	NN	O	(	nn	9	SENT_257	[p18l809t1958r863b1988],
7	150	CD	NUMBER	150	num	9	SENT_257	[p18l809t1958r863b1988],
8	mg/2	NN	O	mg/2	nn	9	SENT_257	[p18l873t1959r941b1988],
9	mg	NN	O	mg	dep	3	SENT_257	[p18l951t1959r999b1988],
10	)	CD	NUMBER	)	num	12	SENT_257	[p18l951t1959r999b1988],
11	Better	NNP	O	Better	nn	12	SENT_257	[p18l1011t1959r1086b1981],
12	Better	NNP	O	Better	dep	3	SENT_257	[p18l1321t1959r1396b1981],

1	Figure	NNP	O	Figure	_	0	SENT_258	[p18l123t2040r207b2072],
2	1	CD	NUMBER	1	dep	1	SENT_258	[p18l219t2042r241b2064],
3	.	.	O	.	_	0	SENT_258	[p18l219t2042r241b2064],

1	Progression-free	JJ	O	progression-free	amod	2	SENT_259	[p18l254t2039r481b2072],
2	Survival	NN	O	survival	_	0	SENT_259	[p18l491t2039r600b2064],
3	and	CC	O	and	_	0	SENT_259	[p18l612t2039r661b2064],
4	Subgroup	NN	O	subgroup	conj_and	2	SENT_259	[p18l673t2039r807b2072],
5	Analyses	NNS	O	analysis	dep	2	SENT_259	[p18l817t2039r947b2072],
6	.	.	O	.	_	0	SENT_259	[p18l817t2039r947b2072],

1	Panel	NN	O	panel	nn	2	SENT_260	[p18l123t2089r195b2115],
2	A	NN	O	a	nsubj	3	SENT_260	[p18l207t2091r226b2114],
3	shows	VBZ	O	show	_	0	SENT_260	[p18l237t2089r323b2115],
4	Kaplan	NNP	PERSON	Kaplan	dobj	3	SENT_260	[p18l337t2089r531b2122],
5	.	.	O	.	_	0	SENT_260	[p18l337t2089r531b2122],

1	—	NN	O	—	_	0	SENT_261	[p18l337t2089r531b2122],
2	.	.	O	.	_	0	SENT_261	[p18l337t2089r531b2122],

1	Meier	NNP	PERSON	Meier	nn	2	SENT_262	[p18l337t2089r531b2122],
2	curves	NNS	O	curve	_	0	SENT_262	[p18l541t2098r630b2115],
3	for	IN	O	for	_	0	SENT_262	[p18l642t2089r680b2114],
4	progression-free	JJ	O	progression-free	amod	5	SENT_262	[p18l692t2089r919b2122],
5	survival	NN	O	survival	prep_for	2	SENT_262	[p18l931t2089r1044b2119],
6	,	,	O	,	_	0	SENT_262	[p18l931t2089r1044b2119],
7	with	IN	O	with	_	0	SENT_262	[p18l1055t2089r1113b2115],
8	progression	NN	O	progression	prep_with	2	SENT_262	[p18l1127t2092r1288b2123],
9	assessed	VBN	O	assess	partmod	8	SENT_262	[p18l1302t2089r1423b2115],
10	by	IN	O	by	_	0	SENT_262	[p18l1438t2089r1466b2122],
11	the	DT	O	the	det	13	SENT_262	[p18l1476t2089r1519b2115],
12	site	NN	O	site	nn	13	SENT_262	[p18l1531t2092r1578b2114],
13	investigators	NNS	O	investigator	agent	9	SENT_262	[p18l1590t2092r1722b2123, p18l120t2136r181b2161],
14	,	,	O	,	_	0	SENT_262	[p18l1590t2092r1722b2123, p18l120t2136r181b2161],
15	in	IN	O	in	_	0	SENT_262	[p18l195t2133r217b2156],
16	an	DT	O	a	det	17	SENT_262	[p18l230t2140r260b2156],
17	analysis	NN	O	analysis	prep_in	9	SENT_262	[p18l273t2131r380b2164],
18	comparing	VBG	O	compare	partmod	17	SENT_262	[p18l393t2133r542b2164],
19	two	CD	NUMBER	two	num	20	SENT_262	[p18l552t2136r602b2156],
20	doses	NNS	O	dose	dobj	18	SENT_262	[p18l614t2131r693b2156],
21	of	IN	O	of	_	0	SENT_262	[p18l705t2131r735b2156],
22	combination	NN	O	combination	nn	24	SENT_262	[p18l742t2131r915b2156],
23	therapy	NN	O	therapy	nn	24	SENT_262	[p18l927t2131r1031b2164],
24	—	NN	O	—	prep_of	20	SENT_262	[p18l1040t2146r1074b2149],
25	150	CD	NUMBER	150	num	26	SENT_262	[p18l1086t2133r1133b2156],
26	mg	NN	O	mg	dep	2	SENT_262	[p18l1145t2140r1187b2164],
27	of	IN	O	of	_	0	SENT_262	[p18l1198t2131r1228b2156],
28	dabrafenib	NN	O	dabrafenib	prep_of	26	SENT_262	[p18l1235t2131r1382b2156],
29	twice	RB	O	twice	advmod	30	SENT_262	[p18l1393t2133r1465b2156],
30	daily	JJ	SET	daily	advmod	28	SENT_262	[p18l1476t2131r1539b2164],
31	plus	CC	O	plus	prep	28	SENT_262	[p18l1551t2131r1607b2164],
32	once-daily	JJ	O	once-daily	amod	33	SENT_262	[p18l1619t2131r1761b2164],
33	trametinib	NN	O	trametinib	dep	31	SENT_262	[p18l120t2173r265b2198],
34	at	IN	O	at	_	0	SENT_262	[p18l277t2177r301b2198],
35	a	DT	O	a	det	41	SENT_262	[p18l312t2182r325b2198],
36	dose	NN	O	dose	nn	41	SENT_262	[p18l337t2173r402b2198],
37	ofeither	NN	O	ofeither	nn	41	SENT_262	[p18l413t2172r529b2198],
38	1	CD	NUMBER	1	num	41	SENT_262	[p18l541t2175r553b2198],
39	mg	NN	O	mg	nn	41	SENT_262	[p18l567t2182r609b2206],
40	(	NN	O	(	nn	41	SENT_262	[p18l623t2173r805b2206],
41	combination	NN	O	combination	prep_at	33	SENT_262	[p18l623t2173r805b2206],
42	150/1	CD	NUMBER	150/1	number	43	SENT_262	[p18l820t2174r903b2206],
43	)	CD	NUMBER	)	dep	41	SENT_262	[p18l820t2174r903b2206],
44	or	CC	O	or	_	0	SENT_262	[p18l917t2182r945b2198],
45	2	CD	NUMBER	2	num	48	SENT_262	[p18l956t2175r970b2198],
46	mg	NN	O	mg	nn	48	SENT_262	[p18l983t2182r1025b2206],
47	(	NN	O	(	nn	48	SENT_262	[p18l1039t2173r1221b2206],
48	combination	NN	O	combination	conj_or	41	SENT_262	[p18l1039t2173r1221b2206],
49	150/2	CD	NUMBER	150/2	number	50	SENT_262	[p18l1236t2174r1321b2206],
50	)	CD	NUMBER	)	num	51	SENT_262	[p18l1236t2174r1321b2206],
51	—	NN	O	—	dep	48	SENT_262	[p18l1334t2188r1367b2191],
52	with	IN	O	with	_	0	SENT_262	[p18l1377t2173r1434b2198],
53	dabrafenib	NN	O	dabrafenib	nn	54	SENT_262	[p18l1447t2172r1594b2198],
54	monotherapy	NN	O	monotherapy	prep_with	28	SENT_262	[p18l1607t2173r1752b2198, p18l121t2223r167b2247],
55	(	CD	NUMBER	(	num	54	SENT_262	[p18l181t2216r288b2247],
56	mono	FW	O	mono	nn	57	SENT_262	[p18l181t2216r288b2247],
57	)	FW	O	)	dep	28	SENT_262	[p18l181t2216r288b2247],
58	.	.	O	.	_	0	SENT_262	[p18l181t2216r288b2247],

1	Panel	NN	O	panel	nn	2	SENT_263	[p18l303t2214r374b2239],
2	B	NN	O	b	nsubj	3	SENT_263	[p18l389t2217r404b2239],
3	shows	VBZ	O	show	_	0	SENT_263	[p18l417t2214r502b2240],
4	subgroup	NN	O	subgroup	nn	5	SENT_263	[p18l515t2214r645b2248],
5	analyses	NNS	O	analysis	dobj	3	SENT_263	[p18l657t2214r773b2247],
6	for	IN	O	for	_	0	SENT_263	[p18l784t2214r823b2240],
7	patients	NNS	O	patient	prep_for	3	SENT_263	[p18l835t2217r944b2247],
8	receiving	VBG	O	receive	partmod	7	SENT_263	[p18l958t2217r1081b2247],
9	either	CC	O	either	preconj	10	SENT_263	[p18l1092t2214r1171b2240],
10	combination	NN	O	combination	dobj	8	SENT_263	[p18l1182t2214r1355b2240],
11	150/2	CD	NUMBER	150/2	num	10	SENT_263	[p18l1370t2216r1445b2247],
12	or	CC	O	or	_	0	SENT_263	[p18l1457t2223r1486b2239],
13	monotherapy	NN	O	monotherapy	conj_or	10	SENT_263	[p18l1497t2214r1688b2247],
14	.	.	O	.	_	0	SENT_263	[p18l1497t2214r1688b2247],

1	Both	DT	O	both	predet	3	SENT_264	[p18l123t2256r184b2281],
2	these	DT	O	these	det	3	SENT_264	[p18l196t2256r271b2281],
3	analyses	NNS	O	analysis	nsubjpass	5	SENT_264	[p18l282t2256r398b2289],
4	were	VBD	O	be	auxpass	5	SENT_264	[p18l409t2265r473b2281],
5	performed	VBN	O	perform	_	0	SENT_264	[p18l486t2256r631b2289],
6	in	IN	O	in	_	0	SENT_264	[p18l645t2258r667b2281],
7	part	NN	O	part	nn	10	SENT_264	[p18l681t2261r736b2289],
8	C	NN	O	c	nn	10	SENT_264	[p18l747t2258r765b2281],
9	ofthe	NN	O	ofthe	nn	10	SENT_264	[p18l776t2256r855b2281],
10	study	NN	O	study	prep_in	5	SENT_264	[p18l867t2256r947b2289],
11	.	.	O	.	_	0	SENT_264	[p18l867t2256r947b2289],

1	The	DT	O	the	det	4	SENT_265	[p18l958t2256r1010b2281],
2	melanoma	NN	O	melanoma	nn	4	SENT_265	[p18l1022t2256r1168b2281],
3	staging	NN	O	staging	nn	4	SENT_265	[p18l1181t2258r1282b2289],
4	criteria	NNS	O	criterion	nsubj	5	SENT_265	[p18l1292t2258r1387b2281],
5	ofthe	VBP	O	ofthe	dep	11	SENT_265	[p18l1399t2256r1478b2281],
6	Americanjoint	NNP	ORGANIZATION	Americanjoint	nn	7	SENT_265	[p18l1489t2258r1697b2288],
7	Committee	NNP	ORGANIZATION	Committee	dobj	5	SENT_265	[p18l121t2300r276b2323],
8	on	IN	O	on	_	0	SENT_265	[p18l288t2307r320b2323],
9	Cancer	NNP	O	Cancer	prep_on	7	SENT_265	[p18l333t2300r429b2323],
10	are	VBP	O	be	auxpass	11	SENT_265	[p18l440t2307r481b2323],
11	defined	VBN	O	define	_	0	SENT_265	[p18l492t2297r595b2323],
12	as	IN	O	as	mark	13	SENT_265	[p18l609t2307r636b2323],
13	follows	VBZ	O	follow	advcl	11	SENT_265	[p18l648t2297r753b2323],
14	:	:	O	:	_	0	SENT_265	[p18l648t2297r753b2323],
15	stage	NN	O	stage	conj_and	13	SENT_265	[p18l766t2302r839b2331],
16	lllc	NN	O	lllc	dobj	15	SENT_265	[p18l852t2300r900b2327],
17	,	,	O	,	_	0	SENT_265	[p18l852t2300r900b2327],
18	metastases	NNS	O	metastase	conj_and	13	SENT_265	[p18l915t2302r1071b2323],
19	to	TO	O	to	_	0	SENT_265	[p18l1082t2302r1109b2323],
20	4	CD	NUMBER	4	num	23	SENT_265	[p18l1120t2300r1134b2323],
21	or	CC	O	or	_	0	SENT_265	[p18l1146t2307r1174b2323],
22	more	JJR	O	more	num	23	SENT_265	[p18l1186t2307r1256b2323],
23	nodes	NNS	O	node	prep_to	18	SENT_265	[p18l1269t2298r1351b2323],
24	(	CD	NUMBER	(	dep	23	SENT_265	[p18l1366t2300r1402b2331],
25	or	CC	O	or	_	0	SENT_265	[p18l1366t2300r1402b2331],
26	in-transit	JJ	O	in-transit	amod	28	SENT_265	[p18l1414t2300r1538b2323],
27	metastasis	NN	O	metastasis	nn	28	SENT_265	[p18l1550t2300r1716b2331],
28	)	NN	O	)	prep_to	18	SENT_265	[p18l1550t2300r1716b2331],
29	;	:	O	;	_	0	SENT_265	[p18l1550t2300r1716b2331],
30	and	CC	O	and	_	0	SENT_265	[p18l121t2339r170b2365],
31	stage	NN	O	stage	conj_and	13	SENT_265	[p18l183t2344r256b2373],
32	IV	CD	NUMBER	iv	nsubjpass	11	SENT_265	[p18l269t2342r300b2369],
33	,	,	O	,	_	0	SENT_265	[p18l269t2342r300b2369],
34	metastases	NNS	O	metastase	appos	32	SENT_265	[p18l314t2344r470b2365],
35	beyond	IN	O	beyond	_	0	SENT_265	[p18l484t2339r581b2372],
36	nodes	NNS	O	node	prep_beyond	34	SENT_265	[p18l596t2339r686b2365],
37	.	.	O	.	_	0	SENT_265	[p18l596t2339r686b2365],

1	The	DT	O	the	det	2	SENT_266	[p18l697t2339r749b2365],
2	criteria	NNS	O	criterion	nsubjpass	7	SENT_266	[p18l760t2342r855b2365],
3	for	IN	O	for	_	0	SENT_266	[p18l866t2339r905b2365],
4	distant	JJ	O	distant	amod	5	SENT_266	[p18l915t2339r1011b2365],
5	metastasis	NN	O	metastasis	prep_for	2	SENT_266	[p18l1023t2342r1171b2365],
6	are	VBP	O	be	auxpass	7	SENT_266	[p18l1184t2348r1224b2365],
7	defined	VBN	O	define	_	0	SENT_266	[p18l1236t2339r1339b2365],
8	as	IN	O	as	dep	9	SENT_266	[p18l1352t2348r1380b2365],
9	follows	VBZ	O	follow	advcl	7	SENT_266	[p18l1391t2339r1497b2365],
10	:	:	O	:	_	0	SENT_266	[p18l1391t2339r1497b2365],
11	Mo	NN	DURATION	mo	nsubj	42	SENT_266	[p18l1512t2341r1561b2369],
12	,	,	O	,	_	0	SENT_266	[p18l1512t2341r1561b2369],
13	no	DT	O	no	det	15	SENT_266	[p18l1576t2348r1608b2365],
14	detectable	JJ	O	detectable	amod	15	SENT_266	[p18l1620t2339r1714b2365, p18l121t2381r177b2406],
15	evidence	NN	O	evidence	appos	11	SENT_266	[p18l188t2381r310b2406],
16	ofdistant	JJ	O	ofdistant	amod	17	SENT_266	[p18l321t2381r453b2406],
17	metastases	NNS	O	metastase	dep	15	SENT_266	[p18l465t2386r630b2411],
18	;	:	O	;	_	0	SENT_266	[p18l465t2386r630b2411],
19	Mla	NNP	O	Mla	appos	11	SENT_266	[p18l644t2383r708b2411],
20	,	,	O	,	_	0	SENT_266	[p18l644t2383r708b2411],
21	metastases	NNS	O	metastase	appos	19	SENT_266	[p18l722t2386r878b2406],
22	to	TO	O	to	_	0	SENT_266	[p18l889t2386r916b2406],
23	skin	NN	O	skin	prep_to	21	SENT_266	[p18l928t2381r989b2411],
24	,	,	O	,	_	0	SENT_266	[p18l928t2381r989b2411],
25	subcutaneous	JJ	O	subcutaneous	amod	26	SENT_266	[p18l1003t2381r1197b2406],
26	tissue	NN	O	tissue	prep_to	21	SENT_266	[p18l1208t2383r1296b2411],
27	,	,	O	,	_	0	SENT_266	[p18l1208t2383r1296b2411],
28	or	CC	O	or	_	0	SENT_266	[p18l1309t2390r1337b2406],
29	distant	JJ	O	distant	amod	31	SENT_266	[p18l1348t2381r1443b2406],
30	lymph	NN	O	lymph	nn	31	SENT_266	[p18l1455t2381r1538b2414],
31	nodes	NNS	O	node	conj_or	23	SENT_266	[p18l1552t2381r1642b2411],
32	;	:	O	;	_	0	SENT_266	[p18l1552t2381r1642b2411],
33	Mlb	NNP	O	Mlb	conj_and	15	SENT_266	[p18l1656t2381r1721b2411],
34	,	,	O	,	_	0	SENT_266	[p18l1656t2381r1721b2411],
35	metastases	NNS	O	metastase	appos	33	SENT_266	[p18l122t2427r279b2448],
36	to	TO	O	to	_	0	SENT_266	[p18l290t2428r316b2448],
37	lung	NN	O	lung	prep_to	35	SENT_266	[p18l329t2423r395b2456],
38	;	:	O	;	_	0	SENT_266	[p18l329t2423r395b2456],
39	and	CC	O	and	_	0	SENT_266	[p18l408t2423r456b2448],
40	Mlc	NNP	O	Mlc	conj_and	15	SENT_266	[p18l471t2425r534b2452],
41	,	,	O	,	_	0	SENT_266	[p18l471t2425r534b2452],
42	metastases	NNS	O	metastase	parataxis	9	SENT_266	[p18l548t2428r704b2448],
43	to	TO	O	to	_	0	SENT_266	[p18l715t2428r742b2448],
44	all	DT	O	all	det	47	SENT_266	[p18l754t2423r782b2448],
45	other	JJ	O	other	amod	47	SENT_266	[p18l795t2423r868b2448],
46	visceral	JJ	O	visceral	amod	47	SENT_266	[p18l877t2423r980b2448],
47	sites	NNS	O	site	prep_to	42	SENT_266	[p18l993t2425r1054b2448],
48	or	CC	O	or	_	0	SENT_266	[p18l1066t2432r1094b2448],
49	distant	JJ	O	distant	amod	50	SENT_266	[p18l1105t2423r1200b2448],
50	metastases	NNS	O	metastase	parataxis	9	SENT_266	[p18l1213t2428r1369b2448],
51	to	TO	O	to	_	0	SENT_266	[p18l1380t2428r1407b2448],
52	any	DT	O	any	det	53	SENT_266	[p18l1419t2432r1465b2456],
53	site	NN	O	site	prep_to	50	SENT_266	[p18l1476t2425r1522b2448],
54	combined	VBN	O	combine	partmod	53	SENT_266	[p18l1534t2423r1670b2448],
55	with	IN	O	with	_	0	SENT_266	[p18l1682t2423r1739b2448],
56	an	DT	O	a	det	60	SENT_266	[p18l121t2473r151b2490],
57	elevated	JJ	O	elevated	amod	60	SENT_266	[p18l164t2464r277b2490],
58	serum	NN	O	serum	nn	60	SENT_266	[p18l291t2473r376b2490],
59	lactate	NN	O	lactate	nn	60	SENT_266	[p18l390t2464r480b2490],
60	dehydrogenase	NN	O	dehydrogenase	prep_with	54	SENT_266	[p18l491t2464r701b2498],
61	(	CD	NUMBER	(	num	64	SENT_266	[p18l716t2466r798b2497],
62	LDH	NN	O	ldh	nn	64	SENT_266	[p18l716t2466r798b2497],
63	)	NN	O	)	nn	64	SENT_266	[p18l716t2466r798b2497],
64	level	NN	O	level	nsubj	9	SENT_266	[p18l814t2464r882b2490],
65	.	.	O	.	_	0	SENT_266	[p18l814t2464r882b2490],

1	ULN	NNP	O	ULN	nsubj	2	SENT_267	[p18l896t2467r955b2490],
2	denotes	VBZ	O	denote	_	0	SENT_267	[p18l969t2464r1078b2490],
3	upper	JJ	O	upper	amod	7	SENT_267	[p18l1092t2473r1172b2497],
4	limit	NN	O	limit	nn	7	SENT_267	[p18l1183t2464r1244b2490],
5	ofthe	NN	O	ofthe	nn	7	SENT_267	[p18l1255t2464r1334b2490],
6	normal	JJ	O	normal	amod	7	SENT_267	[p18l1347t2464r1442b2490],
7	range	NN	O	range	dobj	2	SENT_267	[p18l1457t2473r1539b2498],
8	.	.	O	.	_	0	SENT_267	[p18l1457t2473r1539b2498],

1	N	NN	O	n	nn	3	SENT_268	[p18l594t2628r608b2643],
2	ENGLJ	NN	O	englj	nn	3	SENT_268	[p18l623t2628r701b2650],
3	MED	NN	O	med	_	0	SENT_268	[p18l715t2628r767b2643],
4	367	CD	NUMBER	367	dep	3	SENT_268	[p18l777t2622r855b2650],
5	;	:	O	;	_	0	SENT_268	[p18l777t2622r855b2650],
6	18	CD	NUMBER	18	num	8	SENT_268	[p18l777t2622r855b2650],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_268	[p18l890t2628r1014b2650],
8	NOVEMBER1	NN	O	november1	dep	4	SENT_268	[p18l1051t2628r1282b2648],
9	,2012	CD	NUMBER	,2012	number	10	SENT_268	[p18l1051t2628r1282b2648],
10	1701	CD	DATE	1701	dep	8	SENT_268	[p18l1991t2618r2067b2640],

1	The	DT	O	the	det	4	SENT_269	[p18l753t2661r804b2685],
2	New	NNP	O	New	nn	4	SENT_269	[p18l813t2662r875b2685],
3	England	NNP	O	England	nn	4	SENT_269	[p18l884t2661r995b2692],
4	Journal	NNP	O	Journal	_	0	SENT_269	[p18l1003t2661r1101b2685],
5	of	IN	O	of	_	0	SENT_269	[p18l1110t2661r1139b2685],
6	Medicine	NNP	O	Medicine	prep_of	4	SENT_269	[p18l1146t2661r1271b2685],

1	Copyright	NN	O	copyright	_	0	SENT_270	[p18l545t2743r680b2774],
2	©	CD	NUMBER	©	num	6	SENT_270	[p18l689t2743r712b2767],
3	2012	CD	DATE	2012	num	6	SENT_270	[p18l722t2743r787b2767],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_270	[p18l797t2743r988b2767],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_270	[p18l998t2743r1106b2767],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_270	[p18l1116t2743r1221b2774],
7	.	.	O	.	_	0	SENT_270	[p18l1116t2743r1221b2774],

1	All	DT	O	all	det	2	SENT_271	[p18l1232t2743r1274b2767],
2	rights	NNS	O	rights	nsubj	3	SENT_271	[p18l1283t2743r1357b2774],
3	reserved	VBN	O	reserve	_	0	SENT_271	[p18l1367t2743r1486b2767],
4	.	.	O	.	_	0	SENT_271	[p18l1367t2743r1486b2767],

1	The	DT	O	the	det	4	SENT_272	[p18l673t2849r718b2870],
2	NEW	NNP	O	NEW	nn	4	SENT_272	[p18l737t2851r822b2870],
3	ENGLAND	NNP	O	ENGLAND	nn	4	SENT_272	[p18l841t2851r1029b2870],
4	JOURNAL	NNP	O	JOURNAL	_	0	SENT_272	[p18l1048t2851r1227b2877],
5	of	IN	O	of	_	0	SENT_272	[p18l1247t2849r1275b2876],
6	MEDICINE	NNP	O	MEDICINE	prep_of	4	SENT_272	[p18l1287t2851r1486b2870],

1	We	PRP	O	we	nsubj	2	SENT_273	[p18l138t3081r271b3152],
2	hypothesized	VBD	O	hypothesize	_	0	SENT_273	[p18l302t3073r868b3174],
3	that	IN	O	that	complm	12	SENT_273	[p18l899t3073r1069b3152],
4	progression	NN	O	progression	nsubj	12	SENT_273	[p18l1093t3072r1790b3175],
5	—	CD	NUMBER	—	num	7	SENT_273	[p18l1093t3072r1790b3175],
6	free	JJ	O	free	amod	7	SENT_273	[p18l1093t3072r1790b3175],
7	survival	NN	O	survival	dep	4	SENT_273	[p18l1822t3073r2149b3153],
8	would	MD	O	would	aux	12	SENT_273	[p18l7t3202r267b3281],
9	be	VB	O	be	cop	12	SENT_273	[p18l303t3202r398b3281],
10	an	DT	O	a	det	12	SENT_273	[p18l434t3228r535b3280],
11	important	JJ	O	important	amod	12	SENT_273	[p18l570t3203r998b3302],
12	measure	NN	O	measure	ccomp	2	SENT_273	[p18l1029t3228r1380b3281],
13	of	IN	O	of	_	0	SENT_273	[p18l1417t3201r1515b3281],
14	the	DT	O	the	det	15	SENT_273	[p18l1534t3202r1663b3280],
15	ability	NN	O	ability	prep_of	12	SENT_273	[p18l1698t3202r1957b3302],
16	of	IN	O	of	_	0	SENT_273	[p18l1990t3201r2088b3281],
17	a	DT	O	a	det	19	SENT_273	[p18l2105t3228r2150b3280],
18	MEK	NN	O	mek	nn	19	SENT_273	[p18l9t3338r224b3412],
19	inhibitor	NN	O	inhibitor	prep_of	15	SENT_273	[p18l261t3331r646b3410],
20	to	TO	O	to	aux	21	SENT_273	[p18l685t3348r767b3410],
21	overcome	VB	O	overcome	infmod	15	SENT_273	[p18l810t3357r1221b3410],
22	acquired	VBN	O	acquire	dep	21	SENT_273	[p18l1262t3331r1635b3431],
23	or	CC	O	or	_	0	SENT_273	[p18l1677t3357r1766b3410],
24	de	FW	O	de	nn	26	SENT_273	[p18l1805t3331r1901b3409],
25	novo	FW	O	novo	nn	26	SENT_273	[p18l1943t3357r2147b3410],
26	resistance	NN	O	resistance	conj_or	15	SENT_273	[p18l12t3461r433b3538],
27	to	TO	O	to	_	0	SENT_273	[p18l468t3477r548b3539],
28	BRAF	NN	O	braf	nn	29	SENT_273	[p18l582t3466r824b3543],
29	inhibition	NN	O	inhibition	prep_to	26	SENT_273	[p18l857t3460r1302b3539],
30	.	.	O	.	_	0	SENT_273	[p18l857t3460r1302b3539],

1	Indeed	RB	O	indeed	advmod	10	SENT_274	[p18l1339t3460r1650b3556],
2	,	,	O	,	_	0	SENT_274	[p18l1339t3460r1650b3556],
3	the	DT	O	the	det	9	SENT_274	[p18l1689t3460r1821b3538],
4	combination	NN	O	combination	nn	9	SENT_274	[p18l1855t3460r2147b3539, p18l12t3589r290b3667],
5	150/2	CD	NUMBER	150/2	num	9	SENT_274	[p18l338t3593r567b3678],
6	(	CD	NUMBER	(	num	9	SENT_274	[p18l617t3587r1052b3680],
7	full-dose	NN	O	full-dose	nn	9	SENT_274	[p18l617t3587r1052b3680],
8	)	NN	O	)	nn	9	SENT_274	[p18l617t3587r1052b3680],
9	group	NN	O	group	nsubj	10	SENT_274	[p18l1101t3614r1356b3690],
10	had	VBD	O	have	dep	18	SENT_274	[p18l1402t3588r1560b3667],
11	significantly	RB	O	significantly	advmod	12	SENT_274	[p18l1606t3587r2152b3690],
12	longer	JJR	O	longer	amod	13	SENT_274	[p19l11t21r288b123],
13	progression	NN	O	progression	dobj	10	SENT_274	[p19l353t20r1065b123],
14	—	CD	NUMBER	—	num	16	SENT_274	[p19l353t20r1065b123],
15	free	JJ	O	free	amod	16	SENT_274	[p19l353t20r1065b123],
16	survival	NN	O	survival	npadvmod	17	SENT_274	[p19l1137t21r1471b101],
17	than	IN	O	than	advmod	18	SENT_274	[p19l1541t21r1739b100],
18	did	VBD	O	do	_	0	SENT_274	[p19l1809t21r1944b101],
19	the	DT	O	the	det	24	SENT_274	[p19l2014t21r2148b100],
20	monotherapy	NN	O	monotherapy	nn	24	SENT_274	[p19l12t150r579b250],
21	group	NN	O	group	nn	24	SENT_274	[p19l620t176r869b251],
22	(	CD	NUMBER	(	num	24	SENT_274	[p19l921t150r1242b241],
23	hazard	NN	O	hazard	nn	24	SENT_274	[p19l921t150r1242b241],
24	ratio	NN	O	ratio	nsubj	39	SENT_274	[p19l1287t151r1503b246],
25	,	,	O	,	_	0	SENT_274	[p19l1287t151r1503b246],
26	0.39	CD	NUMBER	0.39	num	28	SENT_274	[p19l1554t155r1751b245],
27	;	:	O	;	_	0	SENT_274	[p19l1554t155r1751b245],
28	95	CD	NUMBER	95	dep	24	SENT_274	[p19l1801t155r1984b229],
29	°	CD	NUMBER	°	dep	28	SENT_274	[p19l1801t155r1984b229],
30	/	:	O	/	punct	28	SENT_274	[p19l1801t155r1984b229],
31	o	NN	O	o	nn	32	SENT_274	[p19l1801t155r1984b229],
32	CI	NN	O	ci	dep	28	SENT_274	[p19l2029t155r2143b246],
33	,	,	O	,	_	0	SENT_274	[p19l2029t155r2143b246],
34	0.25	CD	NUMBER	0.25	num	36	SENT_274	[p19l12t284r186b358],
35	to	TO	O	to	dep	36	SENT_274	[p19l226t295r307b358],
36	0.62	CD	NUMBER	0.62	appos	32	SENT_274	[p19l344t284r542b374],
37	;	:	O	;	_	0	SENT_274	[p19l344t284r542b374],
38	P	NN	O	p	dep	32	SENT_274	[p19l581t284r964b370],
39	<	JJR	O	<	xcomp	18	SENT_274	[p19l581t284r964b370],
40	0.001	CD	NUMBER	0.001	num	41	SENT_274	[p19l581t284r964b370],
41	)	NN	O	)	nsubj	18	SENT_274	[p19l581t284r964b370],
42	.	.	O	.	_	0	SENT_274	[p19l581t284r964b370],

1	The	DT	O	the	det	2	SENT_275	[p19l1001t278r1161b357],
2	percentage	NN	O	percentage	dep	16	SENT_275	[p19l1196t295r1658b380],
3	of	IN	O	of	_	0	SENT_275	[p19l1695t277r1794b357],
4	patients	NNS	O	patient	prep_of	2	SENT_275	[p19l1810t279r2146b379],
5	who	WP	O	who	nsubj	9	SENT_275	[p19l7t407r189b487],
6	Were	VBD	O	be	cop	7	SENT_275	[p19l220t433r420b487],
7	alive	JJ	O	alive	rcmod	4	SENT_275	[p19l453t407r643b487],
8	and	CC	O	and	_	0	SENT_275	[p19l676t407r833b486],
9	progression-free	JJ	O	progression-free	rcmod	4	SENT_275	[p19l865t406r1561b509],
10	at	IN	O	at	_	0	SENT_275	[p19l1595t424r1674b486],
11	1	CD	DURATION	1	prep_at	7	SENT_275	[p19l1705t413r1750b485],
12	year	NN	NUMBER	year	tmod	7	SENT_275	[p19l1780t433r1957b508],
13	was	VBD	O	be	cop	16	SENT_275	[p19l1984t433r2145b487],
14	also	RB	O	also	advmod	16	SENT_275	[p19l11t536r184b615],
15	substantially	RB	O	substantially	advmod	16	SENT_275	[p19l229t536r785b636],
16	higher	JJR	O	higher	_	0	SENT_275	[p19l822t536r1105b637],
17	(	CD	NUMBER	(	num	19	SENT_275	[p19l1149t541r1350b627],
18	41	CD	NUMBER	41	num	19	SENT_275	[p19l1149t541r1350b627],
19	°	NN	O	°	nsubj	16	SENT_275	[p19l1149t541r1350b627],
20	/	:	O	/	punct	21	SENT_275	[p19l1149t541r1350b627],
21	o	NN	O	o	dep	19	SENT_275	[p19l1149t541r1350b627],
22	vs.	IN	O	vs.	_	0	SENT_275	[p19l1387t562r1496b615],
23	9	CD	PERCENT	9	num	24	SENT_275	[p19l1544t541r1704b632],
24	%	NN	PERCENT	%	prep_vs.	21	SENT_275	[p19l1544t541r1704b632],
25	,	,	O	,	_	0	SENT_275	[p19l1544t541r1704b632],
26	P	NN	O	p	dep	27	SENT_275	[p19l1750t541r2142b627],
27	<	JJR	O	<	appos	19	SENT_275	[p19l1750t541r2142b627],
28	0.001	CD	NUMBER	0.001	num	29	SENT_275	[p19l1750t541r2142b627],
29	)	NN	O	)	dep	27	SENT_275	[p19l1750t541r2142b627],
30	.	.	O	.	_	0	SENT_275	[p19l1750t541r2142b627],

1	The	DT	O	the	det	2	SENT_276	[p19l8t664r166b743],
2	extent	NN	O	extent	nsubj	8	SENT_276	[p19l200t681r454b743],
3	of	IN	O	of	_	0	SENT_276	[p19l483t663r581b743],
4	tumor	NN	O	tumor	nn	5	SENT_276	[p19l597t681r858b744],
5	regression	NN	O	regression	prep_of	2	SENT_276	[p19l888t665r1318b766],
6	Was	VBD	O	be	cop	8	SENT_276	[p19l1347t690r1507b744],
7	also	RB	O	also	advmod	8	SENT_276	[p19l1541t664r1708b743],
8	greater	JJR	O	greater	_	0	SENT_276	[p19l1742t681r2036b766],
9	in	IN	O	in	_	0	SENT_276	[p19l2066t665r2147b742],
10	the	DT	O	the	det	13	SENT_276	[p19l12t793r146b871],
11	combination	NN	O	combination	nn	13	SENT_276	[p19l191t793r741b872],
12	150/2	CD	NUMBER	150/2	num	13	SENT_276	[p19l788t798r1017b882],
13	group	NN	O	group	prep_in	8	SENT_276	[p19l1062t819r1339b894],
14	,	,	O	,	_	0	SENT_276	[p19l1062t819r1339b894],
15	with	IN	O	with	_	0	SENT_276	[p19l1384t793r1581b872],
16	an	DT	O	a	det	19	SENT_276	[p19l1624t819r1728b871],
17	objective	JJ	O	objective	amod	19	SENT_276	[p19l1773t793r2148b893],
18	response	NN	O	response	nn	19	SENT_276	[p19l12t947r395b1021],
19	rate	NN	O	rate	prep_with	8	SENT_276	[p19l453t938r614b999],
20	of	IN	O	of	_	0	SENT_276	[p19l673t920r773b1000],
21	76	CD	NUMBER	76	number	22	SENT_276	[p19l813t926r1017b1017],
22	°	CD	NUMBER	°	prep_of	19	SENT_276	[p19l813t926r1017b1017],
23	/	:	O	/	punct	24	SENT_276	[p19l813t926r1017b1017],
24	o	NN	O	o	dep	22	SENT_276	[p19l813t926r1017b1017],
25	,	,	O	,	_	0	SENT_276	[p19l813t926r1017b1017],
26	as	IN	O	as	mark	27	SENT_276	[p19l1080t947r1165b999],
27	compared	VBN	O	compare	advcl	8	SENT_276	[p19l1226t921r1656b1021],
28	With	IN	O	with	_	0	SENT_276	[p19l1709t921r1905b1000],
29	54	CD	PERCENT	54	num	30	SENT_276	[p19l1965t926r2149b1000],
30	%	NN	PERCENT	%	prep_with	27	SENT_276	[p19l1965t926r2149b1000],
31	with	IN	O	with	_	0	SENT_276	[p19l7t1050r204b1129],
32	monotherapy	NN	O	monotherapy	nn	34	SENT_276	[p19l275t1050r852b1150],
33	(	CD	NUMBER	(	num	34	SENT_276	[p19l924t1055r1320b1141],
34	P	NN	O	p	prep_with	30	SENT_276	[p19l924t1055r1320b1141],
35	=	JJ	O	=	amod	37	SENT_276	[p19l924t1055r1320b1141],
36	0.03	CD	NUMBER	0.03	tmod	35	SENT_276	[p19l924t1055r1320b1141],
37	)	NN	O	)	dobj	27	SENT_276	[p19l924t1055r1320b1141],
38	.	.	O	.	_	0	SENT_276	[p19l924t1055r1320b1141],

1	In	IN	O	in	_	0	SENT_277	[p19l1396t1057r1485b1127],
2	addition	NN	O	addition	prep_in	11	SENT_277	[p19l1555t1050r1937b1146],
3	,	,	O	,	_	0	SENT_277	[p19l1555t1050r1937b1146],
4	the	DT	O	the	det	6	SENT_277	[p19l2014t1050r2148b1128],
5	median	JJ	O	median	amod	6	SENT_277	[p19l12t1178r337b1256],
6	duration	NN	O	duration	nsubjpass	11	SENT_277	[p19l390t1178r758b1257],
7	of	IN	O	of	_	0	SENT_277	[p19l811t1177r912b1257],
8	response	NN	O	response	prep_of	6	SENT_277	[p19l945t1204r1328b1278],
9	was	VBD	O	be	auxpass	11	SENT_277	[p19l1376t1204r1539b1257],
10	substantially	RB	O	substantially	advmod	11	SENT_277	[p19l1596t1178r2152b1278],
11	improved	VBN	O	improve	_	0	SENT_277	[p19l11t1307r411b1407],
12	with	IN	O	with	_	0	SENT_277	[p19l439t1307r632b1386],
13	combination	NN	O	combination	nn	14	SENT_277	[p19l666t1307r1205b1386],
14	therapy	NN	O	therapy	prep_with	11	SENT_277	[p19l1239t1307r1568b1407],
15	,	,	O	,	_	0	SENT_277	[p19l1239t1307r1568b1407],
16	as	IN	O	as	_	0	SENT_277	[p19l1606t1333r1691b1385],
17	compared	VBN	O	compare	prepc_as	11	SENT_277	[p19l1727t1307r2148b1407],
18	with	IN	O	with	pcomp	17	SENT_277	[p19l7t1435r204b1514],
19	dabrafenib	NN	O	dabrafenib	nn	20	SENT_277	[p19l255t1434r722b1514],
20	monotherapy	NN	O	monotherapy	pobj	18	SENT_277	[p19l774t1435r1352b1535],
21	(	CD	NUMBER	(	number	22	SENT_277	[p19l1403t1441r1601b1526],
22	10.5	CD	DURATION	10.5	num	23	SENT_277	[p19l1403t1441r1601b1526],
23	months	NNS	NUMBER	month	tmod	20	SENT_277	[p19l1656t1435r1984b1514],
24	vs.	CC	O	vs.	prep	20	SENT_277	[p19l2032t1461r2142b1514],
25	5.6	CD	DURATION	5.6	num	26	SENT_277	[p19l14t1568r137b1642],
26	months	NNS	NUMBER	month	dep	24	SENT_277	[p19l186t1563r566b1654],
27	)	RB	O	)	advmod	18	SENT_277	[p19l186t1563r566b1654],
28	.	.	O	.	_	0	SENT_277	[p19l186t1563r566b1654],

1	Although	IN	O	although	mark	5	SENT_278	[p19l615t1563r1025b1664],
2	We	PRP	O	we	nsubj	5	SENT_278	[p19l1068t1589r1186b1642],
3	did	VBD	O	do	aux	5	SENT_278	[p19l1235t1563r1370b1642],
4	not	RB	O	not	neg	5	SENT_278	[p19l1417t1580r1560b1642],
5	evaluate	VB	O	evaluate	advcl	23	SENT_278	[p19l1603t1563r1951b1642],
6	trametinib	NN	O	trametinib	nn	7	SENT_278	[p19l1998t1580r2147b1641, p19l12t1691r350b1770],
7	monotherapy	NN	O	monotherapy	dobj	5	SENT_278	[p19l395t1691r973b1791],
8	in	IN	O	in	_	0	SENT_278	[p19l1013t1692r1097b1768],
9	this	DT	O	this	det	10	SENT_278	[p19l1142t1691r1303b1769],
10	trial	NN	O	trial	prep_in	5	SENT_278	[p19l1350t1691r1552b1787],
11	,	,	O	,	_	0	SENT_278	[p19l1350t1691r1552b1787],
12	progressionfree	NN	O	progressionfree	nn	13	SENT_278	[p19l1600t1692r2147b1792, p19l12t1818r168b1897],
13	survival	NN	O	survival	nsubj	23	SENT_278	[p19l198t1819r517b1898],
14	with	IN	O	with	_	0	SENT_278	[p19l540t1819r730b1898],
15	trametinib	NN	O	trametinib	prep_with	13	SENT_278	[p19l758t1819r1200b1898],
16	in	IN	O	in	_	0	SENT_278	[p19l1229t1820r1311b1896],
17	patients	NNS	O	patient	prep_in	15	SENT_278	[p19l1337t1820r1666b1919],
18	With	IN	O	with	_	0	SENT_278	[p19l1692t1819r1882b1898],
19	BRAF	NN	O	braf	nn	21	SENT_278	[p19l1908t1826r2147b1902],
20	V600	NN	O	v600	nn	21	SENT_278	[p19l8t1953r221b2027],
21	melanoma	NN	O	melanoma	prep_with	17	SENT_278	[p19l257t1948r710b2027],
22	was	VBD	O	be	cop	23	SENT_278	[p19l739t1974r900b2027],
23	similar	JJ	O	similar	_	0	SENT_278	[p19l939t1948r1241b2026],
24	to	TO	O	to	_	0	SENT_278	[p19l1274t1965r1355b2027],
25	the	DT	O	the	det	26	SENT_278	[p19l1392t1948r1523b2026],
26	outcome	NN	O	outcome	prep_to	23	SENT_278	[p19l1560t1964r1924b2027],
27	with	IN	O	with	_	0	SENT_278	[p19l1955t1948r2148b2027],
28	dabrafenib	NN	O	dabrafenib	nn	31	SENT_278	[p19l13t2075r470b2155],
29	or	CC	O	or	_	0	SENT_278	[p19l503t2102r590b2155],
30	vemurafenib	NN	O	vemurafenib	nn	31	SENT_278	[p19l614t2075r1147b2155],
31	monotherapy	NN	O	monotherapy	prep_with	26	SENT_278	[p19l1179t2076r1746b2176],
32	observed	VBN	O	observe	partmod	31	SENT_278	[p19l1773t2076r2148b2155],
33	in	IN	O	in	_	0	SENT_278	[p19l11t2205r94b2281],
34	our	PRP$	O	we	poss	35	SENT_278	[p19l126t2230r271b2283],
35	trial	NN	O	trial	prep_in	32	SENT_278	[p19l300t2204r475b2282],
36	and	CC	O	and	_	0	SENT_278	[p19l505t2204r662b2283],
37	several	JJ	O	several	amod	39	SENT_278	[p19l695t2204r982b2283],
38	other	JJ	O	other	amod	39	SENT_278	[p19l1013t2204r1238b2283],
39	trials	NNS	O	trial	prep_in	32	SENT_278	[p19l1267t2204r1715b2282],
40	.3	NN	NUMBER	.3	dep	45	SENT_278	[p19l1267t2204r1715b2282],
41	>	JJR	O	>	dep	40	SENT_278	[p19l1267t2204r1715b2282],
42	4	CD	NUMBER	4	num	43	SENT_278	[p19l1267t2204r1715b2282],
43	’	NN	O	’	dep	45	SENT_278	[p19l1267t2204r1715b2282],
44	6	CD	NUMBER	6	num	45	SENT_278	[p19l1267t2204r1715b2282],
45	’	NN	O	’	dep	51	SENT_278	[p19l1267t2204r1715b2282],
46	8	CD	NUMBER	8	dep	45	SENT_278	[p19l1267t2204r1715b2282],
47	Together	RB	O	together	advmod	51	SENT_278	[p19l1744t2204r2143b2305],
48	,	,	O	,	_	0	SENT_278	[p19l1744t2204r2143b2305],
49	these	DT	O	these	det	50	SENT_278	[p19l12t2333r233b2411],
50	data	NNS	O	datum	nsubj	51	SENT_278	[p19l265t2333r446b2412],
51	corroborate	VBP	O	corroborate	ccomp	23	SENT_278	[p19l477t2333r970b2412],
52	previous	JJ	O	previous	amod	53	SENT_278	[p19l1000t2334r1357b2433],
53	reports	NNS	O	report	dobj	51	SENT_278	[p19l1391t2350r1693b2433],
54	that	IN	O	that	complm	62	SENT_278	[p19l1727t2333r1897b2411],
55	resistance	NN	O	resistance	nsubj	62	SENT_278	[p19l1924t2334r2147b2411, p19l12t2479r238b2540],
56	to	TO	O	to	_	0	SENT_278	[p19l274t2479r356b2541],
57	BRAF	NN	O	braf	nn	60	SENT_278	[p19l394t2462r1061b2545],
58	—	NN	O	—	nn	60	SENT_278	[p19l394t2462r1061b2545],
59	inhibitor	NN	O	inhibitor	nn	60	SENT_278	[p19l394t2462r1061b2545],
60	therapy	NN	O	therapy	prep_to	55	SENT_278	[p19l1095t2462r1418b2562],
61	is	VBZ	O	be	cop	62	SENT_278	[p19l1450t2463r1516b2540],
62	dependent	JJ	O	dependent	ccomp	51	SENT_278	[p19l1556t2462r2009b2562],
63	on	IN	O	on	_	0	SENT_278	[p19l2041t2488r2148b2541],
64	the	DT	O	the	det	66	SENT_278	[p19l12t2590r142b2668],
65	MAPK	NN	ORGANIZATION	mapk	nn	66	SENT_278	[p19l170t2597r442b2671],
66	pathway	NN	O	pathway	prep_on	62	SENT_278	[p19l469t2590r819b2690],
67	and	CC	O	and	_	0	SENT_278	[p19l845t2590r999b2668],
68	that	IN	O	that	complm	79	SENT_278	[p19l1031t2590r1198b2668],
69	the	DT	O	the	det	70	SENT_278	[p19l1224t2590r1353b2668],
70	addition	NN	O	addition	nsubj	79	SENT_278	[p19l1384t2590r1728b2669],
71	of	IN	O	of	_	0	SENT_278	[p19l1759t2589r1858b2669],
72	a	DT	O	a	det	74	SENT_278	[p19l1870t2616r1914b2668],
73	MEK	NN	O	mek	nn	74	SENT_278	[p19l1941t2598r2152b2671],
74	inhibitor	NN	O	inhibitor	prep_of	70	SENT_278	[p19l11t2719r387b2798],
75	to	TO	O	to	_	0	SENT_278	[p19l416t2736r497b2798],
76	a	DT	O	a	det	78	SENT_278	[p19l529t2745r573b2797],
77	BRAF	NN	O	braf	nn	78	SENT_278	[p19l603t2725r844b2802],
78	inhibitor	NN	O	inhibitor	prep_to	74	SENT_278	[p19l877t2719r1252b2798],
79	represents	VBZ	O	represent	conj_and	51	SENT_278	[p19l1280t2736r1715b2819],
80	one	CD	NUMBER	one	num	81	SENT_278	[p19l1749t2745r1900b2798],
81	strategy	NN	O	strategy	dobj	79	SENT_278	[p19l1932t2736r2147b2797, p19l12t2873r159b2949],
82	for	IN	O	for	_	0	SENT_278	[p19l187t2846r311b2926],
83	delaying	VBG	O	delay	prepc_for	81	SENT_278	[p19l342t2847r708b2949],
84	the	DT	O	the	det	85	SENT_278	[p19l738t2847r872b2926],
85	emergence	NN	O	emergence	dobj	83	SENT_278	[p19l906t2873r1370b2949],
86	of	IN	O	of	_	0	SENT_278	[p19l1405t2846r1505b2926],
87	this	DT	O	this	det	89	SENT_278	[p19l1521t2847r1682b2926],
88	resistance	NN	O	resistance	nn	89	SENT_278	[p19l1717t2848r2148b2926],
89	mechanism	NN	O	mechanism	prep_of	85	SENT_278	[p19l12t2977r539b3055],
90	.	.	O	.	_	0	SENT_278	[p19l12t2977r539b3055],

1	Currently	RB	DATE	currently	advmod	4	SENT_279	[p19l142t3105r565b3205],
2	,	,	O	,	_	0	SENT_279	[p19l142t3105r565b3205],
3	We	PRP	O	we	nsubj	4	SENT_279	[p19l609t3131r728b3184],
4	have	VBP	O	have	_	0	SENT_279	[p19l771t3105r962b3184],
5	very	RB	O	very	advmod	6	SENT_279	[p19l1001t3131r1180b3205],
6	little	JJ	O	little	amod	7	SENT_279	[p19l1217t3105r1416b3183],
7	insight	NN	O	insight	dobj	4	SENT_279	[p19l1458t3105r1762b3206],
8	into	IN	O	into	_	0	SENT_279	[p19l1799t3106r1969b3184],
9	the	DT	O	the	det	10	SENT_279	[p19l2014t3105r2148b3183],
10	mechanisms	NNS	O	mechanism	prep_into	4	SENT_279	[p19l12t3233r559b3311],
11	of	IN	O	of	_	0	SENT_279	[p19l609t3232r710b3312],
12	resistance	NN	O	resistance	prep_of	10	SENT_279	[p19l739t3234r1169b3311],
13	for	IN	O	for	_	0	SENT_279	[p19l1218t3232r1342b3312],
14	this	DT	O	this	det	16	SENT_279	[p19l1387t3233r1547b3311],
15	combination	NN	O	combination	nn	16	SENT_279	[p19l1598t3233r2148b3312],
16	regimen	NN	O	regimen	prep_for	12	SENT_279	[p19l12t3362r394b3462],
17	.	.	O	.	_	0	SENT_279	[p19l12t3362r394b3462],

1	It	PRP	O	it	nsubj	3	SENT_280	[p19l446t3368r511b3439],
2	is	VBZ	O	be	cop	3	SENT_280	[p19l553t3362r619b3439],
3	critical	JJ	O	critical	_	0	SENT_280	[p19l670t3361r968b3439],
4	to	TO	O	to	aux	5	SENT_280	[p19l1015t3378r1097b3440],
5	determine	VB	O	determine	xcomp	3	SENT_280	[p19l1147t3361r1587b3440],
6	Whether	NNP	O	Whether	nn	7	SENT_280	[p19l1631t3361r1988b3440],
7	resistance	NN	O	resistance	nsubjpass	9	SENT_280	[p19l2033t3387r2147b3439, p19l13t3490r358b3567],
8	is	VBZ	O	be	auxpass	9	SENT_280	[p19l391t3490r456b3567],
9	mediated	VBN	O	mediate	ccomp	5	SENT_280	[p19l492t3489r893b3568],
10	by	IN	O	by	_	0	SENT_280	[p19l927t3489r1025b3589],
11	reactivation	NN	O	reactivation	agent	9	SENT_280	[p19l1053t3490r1559b3568],
12	of	IN	O	of	_	0	SENT_280	[p19l1593t3488r1694b3568],
13	the	DT	O	the	det	15	SENT_280	[p19l1709t3489r1843b3567],
14	MAPK	NN	O	mapk	nn	15	SENT_280	[p19l1873t3496r2152b3570],
15	pathway	NN	O	pathway	prep_of	11	SENT_280	[p19l11t3618r373b3718],
16	or	CC	O	or	_	0	SENT_280	[p19l408t3644r497b3697],
17	by	IN	O	by	_	0	SENT_280	[p19l533t3618r630b3718],
18	MAPK-independent	JJ	O	mapk-independent	amod	21	SENT_280	[p19l660t3618r1505b3718],
19	compensatory	JJ	O	compensatory	amod	21	SENT_280	[p19l1539t3635r2153b3718],
20	signaling	NN	O	signaling	nn	21	SENT_280	[p20l13t21r411b122],
21	pathways	NNS	O	pathway	conj_or	11	SENT_280	[p20l443t21r837b121],
22	that	WDT	O	that	nsubjpass	25	SENT_280	[p20l875t21r1046b99],
23	have	VBP	O	have	aux	25	SENT_280	[p20l1077t21r1265b100],
24	been	VBN	O	be	auxpass	25	SENT_280	[p20l1302t21r1502b100],
25	described	VBN	O	describe	rcmod	21	SENT_280	[p20l1539t21r1944b100],
26	previously	RB	DATE	previously	advmod	25	SENT_280	[p20l1979t47r2147b121, p20l7t149r303b249],
27	in	IN	O	in	_	0	SENT_280	[p20l342t150r425b226],
28	preclinical	JJ	O	preclinical	amod	29	SENT_280	[p20l468t149r926b249],
29	models	NNS	O	model	prep_in	25	SENT_280	[p20l970t149r1281b228],
30	of	IN	O	of	_	0	SENT_280	[p20l1328t148r1429b228],
31	melanoma	NN	O	melanoma	prep_of	29	SENT_280	[p20l1454t149r1914b228],
32	with	IN	O	with	_	0	SENT_280	[p20l1952t149r2148b228],
33	BRAF	NN	O	braf	nn	34	SENT_280	[p20l11t284r253b361],
34	mutations	NNS	O	mutation	prep_with	25	SENT_280	[p20l287t279r739b357],
35	.	.	O	.	_	0	SENT_280	[p20l287t279r739b357],

1	Our	PRP$	O	we	poss	2	SENT_281	[p20l779t283r945b357],
2	trial	NN	O	trial	nsubj	3	SENT_281	[p20l975t278r1150b356],
3	provides	VBZ	O	provide	_	0	SENT_281	[p20l1182t278r1537b378],
4	evidence	NN	O	evidence	dobj	3	SENT_281	[p20l1574t278r1934b357],
5	supporting	VBG	O	support	partmod	4	SENT_281	[p20l1968t304r2147b378, p20l11t407r331b507],
6	the	DT	O	the	det	7	SENT_281	[p20l360t406r492b484],
7	efficacy	NN	O	efficacy	dobj	5	SENT_281	[p20l527t405r863b506],
8	of	IN	O	of	_	0	SENT_281	[p20l893t405r992b485],
9	a	DT	O	a	det	11	SENT_281	[p20l1006t432r1051b484],
10	combination	NN	O	combination	nn	11	SENT_281	[p20l1083t406r1630b485],
11	regimen	NN	O	regimen	prep_of	7	SENT_281	[p20l1663t407r2018b507],
12	of	IN	O	of	_	0	SENT_281	[p20l2053t405r2152b485],
13	BRAF	NN	O	braf	prep_of	11	SENT_281	[p20l11t541r525b618],
14	.	.	O	.	_	0	SENT_281	[p20l11t541r525b618],

1	—	NN	O	—	_	0	SENT_282	[p20l11t541r525b618],
2	.	.	O	.	_	0	SENT_282	[p20l11t541r525b618],

1	MEK	NN	O	mek	nn	2	SENT_283	[p20l11t541r525b618],
2	inhibitors	NNS	O	inhibitor	_	0	SENT_283	[p20l578t535r999b614],
3	in	IN	O	in	_	0	SENT_283	[p20l1058t536r1141b612],
4	advanced	JJ	O	advanced	amod	5	SENT_283	[p20l1197t535r1593b614],
5	melanoma	NN	O	melanoma	prep_in	2	SENT_283	[p20l1650t535r2129b614],
6	.	.	O	.	_	0	SENT_283	[p20l1650t535r2129b614],

1	Two	CD	NUMBER	two	nsubj	2	SENT_284	[p20l8t669r182b742],
2	randomized	VBN	O	randomize	_	0	SENT_284	[p20l214t663r748b759],
3	,	,	O	,	_	0	SENT_284	[p20l214t663r748b759],
4	phase	NN	O	phase	dobj	2	SENT_284	[p20l783t663r1027b763],
5	3	CD	NUMBER	3	num	6	SENT_284	[p20l1059t668r1102b742],
6	trials	NNS	O	trial	nsubjpass	14	SENT_284	[p20l1138t663r1351b741],
7	involving	VBG	O	involve	_	0	SENT_284	[p20l1384t663r1772b764],
8	patients	NNS	O	patient	prep_involving	6	SENT_284	[p20l1798t664r2132b763],
9	With	IN	O	with	_	0	SENT_284	[p20l7t792r202b871],
10	metastatic	JJ	O	metastatic	amod	11	SENT_284	[p20l258t793r705b870],
11	melanoma	NN	O	melanoma	prep_with	8	SENT_284	[p20l760t792r1217b871],
12	have	VBP	O	have	aux	14	SENT_284	[p20l1271t792r1461b871],
13	been	VBN	O	be	auxpass	14	SENT_284	[p20l1518t792r1719b871],
14	initiated	VBN	O	initiate	rcmod	4	SENT_284	[p20l1774t792r2134b871],

1	(	NN	O	(	nn	2	SENT_285	[p20l17t920r804b1021],
2	ClinicalTrials	NNS	O	clinicaltrial	_	0	SENT_285	[p20l17t920r804b1021],
3	.	.	O	.	_	0	SENT_285	[p20l17t920r804b1021],

1	gov	NN	O	gov	nn	2	SENT_286	[p20l17t920r804b1021],
2	numbers	NNS	O	number	_	0	SENT_286	[p20l850t920r1252b1016],
3	,	,	O	,	_	0	SENT_286	[p20l850t920r1252b1016],
4	NCTO1584648	NN	O	ncto1584648	nn	7	SENT_286	[p20l1305t925r1925b999],
5	and	CC	O	and	_	0	SENT_286	[p20l1976t920r2134b999],
6	NCTO1597908	NN	O	ncto1597908	conj_and	4	SENT_286	[p20l10t1054r662b1139],
7	)	NN	O	)	appos	2	SENT_286	[p20l10t1054r662b1139],
8	.	.	O	.	_	0	SENT_286	[p20l10t1054r662b1139],

1	Interpretation	NN	O	interpretation	nsubjpass	8	SENT_287	[p20l699t1049r1289b1148],
2	of	IN	O	of	_	0	SENT_287	[p20l1323t1047r1421b1127],
3	the	DT	O	the	det	5	SENT_287	[p20l1436t1048r1566b1126],
4	survival	NN	O	survival	nn	5	SENT_287	[p20l1600t1048r1924b1127],
5	data	NNS	O	datum	prep_of	1	SENT_287	[p20l1957t1048r2136b1127],
6	may	MD	O	may	aux	8	SENT_287	[p20l12t1202r189b1276],
7	be	VB	O	be	auxpass	8	SENT_287	[p20l217t1176r312b1255],
8	confounded	VBN	O	confound	_	0	SENT_287	[p20l345t1175r848b1255],
9	by	IN	O	by	_	0	SENT_287	[p20l880t1176r976b1276],
10	the	DT	O	the	det	11	SENT_287	[p20l1004t1176r1135b1254],
11	inclusion	NN	O	inclusion	agent	8	SENT_287	[p20l1166t1176r1550b1255],
12	of	IN	O	of	_	0	SENT_287	[p20l1583t1175r1682b1255],
13	a	DT	O	a	det	14	SENT_287	[p20l1695t1202r1739b1254],
14	minority	NN	O	minority	prep_of	11	SENT_287	[p20l1770t1177r2139b1276],
15	of	IN	O	of	_	0	SENT_287	[p20l12t1303r113b1383],
16	patients	NNS	O	patient	prep_of	14	SENT_287	[p20l135t1305r477b1404],
17	who	WP	O	who	nsubj	18	SENT_287	[p20l517t1304r700b1383],
18	received	VBD	O	receive	rcmod	16	SENT_287	[p20l743t1304r1089b1383],
19	immunotherapy	NN	O	immunotherapy	dobj	18	SENT_287	[p20l1131t1304r1827b1404],
20	before	IN	O	before	_	0	SENT_287	[p20l1865t1303r2134b1383],
21	enrollment	NN	O	enrollment	prep_before	18	SENT_287	[p20l12t1432r500b1527],
22	,	,	O	,	_	0	SENT_287	[p20l12t1432r500b1527],
23	and	CC	O	and	_	0	SENT_287	[p20l545t1432r701b1510],
24	additional	JJ	O	additional	amod	25	SENT_287	[p20l741t1432r1168b1510],
25	patients	NNS	O	patient	nsubjpass	28	SENT_287	[p20l1206t1433r1540b1531],
26	Would	MD	O	would	aux	28	SENT_287	[p20l1578t1432r1840b1511],
27	be	VB	O	be	auxpass	28	SENT_287	[p20l1881t1432r1976b1510],
28	expected	VBN	O	expect	conj_and	8	SENT_287	[p20l2018t1458r2133b1509, p20l11t1560r287b1659],
29	to	TO	O	to	aux	30	SENT_287	[p20l338t1576r420b1638],
30	receive	VB	O	receive	xcomp	28	SENT_287	[p20l474t1561r763b1639],
31	such	JJ	O	such	amod	32	SENT_287	[p20l817t1560r1011b1639],
32	therapy	NN	O	therapy	dobj	30	SENT_287	[p20l1063t1560r1385b1659],
33	on	IN	O	on	_	0	SENT_287	[p20l1434t1585r1540b1638],
34	disease	NN	O	disease	nn	35	SENT_287	[p20l1593t1560r1903b1638],
35	progression	NN	O	progression	prep_on	30	SENT_287	[p20l1954t1585r2133b1659, p20l12t1690r397b1789],
36	.	.	O	.	_	0	SENT_287	[p20l1954t1585r2133b1659, p20l12t1690r397b1789],

1	Despite	IN	O	despite	_	0	SENT_288	[p20l140t1817r460b1916],
2	successful	JJ	O	successful	amod	3	SENT_288	[p20l502t1815r941b1895],
3	development	NN	O	development	prep_despite	37	SENT_288	[p20l982t1816r1531b1916],
4	of	IN	O	of	_	0	SENT_288	[p20l1567t1815r1667b1895],
5	oncogenetargeted	JJ	O	oncogenetargeted	amod	6	SENT_288	[p20l1690t1842r2133b1917, p20l12t1944r367b2045],
6	therapy	NN	O	therapy	prep_of	3	SENT_288	[p20l403t1944r724b2044],
7	for	IN	O	for	_	0	SENT_288	[p20l755t1943r878b2023],
8	chronic	JJ	O	chronic	amod	10	SENT_288	[p20l911t1944r1234b2023],
9	myeloid	JJ	O	myeloid	amod	10	SENT_288	[p20l1268t1944r1604b2044],
10	leukemia	NN	O	leukemia	prep_for	6	SENT_288	[p20l1637t1944r2134b2040],
11	,	,	O	,	_	0	SENT_288	[p20l1637t1944r2134b2040],
12	”	CD	NUMBER	”	num	15	SENT_288	[p20l1637t1944r2134b2040],
13	gastrointestinal	JJ	O	gastrointestinal	amod	15	SENT_288	[p20l12t2072r678b2173],
14	stromal	JJ	O	stromal	amod	15	SENT_288	[p20l712t2072r1036b2151],
15	tumor	NN	O	tumor	conj_and	6	SENT_288	[p20l1070t2078r1426b2168],
16	,23	CD	NUMBER	,23	dep	15	SENT_288	[p20l1070t2078r1426b2168],
17	and	CC	O	and	_	0	SENT_288	[p20l1460t2072r1616b2151],
18	subtypes	NNS	O	subtype	conj_and	6	SENT_288	[p20l1650t2072r2018b2172],
19	of	IN	O	of	_	0	SENT_288	[p20l2054t2071r2152b2151],
20	breast	NN	O	breast	nn	21	SENT_288	[p20l12t2200r270b2279],
21	cancer	NN	O	cancer	prep_of	18	SENT_288	[p20l297t2226r572b2278],
22	and	CC	O	and	_	0	SENT_288	[p20l600t2200r755b2279],
23	non	JJ	O	non	amod	29	SENT_288	[p20l786t2200r1415b2279],
24	—	JJ	O	—	amod	29	SENT_288	[p20l786t2200r1415b2279],
25	small	JJ	O	small	amod	29	SENT_288	[p20l786t2200r1415b2279],
26	—	NN	O	—	nn	29	SENT_288	[p20l786t2200r1415b2279],
27	cell	NN	O	cell	nn	29	SENT_288	[p20l786t2200r1415b2279],
28	lung	NN	O	lung	nn	29	SENT_288	[p20l1445t2200r1635b2301],
29	cancer	NN	O	cancer	conj_and	3	SENT_288	[p20l1663t2204r2134b2296],
30	,24	CD	NUMBER	,24	number	31	SENT_288	[p20l1663t2204r2134b2296],
31	'26	CD	NUMBER	'26	dep	29	SENT_288	[p20l1663t2204r2134b2296],
32	it	PRP	O	it	nsubj	37	SENT_288	[p20l11t2329r70b2405],
33	has	VBZ	O	have	aux	37	SENT_288	[p20l104t2328r247b2405],
34	not	RB	O	not	neg	37	SENT_288	[p20l288t2344r430b2406],
35	yet	RB	O	yet	advmod	37	SENT_288	[p20l460t2344r584b2427],
36	been	VBN	O	be	cop	37	SENT_288	[p20l618t2328r820b2406],
37	possible	JJ	O	possible	_	0	SENT_288	[p20l856t2328r1207b2427],
38	to	TO	O	to	aux	39	SENT_288	[p20l1245t2344r1327b2406],
39	develop	VB	O	develop	xcomp	37	SENT_288	[p20l1367t2328r1689b2427],
40	combination	NN	O	combination	dobj	39	SENT_288	[p20l1730t2328r2133b2406, p20l12t2457r181b2535],
41	targeted	VBN	O	target	partmod	40	SENT_288	[p20l221t2456r576b2557],
42	therapies	NNS	O	therapy	dobj	41	SENT_288	[p20l615t2456r1004b2556],
43	that	WDT	O	that	nsubj	44	SENT_288	[p20l1046t2456r1218b2534],
44	circumvent	VBP	O	circumvent	rcmod	42	SENT_288	[p20l1253t2457r1732b2535],
45	acquired	VBN	O	acquire	amod	46	SENT_288	[p20l1765t2456r2134b2556],
46	resistance	NN	O	resistance	dobj	44	SENT_288	[p20l12t2585r463b2663],
47	.	.	O	.	_	0	SENT_288	[p20l12t2585r463b2663],

1	The	DT	O	the	det	3	SENT_289	[p20l510t2584r671b2662],
2	combination	NN	O	combination	nn	3	SENT_289	[p20l717t2584r1263b2663],
3	regimen	NN	O	regimen	nsubj	9	SENT_289	[p20l1308t2585r1665b2685],
4	of	IN	O	of	_	0	SENT_289	[p20l1711t2583r1810b2663],
5	BRAFMEK	NN	O	brafmek	nn	6	SENT_289	[p20l1836t2591r2137b2667, p20l9t2719r223b2792],
6	inhibitors	NNS	O	inhibitor	prep_of	3	SENT_289	[p20l258t2712r680b2790],
7	described	VBN	O	describe	partmod	6	SENT_289	[p20l723t2712r1135b2790],
8	here	RB	O	here	advmod	7	SENT_289	[p20l1174t2712r1356b2789],
9	represents	VBZ	O	represent	_	0	SENT_289	[p20l1396t2728r1838b2811],
10	a	DT	O	a	det	12	SENT_289	[p20l1880t2738r1924b2789],
11	successful	JJ	O	successful	amod	12	SENT_289	[p20l1964t2738r2133b2791, p20l12t2839r309b2919],
12	attempt	NN	O	attempt	dobj	9	SENT_289	[p20l344t2857r679b2940],
13	to	TO	O	to	aux	14	SENT_289	[p20l710t2857r791b2919],
14	combine	VB	O	combine	infmod	12	SENT_289	[p20l829t2840r1198b2919],
15	targeted	VBN	O	target	dep	14	SENT_289	[p20l1233t2840r1589b2941],
16	therapies	NNS	O	therapy	dobj	15	SENT_289	[p20l1624t2840r2014b2940],
17	in	IN	O	in	_	0	SENT_289	[p20l2051t2841r2134b2917],
18	an	DT	O	a	det	20	SENT_289	[p20l11t2994r113b3046],
19	oncogene	NN	O	oncogene	nn	20	SENT_289	[p20l148t2967r909b3069],
20	—	NN	O	—	prep_in	15	SENT_289	[p20l148t2967r909b3069],
21	def1ned	VBN	O	def1ne	partmod	20	SENT_289	[p20l148t2967r909b3069],
22	patient	NN	O	patient	nn	23	SENT_289	[p20l942t2969r1238b3068],
23	population	NN	O	population	dobj	21	SENT_289	[p20l1265t2968r1748b3068],
24	.	.	O	.	_	0	SENT_289	[p20l1265t2968r1748b3068],

1	Furthermore	RB	O	furthermore	advmod	17	SENT_290	[p20l1787t2968r2133b3047, p20l12t3122r250b3192],
2	,	,	O	,	_	0	SENT_290	[p20l1787t2968r2133b3047, p20l12t3122r250b3192],
3	as	IN	O	as	_	0	SENT_290	[p20l305t3122r390b3174],
4	a	DT	O	a	det	5	SENT_290	[p20l443t3122r487b3174],
5	consequence	NN	O	consequence	prep_as	17	SENT_290	[p20l537t3122r1083b3196],
6	of	IN	O	of	_	0	SENT_290	[p20l1134t3095r1235b3175],
7	unique	JJ	O	unique	amod	9	SENT_290	[p20l1266t3097r1560b3196],
8	biochemical	JJ	O	biochemical	amod	9	SENT_290	[p20l1611t3096r2134b3175],
9	effects	NNS	O	effect	prep_of	5	SENT_290	[p20l12t3223r294b3302],
10	observed	VBN	O	observe	partmod	9	SENT_290	[p20l329t3224r710b3303],
11	With	IN	O	with	_	0	SENT_290	[p20l737t3224r932b3303],
12	BRAF	NN	O	braf	nn	13	SENT_290	[p20l964t3231r1207b3307],
13	inhibitors	NNS	O	inhibitor	prep_with	10	SENT_290	[p20l1240t3224r1687b3320],
14	,	,	O	,	_	0	SENT_290	[p20l1240t3224r1687b3320],
15	this	DT	O	this	det	16	SENT_290	[p20l1725t3224r1885b3302],
16	combination	NN	O	combination	nsubj	17	SENT_290	[p20l1920t3250r2133b3303, p20l12t3352r372b3430],
17	appears	VBZ	O	appear	_	0	SENT_290	[p20l405t3378r737b3451],
18	to	TO	O	to	aux	20	SENT_290	[p20l773t3368r855b3430],
19	be	VB	O	be	auxpass	20	SENT_290	[p20l890t3352r986b3430],
20	associated	VBN	O	associate	xcomp	17	SENT_290	[p20l1019t3352r1465b3430],
21	With	IN	O	with	_	0	SENT_290	[p20l1494t3352r1689b3431],
22	a	DT	O	a	det	24	SENT_290	[p20l1721t3378r1766b3429],
23	reduced	VBN	O	reduce	amod	24	SENT_290	[p20l1798t3352r2134b3431],
24	incidence	NN	O	incidence	prep_with	20	SENT_290	[p20l11t3480r416b3559],
25	and	CC	O	and	_	0	SENT_290	[p20l466t3480r625b3559],
26	severity	NN	O	severity	conj_and	24	SENT_290	[p20l676t3481r1002b3580],
27	of	IN	O	of	_	0	SENT_290	[p20l1048t3479r1148b3559],
28	some	DT	O	some	prep_of	26	SENT_290	[p20l1182t3506r1405b3559],
29	of	IN	O	of	_	0	SENT_290	[p20l1457t3479r1557b3559],
30	the	DT	O	the	det	32	SENT_290	[p20l1589t3480r1723b3558],
31	toxic	JJ	O	toxic	amod	32	SENT_290	[p20l1774t3481r1979b3559],
32	effects	NNS	O	effect	prep_of	28	SENT_290	[p20l2030t3479r2133b3558, p20l12t3607r209b3686],
33	of	IN	O	of	_	0	SENT_290	[p20l244t3607r344b3687],
34	monotherapy	NN	O	monotherapy	prep_of	32	SENT_290	[p20l358t3608r932b3708],
35	with	IN	O	with	_	0	SENT_290	[p20l955t3608r1150b3688],
36	either	CC	O	either	preconj	38	SENT_290	[p20l1183t3608r1430b3686],
37	a	DT	O	a	det	38	SENT_290	[p20l1458t3634r1502b3686],
38	BRAF	NN	O	braf	prep_with	34	SENT_290	[p20l1531t3615r1775b3691],
39	or	CC	O	or	_	0	SENT_290	[p20l1809t3634r1898b3687],
40	MEK	NN	O	mek	prep_with	34	SENT_290	[p20l1924t3616r2138b3689],

1	inhibitor	NN	O	inhibitor	_	0	SENT_291	[p21l11t21r402b100],
2	.	.	O	.	_	0	SENT_291	[p21l11t21r402b100],

1	We	PRP	O	we	nsubj	2	SENT_292	[p21l442t29r574b99],
2	believe	VBP	O	believe	_	0	SENT_292	[p21l613t21r898b100],
3	that	IN	O	that	_	0	SENT_292	[p21l938t21r1106b99],
4	the	DT	O	the	det	5	SENT_292	[p21l1141t21r1271b99],
5	combination	NN	O	combination	prep_that	2	SENT_292	[p21l1311t21r1846b100],
6	of	IN	O	of	_	0	SENT_292	[p21l1885t20r1984b100],
7	dabrafenib	NN	O	dabrafenib	prep_of	5	SENT_292	[p21l2005t21r2133b100, p21l12t148r364b228],

1	and	CC	O	and	dep	3	SENT_293	[p21l404t149r560b228],
2	trametinib	NN	O	trametinib	nn	3	SENT_293	[p21l600t149r1049b228],
3	Warrants	NNS	O	warrant	_	0	SENT_293	[p21l1085t166r1461b228],
4	further	RBR	O	further	advmod	5	SENT_293	[p21l1502t148r1804b228],
5	evaluation	NN	O	evaluation	amod	3	SENT_293	[p21l1841t149r2133b228, p21l12t278r179b356],

1	as	IN	O	as	amod	4	SENT_294	[p21l213t303r298b355],
2	a	DT	O	a	det	4	SENT_294	[p21l336t303r380b355],
3	potential	JJ	O	potential	amod	4	SENT_294	[p21l413t277r792b377],
4	treatment	NN	O	treatment	_	0	SENT_294	[p21l828t294r1243b355],
5	for	IN	O	for	_	0	SENT_294	[p21l1275t276r1395b356],
6	metastatic	JJ	O	metastatic	amod	7	SENT_294	[p21l1428t278r1866b355],
7	melanoma	NN	O	melanoma	prep_for	4	SENT_294	[p21l1901t277r2133b355, p21l12t432r249b485],
8	with	IN	O	with	_	0	SENT_294	[p21l322t406r510b485],
9	BRAF	NN	O	braf	nn	11	SENT_294	[p21l587t412r825b489],
10	V600	NN	O	v600	nn	11	SENT_294	[p21l901t411r1110b485],
11	mutations	NNS	O	mutation	prep_with	4	SENT_294	[p21l1189t407r1606b485],
12	and	CC	O	and	_	0	SENT_294	[p21l1686t406r1840b485],
13	other	JJ	O	other	amod	14	SENT_294	[p21l1919t406r2137b485],
14	cancers	NNS	O	cancer	conj_and	11	SENT_294	[p21l12t561r320b613],
15	with	IN	O	with	_	0	SENT_294	[p21l355t535r550b614],
16	these	DT	O	these	det	17	SENT_294	[p21l590t535r813b613],
17	mutations	NNS	O	mutation	prep_with	4	SENT_294	[p21l853t536r1312b614],
18	.	.	O	.	_	0	SENT_294	[p21l853t536r1312b614],

1	Supported	VBN	O	support	_	0	SENT_295	[p21l99t652r435b727],
2	by	IN	O	by	_	0	SENT_295	[p21l461t652r535b727],
3	GlaxoSmithKline	NNP	ORGANIZATION	GlaxoSmithKline	prep_by	1	SENT_295	[p21l557t652r1147b712],
4	.	.	O	.	_	0	SENT_295	[p21l557t652r1147b712],

1	Disclosure	NN	O	disclosure	nsubj	2	SENT_296	[p21l95t737r442b796],
2	forms	VBZ	O	form	_	0	SENT_296	[p21l475t736r667b795],
3	provided	VBN	O	provide	csubj	8	SENT_296	[p21l701t737r988b812],
4	by	IN	O	by	_	0	SENT_296	[p21l1021t737r1095b812],
5	the	DT	O	the	det	6	SENT_296	[p21l1125t737r1226b795],
6	authors	NNS	O	author	prep_by	3	SENT_296	[p21l1259t737r1506b796],
7	are	VBP	O	be	cop	8	SENT_296	[p21l1540t756r1638b795],
8	available	JJ	O	available	ccomp	2	SENT_296	[p21l1671t737r1956b796],
9	with	IN	O	with	_	0	SENT_296	[p21l1986t737r2135b797],
10	the	DT	O	the	det	12	SENT_296	[p21l11t822r113b880],
11	full	JJ	O	full	amod	12	SENT_296	[p21l138t821r252b881],
12	text	NN	O	text	prep_with	8	SENT_296	[p21l278t834r400b880],
13	of	IN	O	of	_	0	SENT_296	[p21l422t821r499b880],
14	this	DT	O	this	det	15	SENT_296	[p21l510t822r632b880],
15	article	NN	O	article	prep_of	12	SENT_296	[p21l659t822r865b880],
16	at	IN	O	at	_	0	SENT_296	[p21l889t834r950b880],
17	NEJM.org	NN	O	nejm.org	prep_at	15	SENT_296	[p21l969t827r1309b897],
18	.	.	O	.	_	0	SENT_296	[p21l969t827r1309b897],

1	We	PRP	O	we	nsubj	2	SENT_297	[p21l95t912r195b965],
2	thank	VBP	O	thank	_	0	SENT_297	[p21l227t907r422b967],
3	the	DT	O	the	det	4	SENT_297	[p21l450t907r551b965],
4	patients	NNS	O	patient	dobj	2	SENT_297	[p21l581t907r843b982],
5	and	CC	O	and	_	0	SENT_297	[p21l876t907r995b965],
6	their	PRP$	O	they	poss	7	SENT_297	[p21l1027t907r1183b965],
7	families	NNS	O	family	dobj	2	SENT_297	[p21l1212t906r1476b965],
8	for	IN	O	for	_	0	SENT_297	[p21l1509t906r1604b965],
9	their	PRP$	O	they	poss	10	SENT_297	[p21l1633t907r1789b965],
10	participation	NN	O	participation	prep_for	7	SENT_297	[p21l1817t907r2134b982, p21l12t991r141b1049],
11	and	CC	O	and	_	0	SENT_297	[p21l163t991r283b1049],
12	the	DT	O	the	det	16	SENT_297	[p21l306t991r407b1049],
13	GlaXoSmithKline	NNP	O	GlaXoSmithKline	nn	16	SENT_297	[p21l430t991r1002b1051],
14	BRF11322O	NNP	O	BRF11322O	nn	16	SENT_297	[p21l1023t995r1396b1053],
15	study	NN	O	study	nn	16	SENT_297	[p21l1421t991r1596b1066],
16	team	NN	O	team	conj_and	4	SENT_297	[p21l1616t1003r1796b1062],
17	,	,	O	,	_	0	SENT_297	[p21l1616t1003r1796b1062],
18	including	VBG	O	include	_	0	SENT_297	[p21l1823t991r2138b1066],
19	Anne-Marie	NNP	PERSON	Anne-Marie	nn	20	SENT_297	[p21l8t1075r399b1133],
20	Martin	NNP	PERSON	Martin	prep_including	16	SENT_297	[p21l420t1075r666b1146],
21	,	,	O	,	_	0	SENT_297	[p21l420t1075r666b1146],
22	Vicki	NNP	PERSON	Vicki	nn	23	SENT_297	[p21l690t1075r857b1134],
23	Goodman	NNP	PERSON	Goodman	prep_including	16	SENT_297	[p21l879t1075r1228b1146],
24	,	,	O	,	_	0	SENT_297	[p21l879t1075r1228b1146],
25	Ohad	NNP	PERSON	Ohad	nn	26	SENT_297	[p21l1254t1075r1430b1133],
26	Amit	NNP	PERSON	Amit	prep_including	16	SENT_297	[p21l1449t1075r1631b1146],
27	,	,	O	,	_	0	SENT_297	[p21l1449t1075r1631b1146],
28	Michael	NNP	PERSON	Michael	nn	29	SENT_297	[p21l1656t1075r1916b1133],
29	Streit	NNP	PERSON	Streit	conj_and	20	SENT_297	[p21l1940t1075r2130b1146],
30	,	,	O	,	_	0	SENT_297	[p21l1940t1075r2130b1146],
31	Laurie	NNP	PERSON	Laurie	nn	32	SENT_297	[p21l10t1159r215b1218],
32	Sherman	NNP	PERSON	Sherman	conj_and	20	SENT_297	[p21l253t1159r563b1230],
33	,	,	O	,	_	0	SENT_297	[p21l253t1159r563b1230],
34	Amy	NNP	PERSON	Amy	nn	35	SENT_297	[p21l600t1164r753b1234],
35	Kline	NNP	PERSON	Kline	conj_and	20	SENT_297	[p21l785t1159r979b1230],
36	,	,	O	,	_	0	SENT_297	[p21l785t1159r979b1230],
37	Karen	NNP	PERSON	Karen	nn	38	SENT_297	[p21l1019t1164r1215b1219],
38	Davis	NNP	PERSON	Davis	conj_and	20	SENT_297	[p21l1249t1159r1447b1230],
39	,	,	O	,	_	0	SENT_297	[p21l1249t1159r1447b1230],
40	Jennifer	NNP	PERSON	Jennifer	nn	41	SENT_297	[p21l1480t1158r1748b1227],
41	Clark	NNP	PERSON	Clark	prep_including	16	SENT_297	[p21l1782t1159r1975b1230],
42	,	,	O	,	_	0	SENT_297	[p21l1782t1159r1975b1230],
43	and	CC	O	and	_	0	SENT_297	[p21l2015t1159r2135b1217],
44	Mary	NNP	PERSON	Mary	nn	45	SENT_297	[p21l9t1249r181b1319],
45	Richardson	NNP	PERSON	Richardson	conj_and	20	SENT_297	[p21l202t1244r599b1315],
46	,	,	O	,	_	0	SENT_297	[p21l202t1244r599b1315],
47	for	IN	O	for	_	0	SENT_297	[p21l629t1243r723b1302],
48	their	PRP$	O	they	poss	49	SENT_297	[p21l747t1244r903b1302],
49	discussions	NNS	O	discussion	prep_for	16	SENT_297	[p21l928t1244r1325b1303],
50	.	.	O	.	_	0	SENT_297	[p21l928t1244r1325b1303],

1	APPENDIX	NN	O	appendix	_	0	SENT_298	[p21l1156t1408r1284b1424],

1	The	DT	O	the	det	2	SENT_299	[p21l376t1465r423b1489],
2	authors	NNS	O	author	nsubj	3	SENT_299	[p21l434t1465r534b1489],
3	’	VBP	O	’	_	0	SENT_299	[p21l434t1465r534b1489],
4	affiliations	NNS	O	affiliation	nsubj	16	SENT_299	[p21l546t1465r678b1489],
5	are	VBP	O	be	cop	16	SENT_299	[p21l689t1473r726b1489],
6	as	IN	O	as	mark	7	SENT_299	[p21l736t1473r761b1489],
7	follows	VBZ	O	follow	dep	16	SENT_299	[p21l772t1465r870b1489],
8	:	:	O	:	_	0	SENT_299	[p21l772t1465r870b1489],
9	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	16	SENT_299	[p21l881t1465r1060b1489],
10	General	NNP	ORGANIZATION	General	nn	16	SENT_299	[p21l1072t1465r1169b1489],
11	Hospital	NNP	ORGANIZATION	Hospital	nn	16	SENT_299	[p21l1179t1465r1285b1495],
12	Cancer	NNP	ORGANIZATION	Cancer	nn	16	SENT_299	[p21l1295t1467r1381b1489],
13	Center	NNP	ORGANIZATION	Center	nn	16	SENT_299	[p21l1391t1467r1473b1489],
14	(	CD	NUMBER	(	num	16	SENT_299	[p21l1485t1467r1578b1492],
15	K.T.F.	NNP	O	K.T.F.	nn	16	SENT_299	[p21l1485t1467r1578b1492],
16	)	NN	O	)	ccomp	3	SENT_299	[p21l1485t1467r1578b1492],
17	and	CC	O	and	_	0	SENT_299	[p21l1590t1465r1636b1489],
18	the	DT	O	the	det	19	SENT_299	[p21l1647t1465r1684b1489],
19	Dana	NNP	PERSON	Dana	ccomp	3	SENT_299	[p21l1695t1465r1855b1489],
20	.	.	O	.	_	0	SENT_299	[p21l1695t1465r1855b1489],

1	—	NN	O	—	_	0	SENT_300	[p21l1695t1465r1855b1489],
2	.	.	O	.	_	0	SENT_300	[p21l1695t1465r1855b1489],

1	Farber	NNP	ORGANIZATION	Farber	nn	3	SENT_301	[p21l1695t1465r1855b1489],
2	Cancer	NNP	ORGANIZATION	Cancer	nn	3	SENT_301	[p21l1865t1467r1951b1489],
3	Institute	NNP	ORGANIZATION	Institute	_	0	SENT_301	[p21l1961t1466r2063b1489],
4	(	NN	O	(	nn	5	SENT_301	[p21l378t1505r408b1529],
5	N	NN	O	n	dep	3	SENT_301	[p21l378t1505r408b1529],
6	.	.	O	.	_	0	SENT_301	[p21l410t1505r443b1529],

1	I.	NN	O	i.	_	0	SENT_302	[p21l410t1505r443b1529],
2	)	CD	NUMBER	)	number	3	SENT_302	[p21l410t1505r443b1529],
3	—	CD	NUMBER	—	num	4	SENT_302	[p21l453t1516r485b1518],
4	both	DT	O	both	dep	1	SENT_302	[p21l494t1503r551b1526],
5	in	IN	O	in	_	0	SENT_302	[p21l560t1503r584b1525],
6	Boston	NNP	LOCATION	Boston	prep_in	4	SENT_302	[p21l594t1505r688b1530],
7	;	:	O	;	_	0	SENT_302	[p21l594t1505r688b1530],
8	the	DT	O	the	det	16	SENT_302	[p21l700t1503r738b1526],
9	Sarah	NNP	ORGANIZATION	Sarah	nn	16	SENT_302	[p21l748t1503r817b1526],
10	Cannon	NNP	ORGANIZATION	Cannon	nn	16	SENT_302	[p21l827t1504r924b1526],
11	Research	NNP	ORGANIZATION	Research	nn	16	SENT_302	[p21l934t1503r1046b1527],
12	Institute/Tennessee	NNP	O	Institute/Tennessee	nn	16	SENT_302	[p21l1056t1503r1297b1529],
13	Oncology	NNP	O	Oncology	nn	16	SENT_302	[p21l1307t1503r1427b1532],
14	(	NNP	O	(	nn	16	SENT_302	[p21l1437t1505r1514b1531],
15	J.	NNP	PERSON	J.	nn	16	SENT_302	[p21l1437t1505r1514b1531],
16	R	NNP	PERSON	R	dep	1	SENT_302	[p21l1437t1505r1514b1531],
17	,	,	O	,	_	0	SENT_302	[p21l1437t1505r1514b1531],
18	I.	NNP	O	I.	conj_and	16	SENT_302	[p21l1437t1505r1514b1531],
19	,	,	O	,	_	0	SENT_302	[p21l1437t1505r1514b1531],
20	H.A.B.	NNP	O	H.A.B.	dep	1	SENT_302	[p21l1525t1505r1617b1529],
21	)	CD	NUMBER	)	num	20	SENT_302	[p21l1525t1505r1617b1529],
22	and	CC	O	and	_	0	SENT_302	[p21l1629t1503r1674b1526],
23	the	DT	O	the	det	24	SENT_302	[p21l1684t1503r1722b1526],
24	Vanderbilt	NNP	ORGANIZATION	Vanderbilt	conj_and	16	SENT_302	[p21l1731t1503r1968b1532],
25	.	.	O	.	_	0	SENT_302	[p21l1731t1503r1968b1532],

1	—	NN	O	—	_	0	SENT_303	[p21l1731t1503r1968b1532],
2	.	.	O	.	_	0	SENT_303	[p21l1731t1503r1968b1532],

1	Ingram	NNP	ORGANIZATION	Ingram	dep	192	SENT_304	[p21l1731t1503r1968b1532],
2	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l1978t1504r2064b1526],
3	Center	NNP	ORGANIZATION	Center	dep	192	SENT_304	[p21l377t1541r465b1568],
4	,	,	O	,	_	0	SENT_304	[p21l377t1541r465b1568],
5	Vanderbilt	NNP	ORGANIZATION	Vanderbilt	dep	192	SENT_304	[p21l477t1539r608b1563],
6	University	NNP	ORGANIZATION	University	dep	192	SENT_304	[p21l618t1540r742b1569],
7	US	NNP	LOCATION	US	dep	192	SENT_304	[p21l754t1541r809b1568],
8	,	,	O	,	_	0	SENT_304	[p21l754t1541r809b1568],
9	I.P.	NNP	O	I.P.	dep	192	SENT_304	[p21l822t1541r871b1566],
10	)	CD	NUMBER	)	dep	192	SENT_304	[p21l822t1541r871b1566],
11	—	CD	NUMBER	—	dep	192	SENT_304	[p21l883t1553r915b1555],
12	both	DT	O	both	dep	192	SENT_304	[p21l925t1539r981b1563],
13	in	IN	O	in	dep	192	SENT_304	[p21l993t1540r1017b1562],
14	Nashville	NNP	LOCATION	Nashville	dep	192	SENT_304	[p21l1027t1539r1149b1567],
15	;	:	O	;	_	0	SENT_304	[p21l1027t1539r1149b1567],
16	University	NNP	ORGANIZATION	University	dep	192	SENT_304	[p21l1162t1540r1286b1569],
17	of	IN	ORGANIZATION	of	dep	192	SENT_304	[p21l1297t1539r1326b1563],
18	California	NNP	ORGANIZATION	California	dep	192	SENT_304	[p21l1332t1539r1455b1563],
19	San	NNP	ORGANIZATION	San	dep	192	SENT_304	[p21l1467t1541r1510b1563],
20	Francisco	NNP	ORGANIZATION	Francisco	dep	192	SENT_304	[p21l1521t1540r1647b1568],
21	,	,	O	,	_	0	SENT_304	[p21l1521t1540r1647b1568],
22	San	NNP	LOCATION	San	dep	192	SENT_304	[p21l1661t1541r1704b1563],
23	Francisco	NNP	LOCATION	Francisco	dep	192	SENT_304	[p21l1715t1540r1833b1563],
24	(	NN	O	(	dep	192	SENT_304	[p21l1847t1541r1917b1567],
25	A.D.	NNP	O	A.D.	dep	192	SENT_304	[p21l1847t1541r1917b1567],
26	,	,	O	,	_	0	SENT_304	[p21l1847t1541r1917b1567],
27	A.	NNP	PERSON	A.	dep	192	SENT_304	[p21l1929t1541r1955b1563],
28	Algazi	NNP	PERSON	Algazi	dep	192	SENT_304	[p21l1967t1539r2062b1569],
29	)	NN	O	)	dep	192	SENT_304	[p21l1967t1539r2062b1569],
30	;	:	O	;	_	0	SENT_304	[p21l1967t1539r2062b1569],
31	University	NNP	ORGANIZATION	University	dep	192	SENT_304	[p21l377t1577r501b1606],
32	of	IN	ORGANIZATION	of	dep	192	SENT_304	[p21l510t1576r539b1600],
33	Colorado	NNP	ORGANIZATION	Colorado	dep	192	SENT_304	[p21l544t1576r657b1600],
34	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l667t1578r753b1600],
35	Center	NNP	ORGANIZATION	Center	dep	192	SENT_304	[p21l762t1578r850b1604],
36	,	,	O	,	_	0	SENT_304	[p21l762t1578r850b1604],
37	Aurora	NNP	LOCATION	Aurora	dep	192	SENT_304	[p21l860t1578r946b1600],
38	(	NNP	O	(	dep	192	SENT_304	[p21l956t1578r1029b1605],
39	R.G.	NNP	LOCATION	R.G.	dep	192	SENT_304	[p21l956t1578r1029b1605],
40	,	,	O	,	_	0	SENT_304	[p21l956t1578r1029b1605],
41	K.L.	NNP	O	K.L.	dep	192	SENT_304	[p21l1040t1578r1108b1604],
42	)	NNP	O	)	dep	192	SENT_304	[p21l1040t1578r1108b1604],
43	;	:	O	;	_	0	SENT_304	[p21l1040t1578r1108b1604],
44	Melanoma	NNP	ORGANIZATION	Melanoma	dep	192	SENT_304	[p21l1118t1576r1250b1600],
45	Institute	NNP	ORGANIZATION	Institute	dep	192	SENT_304	[p21l1258t1577r1361b1600],
46	Australia	NNP	ORGANIZATION	Australia	dep	192	SENT_304	[p21l1370t1576r1487b1605],
47	,	,	O	,	_	0	SENT_304	[p21l1370t1576r1487b1605],
48	Westmead	NNP	ORGANIZATION	Westmead	dep	192	SENT_304	[p21l1497t1576r1628b1600],
49	Institute	NNP	ORGANIZATION	Institute	dep	192	SENT_304	[p21l1637t1577r1740b1600],
50	for	IN	ORGANIZATION	for	dep	192	SENT_304	[p21l1749t1576r1785b1600],
51	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l1794t1578r1880b1600],
52	Research	NNP	ORGANIZATION	Research	dep	192	SENT_304	[p21l1888t1576r2007b1605],
53	,	,	O	,	_	0	SENT_304	[p21l1888t1576r2007b1605],
54	and	CC	O	and	dep	192	SENT_304	[p21l2018t1576r2063b1600],
55	Westmead	NNP	LOCATION	Westmead	dep	192	SENT_304	[p21l376t1613r507b1637],
56	Hospital	NNP	LOCATION	Hospital	dep	192	SENT_304	[p21l520t1613r632b1643],
57	,	,	O	,	_	0	SENT_304	[p21l520t1613r632b1643],
58	University	NNP	ORGANIZATION	University	dep	192	SENT_304	[p21l647t1614r771b1643],
59	of	IN	ORGANIZATION	of	dep	192	SENT_304	[p21l783t1613r813b1637],
60	Sydney	NNP	ORGANIZATION	Sydney	dep	192	SENT_304	[p21l821t1613r913b1643],
61	,	,	O	,	_	0	SENT_304	[p21l821t1613r913b1643],
62	Sydney	NNP	LOCATION	Sydney	dep	192	SENT_304	[p21l928t1613r1014b1643],
63	(	CD	NUMBER	(	dep	192	SENT_304	[p21l1027t1615r1121b1642],
64	R.F.K.	NNP	O	R.F.K.	dep	192	SENT_304	[p21l1027t1615r1121b1642],
65	,	,	O	,	_	0	SENT_304	[p21l1027t1615r1121b1642],
66	G.V.L.	NNP	O	G.V.L.	dep	192	SENT_304	[p21l1136t1615r1232b1641],
67	)	CD	NUMBER	)	dep	192	SENT_304	[p21l1136t1615r1232b1641],
68	,	,	O	,	_	0	SENT_304	[p21l1136t1615r1232b1641],
69	and	CC	O	and	dep	192	SENT_304	[p21l1246t1613r1292b1637],
70	the	DT	O	the	dep	192	SENT_304	[p21l1305t1613r1343b1637],
71	Ludwig	NNP	ORGANIZATION	Ludwig	dep	192	SENT_304	[p21l1356t1613r1449b1643],
72	Institute	NNP	ORGANIZATION	Institute	dep	192	SENT_304	[p21l1460t1614r1563b1637],
73	for	IN	ORGANIZATION	for	dep	192	SENT_304	[p21l1576t1613r1612b1637],
74	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l1625t1615r1711b1637],
75	Research	NNP	ORGANIZATION	Research	dep	192	SENT_304	[p21l1723t1613r1842b1642],
76	,	,	O	,	_	0	SENT_304	[p21l1723t1613r1842b1642],
77	Austin	NNP	LOCATION	Austin	dep	192	SENT_304	[p21l1856t1614r1937b1637],
78	Hospital	NNP	LOCATION	Hospital	dep	192	SENT_304	[p21l1950t1613r2062b1643],
79	,	,	O	,	_	0	SENT_304	[p21l1950t1613r2062b1643],
80	Heidelberg	NNP	LOCATION	Heidelberg	dep	192	SENT_304	[p21l377t1651r520b1680],
81	,	,	O	,	_	0	SENT_304	[p21l377t1651r520b1680],
82	VIC	NNP	ORGANIZATION	VIC	dep	192	SENT_304	[p21l531t1652r576b1674],
83	U.C.	NNP	ORGANIZATION	U.C.	dep	192	SENT_304	[p21l588t1652r648b1677],
84	)	CD	NUMBER	)	dep	192	SENT_304	[p21l588t1652r648b1677],
85	—	CD	NUMBER	—	dep	192	SENT_304	[p21l658t1664r690b1666],
86	both	DT	O	both	dep	192	SENT_304	[p21l699t1651r755b1674],
87	in	IN	O	in	dep	192	SENT_304	[p21l764t1651r788b1673],
88	Australia	NNP	LOCATION	Australia	dep	192	SENT_304	[p21l797t1651r915b1678],
89	;	:	O	;	_	0	SENT_304	[p21l797t1651r915b1678],
90	Experimental	JJ	O	experimental	dep	192	SENT_304	[p21l925t1651r1090b1680],
91	Therapeutics/Immunotherapy	NN	O	therapeutics/immunotherapy	dep	192	SENT_304	[p21l1099t1651r1476b1680],
92	,	,	O	,	_	0	SENT_304	[p21l1099t1651r1476b1680],
93	the	DT	O	the	dep	192	SENT_304	[p21l1487t1651r1525b1674],
94	Angeles	NNP	ORGANIZATION	Angeles	dep	192	SENT_304	[p21l1534t1651r1632b1680],
95	Clinic	NNP	ORGANIZATION	Clinic	dep	192	SENT_304	[p21l1642t1651r1714b1674],
96	and	CC	ORGANIZATION	and	dep	192	SENT_304	[p21l1724t1651r1769b1674],
97	Research	NNP	ORGANIZATION	Research	dep	192	SENT_304	[p21l1778t1651r1891b1675],
98	Institute	NNP	ORGANIZATION	Institute	dep	192	SENT_304	[p21l1900t1651r2009b1678],
99	,	,	O	,	_	0	SENT_304	[p21l1900t1651r2009b1678],
100	Los	NNP	LOCATION	Los	dep	192	SENT_304	[p21l2021t1653r2063b1674],
101	Angeles	NNP	LOCATION	Angeles	dep	192	SENT_304	[p21l376t1687r474b1717],
102	(	NNP	O	(	dep	192	SENT_304	[p21l486t1689r572b1715],
103	O.H.	NNP	ORGANIZATION	O.H.	dep	192	SENT_304	[p21l486t1689r572b1715],
104	)	NNP	O	)	dep	192	SENT_304	[p21l486t1689r572b1715],
105	;	:	O	;	_	0	SENT_304	[p21l486t1689r572b1715],
106	University	NNP	ORGANIZATION	University	dep	192	SENT_304	[p21l584t1688r708b1717],
107	of	IN	ORGANIZATION	of	dep	192	SENT_304	[p21l718t1687r747b1711],
108	Pennsylvania	NNP	ORGANIZATION	Pennsylvania	dep	192	SENT_304	[p21l752t1687r912b1717],
109	Abramson	NNP	ORGANIZATION	Abramson	dep	192	SENT_304	[p21l921t1687r1051b1711],
110	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l1062t1689r1148b1711],
111	Center	NNP	ORGANIZATION	Center	dep	192	SENT_304	[p21l1157t1689r1245b1715],
112	,	,	O	,	_	0	SENT_304	[p21l1157t1689r1245b1715],
113	Philadelphia	NNP	LOCATION	Philadelphia	dep	192	SENT_304	[p21l1257t1687r1411b1717],
114	(	NNP	O	(	dep	192	SENT_304	[p21l1423t1689r1495b1715],
115	L.S.	NNP	LOCATION	L.S.	dep	192	SENT_304	[p21l1423t1689r1495b1715],
116	)	NNP	O	)	dep	192	SENT_304	[p21l1423t1689r1495b1715],
117	;	:	O	;	_	0	SENT_304	[p21l1423t1689r1495b1715],
118	Comprehensive	NNP	ORGANIZATION	Comprehensive	dep	192	SENT_304	[p21l1507t1687r1700b1717],
119	Melanoma	NNP	ORGANIZATION	Melanoma	dep	192	SENT_304	[p21l1709t1687r1842b1711],
120	Research	NNP	ORGANIZATION	Research	dep	192	SENT_304	[p21l1851t1687r1963b1712],
121	Center	NNP	ORGANIZATION	Center	dep	192	SENT_304	[p21l1974t1689r2062b1716],
122	,	,	O	,	_	0	SENT_304	[p21l1974t1689r2062b1716],
123	Mofﬁtt	NNP	ORGANIZATION	Mofﬁtt	dep	192	SENT_304	[p21l376t1724r464b1748],
124	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l474t1726r560b1748],
125	Center	NNP	ORGANIZATION	Center	dep	192	SENT_304	[p21l571t1726r659b1753],
126	,	,	O	,	_	0	SENT_304	[p21l571t1726r659b1753],
127	Tampa	NNP	LOCATION	Tampa	dep	192	SENT_304	[p21l671t1726r764b1754],
128	,	,	O	,	_	0	SENT_304	[p21l671t1726r764b1754],
129	FL	NN	LOCATION	fl	dep	192	SENT_304	[p21l777t1726r807b1747],
130	(	CD	NUMBER	(	dep	192	SENT_304	[p21l819t1726r889b1752],
131	R.K.	NNP	PERSON	R.K.	dep	192	SENT_304	[p21l819t1726r889b1752],
132	,	,	O	,	_	0	SENT_304	[p21l819t1726r889b1752],
133	J.W.	NNP	O	J.W.	dep	192	SENT_304	[p21l899t1726r971b1752],
134	)	NNP	O	)	dep	192	SENT_304	[p21l899t1726r971b1752],
135	;	:	O	;	_	0	SENT_304	[p21l899t1726r971b1752],
136	the	DT	O	the	dep	192	SENT_304	[p21l984t1724r1022b1748],
137	Department	NNP	ORGANIZATION	Department	dep	192	SENT_304	[p21l1033t1726r1183b1754],
138	of	IN	ORGANIZATION	of	dep	192	SENT_304	[p21l1193t1724r1222b1748],
139	Investigational	NNP	ORGANIZATION	Investigational	dep	192	SENT_304	[p21l1228t1724r1410b1754],
140	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l1422t1726r1508b1748],
141	Therapeutics	NNPS	ORGANIZATION	Therapeutics	dep	192	SENT_304	[p21l1517t1724r1677b1754],
142	(	NNP	O	(	dep	192	SENT_304	[p21l1691t1726r1761b1751],
143	G.F.	NNP	LOCATION	G.F.	dep	192	SENT_304	[p21l1691t1726r1761b1751],
144	)	NNP	O	)	dep	192	SENT_304	[p21l1691t1726r1761b1751],
145	and	CC	O	and	dep	192	SENT_304	[p21l1774t1724r1819b1748],
146	the	DT	O	the	dep	192	SENT_304	[p21l1831t1724r1869b1748],
147	Department	NNP	ORGANIZATION	Department	dep	192	SENT_304	[p21l1880t1726r2029b1754],
148	of	IN	ORGANIZATION	of	dep	192	SENT_304	[p21l2040t1724r2069b1748],
149	Melanoma	NNP	ORGANIZATION	Melanoma	dep	192	SENT_304	[p21l376t1761r508b1785],
150	Medical	NNP	ORGANIZATION	Medical	dep	192	SENT_304	[p21l517t1761r615b1785],
151	Oncology	NNP	ORGANIZATION	Oncology	dep	192	SENT_304	[p21l625t1761r750b1791],
152	,	,	O	,	_	0	SENT_304	[p21l625t1761r750b1791],
153	Division	NNP	O	Division	dep	192	SENT_304	[p21l761t1762r863b1785],
154	of	IN	O	of	dep	192	SENT_304	[p21l874t1761r903b1785],
155	Cancer	NNP	O	Cancer	dep	192	SENT_304	[p21l908t1763r994b1785],
156	Medicine	NNP	O	Medicine	dep	192	SENT_304	[p21l1003t1761r1117b1785],
157	(	CD	NUMBER	(	dep	192	SENT_304	[p21l1128t1763r1235b1790],
158	K.B.K.	NNP	O	K.B.K.	dep	192	SENT_304	[p21l1128t1763r1235b1790],
159	)	CD	NUMBER	)	dep	192	SENT_304	[p21l1128t1763r1235b1790],
160	,	,	O	,	_	0	SENT_304	[p21l1128t1763r1235b1790],
161	University	NNP	ORGANIZATION	University	dep	192	SENT_304	[p21l1247t1762r1371b1791],
162	of	IN	ORGANIZATION	of	dep	192	SENT_304	[p21l1381t1761r1410b1785],
163	Texas	NNP	ORGANIZATION	Texas	dep	192	SENT_304	[p21l1414t1763r1484b1785],
164	M.D.	NNP	ORGANIZATION	M.D.	dep	192	SENT_304	[p21l1494t1763r1555b1785],
165	Anderson	NNP	ORGANIZATION	Anderson	dep	192	SENT_304	[p21l1566t1761r1687b1785],
166	Cancer	NNP	ORGANIZATION	Cancer	dep	192	SENT_304	[p21l1697t1763r1783b1785],
167	Center	NNP	ORGANIZATION	Center	dep	192	SENT_304	[p21l1793t1763r1880b1789],
168	,	,	O	,	_	0	SENT_304	[p21l1793t1763r1880b1789],
169	Houston	NNP	LOCATION	Houston	dep	192	SENT_304	[p21l1892t1763r2007b1789],
170	;	:	O	;	_	0	SENT_304	[p21l1892t1763r2007b1789],
171	and	CC	O	and	dep	192	SENT_304	[p21l2018t1761r2063b1785],
172	GlaxoSmithKline	NNP	ORGANIZATION	GlaxoSmithKline	dep	192	SENT_304	[p21l377t1799r596b1826],
173	,	,	O	,	_	0	SENT_304	[p21l377t1799r596b1826],
174	Collegeville	NNP	LOCATION	Collegeville	dep	192	SENT_304	[p21l608t1799r757b1828],
175	,	,	O	,	_	0	SENT_304	[p21l608t1799r757b1828],
176	PA	NN	LOCATION	pa	dep	192	SENT_304	[p21l768t1801r802b1821],
177	(	CD	NUMBER	(	dep	192	SENT_304	[p21l813t1801r875b1827],
178	P.L.	NNP	LOCATION	P.L.	dep	192	SENT_304	[p21l813t1801r875b1827],
179	,	,	O	,	_	0	SENT_304	[p21l813t1801r875b1827],
180	A.S.	NNP	LOCATION	A.S.	dep	192	SENT_304	[p21l885t1800r943b1827],
181	,	,	O	,	_	0	SENT_304	[p21l885t1800r943b1827],
182	S.L.	NNP	LOCATION	S.L.	dep	192	SENT_304	[p21l955t1800r1007b1826],
183	,	,	O	,	_	0	SENT_304	[p21l955t1800r1007b1826],
184	P.S.	NNP	O	P.S.	dep	192	SENT_304	[p21l1019t1800r1072b1826],
185	,	,	O	,	_	0	SENT_304	[p21l1019t1800r1072b1826],
186	A.	NNP	PERSON	A.	dep	192	SENT_304	[p21l1083t1801r1108b1822],
187	Allred	NNP	PERSON	Allred	dep	192	SENT_304	[p21l1119t1799r1200b1826],
188	,	,	O	,	_	0	SENT_304	[p21l1119t1799r1200b1826],
189	D.O.	NNP	LOCATION	D.O.	dep	192	SENT_304	[p21l1211t1800r1277b1827],
190	,	,	O	,	_	0	SENT_304	[p21l1211t1800r1277b1827],
191	K.P.	NNP	O	K.P.	dep	192	SENT_304	[p21l1288t1801r1356b1825],
192	)	NNP	O	)	_	0	SENT_304	[p21l1288t1801r1356b1825],
193	.	.	O	.	_	0	SENT_304	[p21l1288t1801r1356b1825],

1	REFERENCES	NNS	O	reference	_	0	SENT_305	[p21l379t1911r547b1927],

1	1	LS	NUMBER	1	_	0	SENT_306	[p21l378t1973r397b1993],
2	.	.	O	.	_	0	SENT_306	[p21l378t1973r397b1993],

1	Bollag	NNP	PERSON	Bollag	nn	2	SENT_307	[p21l427t1970r509b2000],
2	G	NNP	PERSON	G	_	0	SENT_307	[p21l516t1972r544b1998],
3	,	,	O	,	_	0	SENT_307	[p21l516t1972r544b1998],
4	Hirth	NNP	PERSON	Hirth	nn	5	SENT_307	[p21l553t1970r624b1993],
5	P	NN	PERSON	p	appos	2	SENT_307	[p21l632t1972r651b1998],
6	,	,	O	,	_	0	SENT_307	[p21l632t1972r651b1998],
7	Tsail	NN	O	tsail	appos	2	SENT_307	[p21l660t1970r735b1998],
8	,	,	O	,	_	0	SENT_307	[p21l660t1970r735b1998],
9	et	FW	O	et	nn	10	SENT_307	[p21l745t1975r768b1993],
10	al.	FW	O	al.	appos	2	SENT_307	[p21l775t1970r804b1993],
11	.	.	O	.	_	0	SENT_307	[p21l775t1970r804b1993],

1	Clinical	JJ	O	clinical	_	0	SENT_308	[p21l814t1970r913b1994],
2	2	CD	NUMBER	2	dep	1	SENT_308	[p21l952t1973r973b1993],
3	.	.	O	.	_	0	SENT_308	[p21l952t1973r973b1993],

1	Flaherty	NNP	ORGANIZATION	Flaherty	nn	2	SENT_309	[p21l1002t1970r1107b2000],
2	KT	NNP	ORGANIZATION	KT	_	0	SENT_309	[p21l1115t1972r1157b1998],
3	,	,	O	,	_	0	SENT_309	[p21l1115t1972r1157b1998],
4	Puzanov	NNP	O	Puzanov	appos	2	SENT_309	[p21l1167t1972r1276b1994],
5	1	CD	NUMBER	1	num	4	SENT_309	[p21l1283t1972r1299b1998],
6	,	,	O	,	_	0	SENT_309	[p21l1283t1972r1299b1998],
7	Kim	NNP	PERSON	Kim	nn	8	SENT_309	[p21l1309t1971r1364b1994],
8	KB	NN	PERSON	kb	appos	2	SENT_309	[p21l1372t1972r1417b1998],
9	,	,	O	,	_	0	SENT_309	[p21l1372t1972r1417b1998],
10	et	FW	O	et	nn	11	SENT_309	[p21l1427t1975r1450b1993],
11	al.	FW	O	al.	appos	2	SENT_309	[p21l1458t1970r1487b1994],
12	3	LS	NUMBER	3	dep	11	SENT_309	[p21l1527t1973r1547b1993],
13	.	.	O	.	_	0	SENT_309	[p21l1527t1973r1547b1993],

1	Sosman	NNP	PERSON	Sosman	nn	2	SENT_310	[p21l1578t1972r1678b1994],
2	IA	NNP	O	IA	nn	11	SENT_310	[p21l1689t1972r1725b1998],
3	,	,	O	,	_	0	SENT_310	[p21l1689t1972r1725b1998],
4	Kim	NNP	PERSON	Kim	nn	5	SENT_310	[p21l1740t1970r1794b1994],
5	KB	NN	PERSON	kb	appos	2	SENT_310	[p21l1807t1972r1851b1998],
6	,	,	O	,	_	0	SENT_310	[p21l1807t1972r1851b1998],
7	Schuchter	NNP	PERSON	Schuchter	nn	8	SENT_310	[p21l1867t1970r1993b1994],
8	L	NNP	PERSON	L	appos	2	SENT_310	[p21l2005t1972r2027b1998],
9	,	,	O	,	_	0	SENT_310	[p21l2005t1972r2027b1998],
10	et	FW	O	et	dep	2	SENT_310	[p21l2042t1975r2065b1993],
11	efficacy	NN	O	efficacy	nsubj	16	SENT_310	[p21l377t2007r477b2037],
12	of	IN	O	of	_	0	SENT_310	[p21l491t2007r520b2031],
13	a	DT	O	a	det	15	SENT_310	[p21l529t2015r543b2030],
14	RAF	NN	ORGANIZATION	raf	nn	15	SENT_310	[p21l556t2009r611b2032],
15	inhibitor	NN	O	inhibitor	prep_of	11	SENT_310	[p21l625t2007r739b2031],
16	needs	VBZ	O	need	_	0	SENT_310	[p21l753t2007r825b2031],
17	broad	JJ	O	broad	amod	19	SENT_310	[p21l841t2007r913b2031],
18	target	NN	O	target	nn	19	SENT_310	[p21l377t2049r453b2074],
19	blockade	NN	O	blockade	dobj	16	SENT_310	[p21l463t2044r576b2068],
20	in	IN	O	in	_	0	SENT_310	[p21l587t2044r611b2067],
21	BRAF-mutant	JJ	O	braf-mutant	amod	22	SENT_310	[p21l622t2046r798b2069],
22	melanoma	NN	O	melanoma	prep_in	19	SENT_310	[p21l808t2044r913b2068, p21l377t2089r423b2105],
23	.	.	O	.	_	0	SENT_310	[p21l808t2044r913b2068, p21l377t2089r423b2105],

1	Nature	NNP	O	Nature	_	0	SENT_311	[p21l434t2083r521b2105],
2	2010	CD	DATE	2010	num	1	SENT_311	[p21l531t2083r730b2109],
3	;	:	O	;	_	0	SENT_311	[p21l531t2083r730b2109],
4	467:596	CD	NUMBER	467:596	number	5	SENT_311	[p21l531t2083r730b2109],
5	-9	CD	NUMBER	-9	dep	1	SENT_311	[p21l531t2083r730b2109],
6	.	.	O	.	_	0	SENT_311	[p21l531t2083r730b2109],

1	Inhibition	NN	O	inhibition	_	0	SENT_312	[p21l952t2007r1081b2031],
2	of	IN	O	of	_	0	SENT_312	[p21l1093t2007r1123b2031],
3	mutated	VBN	O	mutate	dep	6	SENT_312	[p21l1130t2007r1242b2035],
4	,	,	O	,	_	0	SENT_312	[p21l1130t2007r1242b2035],
5	activated	VBN	O	activate	amod	6	SENT_312	[p21l1255t2007r1368b2031],
6	BRAF	NN	O	braf	prep_of	1	SENT_312	[p21l1379t2009r1451b2032],
7	in	IN	O	in	_	0	SENT_312	[p21l1463t2007r1488b2030],
8	al.	FW	O	al.	prep_in	6	SENT_312	[p21l1527t2007r1556b2031],
9	.	.	O	.	_	0	SENT_312	[p21l1527t2007r1556b2031],

1	Survival	NN	O	survival	_	0	SENT_313	[p21l1578t2007r1679b2031],
2	in	IN	O	in	_	0	SENT_313	[p21l1698t2007r1723b2030],
3	BRAF	NN	O	braf	nn	5	SENT_313	[p21l1741t2009r1813b2032],
4	V600	NN	O	v600	nn	5	SENT_313	[p21l1832t2009r2007b2031],
5	—	NN	O	—	prep_in	1	SENT_313	[p21l1832t2009r2007b2031],
6	mutant	JJ	O	mutant	amod	8	SENT_313	[p21l1832t2009r2007b2031],
7	admetastatic	JJ	O	admetastatic	amod	8	SENT_313	[p21l2025t2007r2063b2031, p21l952t2044r1085b2067],
8	melanoma	NN	O	melanoma	dep	5	SENT_313	[p21l1094t2044r1236b2068],
9	.	.	O	.	_	0	SENT_313	[p21l1094t2044r1236b2068],

1	N	NN	O	n	nn	3	SENT_314	[p21l1245t2046r1267b2068],
2	Engl	NNP	O	Engl	nn	3	SENT_314	[p21l1275t2044r1349b2074],
3	]	NNP	O	]	nsubj	4	SENT_314	[p21l1275t2044r1349b2074],
4	Med	VBD	O	med	_	0	SENT_314	[p21l1357t2044r1411b2068],
5	2010	CD	DATE	2010	dobj	4	SENT_314	[p21l1420t2046r1487b2072],
6	;	:	O	;	_	0	SENT_314	[p21l1420t2046r1487b2072],
7	vanced	JJ	O	vanced	amod	8	SENT_314	[p21l1526t2044r1614b2068],
8	melanoma	NN	O	melanoma	dep	5	SENT_314	[p21l1637t2044r1773b2068],
9	treated	VBN	O	treat	partmod	8	SENT_314	[p21l1796t2044r1884b2068],
10	with	IN	O	with	_	0	SENT_314	[p21l1906t2044r1964b2068],
11	vemu363	NN	O	vemu363	prep_with	9	SENT_314	[p21l1986t2052r2063b2068, p21l953t2083r1097b2105],
12	:809	CD	NUMBER	:809	number	13	SENT_314	[p21l1986t2052r2063b2068, p21l953t2083r1097b2105],
13	-19	CD	NUMBER	-19	num	11	SENT_314	[p21l1986t2052r2063b2068, p21l953t2083r1097b2105],
14	.	.	O	.	_	0	SENT_314	[p21l1986t2052r2063b2068, p21l953t2083r1097b2105],

1	rafenib	NN	O	rafenib	_	0	SENT_315	[p21l1527t2081r1625b2105],
2	.	.	O	.	_	0	SENT_315	[p21l1527t2081r1625b2105],

1	N	NN	O	n	nn	3	SENT_316	[p21l1636t2083r1658b2105],
2	Engll	NNP	O	Engll	nn	3	SENT_316	[p21l1667t2081r1742b2111],
3	Med	NNP	O	Med	_	0	SENT_316	[p21l1751t2081r1806b2105],
4	2012	CD	DATE	2012	num	3	SENT_316	[p21l1816t2083r2027b2109],
5	;	:	O	;	_	0	SENT_316	[p21l1816t2083r2027b2109],
6	366:707	CD	NUMBER	366:707	number	7	SENT_316	[p21l1816t2083r2027b2109],
7	-14	CD	NUMBER	-14	dep	3	SENT_316	[p21l1816t2083r2027b2109],
8	.	.	O	.	_	0	SENT_316	[p21l1816t2083r2027b2109],

1	N	NN	O	n	nn	3	SENT_317	[p21l877t2185r891b2200],
2	ENGLJ	NN	O	englj	nn	3	SENT_317	[p21l906t2185r984b2207],
3	MED367	NN	O	med367	dep	17	SENT_317	[p21l998t2179r1138b2207],
4	;	:	O	;	_	0	SENT_317	[p21l998t2179r1138b2207],
5	'	''	O	'	_	0	SENT_317	[p21l998t2179r1138b2207],
6	|	SYM	O	|	dep	7	SENT_317	[p21l998t2179r1138b2207],
7	8	CD	NUMBER	8	rcmod	5	SENT_317	[p21l998t2179r1138b2207],
8	NEJM.ORG	NN	O	nejm.org	prep	3	SENT_317	[p21l1173t2185r1297b2207],
9	NOVEMBERl	NN	O	novemberl	nn	12	SENT_317	[p21l1334t2185r1565b2205],
10	,20	CD	NUMBER	,20	num	12	SENT_317	[p21l1334t2185r1565b2205],
11	'	''	O	'	_	0	SENT_317	[p21l1334t2185r1565b2205],
12	|	NN	O	|	dep	8	SENT_317	[p21l1334t2185r1565b2205],
13	2	CD	NUMBER	2	dep	17	SENT_317	[p21l1334t2185r1565b2205],
14	The	DT	O	the	det	17	SENT_317	[p21l877t2242r928b2266],
15	New	NNP	O	New	nn	17	SENT_317	[p21l937t2243r999b2266],
16	England	NNP	O	England	nn	17	SENT_317	[p21l1009t2242r1119b2273],
17	Journal	NNP	O	Journal	_	0	SENT_317	[p21l1128t2242r1226b2266],
18	of	IN	O	of	_	0	SENT_317	[p21l1235t2242r1264b2266],
19	Medicine	NNP	O	Medicine	prep_of	17	SENT_317	[p21l1271t2242r1396b2266],

1	Copyright	NN	O	copyright	_	0	SENT_318	[p21l670t2324r804b2355],
2	©	CD	NUMBER	©	num	6	SENT_318	[p21l814t2324r837b2348],
3	2012	CD	DATE	2012	num	6	SENT_318	[p21l847t2324r912b2348],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_318	[p21l921t2324r1113b2348],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_318	[p21l1122t2324r1231b2348],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_318	[p21l1241t2324r1346b2355],
7	.	.	O	.	_	0	SENT_318	[p21l1241t2324r1346b2355],

1	All	DT	O	all	det	2	SENT_319	[p21l1357t2324r1398b2348],
2	rights	NNS	O	rights	nsubj	3	SENT_319	[p21l1408t2324r1482b2355],
3	reserved	VBN	O	reserve	_	0	SENT_319	[p21l1492t2324r1611b2348],
4	.	.	O	.	_	0	SENT_319	[p21l1492t2324r1611b2348],

1	BRAF	NNS	ORGANIZATION	braf	_	0	SENT_320	[p21l714t2430r798b2449],
2	AND	CC	O	and	_	0	SENT_320	[p21l810t2430r882b2449],
3	MEK	NN	O	mek	nn	4	SENT_320	[p21l896t2430r968b2449],
4	INHIBITION	NN	O	inhibition	conj_and	1	SENT_320	[p21l981t2430r1184b2449],
5	IN	IN	O	in	_	0	SENT_320	[p21l1200t2430r1237b2449],
6	MELANOMA	NN	O	melanoma	prep_in	1	SENT_320	[p21l1252t2430r1446b2449],

1	4	LS	NUMBER	4	_	0	SENT_321	[p21l7t2597r46b2635],
2	.	.	O	.	_	0	SENT_321	[p21l7t2597r46b2635],

1	Chapman	NNP	ORGANIZATION	Chapman	nn	2	SENT_322	[p21l104t2592r337b2647],
2	PB	NN	ORGANIZATION	pb	_	0	SENT_322	[p21l358t2596r432b2645],
3	,	,	O	,	_	0	SENT_322	[p21l358t2596r432b2645],
4	Hauschild	NNP	O	Hauschild	nn	5	SENT_322	[p21l455t2592r703b2636],
5	A	NNP	O	A	appos	2	SENT_322	[p21l721t2596r770b2644],
6	,	,	O	,	_	0	SENT_322	[p21l721t2596r770b2644],
7	Robert	NNP	PERSON	Robert	nn	8	SENT_322	[p21l794t2592r961b2638],
8	C	NNP	PERSON	C	appos	2	SENT_322	[p21l978t2595r1025b2644],
9	,	,	O	,	_	0	SENT_322	[p21l978t2595r1025b2644],
10	et	FW	O	et	nn	11	SENT_322	[p21l9t2671r52b2705],
11	al.	FW	O	al.	appos	2	SENT_322	[p21l67t2662r122b2705],
12	.	.	O	.	_	0	SENT_322	[p21l67t2662r122b2705],

1	Improved	VBN	O	improve	_	0	SENT_323	[p21l143t2662r374b2717],
2	survival	NN	O	survival	dobj	1	SENT_323	[p21l393t2662r581b2706],
3	with	IN	O	with	_	0	SENT_323	[p21l597t2662r706b2706],
4	vemurafenib	NN	O	vemurafenib	prep_with	1	SENT_323	[p21l722t2662r1027b2706],
5	in	IN	O	in	_	0	SENT_323	[p21l8t2734r55b2776],
6	melanoma	NN	O	melanoma	prep_in	4	SENT_323	[p21l71t2733r329b2777],
7	with	IN	O	with	_	0	SENT_323	[p21l342t2733r452b2777],
8	BRAF	NN	O	braf	nn	10	SENT_323	[p21l468t2737r605b2779],
9	V600E	NN	O	v600e	nn	10	SENT_323	[p21l620t2736r772b2777],
10	mutation	NN	O	mutation	prep_with	1	SENT_323	[p21l790t2734r1025b2777],
11	.	.	O	.	_	0	SENT_323	[p21l790t2734r1025b2777],

1	N	NN	O	n	nn	2	SENT_324	[p21l7t2807r49b2847],
2	EnglJ	NN	O	englj	nsubj	3	SENT_324	[p21l66t2803r209b2859],
3	Med	VBD	O	med	_	0	SENT_324	[p21l226t2803r330b2846],
4	2011	CD	DATE	2011	dobj	3	SENT_324	[p21l349t2806r784b2855],
5	;	:	O	;	_	0	SENT_324	[p21l349t2806r784b2855],
6	364:2507	CD	NUMBER	364:2507	num	7	SENT_324	[p21l349t2806r784b2855],
7	-16	CD	NUMBER	-16	dep	4	SENT_324	[p21l349t2806r784b2855],
8	.	.	O	.	_	0	SENT_324	[p21l349t2806r784b2855],

1	5	CD	NUMBER	5	_	0	SENT_325	[p21l9t2878r45b2916],
2	.	.	O	.	_	0	SENT_325	[p21l9t2878r45b2916],

1	Falchook	NNP	O	Falchook	nn	2	SENT_326	[p21l103t2873r326b2917],
2	GS	NN	O	g	_	0	SENT_326	[p21l340t2876r421b2926],
3	,	,	O	,	_	0	SENT_326	[p21l340t2876r421b2926],
4	Long	NNP	O	Long	nn	5	SENT_326	[p21l440t2877r563b2929],
5	GV	NNP	O	GV	appos	2	SENT_326	[p21l579t2876r659b2926],
6	,	,	O	,	_	0	SENT_326	[p21l579t2876r659b2926],
7	Kurzrock	NNP	PERSON	Kurzrock	nn	8	SENT_326	[p21l678t2873r905b2918],
8	R	NNP	PERSON	R	appos	2	SENT_326	[p21l919t2877r967b2926],
9	,	,	O	,	_	0	SENT_326	[p21l919t2877r967b2926],
10	et	FW	O	et	nn	11	SENT_326	[p21l988t2882r1031b2916],
11	al.	FW	O	al.	appos	2	SENT_326	[p21l8t2943r62b2986],
12	.	.	O	.	_	0	SENT_326	[p21l8t2943r62b2986],

1	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_327	[p21l82t2943r349b2986],
2	in	IN	O	in	_	0	SENT_327	[p21l366t2944r413b2986],
3	patients	NNS	O	patient	prep_in	1	SENT_327	[p21l429t2944r618b2998],
4	with	IN	O	with	_	0	SENT_327	[p21l635t2943r743b2987],
5	melanoma	NN	O	melanoma	prep_with	3	SENT_327	[p21l760t2943r1025b2995],
6	,	,	O	,	_	0	SENT_327	[p21l760t2943r1025b2995],
7	untreated	JJ	O	untreated	amod	9	SENT_327	[p21l9t3013r241b3057],
8	brain	NN	O	brain	nn	9	SENT_327	[p21l282t3013r409b3056],
9	metastases	NNS	O	metastase	prep_with	3	SENT_327	[p21l449t3022r730b3066],
10	,	,	O	,	_	0	SENT_327	[p21l449t3022r730b3066],
11	and	CC	O	and	_	0	SENT_327	[p21l773t3013r861b3056],
12	other	JJ	O	other	amod	14	SENT_327	[p21l901t3013r1030b3057],
13	solid	JJ	O	solid	amod	14	SENT_327	[p21l10t3083r125b3126],
14	tumours	NNS	O	tumour	conj_and	5	SENT_327	[p21l147t3092r367b3127],
15	:	:	O	:	_	0	SENT_327	[p21l147t3092r367b3127],
16	a	DT	O	a	det	17	SENT_327	[p21l391t3097r416b3126],
17	phase	NN	O	phase	dep	1	SENT_327	[p21l437t3083r577b3138],
18	1	CD	NUMBER	1	num	20	SENT_327	[p21l602t3086r626b3126],
19	dose-escalation	NN	O	dose-escalation	nn	20	SENT_327	[p21l649t3083r1028b3126],
20	trial	NN	O	trial	dep	17	SENT_327	[p21l9t3153r122b3196],
21	.	.	O	.	_	0	SENT_327	[p21l9t3153r122b3196],

1	Lancet	NNP	O	Lancet	_	0	SENT_328	[p21l144t3157r306b3196],
2	2012	CD	DATE	2012	num	1	SENT_328	[p21l323t3156r791b3205],
3	;	:	O	;	_	0	SENT_328	[p21l323t3156r791b3205],
4	379:1893	CD	NUMBER	379:1893	number	5	SENT_328	[p21l323t3156r791b3205],
5	-901	CD	NUMBER	-901	dep	1	SENT_328	[p21l323t3156r791b3205],
6	.	.	O	.	_	0	SENT_328	[p21l323t3156r791b3205],

1	6	CD	NUMBER	6	_	0	SENT_329	[p21l8t3228r47b3266],
2	.	.	O	.	_	0	SENT_329	[p21l8t3228r47b3266],

1	Hauschild	NNP	O	Hauschild	nn	2	SENT_330	[p21l103t3223r351b3267],
2	A	NNP	O	A	_	0	SENT_330	[p21l370t3227r419b3275],
3	,	,	O	,	_	0	SENT_330	[p21l370t3227r419b3275],
4	Grob	NNP	PERSON	Grob	nn	6	SENT_330	[p21l445t3223r565b3266],
5	J	NNP	O	J	nn	6	SENT_330	[p21l582t3227r633b3275],
6	]	NN	O	]	appos	2	SENT_330	[p21l582t3227r633b3275],
7	,	,	O	,	_	0	SENT_330	[p21l582t3227r633b3275],
8	Demidov	NNP	PERSON	Demidov	nn	9	SENT_330	[p21l658t3223r877b3267],
9	LV	NNP	O	LV	appos	2	SENT_330	[p21l896t3227r963b3275],
10	,	,	O	,	_	0	SENT_330	[p21l896t3227r963b3275],
11	et	FW	O	et	nn	12	SENT_330	[p21l988t3232r1031b3266],
12	al.	FW	O	al.	appos	2	SENT_330	[p21l8t3294r62b3338],
13	.	.	O	.	_	0	SENT_330	[p21l8t3294r62b3338],

1	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_331	[p21l84t3294r351b3338],
2	in	IN	O	in	_	0	SENT_331	[p21l370t3295r417b3337],
3	BRAF-mutated	JJ	O	braf-mutated	prep_in	1	SENT_331	[p21l436t3294r787b3340],
4	metastatmediated	VBN	O	metastatmediate	partmod	3	SENT_331	[p21l807t3303r1027b3338, p21l1103t2592r1328b2635],
5	by	IN	O	by	_	0	SENT_331	[p21l1362t2592r1416b2647],
6	dimerization	NN	O	dimerization	agent	4	SENT_331	[p21l1448t2592r1762b2635],
7	of	IN	O	of	prep	1	SENT_331	[p21l1796t2592r1852b2635],
8	aberrantly	RB	O	aberrantly	pcomp	7	SENT_331	[p21l1875t2592r2125b2647],
9	spliced	VBN	O	splice	partmod	1	SENT_331	[p21l1104t2662r1272b2717],
10	BRAF	NN	O	braf	nsubj	13	SENT_331	[p21l1306t2665r1649b2712],
11	(	CD	NUMBER	(	num	13	SENT_331	[p21l1306t2665r1649b2712],
12	V600E	NN	O	v600e	nn	13	SENT_331	[p21l1306t2665r1649b2712],
13	)	NN	O	)	xcomp	9	SENT_331	[p21l1306t2665r1649b2712],
14	.	.	O	.	_	0	SENT_331	[p21l1306t2665r1649b2712],

1	Nature	NNP	O	Nature	_	0	SENT_332	[p21l1686t2666r1852b2706],
2	2011	CD	DATE	2011	num	1	SENT_332	[p21l1887t2665r2120b2714],
3	;	:	O	;	_	0	SENT_332	[p21l1887t2665r2120b2714],
4	480	CD	NUMBER	480	num	6	SENT_332	[p21l1887t2665r2120b2714],
5	:	:	O	:	_	0	SENT_332	[p21l1887t2665r2120b2714],
6	387-90	CD	NUMBER	387-90	dep	1	SENT_332	[p21l1103t2736r1276b2777],
7	.	.	O	.	_	0	SENT_332	[p21l1103t2736r1276b2777],

1	13	CD	NUMBER	13	_	0	SENT_333	[p21l1105t2808r1167b2846],
2	.	.	O	.	_	0	SENT_333	[p21l1105t2808r1167b2846],

1	Villanueva	NNP	PERSON	Villanueva	nn	2	SENT_334	[p21l1196t2803r1451b2847],
2	J	NNP	PERSON	J	_	0	SENT_334	[p21l1473t2807r1505b2856],
3	,	,	O	,	_	0	SENT_334	[p21l1473t2807r1505b2856],
4	Vultur	NNP	O	Vultur	nn	5	SENT_334	[p21l1535t2803r1689b2847],
5	A	NNP	O	A	appos	2	SENT_334	[p21l1714t2807r1763b2856],
6	,	,	O	,	_	0	SENT_334	[p21l1714t2807r1763b2856],
7	Lee	NNP	PERSON	Lee	nn	8	SENT_334	[p21l1794t2807r1875b2846],
8	JT	NNP	O	JT	appos	2	SENT_334	[p21l1899t2806r1964b2856],
9	,	,	O	,	_	0	SENT_334	[p21l1899t2806r1964b2856],
10	et	FW	O	et	nn	11	SENT_334	[p21l1996t2812r2039b2846],
11	al.	FW	O	al.	appos	2	SENT_334	[p21l2064t2803r2120b2847],
12	.	.	O	.	_	0	SENT_334	[p21l2064t2803r2120b2847],

1	Acquired	VBN	O	acquire	csubjpass	16	SENT_335	[p21l1101t2873r1321b2928],
2	resistance	NN	O	resistance	dobj	1	SENT_335	[p21l1355t2874r1598b2916],
3	to	TO	O	to	_	0	SENT_335	[p21l1632t2882r1677b2916],
4	BRAF	NN	O	braf	nn	5	SENT_335	[p21l1711t2877r1848b2919],
5	inhibitors	NNS	O	inhibitor	prep_to	1	SENT_335	[p21l1883t2873r2121b2917],
6	mediated	VBN	O	mediate	partmod	5	SENT_335	[p21l1103t2943r1328b2986],
7	by	IN	O	by	_	0	SENT_335	[p21l1345t2943r1400b2998],
8	a	DT	O	a	det	11	SENT_335	[p21l1414t2957r1439b2986],
9	RAF	NN	ORGANIZATION	raf	nn	11	SENT_335	[p21l1454t2947r1558b2989],
10	kinase	NN	O	kinase	nn	11	SENT_335	[p21l1575t2943r1733b2987],
11	switch	NN	O	switch	agent	6	SENT_335	[p21l1751t2943r1908b2987],
12	in	IN	O	in	_	0	SENT_335	[p21l1924t2944r1971b2986],
13	melanoma	NN	O	melanoma	prep_in	11	SENT_335	[p21l1988t2943r2122b2986, p21l1103t3027r1240b3057],
14	can	MD	O	can	aux	16	SENT_335	[p21l1276t3027r1359b3056],
15	be	VB	O	be	auxpass	16	SENT_335	[p21l1396t3013r1450b3056],
16	overcome	VBN	O	overcome	_	0	SENT_335	[p21l1487t3027r1717b3057],
17	by	IN	O	by	_	0	SENT_335	[p21l1754t3013r1808b3068],
18	cotargeting	VBG	O	cotarget	agent	16	SENT_335	[p21l1843t3014r2125b3069],
19	MEK	NN	O	mek	dobj	18	SENT_335	[p21l1101t3087r1221b3128],
20	and	CC	O	and	_	0	SENT_335	[p21l1240t3083r1328b3126],
21	IGF-1R	NN	O	igf-1r	conj_and	19	SENT_335	[p21l1349t3086r1667b3132],
22	/	:	O	/	punct	23	SENT_335	[p21l1349t3086r1667b3132],
23	PI3K	NN	O	pi3k	dep	19	SENT_335	[p21l1349t3086r1667b3132],
24	.	.	O	.	_	0	SENT_335	[p21l1349t3086r1667b3132],

1	Cancer	NN	O	cancer	nn	2	SENT_336	[p21l1691t3086r1860b3126],
2	Cell	NN	O	cell	_	0	SENT_336	[p21l1879t3083r1973b3126],
3	2010	CD	DATE	2010	dep	2	SENT_336	[p21l1994t3086r2121b3135],
4	;	:	O	;	_	0	SENT_336	[p21l1994t3086r2121b3135],
5	18:683	CD	NUMBER	18:683	num	6	SENT_336	[p21l1105t3156r1353b3197],
6	-95	CD	NUMBER	-95	dep	2	SENT_336	[p21l1105t3156r1353b3197],
7	.	.	O	.	_	0	SENT_336	[p21l1105t3156r1353b3197],

1	14	CD	NUMBER	14	_	0	SENT_337	[p21l1105t3228r1167b3266],
2	.	.	O	.	_	0	SENT_337	[p21l1105t3228r1167b3266],

1	Straussman	NNP	PERSON	Straussman	nn	2	SENT_338	[p21l1199t3226r1483b3267],
2	R	NNP	PERSON	R	_	0	SENT_338	[p21l1499t3227r1548b3276],
3	,	,	O	,	_	0	SENT_338	[p21l1499t3227r1548b3276],
4	Morikawa	NNP	PERSON	Morikawa	nn	5	SENT_338	[p21l1566t3223r1810b3267],
5	T	NN	O	t	appos	2	SENT_338	[p21l1824t3226r1867b3276],
6	,	,	O	,	_	0	SENT_338	[p21l1824t3226r1867b3276],
7	Shee	NNP	PERSON	Shee	nn	8	SENT_338	[p21l1888t3223r1996b3266],
8	K	NNP	PERSON	K	appos	2	SENT_338	[p21l2013t3227r2062b3276],
9	,	,	O	,	_	0	SENT_338	[p21l2013t3227r2062b3276],
10	et	FW	O	et	nn	11	SENT_338	[p21l2082t3232r2126b3266],
11	al.	FW	O	al.	appos	2	SENT_338	[p21l1102t3294r1158b3338],
12	.	.	O	.	_	0	SENT_338	[p21l1102t3294r1158b3338],

1	Tumour	NN	MISC	tumour	nn	2	SENT_339	[p21l1181t3297r1376b3338],
2	micro-environment	NN	O	micro-environment	nsubj	3	SENT_339	[p21l1397t3295r1873b3338],
3	elicits	VBZ	O	elicit	_	0	SENT_339	[p21l1893t3294r2033b3338],
4	inic	JJ	O	inic	acomp	3	SENT_339	[p21l2057t3295r2122b3337, p22l8t20r46b62],

1	melanoma	NN	O	melanoma	_	0	SENT_340	[p22l75t19r346b63],
2	:	:	O	:	_	0	SENT_340	[p22l75t19r346b63],
3	a	DT	O	a	det	12	SENT_340	[p22l377t33r402b62],
4	multicentre	JJ	O	multicentre	amod	6	SENT_340	[p22l431t19r725b72],
5	,	,	O	,	_	0	SENT_340	[p22l431t19r725b72],
6	open-label	JJ	O	open-label	amod	12	SENT_340	[p22l759t19r1025b74],
7	,	,	O	,	_	0	SENT_340	[p22l759t19r1025b74],
8	phase	NN	O	phase	npadvmod	10	SENT_340	[p22l8t89r148b144],
9	3	CD	NUMBER	3	num	8	SENT_340	[p22l167t92r191b133],
10	randomised	JJ	O	randomised	amod	12	SENT_340	[p22l211t89r501b132],
11	controlled	JJ	O	controlled	amod	12	SENT_340	[p22l520t89r768b132],
12	trial	NN	O	trial	dep	1	SENT_340	[p22l786t89r900b132],
13	.	.	O	.	_	0	SENT_340	[p22l786t89r900b132],

1	Lancet	NNP	O	Lancet	_	0	SENT_341	[p22l920t93r1027b132, p22l9t168r78b202],
2	2012	CD	DATE	2012	num	1	SENT_341	[p22l94t162r508b211],
3	;	:	O	;	_	0	SENT_341	[p22l94t162r508b211],
4	380:358	CD	NUMBER	380:358	number	5	SENT_341	[p22l94t162r508b211],
5	—	CD	NUMBER	—	dep	1	SENT_341	[p22l94t162r508b211],
6	65	CD	NUMBER	65	dep	5	SENT_341	[p22l94t162r508b211],
7	.	.	O	.	_	0	SENT_341	[p22l94t162r508b211],

1	7	CD	NUMBER	7	_	0	SENT_342	[p22l10t234r42b272],
2	.	.	O	.	_	0	SENT_342	[p22l10t234r42b272],

1	Falchook	NNP	O	Falchook	nn	2	SENT_343	[p22l103t229r326b273],
2	GS	NN	O	g	_	0	SENT_343	[p22l341t232r421b282],
3	,	,	O	,	_	0	SENT_343	[p22l341t232r421b282],
4	Lewis	NNP	PERSON	Lewis	nn	5	SENT_343	[p22l441t230r580b273],
5	KD	NN	O	kd	appos	2	SENT_343	[p22l598t233r687b281],
6	,	,	O	,	_	0	SENT_343	[p22l598t233r687b281],
7	Infante	NNP	PERSON	Infante	nn	8	SENT_343	[p22l707t229r883b272],
8	JR	NNP	O	JR	appos	2	SENT_343	[p22l895t233r966b282],
9	,	,	O	,	_	0	SENT_343	[p22l895t233r966b282],
10	et	FW	O	et	nn	11	SENT_343	[p22l987t238r1031b272],
11	al.	FW	O	al.	appos	2	SENT_343	[p22l8t299r63b342],
12	.	.	O	.	_	0	SENT_343	[p22l8t299r63b342],

1	Activity	NN	O	activity	_	0	SENT_344	[p22l86t300r272b354],
2	of	IN	O	of	_	0	SENT_344	[p22l291t299r348b342],
3	the	DT	O	the	det	7	SENT_344	[p22l359t299r434b342],
4	oral	JJ	O	oral	amod	7	SENT_344	[p22l456t299r550b342],
5	MEK	NN	O	mek	nn	7	SENT_344	[p22l569t303r689b344],
6	inhibitor	NN	O	inhibitor	nn	7	SENT_344	[p22l708t299r924b342],
7	trametinib	NN	O	trametinib	prep_of	1	SENT_344	[p22l944t308r1027b342, p22l8t369r198b413],
8	in	IN	O	in	_	0	SENT_344	[p22l223t370r270b412],
9	patients	NNS	O	patient	prep_in	7	SENT_344	[p22l294t370r487b424],
10	with	IN	O	with	_	0	SENT_344	[p22l511t369r621b413],
11	advanced	JJ	O	advanced	amod	12	SENT_344	[p22l645t369r869b413],
12	melanoma	NN	O	melanoma	prep_with	9	SENT_344	[p22l894t369r1027b412, p22l8t453r159b482],
13	:	:	O	:	_	0	SENT_344	[p22l894t369r1027b412, p22l8t453r159b482],
14	a	DT	O	a	det	15	SENT_344	[p22l197t453r221b482],
15	phase	NN	O	phase	dep	1	SENT_344	[p22l256t439r396b494],
16	1	CD	NUMBER	1	num	18	SENT_344	[p22l434t442r459b482],
17	dose-escalation	NN	O	dose-escalation	nn	18	SENT_344	[p22l496t439r875b482],
18	trial	NN	O	trial	dep	15	SENT_344	[p22l911t439r1025b482],
19	.	.	O	.	_	0	SENT_344	[p22l911t439r1025b482],

1	Lancet	NNP	O	Lancet	nn	2	SENT_345	[p22l8t513r170b552],
2	Oncol	NNP	O	Oncol	_	0	SENT_345	[p22l186t509r329b552],
3	2012	CD	DATE	2012	num	2	SENT_345	[p22l348t512r695b561],
4	;	:	O	;	_	0	SENT_345	[p22l348t512r695b561],
5	13:782	CD	NUMBER	13:782	number	6	SENT_345	[p22l348t512r695b561],
6	—	CD	NUMBER	—	dep	2	SENT_345	[p22l348t512r695b561],
7	9	CD	NUMBER	9	dep	6	SENT_345	[p22l348t512r695b561],
8	.	.	O	.	_	0	SENT_345	[p22l348t512r695b561],

1	8	CD	NUMBER	8	_	0	SENT_346	[p22l8t583r47b623],
2	.	.	O	.	_	0	SENT_346	[p22l8t583r47b623],

1	Flaherty	NNP	ORGANIZATION	Flaherty	nn	2	SENT_347	[p22l103t579r303b634],
2	KT	NNP	ORGANIZATION	KT	_	0	SENT_347	[p22l319t583r399b632],
3	,	,	O	,	_	0	SENT_347	[p22l319t583r399b632],
4	Robert	NNP	PERSON	Robert	nn	5	SENT_347	[p22l420t579r587b625],
5	C	NNP	PERSON	C	appos	2	SENT_347	[p22l603t582r649b631],
6	,	,	O	,	_	0	SENT_347	[p22l603t582r649b631],
7	Hersey	NNP	PERSON	Hersey	nn	8	SENT_347	[p22l670t583r837b634],
8	P	NN	PERSON	p	appos	2	SENT_347	[p22l853t583r890b631],
9	,	,	O	,	_	0	SENT_347	[p22l853t583r890b631],
10	et	FW	O	et	nn	11	SENT_347	[p22l912t588r955b622],
11	al.	FW	O	al.	appos	2	SENT_347	[p22l970t579r1025b622],
12	.	.	O	.	_	0	SENT_347	[p22l970t579r1025b622],

1	Improved	VBN	O	improve	_	0	SENT_348	[p22l8t649r239b704],
2	survival	NN	O	survival	dobj	1	SENT_348	[p22l257t649r445b693],
3	with	IN	O	with	_	0	SENT_348	[p22l460t649r570b693],
4	MEK	NN	O	mek	nn	5	SENT_348	[p22l586t653r706b694],
5	inhibition	NN	O	inhibition	prep_with	1	SENT_348	[p22l721t649r964b693],
6	in	IN	O	in	_	0	SENT_348	[p22l981t650r1028b692],
7	BRAF-mutated	JJ	O	braf-mutated	amod	8	SENT_348	[p22l8t719r366b765],
8	melanoma	NN	O	melanoma	prep_in	1	SENT_348	[p22l391t719r661b763],
9	.	.	O	.	_	0	SENT_348	[p22l391t719r661b763],

1	N	NN	O	n	nn	3	SENT_349	[p22l687t723r729b763],
2	Engl	NNP	O	Engl	nn	3	SENT_349	[p22l752t719r862b775],
3	J	NNP	O	J	nsubj	4	SENT_349	[p22l881t723r902b769],
4	Med	VBD	O	med	_	0	SENT_349	[p22l924t719r1028b763],
5	2012	CD	DATE	2012	dobj	4	SENT_349	[p22l8t792r405b841],
6	;	:	O	;	_	0	SENT_349	[p22l8t792r405b841],
7	367:107	CD	NUMBER	367:107	num	8	SENT_349	[p22l8t792r405b841],
8	-14	CD	NUMBER	-14	dep	5	SENT_349	[p22l8t792r405b841],
9	.	.	O	.	_	0	SENT_349	[p22l8t792r405b841],

1	9	CD	NUMBER	9	_	0	SENT_350	[p22l8t864r45b902],
2	.	.	O	.	_	0	SENT_350	[p22l8t864r45b902],

1	Johannessen	NNP	PERSON	Johannessen	nn	2	SENT_351	[p22l98t859r410b909],
2	CM	NN	O	cm	_	0	SENT_351	[p22l433t862r528b912],
3	,	,	O	,	_	0	SENT_351	[p22l433t862r528b912],
4	Boehm	NNP	PERSON	Boehm	nn	5	SENT_351	[p22l554t859r726b902],
5	JS	NNP	O	JS	appos	2	SENT_351	[p22l744t862r805b912],
6	,	,	O	,	_	0	SENT_351	[p22l744t862r805b912],
7	Kim	NNP	PERSON	Kim	nn	8	SENT_351	[p22l831t860r934b904],
8	SY	NNP	PERSON	SY	appos	2	SENT_351	[p22l959t862r1025b911],
9	,	,	O	,	_	0	SENT_351	[p22l959t862r1025b911],
10	et	FW	O	et	nn	11	SENT_351	[p22l9t938r52b972],
11	al.	FW	O	al.	appos	2	SENT_351	[p22l66t929r120b972],
12	.	.	O	.	_	0	SENT_351	[p22l66t929r120b972],

1	COT	NN	O	cot	nn	2	SENT_352	[p22l140t932r250b972],
2	drives	NNS	O	drive	_	0	SENT_352	[p22l265t929r406b973],
3	resistance	NN	O	resistance	dep	2	SENT_352	[p22l424t930r667b972],
4	to	TO	O	to	_	0	SENT_352	[p22l683t938r729b972],
5	RAF	NN	ORGANIZATION	raf	nn	6	SENT_352	[p22l745t933r848b975],
6	inhibition	NN	O	inhibition	prep_to	3	SENT_352	[p22l865t929r1027b972, p22l9t1000r104b1042],
7	through	IN	O	through	_	0	SENT_352	[p22l125t999r321b1055],
8	MAP	NN	O	map	nn	11	SENT_352	[p22l340t1003r457b1042],
9	kinase	NN	O	kinase	nn	11	SENT_352	[p22l477t999r634b1043],
10	pathway	NN	O	pathway	nn	11	SENT_352	[p22l654t999r857b1054],
11	reactivation	NN	O	reactivation	prep_through	6	SENT_352	[p22l875t1000r1027b1042, p22l6t1070r169b1113],
12	.	.	O	.	_	0	SENT_352	[p22l875t1000r1027b1042, p22l6t1070r169b1113],

1	Nature	NNP	O	Nature	_	0	SENT_353	[p22l189t1073r355b1113],
2	2010	CD	DATE	2010	num	1	SENT_353	[p22l374t1072r785b1121],
3	;	:	O	;	_	0	SENT_353	[p22l374t1072r785b1121],
4	468:968	CD	NUMBER	468:968	number	5	SENT_353	[p22l374t1072r785b1121],
5	-72	CD	NUMBER	-72	dep	1	SENT_353	[p22l374t1072r785b1121],
6	.	.	O	.	_	0	SENT_353	[p22l374t1072r785b1121],

1	10	CD	NUMBER	10	_	0	SENT_354	[p22l10t1143r73b1182],
2	.	.	O	.	_	0	SENT_354	[p22l10t1143r73b1182],

1	Nazarian	JJ	PERSON	nazarian	amod	2	SENT_355	[p22l102t1140r327b1183],
2	R	NN	PERSON	r	_	0	SENT_355	[p22l358t1143r407b1192],
3	,	,	O	,	_	0	SENT_355	[p22l358t1143r407b1192],
4	Shi	NN	PERSON	shus	nn	5	SENT_355	[p22l444t1139r518b1182],
5	H	NN	PERSON	h	appos	2	SENT_355	[p22l549t1143r603b1192],
6	,	,	O	,	_	0	SENT_355	[p22l549t1143r603b1192],
7	Wang	NNP	PERSON	Wang	nn	8	SENT_355	[p22l637t1143r777b1195],
8	Q	NNP	O	Q	appos	2	SENT_355	[p22l808t1142r861b1193],
9	,	,	O	,	_	0	SENT_355	[p22l808t1142r861b1193],
10	et	FW	O	et	nn	11	SENT_355	[p22l897t1148r941b1182],
11	al.	FW	O	al.	appos	2	SENT_355	[p22l970t1139r1025b1182],
12	.	.	O	.	_	0	SENT_355	[p22l970t1139r1025b1182],

1	Melanomas	NNS	O	melanoma	nsubj	2	SENT_356	[p22l7t1209r288b1252],
2	acquire	VBP	O	acquire	_	0	SENT_356	[p22l318t1210r496b1264],
3	resistance	NN	O	resistance	dobj	2	SENT_356	[p22l525t1210r767b1252],
4	to	TO	O	to	_	0	SENT_356	[p22l797t1218r842b1252],
5	B-RAF	NN	O	b-raf	nn	9	SENT_356	[p22l871t1213r1027b1255],
6	(	CD	NUMBER	(	num	9	SENT_356	[p22l11t1282r197b1329],
7	V600E	NN	O	v600e	nn	9	SENT_356	[p22l11t1282r197b1329],
8	)	NN	O	)	nn	9	SENT_356	[p22l11t1282r197b1329],
9	inhibition	NN	O	inhibition	prep_to	2	SENT_356	[p22l223t1279r466b1322],
10	by	IN	O	by	_	0	SENT_356	[p22l489t1279r544b1334],
11	RTK	NN	O	rtk	nn	14	SENT_356	[p22l564t1282r671b1325],
12	or	CC	O	or	_	0	SENT_356	[p22l693t1293r743b1322],
13	N-RAS	NN	O	n-ra	nn	14	SENT_356	[p22l763t1282r924b1325],
14	upregulation	NN	O	upregulation	prep_by	2	SENT_356	[p22l949t1293r1027b1334, p22l8t1349r274b1405],
15	.	.	O	.	_	0	SENT_356	[p22l949t1293r1027b1334, p22l8t1349r274b1405],

1	Nature	NNP	O	Nature	_	0	SENT_357	[p22l295t1353r461b1393],
2	2010	CD	DATE	2010	num	1	SENT_357	[p22l480t1352r853b1401],
3	;	:	O	;	_	0	SENT_357	[p22l480t1352r853b1401],
4	468:973	CD	NUMBER	468:973	number	5	SENT_357	[p22l480t1352r853b1401],
5	-7	CD	NUMBER	-7	dep	1	SENT_357	[p22l480t1352r853b1401],
6	.	.	O	.	_	0	SENT_357	[p22l480t1352r853b1401],

1	11	CD	NUMBER	11	_	0	SENT_358	[p22l10t1424r73b1462],
2	.	.	O	.	_	0	SENT_358	[p22l10t1424r73b1462],

1	Emery	NNP	ORGANIZATION	Emery	nn	2	SENT_359	[p22l103t1423r258b1474],
2	CM	NN	ORGANIZATION	cm	_	0	SENT_359	[p22l293t1422r389b1472],
3	,	,	O	,	_	0	SENT_359	[p22l293t1422r389b1472],
4	Vijayendran	NNP	O	Vijayendran	nn	5	SENT_359	[p22l427t1419r714b1474],
5	KG	NNP	O	KG	appos	2	SENT_359	[p22l751t1422r839b1472],
6	,	,	O	,	_	0	SENT_359	[p22l751t1422r839b1472],
7	Zipser	NNP	PERSON	Zipser	nn	8	SENT_359	[p22l879t1420r1030b1474],
8	MC	NNP	O	MC	appos	2	SENT_359	[p22l7t1492r103b1542],
9	,	,	O	,	_	0	SENT_359	[p22l7t1492r103b1542],
10	et	FW	O	et	nn	11	SENT_359	[p22l131t1498r175b1532],
11	al.	FW	O	al.	appos	2	SENT_359	[p22l196t1489r251b1532],
12	.	.	O	.	_	0	SENT_359	[p22l196t1489r251b1532],

1	MEK1	NN	O	mek1	nn	2	SENT_360	[p22l277t1492r425b1534],
2	mutations	NNS	O	mutation	nsubj	3	SENT_360	[p22l449t1490r695b1533],
3	confer	VBP	O	confer	_	0	SENT_360	[p22l721t1489r876b1532],
4	resistance	NN	O	resistance	dobj	3	SENT_360	[p22l899t1490r1027b1532, p22l9t1568r138b1602],
5	to	TO	O	to	_	0	SENT_360	[p22l158t1568r203b1602],
6	MEK	NN	O	mek	nn	9	SENT_360	[p22l222t1563r342b1604],
7	and	CC	O	and	_	0	SENT_360	[p22l359t1559r448b1602],
8	B-RAF	NN	O	b-raf	nn	9	SENT_360	[p22l467t1563r623b1605],
9	inhibition	NN	O	inhibition	prep_to	3	SENT_360	[p22l643t1559r899b1602],
10	.	.	O	.	_	0	SENT_360	[p22l643t1559r899b1602],

1	Proc	NNP	O	Proc	nn	7	SENT_361	[p22l921t1563r1028b1602],
2	Natl	NNP	O	Natl	nn	7	SENT_361	[p22l7t1629r110b1673],
3	Acad	NNP	O	Acad	nn	7	SENT_361	[p22l127t1629r246b1673],
4	Sci	NNP	O	Sci	nn	7	SENT_361	[p22l267t1630r334b1673],
5	U	NNP	O	U	nn	7	SENT_361	[p22l352t1633r390b1672],
6	S	NNP	O	S	nn	7	SENT_361	[p22l409t1632r433b1672],
7	A	NNP	O	A	_	0	SENT_361	[p22l452t1633r488b1672],
8	2009	CD	DATE	2009	num	7	SENT_361	[p22l506t1632r948b1681],
9	;	:	O	;	_	0	SENT_361	[p22l506t1632r948b1681],
10	106:20411	CD	NUMBER	106:20411	number	11	SENT_361	[p22l506t1632r948b1681],
11	-6	CD	NUMBER	-6	dep	7	SENT_361	[p22l506t1632r948b1681],
12	.	.	O	.	_	0	SENT_361	[p22l506t1632r948b1681],

1	12	CD	NUMBER	12	_	0	SENT_362	[p22l10t1704r74b1742],
2	.	.	O	.	_	0	SENT_362	[p22l10t1704r74b1742],

1	Poulikakos	NNP	O	Poulikakos	nn	2	SENT_363	[p22l103t1699r372b1743],
2	PI	NN	O	pi	_	0	SENT_363	[p22l408t1703r467b1752],
3	,	,	O	,	_	0	SENT_363	[p22l408t1703r467b1752],
4	Persaud	NNP	PERSON	Persaud	nn	5	SENT_363	[p22l506t1699r695b1743],
5	Y	NN	PERSON	y	appos	2	SENT_363	[p22l729t1703r769b1752],
6	,	,	O	,	_	0	SENT_363	[p22l729t1703r769b1752],
7	Janakiraman	NN	O	janakiraman	nn	8	SENT_363	[p22l803t1699r1027b1749, p22l8t1783r116b1812],
8	M	NN	O	m	appos	2	SENT_363	[p22l136t1773r197b1821],
9	,	,	O	,	_	0	SENT_363	[p22l136t1773r197b1821],
10	et	FW	O	et	nn	11	SENT_363	[p22l222t1778r265b1812],
11	al.	FW	O	al.	appos	2	SENT_363	[p22l284t1769r339b1812],
12	.	.	O	.	_	0	SENT_363	[p22l284t1769r339b1812],

1	RAF	NN	ORGANIZATION	raf	nn	3	SENT_364	[p22l363t1773r467b1815],
2	inhibitor	NN	O	inhibitor	nn	3	SENT_364	[p22l489t1769r705b1812],
3	resistance	NN	O	resistance	nsubj	6	SENT_364	[p22l725t1770r968b1812],
4	is	VBZ	O	be	cop	6	SENT_364	[p22l990t1770r1027b1812],
5	nate	JJ	O	nate	amod	6	SENT_364	[p22l1103t28r1204b62],
6	resistance	NN	O	resistance	_	0	SENT_364	[p22l1222t20r1465b62],
7	to	TO	O	to	_	0	SENT_364	[p22l1483t28r1529b62],
8	RAF	NN	ORGANIZATION	raf	nn	9	SENT_364	[p22l1547t23r1650b65],
9	inhibitors	NNS	O	inhibitor	prep_to	6	SENT_364	[p22l1668t19r1907b63],
10	through	IN	O	through	_	0	SENT_364	[p22l1926t19r2123b75],
11	HGF	NN	O	hgf	nn	12	SENT_364	[p22l1102t92r1213b132],
12	secretion	NN	O	secretion	prep_through	6	SENT_364	[p22l1234t90r1467b132],
13	.	.	O	.	_	0	SENT_364	[p22l1234t90r1467b132],

1	Nature	NNP	O	Nature	_	0	SENT_365	[p22l1488t93r1654b133],
2	2012	CD	DATE	2012	num	1	SENT_365	[p22l1673t92r2058b141],
3	;	:	O	;	_	0	SENT_365	[p22l1673t92r2058b141],
4	487:500	CD	NUMBER	487:500	number	5	SENT_365	[p22l1673t92r2058b141],
5	-4	CD	NUMBER	-4	dep	1	SENT_365	[p22l1673t92r2058b141],
6	.	.	O	.	_	0	SENT_365	[p22l1673t92r2058b141],

1	15	CD	NUMBER	15	_	0	SENT_366	[p22l1105t164r1167b202],
2	.	.	O	.	_	0	SENT_366	[p22l1105t164r1167b202],

1	Paraiso	NNP	O	Paraiso	nn	2	SENT_367	[p22l1197t160r1375b202],
2	KH	NNP	O	KH	_	0	SENT_367	[p22l1392t163r1485b211],
3	,	,	O	,	_	0	SENT_367	[p22l1392t163r1485b211],
4	Fedorenko	NNP	PERSON	Fedorenko	appos	2	SENT_367	[p22l1504t159r1760b203],
5	IV	CD	NUMBER	iv	num	4	SENT_367	[p22l1776t163r1837b211],
6	,	,	O	,	_	0	SENT_367	[p22l1776t163r1837b211],
7	Cantini	NNP	ORGANIZATION	Cantini	nn	8	SENT_367	[p22l1856t160r2037b202],
8	LP	NN	ORGANIZATION	lp	appos	2	SENT_367	[p22l2052t163r2120b212],
9	,	,	O	,	_	0	SENT_367	[p22l2052t163r2120b212],
10	et	FW	O	et	nn	11	SENT_367	[p22l1103t238r1147b272],
11	al.	FW	O	al.	appos	2	SENT_367	[p22l1173t229r1228b272],
12	.	.	O	.	_	0	SENT_367	[p22l1173t229r1228b272],

1	Recovery	NN	O	recovery	_	0	SENT_368	[p22l1260t233r1479b284],
2	of	IN	O	of	_	0	SENT_368	[p22l1507t229r1563b272],
3	phospho	NN	O	phospho	prep_of	1	SENT_368	[p22l1581t229r1922b284],
4	.	.	O	.	_	0	SENT_368	[p22l1581t229r1922b284],

1	—	NN	O	—	_	0	SENT_369	[p22l1581t229r1922b284],
2	.	.	O	.	_	0	SENT_369	[p22l1581t229r1922b284],

1	ERK	NN	O	erk	nn	2	SENT_370	[p22l1581t229r1922b284],
2	activity	NN	O	activity	nsubj	3	SENT_370	[p22l1950t230r2125b284],
3	allows	VBZ	O	allow	_	0	SENT_370	[p22l1102t299r1258b343],
4	melanoma	NN	O	melanoma	nn	5	SENT_370	[p22l1294t299r1551b342],
5	cells	NNS	O	cell	nsubj	7	SENT_370	[p22l1586t299r1692b342],
6	to	TO	O	to	aux	7	SENT_370	[p22l1728t308r1774b342],
7	escape	VB	O	escape	xcomp	3	SENT_370	[p22l1810t313r1969b354],
8	from	IN	O	from	_	0	SENT_370	[p22l2004t299r2123b342],
9	BRAF	NN	O	braf	nn	11	SENT_370	[p22l1102t373r1239b415],
10	inhibitor	NN	O	inhibitor	nn	11	SENT_370	[p22l1258t369r1475b412],
11	therapy	NN	O	therapy	prep_from	7	SENT_370	[p22l1492t369r1682b424],
12	.	.	O	.	_	0	SENT_370	[p22l1492t369r1682b424],

1	Br	NN	O	br	_	0	SENT_371	[p22l1703t373r1790b419],
2	]	CD	NUMBER	]	num	1	SENT_371	[p22l1703t373r1790b419],
3	Cancer	NN	O	cancer	dep	1	SENT_371	[p22l1807t372r1976b412],
4	2010	CD	DATE	2010	num	3	SENT_371	[p22l1994t372r2120b421],
5	;	:	O	;	_	0	SENT_371	[p22l1994t372r2120b421],
6	102:1724	CD	NUMBER	102:1724	num	7	SENT_371	[p22l1105t442r1406b483],
7	-30	CD	NUMBER	-30	dep	1	SENT_371	[p22l1105t442r1406b483],
8	.	.	O	.	_	0	SENT_371	[p22l1105t442r1406b483],

1	16	CD	NUMBER	16	_	0	SENT_372	[p22l1105t514r1167b552],
2	.	.	O	.	_	0	SENT_372	[p22l1105t514r1167b552],

1	Sturm	NNP	ORGANIZATION	Sturm	nn	2	SENT_373	[p22l1199t512r1347b553],
2	OE	NNP	ORGANIZATION	OE	_	0	SENT_373	[p22l1370t512r1453b562],
3	,	,	O	,	_	0	SENT_373	[p22l1370t512r1453b562],
4	Orton	NNP	PERSON	Orton	nn	5	SENT_373	[p22l1478t512r1621b552],
5	R	NNP	PERSON	R	appos	2	SENT_373	[p22l1643t513r1692b562],
6	,	,	O	,	_	0	SENT_373	[p22l1643t513r1692b562],
7	Grindlay	NNP	PERSON	Grindlay	nn	8	SENT_373	[p22l1717t509r1930b564],
8	J	NNP	PERSON	J	appos	2	SENT_373	[p22l1945t513r1976b561],
9	,	,	O	,	_	0	SENT_373	[p22l1945t513r1976b561],
10	et	FW	O	et	nn	11	SENT_373	[p22l2002t518r2046b552],
11	al.	FW	O	al.	appos	2	SENT_373	[p22l2065t509r2120b552],
12	.	.	O	.	_	0	SENT_373	[p22l2065t509r2120b552],

1	The	DT	O	the	det	4	SENT_374	[p22l1101t579r1191b622],
2	mammalian	JJ	O	mammalian	amod	4	SENT_374	[p22l1213t579r1511b622],
3	MAPK/ERK	NN	O	mapk/erk	nn	4	SENT_374	[p22l1531t582r1813b628],
4	pathway	NN	O	pathway	nsubj	5	SENT_374	[p22l1832t579r2036b634],
5	exhibits	VBZ	O	exhibit	_	0	SENT_374	[p22l2056t593r2122b622, p22l1103t649r1239b693],
6	properties	NNS	O	property	dobj	5	SENT_374	[p22l1269t650r1517b704],
7	of	IN	O	of	_	0	SENT_374	[p22l1549t649r1605b692],
8	a	DT	O	a	det	11	SENT_374	[p22l1625t663r1649b692],
9	negative	JJ	O	negative	amod	11	SENT_374	[p22l1678t650r1878b705],
10	feedback	NN	O	feedback	nn	11	SENT_374	[p22l1908t649r2125b693],
11	amplifier	NN	O	amplifier	prep_of	6	SENT_374	[p22l1102t719r1340b774],
12	.	.	O	.	_	0	SENT_374	[p22l1102t719r1340b774],

1	Sci	NNP	O	Sci	nn	2	SENT_375	[p22l1364t720r1431b763],
2	Signal	NNP	O	Signal	_	0	SENT_375	[p22l1451t719r1601b775],
3	2010	CD	DATE	2010	num	2	SENT_375	[p22l1619t722r1915b771],
4	;	:	O	;	_	0	SENT_375	[p22l1619t722r1915b771],
5	3	CD	NUMBER	3	num	7	SENT_375	[p22l1619t722r1915b771],
6	:	:	O	:	_	0	SENT_375	[p22l1619t722r1915b771],
7	ra90	CD	NUMBER	ra90	dep	2	SENT_375	[p22l1619t722r1915b771],
8	.	.	O	.	_	0	SENT_375	[p22l1619t722r1915b771],

1	17	CD	NUMBER	17	_	0	SENT_376	[p22l1105t794r1163b832],
2	.	.	O	.	_	0	SENT_376	[p22l1105t794r1163b832],

1	Su	FW	O	su	_	0	SENT_377	[p22l1199t792r1255b833],
2	F	NN	O	f	dep	1	SENT_377	[p22l1281t793r1319b842],
3	,	,	O	,	_	0	SENT_377	[p22l1281t793r1319b842],
4	Viros	NNP	PERSON	Viros	nn	5	SENT_377	[p22l1347t790r1473b833],
5	A	NNP	O	A	appos	2	SENT_377	[p22l1499t793r1548b842],
6	,	,	O	,	_	0	SENT_377	[p22l1499t793r1548b842],
7	Milagre	NNP	O	Milagre	nn	8	SENT_377	[p22l1576t789r1765b845],
8	C	NNP	O	C	appos	2	SENT_377	[p22l1792t792r1838b842],
9	,	,	O	,	_	0	SENT_377	[p22l1792t792r1838b842],
10	et	FW	O	et	nn	11	SENT_377	[p22l1869t798r1912b832],
11	al.	FW	O	al.	appos	2	SENT_377	[p22l1936t789r1991b832],
12	.	.	O	.	_	0	SENT_377	[p22l1936t789r1991b832],

1	RAS	NN	O	ra	nn	2	SENT_378	[p22l2020t792r2121b835],
2	mutations	NNS	O	mutation	nsubj	9	SENT_378	[p22l1103t860r1348b903],
3	in	IN	O	in	_	0	SENT_378	[p22l1391t860r1438b902],
4	cutaneous	JJ	O	cutaneous	amod	6	SENT_378	[p22l1480t868r1726b903],
5	squamous-cell	JJ	O	squamous-cell	amod	6	SENT_378	[p22l1770t859r2123b914],
6	carcinomas	NNS	O	carcinoma	prep_in	2	SENT_378	[p22l1103t930r1382b972],
7	in	IN	O	in	_	0	SENT_378	[p22l1400t930r1447b972],
8	patients	NNS	O	patient	prep_in	6	SENT_378	[p22l1464t930r1657b984],
9	treated	VBN	O	treat	_	0	SENT_378	[p22l1675t929r1845b972],
10	with	IN	O	with	_	0	SENT_378	[p22l1859t929r1969b973],
11	BRAF	NN	O	braf	nn	12	SENT_378	[p22l1985t933r2122b975],
12	inhibitors	NNS	O	inhibitor	prep_with	9	SENT_378	[p22l1102t999r1356b1042],
13	.	.	O	.	_	0	SENT_378	[p22l1102t999r1356b1042],

1	N	NN	O	n	nn	3	SENT_379	[p22l1375t1003r1417b1043],
2	Engl	NNP	O	Engl	nn	3	SENT_379	[p22l1433t999r1542b1055],
3	J	NNP	O	J	nsubj	4	SENT_379	[p22l1555t1003r1575b1049],
4	Med	VBD	O	med	_	0	SENT_379	[p22l1590t999r1695b1042],
5	2012	CD	DATE	2012	dobj	4	SENT_379	[p22l1713t1002r2119b1051],
6	;	:	O	;	_	0	SENT_379	[p22l1713t1002r2119b1051],
7	366:207	CD	NUMBER	366:207	num	8	SENT_379	[p22l1713t1002r2119b1051],
8	-15	CD	NUMBER	-15	dep	5	SENT_379	[p22l1713t1002r2119b1051],
9	.	.	O	.	_	0	SENT_379	[p22l1713t1002r2119b1051],

1	18	CD	NUMBER	18	_	0	SENT_380	[p22l1105t1073r1168b1113],
2	.	.	O	.	_	0	SENT_380	[p22l1105t1073r1168b1113],

1	Shi	NN	PERSON	shus	nn	2	SENT_381	[p22l1199t1069r1273b1112],
2	H	NN	O	h	_	0	SENT_381	[p22l1307t1073r1361b1122],
3	,	,	O	,	_	0	SENT_381	[p22l1307t1073r1361b1122],
4	Moriceau	NNP	O	Moriceau	nn	5	SENT_381	[p22l1396t1070r1623b1113],
5	G	NNP	O	G	appos	2	SENT_381	[p22l1657t1072r1709b1122],
6	,	,	O	,	_	0	SENT_381	[p22l1657t1072r1709b1122],
7	Kong	NNP	PERSON	Kong	nn	8	SENT_381	[p22l1746t1073r1875b1125],
8	X	NN	PERSON	x	appos	2	SENT_381	[p22l1905t1073r1952b1122],
9	,	,	O	,	_	0	SENT_381	[p22l1905t1073r1952b1122],
10	et	FW	O	et	nn	11	SENT_381	[p22l1990t1078r2033b1112],
11	al.	FW	O	al.	appos	2	SENT_381	[p22l2064t1069r2120b1112],
12	.	.	O	.	_	0	SENT_381	[p22l2064t1069r2120b1112],

1	Melanoma	NN	O	melanoma	nn	3	SENT_382	[p22l1101t1139r1360b1183],
2	whole-exome	JJ	O	whole-exome	amod	3	SENT_382	[p22l1372t1139r1696b1183],
3	sequencing	NN	O	sequencing	nsubj	4	SENT_382	[p22l1713t1140r1988b1195],
4	identifies	VBZ	O	identify	_	0	SENT_382	[p22l2001t1139r2122b1182, p22l1103t1209r1226b1252],
5	(	CD	NUMBER	(	num	6	SENT_382	[p22l1258t1212r1604b1259],
6	V600E	NN	O	v600e	dobj	4	SENT_382	[p22l1258t1212r1604b1259],
7	)	CD	NUMBER	)	num	8	SENT_382	[p22l1258t1212r1604b1259],
8	B-RAF	NN	O	b-raf	nsubj	9	SENT_382	[p22l1258t1212r1604b1259],
9	amplificationmediated	VBD	O	amplificationmediate	rcmod	6	SENT_382	[p22l1632t1209r2122b1264, p22l1102t1279r1203b1322],
10	acquired	VBN	O	acquire	amod	13	SENT_382	[p22l1223t1279r1432b1334],
11	B-RAF	JJ	O	b-raf	amod	13	SENT_382	[p22l1451t1283r1608b1325],
12	inhibitor	NN	O	inhibitor	nn	13	SENT_382	[p22l1628t1279r1845b1322],
13	resistance	NN	O	resistance	dobj	9	SENT_382	[p22l1863t1280r2119b1322],
14	.	.	O	.	_	0	SENT_382	[p22l1863t1280r2119b1322],

1	Nat	NNP	PERSON	Nat	nn	2	SENT_383	[p22l1101t1353r1189b1393],
2	Commun	NNP	PERSON	Commun	_	0	SENT_383	[p22l1205t1352r1432b1393],
3	2012	CD	DATE	2012	num	2	SENT_383	[p22l1451t1352r1723b1401],
4	;	:	O	;	_	0	SENT_383	[p22l1451t1352r1723b1401],
5	3:724	CD	NUMBER	3:724	dep	2	SENT_383	[p22l1451t1352r1723b1401],
6	.	.	O	.	_	0	SENT_383	[p22l1451t1352r1723b1401],

1	19	CD	NUMBER	19	_	0	SENT_384	[p22l1105t1424r1166b1462],
2	.	.	O	.	_	0	SENT_384	[p22l1105t1424r1166b1462],

1	Heidorn	NNP	ORGANIZATION	Heidorn	nn	2	SENT_385	[p22l1197t1419r1396b1463],
2	SJ	NNP	ORGANIZATION	SJ	_	0	SENT_385	[p22l1414t1422r1469b1472],
3	,	,	O	,	_	0	SENT_385	[p22l1414t1422r1469b1472],
4	Milagre	NNP	O	Milagre	nn	5	SENT_385	[p22l1488t1419r1676b1475],
5	C	NNP	O	C	appos	2	SENT_385	[p22l1693t1422r1740b1472],
6	,	,	O	,	_	0	SENT_385	[p22l1693t1422r1740b1472],
7	Whittaker	NNP	PERSON	Whittaker	nn	8	SENT_385	[p22l1758t1419r2007b1463],
8	S	NNP	O	S	appos	2	SENT_385	[p22l2023t1422r2062b1472],
9	,	,	O	,	_	0	SENT_385	[p22l2023t1422r2062b1472],
10	et	FW	O	et	nn	11	SENT_385	[p22l2082t1428r2126b1462],
11	al.	FW	O	al.	appos	2	SENT_385	[p22l1102t1489r1158b1532],
12	.	.	O	.	_	0	SENT_385	[p22l1102t1489r1158b1532],

1	Kinase-dead	JJ	O	kinase-dead	amod	2	SENT_386	[p22l1177t1489r1480b1534],
2	BRAF	NN	O	braf	nsubj	6	SENT_386	[p22l1496t1493r1633b1535],
3	and	CC	O	and	_	0	SENT_386	[p22l1650t1489r1739b1533],
4	oncogenic	JJ	O	oncogenic	amod	5	SENT_386	[p22l1756t1490r2005b1545],
5	RAS	NN	O	ra	nsubj	6	SENT_386	[p22l2021t1492r2121b1535],
6	cooperate	VBP	O	cooperate	_	0	SENT_386	[p22l1103t1568r1339b1614],
7	to	TO	O	to	aux	8	SENT_386	[p22l1385t1568r1430b1603],
8	drive	VB	O	drive	xcomp	6	SENT_386	[p22l1477t1559r1594b1603],
9	tumor	NN	O	tumor	nn	10	SENT_386	[p22l1640t1568r1791b1603],
10	progression	NN	O	progression	dobj	8	SENT_386	[p22l1833t1560r2123b1615],
11	through	IN	O	through	_	0	SENT_386	[p22l1103t1629r1300b1685],
12	CRAF	NN	ORGANIZATION	craf	prep_through	8	SENT_386	[p22l1319t1632r1468b1675],
13	.	.	O	.	_	0	SENT_386	[p22l1319t1632r1468b1675],

1	Cell	NN	O	cell	_	0	SENT_387	[p22l1491t1629r1584b1673],
2	2010	CD	DATE	2010	num	1	SENT_387	[p22l1603t1632r2011b1681],
3	;	:	O	;	_	0	SENT_387	[p22l1603t1632r2011b1681],
4	140:209	CD	NUMBER	140:209	number	5	SENT_387	[p22l1603t1632r2011b1681],
5	-21	CD	NUMBER	-21	dep	1	SENT_387	[p22l1603t1632r2011b1681],
6	.	.	O	.	_	0	SENT_387	[p22l1603t1632r2011b1681],

1	20	CD	NUMBER	20	_	0	SENT_388	[p22l1102t1703r1169b1742],
2	.	.	O	.	_	0	SENT_388	[p22l1102t1703r1169b1742],

1	Poulikakos	NNP	O	Poulikakos	nn	2	SENT_389	[p22l1197t1699r1466b1743],
2	PI	NN	O	pi	nsubj	17	SENT_389	[p22l1503t1703r1562b1752],
3	,	,	O	,	_	0	SENT_389	[p22l1503t1703r1562b1752],
4	Zhang	NNP	PERSON	Zhang	nn	5	SENT_389	[p22l1601t1699r1756b1755],
5	C	NNP	PERSON	C	appos	2	SENT_389	[p22l1791t1702r1838b1752],
6	,	,	O	,	_	0	SENT_389	[p22l1791t1702r1838b1752],
7	Bollag	NNP	PERSON	Bollag	nn	8	SENT_389	[p22l1877t1699r2033b1755],
8	G	NNP	PERSON	G	appos	2	SENT_389	[p22l2068t1702r2120b1752],
9	,	,	O	,	_	0	SENT_389	[p22l2068t1702r2120b1752],
10	Shokat	NNP	O	Shokat	nn	11	SENT_389	[p22l1104t1769r1269b1813],
11	KM	NNP	O	KM	appos	2	SENT_389	[p22l1307t1773r1407b1821],
12	,	,	O	,	_	0	SENT_389	[p22l1307t1773r1407b1821],
13	Rosen	NNP	PERSON	Rosen	nn	16	SENT_389	[p22l1451t1773r1600b1815],
14	N.	NNP	O	N.	nn	16	SENT_389	[p22l1641t1773r1693b1812],
15	RAF	NN	O	raf	nn	16	SENT_389	[p22l1737t1773r1840b1815],
16	inhibitors	NNS	O	inhibitor	appos	2	SENT_389	[p22l1883t1769r2121b1812],
17	transactivate	VBP	O	transactivate	_	0	SENT_389	[p22l94t2256r746b2342],
18	RAF	NN	ORGANIZATION	raf	nn	19	SENT_389	[p22l796t2261r1009b2346],
19	dimers	NNS	O	dimer	dobj	17	SENT_389	[p22l1062t2254r1409b2342],
20	and	CC	O	and	_	0	SENT_389	[p22l1463t2254r1645b2342],
21	ERK	NN	O	erk	nn	22	SENT_389	[p22l1695t2261r1919b2346],
22	signalling	NN	O	signalling	dobj	17	SENT_389	[p22l1967t2256r2146b2367, p22l94t2398r459b2511],

1	in	IN	O	in	_	0	SENT_390	[p22l496t2400r591b2484],
2	cells	NNS	O	cell	pobj	1	SENT_390	[p22l631t2398r844b2485],
3	With	IN	O	with	_	0	SENT_390	[p22l880t2398r1101b2486],
4	Wild-type	JJ	O	wild-type	amod	5	SENT_390	[p22l1135t2398r1597b2509],
5	BRAF	NN	O	braf	prep_with	2	SENT_390	[p22l1635t2405r1933b2490],
6	.	.	O	.	_	0	SENT_390	[p22l1635t2405r1933b2490],

1	Nature	NNP	O	Nature	_	0	SENT_391	[p22l1976t2406r2146b2486, p22l94t2560r288b2630],

1	2010	CD	DATE	2010	_	0	SENT_392	[p22l326t2547r1147b2647],
2	;	:	O	;	_	0	SENT_392	[p22l326t2547r1147b2647],
3	464:427	CD	NUMBER	464:427	number	4	SENT_392	[p22l326t2547r1147b2647],
4	-30	CD	NUMBER	-30	dep	1	SENT_392	[p22l326t2547r1147b2647],
5	.	.	O	.	_	0	SENT_392	[p22l326t2547r1147b2647],

1	21	CD	NUMBER	21	_	0	SENT_393	[p22l92t2697r225b2774],
2	.	.	O	.	_	0	SENT_393	[p22l92t2697r225b2774],

1	Hatzivassiliou	NNP	O	Hatzivassiliou	nn	2	SENT_394	[p22l284t2686r980b2774],
2	G	NNP	O	G	_	0	SENT_394	[p22l1020t2692r1124b2793],
3	,	,	O	,	_	0	SENT_394	[p22l1020t2692r1124b2793],
4	Song	NN	O	song	nn	5	SENT_394	[p22l1173t2692r1415b2799],
5	K	NN	O	k	appos	2	SENT_394	[p22l1451t2694r1549b2792],
6	,	,	O	,	_	0	SENT_394	[p22l1451t2694r1549b2792],
7	Yen	NN	O	yen	nn	8	SENT_394	[p22l1591t2694r1762b2774],
8	I	NN	O	i	appos	2	SENT_394	[p22l1802t2694r1860b2792],
9	,	,	O	,	_	0	SENT_394	[p22l1802t2694r1860b2792],
10	et	FW	O	et	nn	11	SENT_394	[p22l1909t2705r1996b2773],
11	al.	FW	O	al.	appos	2	SENT_394	[p22l2030t2686r2141b2774],
12	.	.	O	.	_	0	SENT_394	[p22l2030t2686r2141b2774],

1	RAF	NN	ORGANIZATION	raf	nn	2	SENT_395	[p22l92t2837r299b2922],
2	inhibitors	NNS	O	inhibitor	_	0	SENT_395	[p22l364t2830r846b2918],
3	prime	JJ	O	prime	amod	5	SENT_395	[p22l909t2832r1197b2941],
4	wild-type	JJ	O	wild-type	amod	5	SENT_395	[p22l1256t2830r1718b2941],
5	RAF	NN	ORGANIZATION	raf	dep	2	SENT_395	[p22l1781t2837r1988b2922],
6	to	TO	O	to	aux	7	SENT_395	[p22l2053t2849r2146b2918],
7	activate	VB	O	activate	infmod	2	SENT_395	[p22l92t2976r460b3062],
8	the	DT	O	the	det	10	SENT_395	[p22l510t2974r660b3062],
9	MAJPK	NN	O	majpk	nn	10	SENT_395	[p22l705t2981r1018b3064],
10	pathway	NN	O	pathway	dobj	7	SENT_395	[p22l1060t2974r1471b3085],
11	and	CC	O	and	_	0	SENT_395	[p22l1514t2974r1691b3062],
12	enhance	VBP	O	enhance	infmod	2	SENT_395	[p22l1741t2974r2147b3060],
13	growth	NN	O	growth	dobj	12	SENT_395	[p22l92t3118r476b3231],
14	.	.	O	.	_	0	SENT_395	[p22l92t3118r476b3231],

1	Nature	NNP	O	Nature	_	0	SENT_396	[p22l518t3126r853b3206],
2	2010	CD	DATE	2010	num	1	SENT_396	[p22l892t3124r1651b3224],
3	;	:	O	;	_	0	SENT_396	[p22l892t3124r1651b3224],
4	464:431	CD	NUMBER	464:431	number	5	SENT_396	[p22l892t3124r1651b3224],
5	-5	CD	NUMBER	-5	dep	1	SENT_396	[p22l892t3124r1651b3224],
6	.	.	O	.	_	0	SENT_396	[p22l892t3124r1651b3224],

1	22	CD	NUMBER	22	_	0	SENT_397	[p22l92t3273r228b3350],
2	.	.	O	.	_	0	SENT_397	[p22l92t3273r228b3350],

1	Druker	NN	PERSON	druker	nn	3	SENT_398	[p22l284t3262r631b3350],
2	B	NN	O	b	nn	3	SENT_398	[p22l675t3269r796b3369],
3	]	NN	O	]	_	0	SENT_398	[p22l675t3269r796b3369],
4	,	,	O	,	_	0	SENT_398	[p22l675t3269r796b3369],
5	Talpaz	NNP	O	Talpaz	nn	6	SENT_398	[p22l848t3262r1174b3373],
6	M	NNP	O	M	appos	3	SENT_398	[p22l1219t3270r1342b3369],
7	,	,	O	,	_	0	SENT_398	[p22l1219t3270r1342b3369],
8	Resta	NNP	ORGANIZATION	Resta	nn	9	SENT_398	[p22l1396t3269r1664b3354],
9	DJ	NNP	ORGANIZATION	DJ	appos	3	SENT_398	[p22l1710t3269r1845b3369],
10	,	,	O	,	_	0	SENT_398	[p22l1710t3269r1845b3369],
11	et	FW	O	et	nn	12	SENT_398	[p22l1900t3281r1988b3348],
12	al.	FW	O	al.	appos	3	SENT_398	[p22l2030t3262r2142b3350],
13	.	.	O	.	_	0	SENT_398	[p22l2030t3262r2142b3350],

1	Efficacy	NN	O	efficacy	_	0	SENT_399	[p22l92t3406r489b3517],
2	and	CC	O	and	_	0	SENT_399	[p22l525t3406r704b3494],
3	safety	NN	O	safety	conj_and	1	SENT_399	[p22l748t3406r1035b3517],
4	of	IN	O	of	_	0	SENT_399	[p22l1073t3406r1185b3494],
5	a	DT	O	a	det	7	SENT_399	[p22l1206t3435r1256b3492],
6	specific	JJ	O	specific	amod	7	SENT_399	[p22l1298t3406r1674b3517],
7	inhibitor	NN	O	inhibitor	prep_of	1	SENT_399	[p22l1714t3406r2151b3494],
8	of	IN	O	of	_	0	SENT_399	[p22l94t3550r207b3638],
9	the	DT	O	the	det	12	SENT_399	[p22l219t3550r370b3636],
10	BCR-ABL	NN	MISC	bcr-abl	nn	12	SENT_399	[p22l401t3556r846b3642],
11	tyrosine	NN	O	tyrosine	nn	12	SENT_399	[p22l876t3552r1271b3661],
12	kinase	NN	O	kinase	prep_of	7	SENT_399	[p22l1304t3550r1620b3638],
13	in	IN	O	in	_	0	SENT_399	[p22l1653t3552r1747b3636],
14	chronic	JJ	O	chronic	amod	16	SENT_399	[p22l1781t3550r2149b3638],
15	myeloid	JJ	O	myeloid	amod	16	SENT_399	[p22l94t3694r476b3805],
16	leukemia	NN	O	leukemia	prep_in	1	SENT_399	[p22l504t3694r978b3782],
17	.	.	O	.	_	0	SENT_399	[p22l504t3694r978b3782],

1	N	NN	O	n	nn	3	SENT_400	[p22l1012t3702r1097b3782],
2	Engl	NNP	O	Engl	nn	3	SENT_400	[p22l1123t3694r1404b3807],
3	]	NNP	O	]	nsubj	4	SENT_400	[p22l1123t3694r1404b3807],
4	Med	VBD	O	med	_	0	SENT_400	[p22l1428t3694r1639b3782],
5	2001	CD	DATE	2001	dobj	4	SENT_400	[p22l1670t3700r2143b3800],
6	;	:	O	;	_	0	SENT_400	[p22l1670t3700r2143b3800],
7	344	CD	NUMBER	344	dep	5	SENT_400	[p22l1670t3700r2143b3800],
8	:	:	O	:	_	0	SENT_400	[p22l1670t3700r2143b3800],

1	1031-7	CD	NUMBER	1031-7	_	0	SENT_401	[p23l98t29r416b111],
2	.	.	O	.	_	0	SENT_401	[p23l98t29r416b111],

1	23	CD	NUMBER	23	_	0	SENT_402	[p23l92t177r225b252],
2	.	.	O	.	_	0	SENT_402	[p23l92t177r225b252],

1	Demetri	NNP	PERSON	Demetri	nn	2	SENT_403	[p23l284t168r685b252],
2	GD	NN	O	gd	_	0	SENT_403	[p23l738t172r921b271],
3	,	,	O	,	_	0	SENT_403	[p23l738t172r921b271],
4	Von	NNP	PERSON	Von	nn	6	SENT_403	[p23l978t194r1151b254],
5	Mehren	NNP	PERSON	Mehren	nn	6	SENT_403	[p23l1204t166r1580b252],
6	M	NN	O	m	appos	2	SENT_403	[p23l1631t174r1753b271],
7	,	,	O	,	_	0	SENT_403	[p23l1631t174r1753b271],
8	Blanke	NNP	PERSON	Blanke	nn	9	SENT_403	[p23l1814t166r2147b254],
9	CD	NNP	O	CD	appos	2	SENT_403	[p23l94t316r265b417],
10	,	,	O	,	_	0	SENT_403	[p23l94t316r265b417],
11	et	FW	O	et	nn	12	SENT_403	[p23l316t329r405b396],
12	al.	FW	O	al.	appos	2	SENT_403	[p23l443t310r553b398],
13	.	.	O	.	_	0	SENT_403	[p23l443t310r553b398],

1	Efficacy	NN	O	efficacy	_	0	SENT_404	[p23l602t310r999b421],
2	and	CC	O	and	_	0	SENT_404	[p23l1037t310r1216b398],
3	safety	NN	O	safety	conj_and	1	SENT_404	[p23l1263t310r1551b421],
4	of	IN	O	of	_	0	SENT_404	[p23l1591t310r1704b398],
5	imatinib	NN	O	imatinib	nn	6	SENT_404	[p23l1727t310r2146b398],
6	mesylate	NN	O	mesylate	prep_of	1	SENT_404	[p23l94t454r518b565],
7	in	IN	O	in	_	0	SENT_404	[p23l619t456r714b540],
8	advanced	JJ	O	advanced	amod	11	SENT_404	[p23l817t454r1266b542],
9	gastrointestinal	JJ	O	gastrointestinal	amod	11	SENT_404	[p23l1369t454r2148b567],
10	stromal	JJ	O	stromal	amod	11	SENT_404	[p23l96t598r472b686],
11	tumors	NNS	O	tumor	prep_in	1	SENT_404	[p23l520t617r898b686],
12	.	.	O	.	_	0	SENT_404	[p23l520t617r898b686],

1	N	NN	O	n	nn	3	SENT_405	[p23l951t606r1035b686],
2	Engl	NNP	O	Engl	nn	3	SENT_405	[p23l1081t598r1300b711],
3	J	NNP	O	J	nsubj	4	SENT_405	[p23l1338t606r1380b700],
4	Med	VBD	O	med	_	0	SENT_405	[p23l1423t598r1634b686],
5	2002	CD	DATE	2002	dobj	4	SENT_405	[p23l1683t604r2143b704],
6	;	:	O	;	_	0	SENT_405	[p23l1683t604r2143b704],
7	347	CD	NUMBER	347	num	9	SENT_405	[p23l1683t604r2143b704],
8	:	:	O	:	_	0	SENT_405	[p23l1683t604r2143b704],
9	472-80	CD	NUMBER	472-80	dep	5	SENT_405	[p23l92t747r443b829],
10	.	.	O	.	_	0	SENT_405	[p23l92t747r443b829],

1	24	CD	NUMBER	24	_	0	SENT_406	[p23l92t896r225b973],
2	.	.	O	.	_	0	SENT_406	[p23l92t896r225b973],

1	Cobleigh	NNP	ORGANIZATION	Cobleigh	nn	2	SENT_407	[p23l284t885r721b998],
2	MA	NNP	ORGANIZATION	MA	_	0	SENT_407	[p23l751t893r949b992],
3	,	,	O	,	_	0	SENT_407	[p23l751t893r949b992],
4	Vogel	NNP	ORGANIZATION	Vogel	nn	5	SENT_407	[p23l985t885r1256b998],
5	CL	NN	ORGANIZATION	cl	appos	2	SENT_407	[p23l1290t891r1446b991],
6	,	,	O	,	_	0	SENT_407	[p23l1290t891r1446b991],
7	Tripathy	NN	PERSON	tripathy	nn	8	SENT_407	[p23l1482t885r1898b996],
8	D	NN	O	d	appos	2	SENT_407	[p23l1925t892r2025b992],
9	,	,	O	,	_	0	SENT_407	[p23l1925t892r2025b992],
10	et	FW	O	et	nn	11	SENT_407	[p23l2067t904r2153b972],
11	al.	FW	O	al.	appos	2	SENT_407	[p23l92t1029r204b1117],
12	.	.	O	.	_	0	SENT_407	[p23l92t1029r204b1117],

1	Multinational	JJ	O	multinational	amod	2	SENT_408	[p23l240t1029r918b1117],
2	study	NN	O	study	_	0	SENT_408	[p23l953t1029r1214b1140],
3	of	IN	O	of	_	0	SENT_408	[p23l1244t1029r1358b1117],
4	the	DT	O	the	det	5	SENT_408	[p23l1372t1029r1522b1115],
5	efficacy	NN	O	efficacy	prep_of	2	SENT_408	[p23l1558t1029r1940b1140],
6	and	CC	O	and	_	0	SENT_408	[p23l1969t1029r2148b1117],
7	safety	NN	O	safety	conj_and	5	SENT_408	[p23l94t1173r382b1284],
8	of	IN	O	of	_	0	SENT_408	[p23l414t1173r528b1261],
9	humanized	JJ	O	humanized	amod	10	SENT_408	[p23l543t1173r1097b1261],
10	anti	JJ	O	anti	prep_of	5	SENT_408	[p23l1131t1175r1643b1265],
11	.	.	O	.	_	0	SENT_408	[p23l1131t1175r1643b1265],

1	—	NN	O	—	_	0	SENT_409	[p23l1131t1175r1643b1265],
2	.	.	O	.	_	0	SENT_409	[p23l1131t1175r1643b1265],

1	HER2	NN	O	her2	nn	3	SENT_410	[p23l1131t1175r1643b1265],
2	monoclonal	JJ	O	monoclonal	amod	3	SENT_410	[p23l1679t1173r2146b1261, p23l94t1317r244b1403],
3	antibody	NN	O	antibody	_	0	SENT_410	[p23l292t1317r723b1428],
4	in	IN	O	in	_	0	SENT_410	[p23l767t1319r861b1403],
5	Women	NNS	O	woman	prep_in	3	SENT_410	[p23l905t1346r1264b1405],
6	Who	WP	O	who	nsubj	7	SENT_410	[p23l1307t1317r1513b1405],
7	have	VBP	O	have	rcmod	5	SENT_410	[p23l1564t1317r1779b1405],
8	HERZoverexpressing	NN	O	herzoverexpressing	dobj	7	SENT_410	[p23l1829t1323r2146b1409, p23l94t1463r827b1574],
9	metastatic	JJ	O	metastatic	amod	11	SENT_410	[p23l891t1463r1400b1549],
10	breast	NN	O	breast	nn	11	SENT_410	[p23l1469t1461r1768b1549],
11	cancer	NN	O	cancer	dep	3	SENT_410	[p23l1831t1490r2151b1549],
12	that	WDT	O	that	nsubj	14	SENT_410	[p23l94t1605r290b1692],
13	has	VBZ	O	have	aux	14	SENT_410	[p23l345t1605r507b1692],
14	progressed	VBN	O	progress	rcmod	11	SENT_410	[p23l568t1605r1110b1718],
15	after	IN	O	after	_	0	SENT_410	[p23l1169t1605r1400b1693],
16	chemotherapy	NN	O	chemotherapy	prep_after	14	SENT_410	[p23l1457t1605r2153b1716],
17	for	IN	O	for	_	0	SENT_410	[p23l94t1748r234b1836],
18	metastatic	JJ	O	metastatic	amod	19	SENT_410	[p23l269t1750r779b1834],
19	disease	NN	O	disease	prep_for	16	SENT_410	[p23l819t1748r1199b1836],
20	.	.	O	.	_	0	SENT_410	[p23l819t1748r1199b1836],

1	J	NNP	O	J	nn	3	SENT_411	[p23l1235t1756r1275b1849],
2	Clin	NNP	O	Clin	nn	3	SENT_411	[p23l1313t1748r1513b1836],
3	Oncol	NNP	O	Oncol	_	0	SENT_411	[p23l1555t1748r1842b1836],
4	1999	CD	DATE	1999	num	3	SENT_411	[p23l1885t1754r2143b1853],
5	;	:	O	;	_	0	SENT_411	[p23l1885t1754r2143b1853],
6	17:2639	CD	NUMBER	17:2639	number	7	SENT_411	[p23l98t1897r654b1979],
7	—	CD	NUMBER	—	dep	3	SENT_411	[p23l98t1897r654b1979],
8	48	CD	NUMBER	48	dep	7	SENT_411	[p23l98t1897r654b1979],
9	.	.	O	.	_	0	SENT_411	[p23l98t1897r654b1979],

1	25	CD	NUMBER	25	_	0	SENT_412	[p23l92t2046r225b2123],
2	.	.	O	.	_	0	SENT_412	[p23l92t2046r225b2123],

1	Lynch	NNP	PERSON	Lynch	nn	3	SENT_413	[p23l284t2035r572b2146],
2	T	NN	O	t	nn	3	SENT_413	[p23l619t2042r748b2141],
3	]	NN	O	]	_	0	SENT_413	[p23l619t2042r748b2141],
4	,	,	O	,	_	0	SENT_413	[p23l619t2042r748b2141],
5	Bell	NNP	ORGANIZATION	Bell	nn	6	SENT_413	[p23l804t2035r990b2121],
6	DW	NNP	ORGANIZATION	DW	appos	3	SENT_413	[p23l1039t2042r1237b2141],
7	,	,	O	,	_	0	SENT_413	[p23l1039t2042r1237b2141],
8	Sordella	NNP	PERSON	Sordella	nn	9	SENT_413	[p23l1298t2035r1691b2123],
9	R	NNP	PERSON	R	appos	3	SENT_413	[p23l1741t2042r1839b2142],
10	,	,	O	,	_	0	SENT_413	[p23l1741t2042r1839b2142],
11	et	FW	O	et	nn	12	SENT_413	[p23l1898t2054r1985b2121],
12	al.	FW	O	al.	appos	3	SENT_413	[p23l2030t2035r2142b2123],
13	.	.	O	.	_	0	SENT_413	[p23l2030t2035r2142b2123],

1	Activating	VBG	O	activate	amod	2	SENT_414	[p23l89t2181r593b2292],
2	mutations	NNS	O	mutation	_	0	SENT_414	[p23l671t2181r1164b2267],
3	in	IN	O	in	_	0	SENT_414	[p23l1248t2181r1342b2265],
4	the	DT	O	the	det	7	SENT_414	[p23l1424t2179r1574b2266],
5	epidermal	JJ	O	epidermal	amod	7	SENT_414	[p23l1656t2179r2148b2290],
6	growth	NN	O	growth	nn	7	SENT_414	[p23l92t2323r449b2436],
7	factor	NN	O	factor	prep_in	2	SENT_414	[p23l539t2323r825b2411],
8	receptor	NN	O	receptor	nn	10	SENT_414	[p23l911t2342r1315b2434],
9	underlying	VBG	O	underlie	amod	10	SENT_414	[p23l1401t2323r1933b2436],
10	responsiveness	NN	O	responsiveness	dep	2	SENT_414	[p23l2017t2352r2146b2410, p23l94t2469r727b2578],
11	of	IN	O	of	_	0	SENT_414	[p23l773t2467r886b2555],
12	non	JJ	O	non	amod	16	SENT_414	[p23l907t2467r1641b2555],
13	—	JJ	O	—	amod	16	SENT_414	[p23l907t2467r1641b2555],
14	small-cell	NN	O	small-cell	nn	16	SENT_414	[p23l907t2467r1641b2555],
15	lung	NN	O	lung	nn	16	SENT_414	[p23l1681t2467r1900b2580],
16	cancer	NN	O	cancer	prep_of	10	SENT_414	[p23l1940t2496r2146b2554, p23l94t2640r238b2699],
17	to	TO	O	to	_	0	SENT_414	[p23l286t2630r378b2699],
18	gefitinib	NN	O	gefitinib	prep_to	10	SENT_414	[p23l429t2611r880b2724],
19	.	.	O	.	_	0	SENT_414	[p23l429t2611r880b2724],

1	N	NN	O	n	nn	3	SENT_415	[p23l935t2619r1018b2699],
2	Engl	NNP	O	Engl	nn	3	SENT_415	[p23l1066t2611r1285b2724],
3	J	NNP	O	J	nsubj	4	SENT_415	[p23l1325t2619r1367b2713],
4	Med	VBD	O	med	_	0	SENT_415	[p23l1411t2611r1622b2699],
5	2004	CD	DATE	2004	dobj	4	SENT_415	[p23l1672t2617r2143b2717],
6	;	:	O	;	_	0	SENT_415	[p23l1672t2617r2143b2717],
7	350	CD	NUMBER	350	num	9	SENT_415	[p23l1672t2617r2143b2717],
8	:	:	O	:	_	0	SENT_415	[p23l1672t2617r2143b2717],
9	2129-39	CD	NUMBER	2129-39	dep	5	SENT_415	[p23l94t2760r503b2842],
10	.	.	O	.	_	0	SENT_415	[p23l94t2760r503b2842],

1	26	CD	NUMBER	26	_	0	SENT_416	[p23l92t2909r227b2986],
2	.	.	O	.	_	0	SENT_416	[p23l92t2909r227b2986],

1	Kwak	NNP	PERSON	Kwak	nn	2	SENT_417	[p23l284t2898r556b2988],
2	EL	NNP	O	EL	_	0	SENT_417	[p23l583t2906r733b3005],
3	,	,	O	,	_	0	SENT_417	[p23l583t2906r733b3005],
4	Bang	NNP	O	Bang	nn	5	SENT_417	[p23l771t2905r1022b3011],
5	Y-J	NNP	O	Y-J	appos	2	SENT_417	[p23l1047t2906r1195b3005],
6	,	,	O	,	_	0	SENT_417	[p23l1047t2906r1195b3005],
7	Camidge	NNP	O	Camidge	nn	8	SENT_417	[p23l1235t2898r1666b3011],
8	DR	NN	O	dr	appos	2	SENT_417	[p23l1699t2905r1877b3004],
9	,	,	O	,	_	0	SENT_417	[p23l1699t2905r1877b3004],
10	et	FW	O	et	nn	11	SENT_417	[p23l1917t2917r2004b2985],
11	al.	FW	O	al.	appos	2	SENT_417	[p23l2030t2898r2142b2986],
12	.	.	O	.	_	0	SENT_417	[p23l2030t2898r2142b2986],

1	Anaplastic	JJ	MISC	anaplastic	amod	4	SENT_418	[p23l89t3042r599b3153],
2	lymphoma	NN	O	lymphoma	nn	4	SENT_418	[p23l636t3042r1150b3153],
3	kinase	NN	O	kinase	nn	4	SENT_418	[p23l1187t3042r1498b3130],
4	inhibition	NN	O	inhibition	_	0	SENT_418	[p23l1537t3042r2015b3130],
5	in	IN	O	in	_	0	SENT_418	[p23l2055t3044r2147b3128],
6	non	JJ	O	non	amod	10	SENT_418	[p23l94t3186r826b3274],
7	—	JJ	O	—	amod	10	SENT_418	[p23l94t3186r826b3274],
8	small-cell	NN	O	small-cell	nn	10	SENT_418	[p23l94t3186r826b3274],
9	lung	NN	O	lung	nn	10	SENT_418	[p23l861t3186r1082b3299],
10	cancer	NN	O	cancer	prep_in	4	SENT_418	[p23l1116t3215r1457b3274],
11	.	.	O	.	_	0	SENT_418	[p23l1116t3215r1457b3274],

1	N	NN	O	n	nn	3	SENT_419	[p23l1499t3194r1582b3274],
2	Engl	NNP	O	Engl	nn	3	SENT_419	[p23l1616t3186r1904b3299],
3	]	NNP	O	]	nsubj	4	SENT_419	[p23l1616t3186r1904b3299],
4	Med	VBD	O	med	_	0	SENT_419	[p23l1936t3186r2147b3274],
5	2010	CD	DATE	2010	dobj	4	SENT_419	[p23l94t3336r978b3436],
6	;	:	O	;	_	0	SENT_419	[p23l94t3336r978b3436],
7	363:1693	CD	NUMBER	363:1693	num	8	SENT_419	[p23l94t3336r978b3436],
8	—	NN	O	—	dep	5	SENT_419	[p23l94t3336r978b3436],
9	703	CD	NUMBER	703	dep	8	SENT_419	[p23l94t3336r978b3436],
10	.	.	O	.	_	0	SENT_419	[p23l94t3336r978b3436],

1	[	NN	O	[	nn	2	SENT_420	[p23l1031t3338r1478b3436],
2	Erratum	NN	O	erratum	nsubj	7	SENT_420	[p23l1031t3338r1478b3436],
3	,	,	O	,	_	0	SENT_420	[p23l1031t3338r1478b3436],
4	N	NN	O	n	appos	2	SENT_420	[p23l1518t3338r1601b3418],
5	Engl	NNP	O	Engl	nn	6	SENT_420	[p23l1633t3330r1912b3443],
6	]	NNP	O	]	dep	4	SENT_420	[p23l1633t3330r1912b3443],
7	Med	VBD	O	med	_	0	SENT_420	[p23l1942t3330r2147b3418],
8	2011	CD	DATE	2011	dobj	7	SENT_420	[p23l94t3479r802b3579],
9	;	:	O	;	_	0	SENT_420	[p23l94t3479r802b3579],
10	364:588	CD	NUMBER	364:588	dep	8	SENT_420	[p23l94t3479r802b3579],
11	.	.	O	.	_	0	SENT_420	[p23l94t3479r802b3579],
12	]	SYM	O	]	dep	8	SENT_420	[p23l94t3479r802b3579],

1	Copyright	NN	O	copyright	_	0	SENT_421	[p23l96t3633r453b3729],
2	©	CD	NUMBER	©	num	6	SENT_421	[p23l489t3640r568b3720],
3	2012	CD	DATE	2012	num	6	SENT_421	[p23l608t3637r796b3704],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_421	[p23l830t3633r1367b3704],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_421	[p23l1401t3633r1697b3706],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_421	[p23l1726t3635r2003b3727],
7	.	.	O	.	_	0	SENT_421	[p23l1726t3635r2003b3727],

1	ICMJE	NNP	O	ICMJE	_	0	SENT_422	[p24l578t299r664b326],
2	SEEKING	VBG	O	seek	dep	1	SENT_422	[p24l679t299r813b318],
3	TWO	CD	NUMBER	two	num	5	SENT_422	[p24l828t299r895b318],
4	NEW	JJ	O	new	amod	5	SENT_422	[p24l913t299r980b318],
5	MEMBERJOURNALS	NNS	O	memberjournal	dobj	2	SENT_422	[p24l997t299r1298b326],

1	The	DT	O	the	det	3	SENT_423	[p24l113t337r161b360],
2	International	NNP	ORGANIZATION	International	nn	3	SENT_423	[p24l169t337r334b360],
3	Committee	NNP	ORGANIZATION	Committee	nsubj	12	SENT_423	[p24l342t337r482b360],
4	of	IN	ORGANIZATION	of	_	0	SENT_423	[p24l490t336r520b360],
5	Medical	NNP	ORGANIZATION	Medical	nn	7	SENT_423	[p24l523t337r622b360],
6	Journal	NNP	ORGANIZATION	Journal	nn	7	SENT_423	[p24l627t337r721b363],
7	Editors	NNP	ORGANIZATION	Editors	prep_of	3	SENT_423	[p24l729t337r819b360],
8	(	CD	NUMBER	(	num	10	SENT_423	[p24l829t338r926b363],
9	ICMIE	NN	O	icmie	nn	10	SENT_423	[p24l829t338r926b363],
10	)	NN	O	)	dep	7	SENT_423	[p24l829t338r926b363],
11	is	VBZ	O	be	aux	12	SENT_423	[p24l936t337r956b359],
12	seeking	VBG	O	seek	_	0	SENT_423	[p24l965t337r1062b366],
13	two	CD	NUMBER	two	num	16	SENT_423	[p24l1070t341r1115b360],
14	new	JJ	O	new	amod	16	SENT_423	[p24l1124t344r1176b360],
15	member	NN	O	member	nn	16	SENT_423	[p24l1183t337r1289b360],
16	journals	NNS	O	journal	dobj	12	SENT_423	[p24l1292t337r1398b366],
17	to	TO	O	to	aux	19	SENT_423	[p24l1407t341r1430b360],
18	be	VB	O	be	auxpass	19	SENT_423	[p24l1440t337r1468b360],
19	represented	VBN	O	represent	xcomp	12	SENT_423	[p24l1477t337r1624b366],
20	by	IN	O	by	_	0	SENT_423	[p24l1633t337r1662b366],
21	their	PRP$	O	they	poss	22	SENT_423	[p24l1669t337r1728b360],
22	editors-in-chief	NN	O	editors-in-chief	agent	19	SENT_423	[p24l114t374r314b397],
23	.	.	O	.	_	0	SENT_423	[p24l114t374r314b397],

1	Information	NN	O	information	nsubj	6	SENT_424	[p24l323t374r475b397],
2	about	IN	O	about	_	0	SENT_424	[p24l483t374r555b397],
3	the	DT	O	the	det	4	SENT_424	[p24l562t374r600b397],
4	ICMJE	NN	O	icmje	prep_about	1	SENT_424	[p24l608t376r686b401],
5	is	VBZ	O	be	cop	6	SENT_424	[p24l695t374r714b397],
6	available	JJ	O	available	_	0	SENT_424	[p24l723t374r830b397],
7	at	IN	O	at	_	0	SENT_424	[p24l839t379r862b397],
8	wvvw.icmje.org	NN	O	wvvw.icmje.org	prep_at	6	SENT_424	[p24l867t374r1066b404],
9	.	.	O	.	_	0	SENT_424	[p24l867t374r1066b404],

1	Candidate	NN	O	candidate	nn	2	SENT_425	[p24l1076t374r1202b397],
2	journals	NNS	O	journal	nsubj	4	SENT_425	[p24l1206t374r1310b403],
3	should	MD	O	should	aux	4	SENT_425	[p24l1320t374r1404b397],
4	meet	VB	O	meet	_	0	SENT_425	[p24l1412t379r1474b397],
5	the	DT	O	the	det	7	SENT_425	[p24l1481t374r1519b397],
6	following	VBG	O	follow	amod	7	SENT_425	[p24l1527t374r1648b404],
7	criteria	NNS	O	criterion	dobj	4	SENT_425	[p24l1655t374r1749b397],
8	:	:	O	:	_	0	SENT_425	[p24l1655t374r1749b397],
9	-	:	O	-	_	0	SENT_425	[p24l158t433r165b440],
10	be	VB	O	be	cop	15	SENT_425	[p24l181t424r209b447],
11	a	DT	O	a	det	15	SENT_425	[p24l218t432r230b447],
12	peer-reviewed	JJ	O	peer-reviewed	amod	15	SENT_425	[p24l238t424r414b453],
13	general	JJ	O	general	amod	15	SENT_425	[p24l422t424r515b454],
14	medical	JJ	O	medical	amod	15	SENT_425	[p24l524t424r622b447],
15	journal	NN	O	journal	parataxis	23	SENT_425	[p24l627t424r719b453],
16	that	WDT	O	that	nsubj	17	SENT_425	[p24l728t424r778b447],
17	publishes	VBZ	O	publish	rcmod	15	SENT_425	[p24l784t424r905b453],
18	original	JJ	O	original	amod	19	SENT_425	[p24l915t424r1013b454],
19	research	NN	O	research	dobj	17	SENT_425	[p24l1021t424r1127b447],
20	involving	VBG	O	involve	partmod	19	SENT_425	[p24l1135t424r1252b454],
21	humans	NNS	O	human	dobj	20	SENT_425	[p24l1259t424r1360b447],
22	-	:	O	-	_	0	SENT_425	[p24l158t471r165b478],
23	have	VB	O	have	dep	4	SENT_425	[p24l181t462r236b485],
24	a	DT	O	a	det	25	SENT_425	[p24l245t469r258b485],
25	governance	NN	O	governance	iobj	23	SENT_425	[p24l266t469r409b491],
26	structure	NN	O	structure	dobj	23	SENT_425	[p24l418t467r530b485],
27	that	WDT	O	that	nsubj	28	SENT_425	[p24l539t462r588b485],
28	ensures	VBZ	O	ensure	rcmod	26	SENT_425	[p24l596t469r691b485],
29	editorial	NN	O	editorial	nn	30	SENT_425	[p24l701t462r805b485],
30	independence	NN	O	independence	dobj	28	SENT_425	[p24l813t462r989b491],
31	-	:	O	-	_	0	SENT_425	[p24l158t508r165b515],
32	have	VBP	O	have	rcmod	26	SENT_425	[p24l181t499r236b522],
33	an	DT	O	a	det	34	SENT_425	[p24l245t507r274b522],
34	editor	NN	O	editor	dobj	32	SENT_425	[p24l283t499r358b522],
35	with	IN	O	with	_	0	SENT_425	[p24l364t499r420b522],
36	experience	NN	O	experience	prep_with	34	SENT_425	[p24l429t499r562b529],
37	in	IN	O	in	_	0	SENT_425	[p24l571t499r595b522],
38	the	DT	O	the	det	39	SENT_425	[p24l604t499r642b522],
39	position	NN	O	position	prep_in	32	SENT_425	[p24l651t499r754b529],
40	who	WP	O	who	nsubj	41	SENT_425	[p24l762t499r816b522],
41	expects	VBZ	O	expect	rcmod	39	SENT_425	[p24l825t504r916b529],
42	to	TO	O	to	aux	43	SENT_425	[p24l926t504r949b522],
43	continue	VB	O	continue	xcomp	41	SENT_425	[p24l958t499r1068b522],
44	in	IN	O	in	_	0	SENT_425	[p24l1076t499r1100b522],
45	the	DT	O	the	det	46	SENT_425	[p24l1109t499r1147b522],
46	position	NN	O	position	prep_in	43	SENT_425	[p24l1156t499r1260b529],
47	for	IN	O	for	_	0	SENT_425	[p24l1268t499r1305b522],
48	at	IN	DURATION	at	quantmod	51	SENT_425	[p24l1312t504r1336b522],
49	least	JJS	DURATION	least	mwe	48	SENT_425	[p24l1343t499r1401b522],
50	another	DT	DURATION	another	quantmod	51	SENT_425	[p24l1408t499r1506b522],
51	3	CD	DURATION	3	num	52	SENT_425	[p24l1514t501r1527b522],
52	years	NNS	NUMBER	year	prep_for	46	SENT_425	[p24l1536t507r1599b528],
53	-	:	O	-	_	0	SENT_425	[p24l158t546r165b553],
54	be	VB	O	be	cop	56	SENT_425	[p24l181t537r209b560],
55	ﬁnancially	RB	O	ﬁnancially	advmod	56	SENT_425	[p24l218t536r349b566],
56	able	JJ	O	able	dep	43	SENT_425	[p24l356t537r407b560],
57	to	TO	O	to	aux	58	SENT_425	[p24l416t542r440b560],
58	support	VB	O	support	xcomp	56	SENT_425	[p24l449t542r548b566],
59	the	DT	O	the	det	60	SENT_425	[p24l555t537r593b560],
60	editor	NN	O	editor	poss	62	SENT_425	[p24l602t537r696b560],
61	’s	POS	O	’s	_	0	SENT_425	[p24l602t537r696b560],
62	participation	NN	O	participation	dobj	58	SENT_425	[p24l705t537r867b566],
63	in	IN	O	in	_	0	SENT_425	[p24l875t537r899b559],
64	ICMJE	NN	O	icmje	nn	65	SENT_425	[p24l907t538r986b563],
65	activities	NNS	O	activity	prep_in	62	SENT_425	[p24l996t537r1104b560],

1	In	IN	O	in	_	0	SENT_426	[p24l114t601r139b622],
2	considering	VBG	O	consider	prepc_in	8	SENT_426	[p24l148t599r298b629],
3	candidates	NNS	O	candidate	dobj	2	SENT_426	[p24l306t599r447b627],
4	,	,	O	,	_	0	SENT_426	[p24l306t599r447b627],
5	the	DT	O	the	det	6	SENT_426	[p24l457t599r495b622],
6	ICMJE	NN	O	icmje	nsubj	8	SENT_426	[p24l504t601r583b626],
7	may	MD	O	may	aux	8	SENT_426	[p24l592t607r644b628],
8	seek	VB	O	seek	_	0	SENT_426	[p24l652t599r707b623],
9	to	TO	O	to	aux	10	SENT_426	[p24l715t604r738b622],
10	improve	VB	O	improve	xcomp	8	SENT_426	[p24l747t600r850b629],
11	the	DT	O	the	det	12	SENT_426	[p24l859t599r897b622],
12	balance	NN	O	balance	dobj	10	SENT_426	[p24l906t599r1001b622],
13	of	IN	O	of	_	0	SENT_426	[p24l1010t599r1040b622],
14	geographic	JJ	O	geographic	amod	15	SENT_426	[p24l1043t599r1184b629],
15	areas	NNS	O	area	prep_of	12	SENT_426	[p24l1192t607r1256b622],
16	and	CC	O	and	_	0	SENT_426	[p24l1265t599r1311b622],
17	publishing	NN	O	publishing	nn	18	SENT_426	[p24l1320t599r1457b629],
18	models	NNS	O	model	prep_of	12	SENT_426	[p24l1465t599r1556b622],
19	among	IN	O	among	_	0	SENT_426	[p24l1565t607r1653b629],
20	its	PRP$	O	its	poss	21	SENT_426	[p24l1661t599r1689b622],
21	membership	NN	O	membership	prep_among	10	SENT_426	[p24l114t637r281b666],
22	.	.	O	.	_	0	SENT_426	[p24l114t637r281b666],

1	To	TO	O	to	dep	136	SENT_427	[p24l113t701r146b722],
2	apply	VB	O	apply	dep	136	SENT_427	[p24l155t699r229b729],
3	,	,	O	,	_	0	SENT_427	[p24l155t699r229b729],
4	editors	NNS	O	editor	dep	136	SENT_427	[p24l239t699r439b722],
5	—	VBP	O	—	dep	136	SENT_427	[p24l239t699r439b722],
6	in	IN	O	in	dep	136	SENT_427	[p24l239t699r439b722],
7	—	CD	NUMBER	—	dep	136	SENT_427	[p24l239t699r439b722],
8	chief	NN	O	chief	dep	136	SENT_427	[p24l239t699r439b722],
9	of	IN	O	of	dep	136	SENT_427	[p24l443t699r472b722],
10	interested	JJ	O	interested	dep	136	SENT_427	[p24l475t699r600b722],
11	journals	NNS	O	journal	dep	136	SENT_427	[p24l605t699r710b729],
12	should	MD	O	should	dep	136	SENT_427	[p24l719t699r804b723],
13	submit	VB	O	submit	dep	136	SENT_427	[p24l814t699r902b722],
14	the	DT	O	the	dep	136	SENT_427	[p24l909t699r948b722],
15	following	JJ	O	following	dep	136	SENT_427	[p24l956t699r1078b729],
16	materials	NNS	O	material	dep	136	SENT_427	[p24l1085t699r1201b722],
17	to	TO	O	to	dep	136	SENT_427	[p24l1210t704r1234b722],
18	the	DT	O	the	dep	136	SENT_427	[p24l1243t699r1281b722],
19	ICMJE	NN	O	icmje	dep	136	SENT_427	[p24l1290t701r1368b726],
20	(	NN	O	(	dep	136	SENT_427	[p24l1379t701r1411b726],
21	at	IN	O	at	dep	136	SENT_427	[p24l1379t701r1411b726],
22	icmje@acponline.org	NN	O	icmje@acponline.org	dep	136	SENT_427	[p24l1418t699r1705b729],
23	)	CD	NUMBER	)	dep	136	SENT_427	[p24l1418t699r1705b729],
24	:	:	O	:	_	0	SENT_427	[p24l1418t699r1705b729],
25	-	:	O	-	_	0	SENT_427	[p24l158t759r165b765],
26	brief	JJ	O	brief	dep	136	SENT_427	[p24l181t749r244b772],
27	curriculum	NN	O	curriculum	dep	136	SENT_427	[p24l247t749r386b773],
28	vitae	NN	O	vita	dep	136	SENT_427	[p24l393t750r451b772],
29	-	:	O	-	_	0	SENT_427	[p24l158t796r165b803],
30	cover	NN	O	cover	dep	136	SENT_427	[p24l181t794r247b810],
31	letter	NN	O	letter	dep	136	SENT_427	[p24l254t787r320b810],
32	describing	VBG	O	describe	dep	136	SENT_427	[p24l328t787r461b816],
33	the	DT	O	the	dep	136	SENT_427	[p24l469t787r507b810],
34	journal	NN	O	journal	dep	136	SENT_427	[p24l511t787r611b816],
35	,	,	O	,	_	0	SENT_427	[p24l511t787r611b816],
36	including	VBG	O	include	dep	136	SENT_427	[p24l622t787r743b816],
37	but	CC	O	but	dep	136	SENT_427	[p24l750t787r792b810],
38	not	RB	O	not	dep	136	SENT_427	[p24l799t792r842b810],
39	necessarily	RB	O	necessarily	dep	136	SENT_427	[p24l849t787r987b816],
40	limited	VBN	O	limit	dep	136	SENT_427	[p24l994t787r1083b810],
41	to	TO	O	to	dep	136	SENT_427	[p24l1092t792r1115b810],
42	details	NNS	O	detail	dep	136	SENT_427	[p24l1124t787r1205b810],
43	of	IN	O	of	dep	136	SENT_427	[p24l1215t787r1244b810],
44	the	DT	O	the	dep	136	SENT_427	[p24l1248t787r1286b810],
45	journal	NN	O	journal	dep	136	SENT_427	[p24l1291t787r1404b816],
46	’s	POS	O	’s	dep	136	SENT_427	[p24l1291t787r1404b816],
47	history	NN	O	history	dep	136	SENT_427	[p24l1414t787r1507b816],
48	,	,	O	,	_	0	SENT_427	[p24l1414t787r1507b816],
49	sponsor	NN	O	sponsor	dep	136	SENT_427	[p24l1518t794r1619b816],
50	or	CC	O	or	dep	136	SENT_427	[p24l1627t794r1654b810],
51	publisher	NN	O	publisher	dep	136	SENT_427	[p24l180t824r307b854],
52	,	,	O	,	_	0	SENT_427	[p24l180t824r307b854],
53	governance	NN	O	governance	dep	136	SENT_427	[p24l317t832r460b854],
54	structure	NN	O	structure	dep	136	SENT_427	[p24l470t829r588b852],
55	,	,	O	,	_	0	SENT_427	[p24l470t829r588b852],
56	publishing	VBG	O	publish	dep	136	SENT_427	[p24l598t824r736b854],
57	model	NN	O	model	dep	136	SENT_427	[p24l743t824r822b847],
58	(	CD	NUMBER	(	dep	136	SENT_427	[p24l832t826r894b854],
59	e.g.	FW	O	e.g.	dep	136	SENT_427	[p24l832t826r894b854],
60	,	,	O	,	_	0	SENT_427	[p24l832t826r894b854],
61	subscription	NN	O	subscription	dep	136	SENT_427	[p24l904t824r1069b854],
62	,	,	O	,	_	0	SENT_427	[p24l904t824r1069b854],
63	author	NN	O	author	dep	136	SENT_427	[p24l1079t824r1227b854],
64	—	CD	NUMBER	—	dep	136	SENT_427	[p24l1079t824r1227b854],
65	pays	VBZ	O	pay	dep	136	SENT_427	[p24l1079t824r1227b854],
66	open	JJ	O	open	dep	136	SENT_427	[p24l1237t832r1298b854],
67	access	NN	O	access	dep	136	SENT_427	[p24l1307t826r1403b852],
68	)	NN	O	)	dep	136	SENT_427	[p24l1307t826r1403b852],
69	,	,	O	,	_	0	SENT_427	[p24l1307t826r1403b852],
70	target	NN	O	target	dep	136	SENT_427	[p24l1414t829r1487b854],
71	audience	NN	O	audience	dep	136	SENT_427	[p24l1494t824r1613b852],
72	,	,	O	,	_	0	SENT_427	[p24l1494t824r1613b852],
73	print	NN	O	print	dep	136	SENT_427	[p24l1623t825r1685b854],
74	circulation	NN	O	circulation	dep	136	SENT_427	[p24l181t862r315b885],
75	and	CC	O	and	dep	136	SENT_427	[p24l323t862r370b885],
76	online	NN	O	online	dep	136	SENT_427	[p24l378t862r457b885],
77	traffic	NN	O	traffic	dep	136	SENT_427	[p24l466t862r548b890],
78	,	,	O	,	_	0	SENT_427	[p24l466t862r548b890],
79	number	NN	O	number	dep	136	SENT_427	[p24l558t862r657b885],
80	of	IN	O	of	dep	136	SENT_427	[p24l665t862r695b885],
81	manuscript	NN	O	manuscript	dep	136	SENT_427	[p24l698t862r843b891],
82	submissions	NNS	O	submission	dep	136	SENT_427	[p24l851t862r1008b885],
83	per	IN	O	per	dep	136	SENT_427	[p24l1017t869r1058b891],
84	year	NN	DURATION	year	dep	136	SENT_427	[p24l1065t869r1123b891],
85	,	,	O	,	_	0	SENT_427	[p24l1065t869r1123b891],
86	processes	NNS	O	process	dep	136	SENT_427	[p24l1133t869r1254b891],
87	used	VBN	O	use	dep	136	SENT_427	[p24l1264t862r1321b885],
88	to	TO	O	to	dep	136	SENT_427	[p24l1330t867r1354b885],
89	select	VB	O	select	dep	136	SENT_427	[p24l1363t862r1434b885],
90	material	NN	O	material	dep	136	SENT_427	[p24l1441t862r1544b885],
91	for	IN	O	for	dep	136	SENT_427	[p24l1553t862r1589b885],
92	publication	NN	O	publication	dep	136	SENT_427	[p24l1597t862r1747b891],
93	,	,	O	,	_	0	SENT_427	[p24l1597t862r1747b891],
94	acceptance	NN	O	acceptance	dep	136	SENT_427	[p24l180t904r317b929],
95	rate	NN	O	rate	dep	136	SENT_427	[p24l326t904r380b927],
96	,	,	O	,	_	0	SENT_427	[p24l326t904r380b927],
97	databases	NNS	O	database	dep	136	SENT_427	[p24l390t899r512b922],
98	where	WRB	O	where	dep	136	SENT_427	[p24l520t899r596b923],
99	indexed	VBN	O	index	dep	136	SENT_427	[p24l605t899r710b927],
100	,	,	O	,	_	0	SENT_427	[p24l605t899r710b927],
101	website	NN	O	website	dep	136	SENT_427	[p24l719t899r815b923],
102	address	NN	O	address	dep	136	SENT_427	[p24l823t899r927b927],
103	,	,	O	,	_	0	SENT_427	[p24l823t899r927b927],
104	and	CC	O	and	dep	136	SENT_427	[p24l937t899r983b922],
105	guidelines	NNS	O	guideline	dep	136	SENT_427	[p24l991t899r1120b929],
106	for	IN	O	for	dep	136	SENT_427	[p24l1130t899r1166b922],
107	authors	NNS	O	author	dep	136	SENT_427	[p24l1174t899r1269b923],
108	-	:	O	-	_	0	SENT_427	[p24l158t946r165b953],
109	statement	NN	O	statement	dep	136	SENT_427	[p24l181t942r306b960],
110	on	IN	O	on	dep	136	SENT_427	[p24l313t944r344b960],
111	how	WRB	O	how	dep	136	SENT_427	[p24l353t937r407b960],
112	the	DT	O	the	dep	136	SENT_427	[p24l415t937r453b960],
113	journal	NN	O	journal	dep	136	SENT_427	[p24l458t937r551b966],
114	might	MD	O	might	dep	136	SENT_427	[p24l559t937r636b966],
115	beneﬁt	VB	O	beneﬁt	dep	136	SENT_427	[p24l643t937r731b960],
116	from	IN	O	from	dep	136	SENT_427	[p24l739t937r800b960],
117	ICMJE	NN	O	icmje	dep	136	SENT_427	[p24l808t939r887b964],
118	membership	NN	O	membership	dep	136	SENT_427	[p24l896t937r1056b966],
119	and	CC	O	and	dep	136	SENT_427	[p24l1064t937r1111b960],
120	how	WRB	O	how	dep	136	SENT_427	[p24l1119t937r1173b960],
121	the	DT	O	the	dep	136	SENT_427	[p24l1181t937r1219b960],
122	ICMJE	NN	O	icmje	dep	136	SENT_427	[p24l1228t939r1307b964],
123	might	MD	O	might	dep	136	SENT_427	[p24l1316t937r1392b966],
124	benefit	VB	O	benefit	dep	136	SENT_427	[p24l1400t937r1488b960],
125	from	IN	O	from	dep	136	SENT_427	[p24l1495t937r1556b960],
126	the	DT	O	the	dep	136	SENT_427	[p24l1565t937r1604b960],
127	journal	NN	O	journal	dep	136	SENT_427	[p24l1608t937r1722b966],
128	’s	POS	O	’s	dep	136	SENT_427	[p24l1608t937r1722b966],
129	membership	NN	O	membership	dep	136	SENT_427	[p24l181t974r340b1004],
130	(	NN	O	(	dep	136	SENT_427	[p24l350t974r445b1001],
131	should	MD	O	should	dep	136	SENT_427	[p24l350t974r445b1001],
132	not	RB	O	not	dep	136	SENT_427	[p24l453t979r496b997],
133	exceed	VB	O	exceed	dep	136	SENT_427	[p24l503t974r586b997],
134	1000	CD	NUMBER	1000	dep	136	SENT_427	[p24l596t976r656b997],
135	words	NNS	O	word	dep	136	SENT_427	[p24l664t974r750b1001],
136	)	IN	O	)	_	0	SENT_427	[p24l664t974r750b1001],

1	The	DT	O	the	det	2	SENT_428	[p24l113t1037r161b1060],
2	deadline	NN	O	deadline	nsubj	5	SENT_428	[p24l170t1037r276b1060],
3	for	IN	O	for	_	0	SENT_428	[p24l285t1037r321b1060],
4	applications	NNS	O	application	prep_for	2	SENT_428	[p24l328t1037r482b1066],
5	is	VBZ	O	be	_	0	SENT_428	[p24l491t1037r510b1060],
6	January	NNP	DATE	January	tmod	5	SENT_428	[p24l517t1039r613b1066],
7	31	CD	DATE	31	num	6	SENT_428	[p24l621t1039r658b1065],
8	,	,	DATE	,	_	0	SENT_428	[p24l621t1039r658b1065],
9	2013	CD	DATE	2013	num	6	SENT_428	[p24l668t1039r736b1060],
10	.	.	O	.	_	0	SENT_428	[p24l668t1039r736b1060],

1	N	NN	O	n	nn	3	SENT_429	[p24l594t1205r608b1220],
2	ENGLJ	NN	O	englj	nn	3	SENT_429	[p24l623t1205r701b1227],
3	MED	NN	O	med	_	0	SENT_429	[p24l715t1205r767b1220],
4	367	CD	NUMBER	367	dep	3	SENT_429	[p24l777t1199r855b1227],
5	;	:	O	;	_	0	SENT_429	[p24l777t1199r855b1227],
6	18	CD	NUMBER	18	num	8	SENT_429	[p24l777t1199r855b1227],
7	NEJM.ORG	NN	O	nejm.org	nn	8	SENT_429	[p24l890t1205r1014b1227],
8	N0VEMBER1	NN	O	n0vember1	dep	4	SENT_429	[p24l1051t1205r1282b1225],
9	,2	CD	NUMBER	,2	num	10	SENT_429	[p24l1051t1205r1282b1225],
10	O12	NN	O	o12	dep	8	SENT_429	[p24l1051t1205r1282b1225],
11	1703	CD	DATE	1703	dep	3	SENT_429	[p24l1991t1195r2066b1218],

1	The	DT	O	the	det	5	SENT_430	[p24l753t1238r804b1262],
2	New	NNP	O	New	nn	5	SENT_430	[p24l813t1239r875b1262],
3	England	NNP	O	England	nn	5	SENT_430	[p24l884t1238r995b1269],
4	J	NNP	O	J	nn	5	SENT_430	[p24l1003t1239r1016b1262],
5	oumal	NN	O	oumal	_	0	SENT_430	[p24l1017t1238r1101b1262],
6	of	IN	O	of	_	0	SENT_430	[p24l1110t1238r1139b1262],
7	Medicine	NN	O	medicine	prep_of	5	SENT_430	[p24l1146t1238r1271b1262],

1	Copyright	NN	O	copyright	_	0	SENT_431	[p24l545t1320r680b1351],
2	©	CD	NUMBER	©	num	6	SENT_431	[p24l689t1320r712b1344],
3	2012	CD	DATE	2012	num	6	SENT_431	[p24l722t1320r787b1344],
4	Massachusetts	NNP	ORGANIZATION	Massachusetts	nn	6	SENT_431	[p24l797t1320r988b1344],
5	Medical	NNP	ORGANIZATION	Medical	nn	6	SENT_431	[p24l998t1320r1106b1344],
6	Society	NNP	ORGANIZATION	Society	dep	1	SENT_431	[p24l1116t1320r1221b1351],
7	.	.	O	.	_	0	SENT_431	[p24l1116t1320r1221b1351],

1	All	DT	O	all	det	2	SENT_432	[p24l1232t1320r1274b1344],
2	rights	NNS	O	rights	nsubj	3	SENT_432	[p24l1283t1320r1357b1351],
3	reserved	VBN	O	reserve	_	0	SENT_432	[p24l1367t1320r1486b1344],
4	.	.	O	.	_	0	SENT_432	[p24l1367t1320r1486b1344],

